Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.2.1.18 - exo-alpha-sialidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice.
Abscess
A Sialidase-Deficient Porphyromonas gingivalis Mutant Strain Induces Less IL-1? and TNF? in epi4 Cells than the W83 Strain Through Regulation of the JNK Pathway.
[Neuraminidase as a pathogenetic factor in an abscess caused by Bacteroides fragilis]
Acidosis, Lactic
Alterations in the ganglioside composition of rat cortical brain slices during experimental lactic acidosis: implications of an enzymatic process independent of the oxidative stress.
Acne Vulgaris
Acne vaccines targeting Propionibacterium acnes.
Neuraminidase production by Propionibacterium acnes-strains isolated from patients with acne vulgaris, seborrheic eczema and healthy subjects.
Vaccination Targeting a Surface Sialidase of P. acnes: Implication for New Treatment of Acne Vulgaris.
Vaccine therapy for P. acnes-associated diseases.
Acquired Immunodeficiency Syndrome
AML1 protein interacts with influenza A virus neuraminidase and upregulates IFN-? response in infected mammalian cells.
Changes in ganglioside content affect the binding of Clostridium perfringens epsilon-toxin to detergent-resistant membranes of Madin-Darby canine kidney cells.
Defensive role of pleural mesothelial cell sialomucins in tumor metastasis.
Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase.
Influenza A virus neuraminidase protein enhances cell survival through interaction with CEACAM6.
Influenza viruses with receptor-binding n1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice.
Recombinant sialidase NanA (rNanA) cleaves ?2-3 linked sialic acid of host cell surface N-linked glycoprotein to promote Edwardsiella tarda infection.
Acute Kidney Injury
Hepatocellular injury in Streptococcus pneumoniae-associated hemolytic uremic syndrome in children.
Acute Lung Injury
Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.
Neuraminidase Reprograms Lung Tissue and Potentiates Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Adenocarcinoma
Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells.
Enzymically-mediated changes in murine mammary adenocarcinoma cell membrane induces changes in lymphoid tissue immune ribonucleic acids.
Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
Histochemical and biochemical aspects of lectin binding glycoproteins in primary and metastatic adenocarcinoma in the lung.
Human colon sialidase: characterization and activity levels in normal mucosa and colonic adenocarcinoma.
Immunohistochemical localization of T antigen-like substance in benign hyperplasia and adenocarcinoma of the prostate.
Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2.
Lectin histochemistry of normal lung and pulmonary adenocarcinoma.
Modification of the immunologic properties of the cell surface.
Preparation of fixed antigenic, non-oncogenic and protective neoplastic cells.
Production and characterization of monoclonal antibody to a 60-kD glycoprotein in ovarian carcinoma.
Proton NMR examination of tumor cells of high or low metastatic potential.
Sialic acid and epithelial differentiation in colorectal polyps and cancer--a morphological, mucin and lectin histochemical study.
The loss of lectin reactivity from human endometrium is a feature of malignant change.
Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression.
Variation of leukocyte neuraminidase with Duke stage in patients with adenocarcinoma of the colon and rectum.
[Peanut lectin-binding sites in gastric carcinoma and the adjacent mucosa]
[Successful liver metastasis model with neuraminidase treated colon 26 adenocarcinoma via portal vein: preliminary report]
Adenocarcinoma of Lung
Mutations in the Neuraminidase-Like Protein of Bat Influenza H18N11 Virus Enhance Virus Replication in Mammalian Cells, Mice, and Ferrets.
Adenocarcinoma, Clear Cell
Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
Adenocarcinoma, Mucinous
[Histochemical characteristics of the mucus in pseudomyxoma peritonei]
Adenoma
Cellular localization of PNA binding in colorectal adenomas: comparison with differentiation, nuclear:cell height ratio and effect of desialylation.
Enhancement of carcinoembryonic antigen (CEA) expression in colorectal tumors by neuraminidase.
Human colorectal carcinoma-specific glycoconjugates detected by pokeweed mitogen lectin.
Lectin histochemistry as a predictor of dysplasia grade in colorectal adenomas.
Lectin-binding sites in human parathyroid tissue.
Sialic acid and epithelial differentiation in colorectal polyps and cancer--a morphological, mucin and lectin histochemical study.
Adenoma, Pleomorphic
[Lectin-histochemical analysis of pleomorphic adenoma of the lacrimal gland]
adenylate kinase deficiency
[Mucolipidosis: clinical and genetic aspects]
Adrenal Hyperplasia, Congenital
The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene.
Albuminuria
Protective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes.
Removal of heparan sulfate from the glomerular basement membrane blocks protein passage.
alpha-n-acetylglucosaminidase deficiency
The atomic model of the human protective protein/cathepsin A suggests a structural basis for galactosialidosis.
Alzheimer Disease
Diversity of sialidases found in the human body - A review.
Pharmacological activities and structure-modification of resveratrol analogues.
Amebiasis
A membrane-associated neuraminidase in Entamoeba histolytica trophozoites.
Characterization of sialidase from Entamoaeba hystolitica and possible pathogenic role in amebiasis.
Amyloidosis
On the influence of neuraminidase on casein-induced amyloidosis in C 3 H mice.
Anaphylaxis
Sialylation of immunoglobulin E is a determinant of allergic pathogenicity.
Anemia
A bloodstream Trypanosoma congolense sialidase could be involved in anemia during experimental trypanosomiasis.
Bacterial neuraminidase-mediated erythrocyte desialylation provokes cell surface aminophospholipid exposure.
Erythrocyte surface sialic acid in Ndama and Zebu cattle.
Erythrocyte surface sialic acid levels of clinically healthy mongrel and exotic (alsatian and terrier) breeds of dogs.
Neuraminidase-like activity in sera of uremic anemic patients.
Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.
Production, purification and crystallization of a trans-sialidase from Trypanosoma vivax.
Stigmasterol retards the proliferation and pathological features of Trypanosoma congolense infection in rats and inhibits trypanosomal sialidase in vitro and in silico.
The therapeutic potential of phytol towards Trypanosoma congolense infection and the inhibitory effects against trypanosomal sialidase.
Therapeutic targeting of liver cancer with a recombinant DNA vaccine containing the hemagglutinin-neuraminidase gene of Newcastle disease virus via apoptotic-dependent pathways.
Trypanostatic activity of geranylacetone: Mitigation of Trypanosoma congolense-associated pathological pertubations and insight into the mechanism of anaemia amelioration using in vitro and in silico models.
Trypanosuppresive effects of ellagic acid and amelioration of the trypanosome-associated pathological features coupled with inhibitory effects on trypanosomal sialidase in vitro and in silico.
Variation in erythrocyte surface and free serum sialic acid concentrations during experimental Trypanosoma vivax infection in cattle.
Anemia, Hemolytic
Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: treatment by exchange transfusion.
Monoclonal antibodies for the detection of desialylation of erythrocyte membranes during haemolytic disease and haemolytic uraemic syndrome caused by the in vivo action of microbial neuraminidase.
Presence of T-antigen on the vascular endothelium.
[Neuraminidase induced hemolytic anemia. Experimental and clinical observations (author's transl)]
Anemia, Hemolytic, Autoimmune
[Flow cytometry detection of erythrocyte antigens and antibodies. Technical aspects and new clinical applications]
Angiokeratoma
beta-Galactosidase and neuraminidase deficiency associated with angiokeratoma corporis diffusum.
Anthrax
Investigation of spore surface antigens in the genus Bacillus by the use of polyclonal antibodies in immunofluorescence tests.
Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
Arteriosclerosis
Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids.
Arteritis
Adhesion of Erysipelothrix rhusiopathiae to cultured rat aortic endothelial cells. Role of bacterial neuraminidase in the induction of arteritis.
An experimental model of arteritis: periarteritis induced by Erysipelothrix rhusiopathiae in young rats.
Experimental arteritis in young rats induced by Erysipelothrix rhusiopathiae.
Possible role of neuraminidase in the pathogenesis of arteritis and thrombocytopenia induced in rats by Erysipelothrix rhusiopathiae.
Arthritis
Neuraminidase Inhibitor Zanamivir Ameliorates Collagen-Induced Arthritis.
Arthritis, Experimental
Neuraminidase Inhibitor Zanamivir Ameliorates Collagen-Induced Arthritis.
The effect of orengedokuto on experimentally-inflamed rats.
Arthritis, Rheumatoid
?-2,3-Sialyltransferase 1 and neuraminidase-3 from monocytes in patients with rheumatoid arthritis correlate with disease activity measures: A pilot study.
Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study.
aspartoacylase deficiency
Coincident neuraminidase and aspartoacylase deficiency associated with chromosome 9Q paracentric inversion in a Saudi family.
Asthma
A crucial role of sialidase Neu1 in hyaluronan receptor function of CD44 in T helper type 2-mediated airway inflammation of murine acute asthmatic model.
Identification and characterization of acidic mammalian chitinase inhibitors.
The isoelectric focusing pattern of desialylated alpha 1-antichymotrypsin of heterozygous alpha 1-antichymotrypsin deficiency and of acute phase plasma.
Astrocytoma
Immunological differential diagnosis of human brain tumours.
Ataxia
Identification of a homozygous deletion of the NEU1 gene in a patient with type II sialidosis presenting isolated fetal ascites and central nervous system hypoplasia.
Lysosomal enzymes in ataxia: discovery of two new cases of late onset hexosaminidase A and B deficiency (adult Sandhoff disease) in French Canadians.
Atherosclerosis
Adverse Effects of Oseltamivir Phosphate Therapy on the Liver of LDLR-/- Mice Without Any Benefit on Atherosclerosis and Thrombosis.
Commentary: Comparison of the Protective Effects of Individual Components of Particulated trans-Sialidase (PTCTS), PTC and TS, against High Cholesterol Diet-Induced Atherosclerosis in Rabbits.
Comparison of the Protective Effects of Individual Components of Particulated trans-Sialidase (PTCTS), PTC and TS, against High Cholesterol Diet-Induced Atherosclerosis in Rabbits.
Diagnostics and Therapy of human diseases - Focus on sialidases.
Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein.
Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low-Density Lipoproteins and Increasing Their Uptake by Macrophages.
Overexpression of membrane sialic acid-specific sialidase Neu3 inhibits matrix metalloproteinase-9 expression in vascular smooth muscle cells.
Sialidase Activity in Human Blood Serum Has a Distinct Seasonal Pattern: A Pilot Study.
Sialidase down-regulation reduces non-HDL cholesterol, inhibits leukocyte transmigration, and attenuates atherosclerosis in ApoE knockout mice.
The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis.
Trans-sialidase Associated with Atherosclerosis: Defining the Identity of a Key Enzyme Involved in the Pathology.
Autoimmune Diseases
Comparative Biochemistry of GH3, GH20 and GH84 ?-N-acetyl-D-hexosaminidases and Recent Progress in Selective Inhibitor Discovery.
NEU1 is more abundant in uveitic retina with concomitant desialylation of retinal cells.
Avian Leukosis
Retroviral expressed hemagglutinin-neuraminidase protein protects chickens from Newcastle disease virus induced disease.
Bacteremia
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Bacterial Infections
Binding of bacteria to HEp-2 cells infected with influenza A virus.
CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway.
Chitinase 3-like-1 deficient donor splenocytes accentuated the pathogenesis of acute graft-versus-host diseases through regulating T cell expansion and type I inflammation.
Design, synthesis, and evaluation of curcumin analogues as potential inhibitors of bacterial sialidase.
Evaluation of microbial enzymes in normal and abnormal cervicovaginal fluids of cervical dysplasia: a case control study.
Factors associated with fatality due to avian influenza A(H7N9) infection in China.
Highly potent bacterial neuraminidase inhibitors, chromenone derivatives from Flemingia philippinensis.
Identification and evaluation of flavone-glucosides isolated from barley sprouts and their inhibitory activity against bacterial neuraminidase.
Modelling, synthesis and biological evaluation of novel glucuronide-based probes of Vibrio cholerae sialidase.
Respiratory viruses predisposing to bacterial infections: role of neuraminidase.
beta-galactosidase deficiency
A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine.
Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis.
Biochemical comparison of the dysmorphic type with the normosomatic type of sialidosis.
Carrier detection of sialidosis with partial beta-galactosidase deficiency by the assay of lysosomal sialidase in lymphocytes.
Combined sialidase (neuraminidase) and beta-galactosidase deficiency. Clinical, morphological and enzymological observations in a patient.
Homologous modeling of the lysosomal protective protein/carboxypeptidase L: structural and functional implications of mutations identified in galactosialidosis patients.
Immunoelectron microscopical localization of lysosomal beta-galactosidase and its precursor forms in normal and mutant human fibroblasts.
Km defect in neuraminidase of dysmorphic type sialidosis with and without beta-galactosidase deficiency.
Lysosomal sialidase deficiency in sialidosis with partial beta-galactosidase deficiency.
Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies.
Mucolipidosis I: studies of sialidase activity and a prenatal diagnosis.
Neuraminidase deficiency and accumulation of sialic acid in lymphocytes in adult type sialidosis with partial beta-galactosidase deficiency.
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Partial characterization and studies of fibroblast and leucocyte neuraminidase activities towards sialyloligosaccharides in adult sialidosis and mucolipidosis II and III.
Prenatal diagnosis of sialidosis with combined neuraminidase and beta-galactosidase deficiency.
beta-galactoside alpha-2,3-sialyltransferase deficiency
Sialyltransferase specificity in selectin ligand formation.
Blindness
Altered expression of ?-galactosidase-1-like protein 3 (Glb1l3) in the retinal pigment epithelium (RPE)-specific 65-kDa protein knock-out mouse model of Leber's congenital amaurosis.
Blister
Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes.
Rounding and steroidogenesis of enzyme- and ACTH-treated Y-l mouse adrenal tumor cells.
Brain Abscess
Production of specific glycosidase activities by Streptococcus intermedius strain UNS35 grown in the presence of mucin.
Brain Diseases
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Salla disease variants. Sialoylaciduric encephalopathy with increased sialidase activity in two non-Finnish children.
Brain Neoplasms
Cell surface glycoproteins of human tumor cell lines: unusual characteristics of malignant melanoma.
Breast Neoplasms
Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.
Biochemical and immunochemical analysis of a breast carcinoma associated antigen defined by the monoclonal antibody NCRC-11.
Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin--comparison of antigen MUSE11 with CA15-3.
Correlation between low neuraminidase blood levels and a predisposition toward family-related breast cancer.
Enzymically-modified human mammary carcinoma cells: modulators of macrophage functions.
Epitope analysis of monoclonal antibody NCRC-11 defined antigen isolated from human ovarian and breast carcinomas.
Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA.
Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines.
Isoenzyme-Selective Inhibitors of Human Neuraminidases Reveal Distinct Effects on Cell Migration.
Macrophage-mediated tumor cytotoxicity: role of macrophage surface sialic acid.
MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 ?1,6-N-acetylglucosaminyltransferase and ?-galactoside ?2,3-sialyltransferase.
Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody.
Overexpression of ?2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis.
Pulsed Low-Frequency Magnetic Fields Induce Tumor Membrane Disruption and Altered Cell Viability.
Tissue and serum sialidase levels in breast cancer.
Bronchial Spasm
Neuraminidase inhibitors for preventing and treating influenza in children.
Bronchitis
Antiviral Medications in Seasonal and Pandemic Influenza.
Detection and differentiation of four poultry diseases using asymmetric reverse transcription polymerase chain reaction in combination with oligonucleotide microarrays.
Neuraminidase treatment of avian infectious bronchitis coronavirus reveals a hemagglutinating activity that is dependent on sialic acid-containing receptors on erythrocytes.
Recombinant infectious bronchitis virus (IBV) H120 vaccine strain expressing the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) protects chickens against IBV and NDV challenge.
Burkitt Lymphoma
Glycosidases from the interferon producing lymphoid cell line Namalva and from three other lymphoid cell lines.
Canavan Disease
Coincident neuraminidase and aspartoacylase deficiency associated with chromosome 9Q paracentric inversion in a Saudi family.
Candidiasis
Immunoglobulin A response against Gardnerella vaginalis hemolysin and sialidase activity in bacterial vaginosis.
Carcinogenesis
Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Detection of hepatitis B virus DNA in hepatocellular carcinoma: analysis by hybridization with subgenomic DNA fragments.
Down-regulation of sialidase NEU4 may contribute to invasive properties of human colon cancers.
Monoclonal antibodies recognizing normal and retrovirus-transformed chicken hematopoietic cells.
Multiple forms of mammalian sialidase: altered expression in carcinogenesis.
NEU3 sialidase protein interactors in the plasma membrane and in the endosomes.
Neuraminidase-1: A novel therapeutic target in multistage tumorigenesis.
Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells.
Oseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic cancer cell survival.
Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cells.
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.
Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase.
Regulation of plasma-membrane-associated sialidase NEU3 gene by Sp1/Sp3 transcription factors.
Sialidase and malignancy: a minireview.
Sialidase significance for cancer progression.
[Action of Vibrio cholera neuraminidase on chemically induced carcinogenesis]
[Use of the enzyme neuraminidase for immunotherapeutic treatment of chemically induced carcinogenesis]
Carcinoid Tumor
Peanut lectin: a histochemical marker for phaeochromocytomas.
Carcinoma
Alkaline phosphatase isoenzyme of colonic carcinoma in Wistar-Furth rats.
Alkaline phosphatase isoenzymes in intestinal metaplasia and carcinoma of rat stomach induced by N-methyl-N'-nitro-N-nitrosoguanidine.
Analysis of carbohydrate composition and sialidase activity in oral secretions of patients with tumors in the upper aerodigestive tract.
Analysis of MUC4 mucin expression in lung carcinoma cells and its immunogenicity.
Bauhinia purpurea (BPA) binding to normal and neoplastic thyroid glands.
Blood group ABH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas.
CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas.
Cellular site of synthesis and dynamics of cell surface re-expression of polysialic acid of the neural cell adhesion molecule.
Characterization of a colon carcinoma cell line for tumor immunotherapy.
Characterization of variant gamma-glutamyl transpeptidase produced by pancreatocholangiocarcinoma cell lines in a protein-free, chemically defined medium.
Colonic oligosaccharide structures deduced from lectin-binding studies before and after desialylation.
Combination chemoimmunotherapy for advanced gastric carcinoma.
Correlation between glycoconjugate expression and fucosyltransferase activity in human colorectal carcinoma.
Difference of hyaluronidase produced by human tumor cell lines with hyaluronidase present in human serum as revealed by zymography.
Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas.
Differential expression of alpha2,6-sialyltransferase in colon tumors recognized by a monoclonal antibody.
Effect of neuraminidase on electrophoretic mobility and immune cytolysis of human uterine cervix carcinoma cells.
Effectiveness of neuraminidase in experimental immunotherapy of two murine pulmonary carcinomas.
Enzymatic modulation of the cell surface in malignant transformation of normal human mammary epithelial cells and in conversion of mammary carcinoma cells.
Enzymically-modified human mammary carcinoma cells: modulators of macrophage functions.
Experimental cancer immunotherapy: modification of tumor cells to increase immunogenicity.
Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.
Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines.
Histochemical and morphologic studies of mucosa bordering rectosigmoid carcinomas: comparisons with normal, diseased, and malignant colonic epithelium.
Human colorectal carcinoma-specific glycoconjugates detected by pokeweed mitogen lectin.
Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen.
Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma.
Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Isolation and partial characterization of surface components of cell line MDA-MB-231 derived from a human metastatic breast carcinoma.
Lectin histochemistry of normal and neoplastic nasopharyngeal epithelium.
Lymphocyte blastogenic response to autologous tumor cells pretreated with neuraminidase in patients with gastric carcinoma.
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium.
Mucoid carcinomas of the breast: a study using mucin histochemistry and peanut lectin.
Neuraminidase 1 regulates proliferation, apoptosis and the expression of Cadherins in mammary carcinoma cells.
Neuraminidase of Influenza A Virus Binds Lysosome-Associated Membrane Proteins Directly and Induces Lysosome Rupture.
p37 Induces tumor invasiveness.
Phytomitogen and neuraminidase in the treatment of Ehrlich carcinoma in mice.
Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility.
Properties of the amylase produced in carcinoma of the lung.
Regression of spontaneous mammary carcinomas using direct injections of neuraminidase and BCG.
Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines.
The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling ?1 integrin internalization and recycling.
The receptor and transporter for internalization of Clostridium botulinum type C progenitor toxin into HT-29 cells.
The Thomsen-Friedenreich antigen on human urothelial cell lines detectable by peanut lectin and monoclonal antibody raised against human glycophorin A.
The Trypanosoma cruzi trans-sialidase, through its COOH-terminal tandem repeat, upregulates interleukin 6 secretion in normal human intestinal microvascular endothelial cells and peripheral blood mononuclear cells.
Thomsen-Friedenreich-related antigen in human endometrium. An immunohistochemical study employing the monoclonal antibody 49H.8. A preliminary report.
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Utility of peanut agglutinin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma.
[Establishment of a method to detect multiple antennae carcinoembryonic antigen (MA-CEA) and MA-CEA level in the sera of patients with malignant tumors]
[Expression of human membrane associated sialidase gene in prostate carcinoma PC-3 cell line].
[Immunohistochemical studies of bronchial carcinoma using monoclonal antibody A63-C/A3]
[Lectin histochemistry in the kidney and renal tumors]
Carcinoma, Bronchogenic
[Immunohistochemical studies of bronchial carcinoma using monoclonal antibody A63-C/A3]
Carcinoma, Ehrlich Tumor
Curcumin's effects on sialic acid level and sialidase activity in Ehrlich ascites tumor bearing mice.
On the lysosomal occurrence and the properties of the neuraminidase of rat liver and of Ehrlich ascites tumor cells.
[Action of x-rays and neuraminidase on pinocytotic activity and microtubule-microfilament system of Ehrlich ascites tumor cells in monolayer culture (author's transl)]
[Effect of neuraminidase and x-rays (2 Gy and 8 Gy) on microvilli and membrane invaginations of Ehrlich ascites tumor cells in monolayer culture]
Carcinoma, Hepatocellular
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
Alpha-fetoprotein antibody-lectin enzyme immunoassay to characterize sugar chains for the study of liver diseases.
Biased G protein-coupled receptor agonism mediates Neu1 sialidase and matrix metalloproteinase-9 crosstalk to induce transactivation of insulin receptor signaling.
Characterization of hepatitis B virus major surface antigen gene transcriptional regulatory elements in differentiated hepatoma cell lines.
Complex regulation of transcription from the hepatitis B virus major surface antigen promoter in human hepatoma cell lines.
Effect of neuraminidase and papain treatment on lectin-induced agglutination of Novikoff tumor cells and assay of lectin receptor activity of the glycopeptides released from the cell surface by papain.
Glycosyltransferases and glycosidases in Morris hepatomas.
Hepatitis B virus core protein promotes the expression of neuraminidase 1 to facilitate hepatocarcinogenesis.
Increased binding and killing of neuraminidase-galactose oxidase-treated tumor cells by normal macrophages.
Killing Effects of IFN R-/- Mouse NK Cells Activated by HN Protein of NDV on Mouse Hepatoma Cells and Possible Mechanism with Syk and NF-?B.
Localization of membrane glycoproteins by in situ neuraminidase treatment of rat hepatoma tissue culture cells and two-dimensional gel electrophoretic analysis of the modified proteins.
Membrane-associated sialidase of rat liver and its decrease in hepatomas.
Modulation of expression of the hepatitis B virus surface antigen gene by the viral X-gene product.
Multiple forms of mammalian sialidase: altered expression in carcinogenesis.
Neoplastic alteration of a membrane-associated sialidase of rat liver.
Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma.
Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor.
RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer.
Sialidase of rat hepatomas: qualitative and quantitative comparison with rat liver sialidase.
Targeting of loaded Sendai virus envelopes by covalently attached insulin molecules to virus receptor-depleted cells: fusion-mediated microinjection of ricin A and simian virus 40 DNA.
Unique structural properties of apolipoprotein B in low-density lipoproteins produced by several human hepatoma-derived cell lines.
[On the activity of neuraminic acid aldolase and neuraminidase in the cells of ascite and solid forms of hepatoma 22 in mice]
[STUDIES ON NEURAMINIC ACID DERIVATIVES SEPARABLE WITH NEURAMINIDASE FROM SURFACE MEMBRANES OF NORMAL LIVER CELLS AND ASCITES HEPATOMA CELLS IN RATS.]
Carcinoma, Non-Small-Cell Lung
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.
Carcinoma, Papillary
[Blood group antigen expression in papillary carcinoma of the thyroid gland. An immunohistochemical and clinical study of expression of Lewis, ABO and related antigens]
Carcinoma, Renal Cell
A novel gamma-glutamyl transpeptidase in renal carcinoma in comparison with normal kidney enzyme.
Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility.
The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling ?1 integrin internalization and recycling.
[Lectin histochemistry in the kidney and renal tumors]
Carcinoma, Squamous Cell
Epidermal growth factor-induced mobilization of a ganglioside-specific sialidase (NEU3) to membrane ruffles.
Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Role of sialoglycan structures for the function of the epidermal growth factor receptor and the in vitro proliferation of head and neck cancer.
Sialidase gene transfection enhances epidermal growth factor receptor activity in an epidermoid carcinoma cell line, A431.
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Utility of peanut agglutinin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma.
Cardiomegaly
Neuraminidase 1 is a driver of experimental cardiac hypertrophy.
Cardiomyopathy, Hypertrophic
Neuraminidase 1 is a driver of experimental cardiac hypertrophy.
Cardiovascular Diseases
Neuraminidase 1 and its Inhibitors from Chinese Herbal Medicines: An Emerging Role for Cardiovascular Diseases.
Cataract
Kidney sialidase and sialyltransferase activities in spontaneously and experimentally diabetic rats. Influence of insulin and sorbinil treatments.
Cerebellar Ataxia
Adult type GMl-gangliosidosis: a complementation study on somatic cell hybrids.
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Cerebrovascular Disorders
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Cervical Intraepithelial Neoplasia
[Interaction between vaginal micro-environment alterations and HPV16 infection in cervical intraepithelial neoplasia].
Chagas Disease
A functional network of intramolecular cross-reacting epitopes delays the elicitation of neutralizing antibodies to Trypanosoma cruzi trans-sialidase.
A new class of mechanism-based inhibitors for Trypanosoma cruzi trans-sialidase and their influence on parasite virulence.
A proteolytic fragment of Trypanosoma cruzi trans-sialidase lacking the carboxyl-terminal domain is active, monomeric, and generates antibodies that inhibit enzymatic activity.
A sialidase mutant displaying trans-sialidase activity.
A trypanosomal protein synergizes with the cytokines ciliary neurotrophic factor and leukemia inhibitory factor to prevent apoptosis of neuronal cells.
An influenza virus model for Trypanosoma cruzi infection: interactive roles for neuraminidase and lectin.
Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections.
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.
Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase.
Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.
Costimulation of host T lymphocytes by a trypanosomal trans-sialidase: involvement of CD43 signaling.
Design of e-pharmacophore models using compound fragments for the trans-sialidase of Trypanosoma cruzi: Screening for novel inhibitor scaffolds.
Development and assessment of a new cage-like particle adjuvant.
Diagnostic Applicability of Neutralizing Antibodies to Trypanosoma cruzi Trans-sialidase.
Discovery of novel inhibitors of Trypanosoma cruzitrans-sialidase from in silico screening.
Effect of primary structure modifications in Trypanosoma cruzi neuraminidase/trans-sialidase activities.
Effect of the Tc13Tul antigen from Trypanosoma cruzi on splenocytes from naïve mice.
Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Endothelial cell signalling induced by trans-sialidase from Trypanosoma cruzi.
Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.
Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.
Evidence of ternary complex formation in Trypanosoma cruzi trans-sialidase catalysis.
Free energy study of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. From the Michaelis complex to the covalent intermediate.
Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype.
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.
Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence.
HLA Class I-T Cell Epitopes from trans-Sialidase Proteins Reveal Functionally Distinct Subsets of CD8 T Cells in Chronic Chagas Disease.
Identification and characterization of a sialidase released by the salivary gland of the hematophagous insect Triatoma infestans.
Identification of glycoproteins targeted by Trypanosoma cruzi trans-sialidase, a virulence factor that disturbs lymphocyte glycosylation.
Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice.
Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
Immunological and pathological responses in BALB/c mice induced by genetic administration of Tc 13 Tul antigen of Trypanosoma cruzi.
Invasive phenotype of Trypanosoma cruzi restricted to a population expressing trans-sialidase.
Long-lasting antibodies detected by a trans-sialidase inhibition assay of sera from parasite-free, serologically cured chagasic patients.
Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.
Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase.
Machine Learning Techniques for the Automated Classification of Adhesin-Like Proteins in the Human Protozoan Parasite Trypanosoma cruzi.
Medium scale production and purification to homogeneity of a recombinant trans-sialidase from Trypanosoma cruzi.
Metabolic Labeling of Surface Neo-sialylglyconjugates Catalyzed by Trypanosoma cruzi trans-Sialidase.
Modulation of catalytic function by differential plasticity of the active site: case study of Trypanosoma cruzi trans-sialidase and Trypanosoma rangeli Sialidase.
Parasite-host glycan interactions during Trypanosoma cruzi infection: trans-Sialidase rides the show.
Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease.
Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.
Probing molecular function of trypanosomal sialidases: single point mutations can change substrate specificity and increase hydrolytic activity.
Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.
Proton transfer facilitated by ligand binding. An energetic analysis of the catalytic mechanism of Trypanosoma cruzi trans-sialidase.
Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease.
Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi.
Serum neuraminidase activity and hematological alterations in acute human Chagas' disease.
Sialic acid C-glycosides with aromatic residues: Investigating enzyme binding and inhibition of Trypanosoma cruzi trans-sialidase.
Sialic acid removal by trans-sialidase modulates MMP-2 activity during Trypanosoma cruzi infection.
Sialic acid: a sweet swing between mammalian host and Trypanosoma cruzi.
Structural basis of sialyltransferase activity in trypanosomal sialidases.
Synthesis of a model trisaccharide for studying the interplay between the anti ?-Gal antibody and the trans-sialidase reactions in Trypanosoma cruzi.
Synthesis of PEGylated lactose analogs for inhibition studies on T.cruzi trans-sialidase.
T rypanosoma cruzi trans-sialidase as a multifunctional enzyme in Chagas' disease.
Temperature differences for trans-glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of Trypanosoma cruzi trans-sialidase.
The role of natural selection in shaping genetic variation in a promising Chagas disease drug target: Trypanosoma cruzi trans-sialidase.
The synthesis and kinetic evaluation of aryl ?-aminophosphonates as novel inhibitors of T. cruzi trans-sialidase.
The trans-sialidase from Trypanosoma cruzi efficiently transfers alpha-(2-->3)-linked N-glycolylneuraminic acid to terminal beta-galactosyl units.
The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents.
Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection.
trans-Sialidase from Trypanosoma cruzi binds host T-lymphocytes in a lectin manner.
Trans-sialidase from Trypanosoma cruzi induces apoptosis in cells from the immune system in vivo.
Trans-sialidase inhibition assay detects Trypanosoma cruzi infection in different wild mammal species.
Trans-sialidase inhibition assay for the detection of Trypanosoma cruzi infection in blood donor samples from Argentina.
trans-sialidase inhibition assay, a highly sensitive and specific diagnostic test for Chagas' disease.
Trypanosoma cruzi trans-sialidase and cell invasion.
Trypanosoma cruzi trans-sialidase as a drug target against Chagas disease (American trypanosomiasis).
Trypanosoma cruzi trans-sialidase inhibits human lymphocyte proliferation by nonapoptotic mechanisms: implications in pathogenesis and transplant immunology.
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Trypanosoma cruzi Virulence Factors for the Diagnosis of Chagas' Disease.
Trypanosoma cruzi: the effect of nitric oxide synthesis inhibition on the CD4 T cell response to the trans-sialidase superfamily.
Tryptophan as a molecular shovel in the glycosyl transfer activity of Trypanosoma cruzi trans-sialidase.
Use of trans-Sialidase inhibition assay in a population serologically negative for Trypanosoma cruzi but at a high risk of infection.
Virulence in Trypanosoma cruzi infection correlates with the expression of a distinct family of sialidase superfamily genes.
Chickenpox
Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine.
Chlamydia Infections
Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia.
Cholera
A rapid and sensitive assay for neuraminidase using peanut lectin hemagglutination: application to Vibrio cholera and Trypanosoma cruzi.
A sialidase-susceptible ganglioside, IV3 alpha(NeuGc alpha 2-8NeuGc)-Gg4Cer, is a major disialoganglioside in WHT/Ht mouse thymoma and thymocytes.
Action of alpha-galactosidase from Clostridium sporogenes and coffee beans on blood group B antigen of erythrocytes. The effect on the viability of erythrocytes in circulation.
Alteration of glycolipids in ras-transfected NIH 3T3 cells.
An activation-associated ganglioside in rat thymocytes.
Characterization of ganglioside associated with the thyrotrophin receptor.
Characterization of Vibrio cholerae neuraminidase by a novel mechanism-based fluorescent labeling reagent.
Chemical and histochemical studies of normal and diseased human gastrointestinal tract. I. A comparison between histologically normal colon, colonic tumours, ulcerative colitis and diverticular disease of the colon.
Cloning and characterization of sialidases with 2-6' and 2-3' sialyl lactose specificity from Pasteurella multocida.
Coexpression of lactosyl and gangliotetraosyl gangliosides in rat cerebellar radial glial cells in culture.
Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer.
Correlation between macrophages and their membrane fraction. Cytocidal activities on neoplastic cells.
Correlation between plasminogen activator activity of immunizing tumor cells and complement-mediated cytotoxic antibodies secreted by cloned hybrid cells.
Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Crystal structure of Vibrio cholerae neuraminidase reveals dual lectin-like domains in addition to the catalytic domain.
Dependence of cardiac cell Ca2+ permeability on sialic acid-containing sarcolemmal gangliosides.
Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase.
Dermatonecrotic lesions in rabbits caused by neuraminidase.
Desialylation of extracellular GD1a-neoganglioprotein suggests cell surface orientation of the plasma membrane-bound ganglioside sialidase activity in human neuroblastoma cells.
Determination of gangliosides and sulfatide in human cerebrospinal fluid with a microimmunoaffinity technique.
Differential expression of gangliosides on the surfaces of myelinated nerve fibers.
Effects of cell surface receptor-altering agents on the binding and biological activity of 12-O-tetradecanoylphorbol-13-acetate in isolated epidermal cells.
Endogenous GM1 ganglioside of the plasma membrane promotes neuritogenesis by two mechanisms.
Enzymically-mediated changes in murine mammary adenocarcinoma cell membrane induces changes in lymphoid tissue immune ribonucleic acids.
Enzymically-modified human mammary carcinoma cells: modulators of macrophage functions.
Evidence for mucins and sialic acid as receptors for Pseudomonas aeruginosa in the lower respiratory tract.
Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
Expression of gangliosides as receptors at the cell surface controls infection of NCTC 2071 cells by Sendai virus.
Expression of gangliosides in neuronal development of P19 embryonal carcinoma stem cells.
Fer de Lance virus (FDLV): a probable paramyxovirus isolated from a reptile.
Fibrillar organization of fibronectin is expressed coordinately with cell surface gangliosides in a variant murine fibroblast.
Further studies on the gangliosidic nature of the cholinergic-specific antigen, Chol-1.
Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture.
Ganglioside localization on myelinated nerve fibres by cholera toxin binding.
Gangliosides and sulphatide in human cerebrospinal fluid: quantitation with immunoaffinity techniques.
Gangliosides modulate sodium transport in cultured toad kidney epithelia.
Glycosylation Characterization of an Influenza H5N7 Hemagglutinin Series with Engineered Glycosylation Patterns: Implications for Structure-Function Relationships.
Hepatic and pancreatic glycosphingolipid phenotypes of the neurological different rat strains.
Heterogeneity in the specificity of the islet cell cytoplasmic antibody response in insulin-dependent diabetes mellitus.
Immunofluorescent studies on antibodies directed to a buried membrane structure present in lymphocytes and erythrocytes.
In vivo and in vitro expression of gangliosides in chick retina Müeller cells.
Induction of axon-like and dendrite-like processes in neuroblastoma cells.
Inhibition of neurite outgrowth of neuroblastoma Neuro-2a cells by cholera toxin B-subunit and anti-GM1 antibody.
Interaction of cholera toxin and ganglioside G(M1).
Interaction of ganglioside GM1 with the B subunit of cholera toxin modulates growth and differentiation of neuroblastoma N18 cells.
Intestinal epithelium brush border and microsome chemistry. II. Cholera exoenterotoxin and neuramindase effects.
Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Isolation and structural characterization of N-acetyl- and N-glycolylneuraminic-acid-containing GalNAc-GD1a isomers, IV4GalNAcIV3Neu5AcII3Neu5GcGgOse4Cer and IV4GalNAcIV3Neu5GcII3Neu5AcGgOse4Cer, from bovine brain.
Micro-necrotic foci in regression of a murine calvarium transplantable tumor. 2. Enzymatic modification of the transformed calvarium cell immunological characteristics.
Micro-necrotic foci in regression of a murine calvarium transplantable tumor. 3. Histological characteristics of the micro-necrotic foci.
Neuraminidase treatment of adrenal cells increases their response to cholera enterotoxin.
Occurrence of gangliosides in the common squid and pacific octopus among protostomia.
Pandemics, pathogenicity and changing molecular epidemiology of cholera in the era of global warming.
Peroxidase-amplified assay of sialidase activity toward gangliosides.
Plasma and Mucosal Immunoglobulin M, Immunoglobulin A, and Immunoglobulin G Responses to the Vibrio cholerae O1 Protein Immunome in Adults With Cholera in Bangladesh.
Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies.
Preparation of fixed antigenic, non-oncogenic and protective neoplastic cells.
Purification and renaturation of membrane neuraminidase from Haemophilus parasuis.
Quantification of gangliotetraose gangliosides with cholera toxin.
Reevaluation of the role of gangliosides in the binding and action of thyrotropin.
Regeneration of membrane sialic acid after neuraminidase treatment of leukemic granulocytes.
Removal of O-acetylated sialic acids from rat colonic epithelial glycoproteins by cell-free extracts of rat faeces.
Role of Vibrio cholerae neuraminidase in the function of cholera toxin.
Saturation transfer difference (STD) 1H-NMR experiments and in silico docking experiments to probe the binding of N-acetylneuraminic acid and derivatives to Vibrio cholerae sialidase.
Serum sialic acid levels in Vibrio cholera serotype Hikojima infected Nigerian patients.
Sialic acid in mature megakaryocytes: detection by wheat germ agglutinin.
Sialic acid recognition by Vibrio cholerae neuraminidase.
Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells.
Structural analysis and functional role of the carbohydrate component of somatostatin receptors.
Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.
Study of the activation mechanism of adriamycin on rat mast cells.
Surface distribution of monosialoganglioside GM1 on human blood cells and the effect of exogenous GM1 and neuraminidase on cholera toxin surface labeling. A quantitative immunocytochemical study.
Terminal glycosylation of bovine uroplakin III, one of the major integral-membrane glycoproteins of mammalian bladder.
Three pathogenicity islands of Vibrio cholerae can excise from the chromosome and form circular intermediates.
Unmasking of actual and potential receptor sites for cholera toxin in intestinal mucosal homogenates.
Upregulation of nuclear GM1 accompanies axon-like, but not dendrite-like, outgrowth in NG108-15 cells.
Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.
[A comparison of biological and chemical methods of determining fecal neuraminidase in cholera studies]
[Action of Vibrio cholera neuraminidase on chemically induced carcinogenesis]
[Analysis of toxin genetic determinants of Vibrio cholerae virulence cassette and neuraminidase with DNA probes]
[Biochemical and immunochemical characteristics of a new oral, chemical cholera bivalent vaccine and results of a trial of the preparation on volunteers]
[Cholera vibrios lectins as main pathogenicity and persistence factors (biotechnological aspects of use)].
[Choleragen and neuraminidase production by Vibrio in vitro]
[Inhibiting effect of cholera vibrio neuraminidase in Rauscher mouse leukemia]
[Inhibitory effect of combined administration of neuraminidase and interferon in mice with Rauscher leukemia]
[Isolation and properties of cholera vibrio neuraminidase]
[Localization and activity of the neuraminidase in cholera vibrios]
[Macrophages and erythrocytes]
[On the effect of cholera neuraminidase in comparison with other neuraminic acid splitting enzymes of plant and animal origin on a few physico-chemical properties of human erythrocytes]
[Reduction of the biological activity of Vibrio cholerae culture filtrates exposed to neuraminidase inhibitors]
[Role of enterotoxin and neuraminidase in the biological activity of E1 Tor vibrios]
[Role of neuraminidase from cholera vibrions in the pathogenesis of experimental cholera]
[Role of neuraminidase in the pathogenicity of Vibrio cholera 01 and Vibrio cholerae not 01]
[Serological study of the neuraminidase activity of cholera filtrate and influenza virus]
[Synthesis of protective antigens during submerged cultivation of Vibrio cholerae]
[Use of the aggregate hemagglutination method for determining cholera vibrio neuraminidase]
Chordoma
Lectin histochemistry of human fetal notochord, ecchordosis physaliphora, and chordomas.
Choriocarcinoma
Lectin binding in tissues from hydatidiform mole, invasive mole and choriocarcinoma to concanavalin-A, wheat germ agglutinin and peanut agglutinin.
Chromoblastomycosis
Exploring the genomic diversity of black yeasts and relatives (Chaetothyriales, Ascomycota).
Clostridium Infections
The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation.
Coinfection
Competitive Fitness of Influenza B Viruses with Neuraminidase Inhibitor-Resistant Substitutions in a Co-infection Model of the Human Airway Epithelium.
Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus.
Expression of cDNA encoding the Sendai virus hemagglutinin-neuraminidase gene: characterization of wild-type and mutant gene products.
Gardnerella vaginalis and Prevotella bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis.
H1N1 influenza A virus neuraminidase modulates infectivity in mice.
Influenza A Viruses from Overwintering and Spring-Migrating Waterfowl in the Lake Erie Basin, United States.
Influenza and Community-acquired Pneumonia Interactions: The Impact of Order and Time of Infection on Population Patterns.
Influenza viral neuraminidase primes bacterial coinfection through TGF-?-mediated expression of host cell receptors.
Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Modulation of vaginal immune response among pregnant women with bacterial vaginosis by Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and yeast.
Mutations to A/Puerto Rico/8/34 PB1 gene improves seasonal reassortant influenza A virus growth kinetics.
Pneumococcal Neuraminidase A (NanA) Promotes Biofilm Formation and Synergizes with Influenza A Virus in Nasal Colonization and Middle Ear Infection.
Simultaneous Differentiation of the N1 to N9 Neuraminidase Subtypes of Avian Influenza Virus by a GeXP Analyzer-Based Multiplex Reverse Transcription PCR Assay.
The public health policy implications of understanding metabiosis.
The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia.
Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia.
Use of hemagglutinin and neuraminidase amplicon-based high-throughput sequencing with variant analysis to detect co-infection and resolve identical consensus sequences of seasonal influenza in a university setting.
Colitis
Neu3 neuraminidase induction triggers intestinal inflammation and colitis in a model of recurrent human food-poisoning.
Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in mice.
Survey of neuraminidase production by Clostridium butyricum, Clostridium beijerinckii, and Clostridium difficile strains from clinical and nonclinical sources.
[Acute hemorrhagic colitis induced by the neuraminidase inhibitor oseltamivir]
Colitis, Ulcerative
Histochemical demonstration of desialation and desulphation of normal and inflammatory bowel disease rectal mucus by faecal extracts.
The roles of enteric bacterial sialidase, sialate O-acetyl esterase and glycosulfatase in the degradation of human colonic mucin.
Colonic Neoplasms
Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4.
Detection of 4-O-acetyl-N-glycolylneuraminyl lactosylceramide as one of tumor-associated antigens in human colon cancer tissues by specific antibody.
Down-regulation of sialidase NEU4 may contribute to invasive properties of human colon cancers.
Imaging of Sialidase Activity and Its Clinical Application.
Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice.
Plasma-membrane-associated sialidase (NEU3) differentially regulates integrin-mediated cell proliferation through laminin- and fibronectin-derived signalling.
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.
Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4.
Sialidase NEU3 contributes neoplastic potential on colon cancer cells as a key modulator of gangliosides by regulating Wnt signaling.
Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression.
Colorectal Neoplasms
Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients.
Enhancement of carcinoembryonic antigen (CEA) expression in colorectal tumors by neuraminidase.
Human colorectal carcinoma-specific glycoconjugates detected by pokeweed mitogen lectin.
NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels.
Communicable Diseases
A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations.
Approved Antiviral Drugs over the Past 50 Years.
Bakkenolides and Caffeoylquinic Acids from the Aerial Portion of Petasites japonicus and Their Bacterial Neuraminidase Inhibition Ability.
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Genotyping of a nosocomial outbreak of pandemic influenza A/H1N1 2009.
Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies.
Prenylated pterocarpans as bacterial neuraminidase inhibitors.
Proposition of real-time precise prediction model of infectious disease patients from Prescription Surveillance using the National Database of Electronic Medical Claims.
Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.
Communicable Diseases, Emerging
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Congenital Abnormalities
A case of neuraminidase deficiency associated with a partial beta-galactosidase defect. Clinical, biochemical and radiological studies.
Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
High-resolution capillary zone electrophoresis and mass spectrometry for distinction of undersialylated and hypoglycosylated transferrin glycoforms in body fluids.
Conjunctivitis
Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection.
Characterisation of an avian influenza A virus isolated from a human--is an intermediate host necessary for the emergence of pandemic influenza viruses?
Effect of polycations, polyanions and neuraminidase on the infectivity of trachoma-inclusin conjunctivitis and lymphogranuloma venereum organisms HeLa cells: sialic acid residues as possible receptors for trachoma-inclusion conjunction.
Contracture
Changes in contractility and calcium binding of guinea pig taenia coli by treatment with enzymes which hydrolyze sialic acid.
Dependence of cardiac cell Ca2+ permeability on sialic acid-containing sarcolemmal gangliosides.
Coronary Artery Disease
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low-Density Lipoproteins and Increasing Their Uptake by Macrophages.
Coronary Disease
Carbohydrate-deficient transferrin and sialidase levels in coronary heart disease.
The relationship between the electrophoretic mobility of lipoproteins and coronary heart disease.
Coronavirus Infections
Role of proteases in the release of porcine epidemic diarrhea virus from infected cells.
COVID-19
A global treatments for coronaviruses including COVID-19.
COVID 19 SCIENTIFIC PUBLICATIONS FROM TURKEY.
Echoes of 2009 H1N1 Influenza Pandemic in the COVID Pandemic.
Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review.
Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19.
Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181.
Crohn Disease
Chemical and histochemical studies of normal and diseased human gastrointestinal tract. II. A comparison between histologically normal small intestine and Crohn's disease of the small intestine.
Elevated liver isoenzymes of alkaline phosphatase and disease activity in patients with Crohn's disease.
Histochemical comparison of the epithelial mucins in the ileum in Crohn's disease and in normal controls.
Histochemical demonstration of desialation and desulphation of normal and inflammatory bowel disease rectal mucus by faecal extracts.
Cross Infection
[Control of hospital infection of influenza: administration of neuraminidase inhibitor and cohort isolation of influenza patients]
Cryptorchidism
The oligosaccharidic content of the glycoconjugates of the prepubertal descended and undescended testis: lectin histochemical study.
Cystic Fibrosis
Cobalamin R binder as a possible model molecule for glycoprotein study in cystic fibrosis.
Extracellular neuraminidase production by a strain of Pseudomonas aeruginosa isolated from cystic fibrosis.
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.
Pseudomonas aeruginosa and cystic fibrosis: correlation between exoenzyme production and patient's clinical state.
Reduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition.
Susceptibility to neuraminidase of alpha-L-fucosidase and N-acetyl-beta-D-glucosaminidase of cystic fibrosis, I-cell and neuraminidase-deficient fibroblasts.
Cysts
Identification and Characterization of the Most Abundant Cellulases in Stylet Secretions from Globodera rostochiensis
Identification and characterization of the most abundant cellulases in stylet secretions from Globodera rostochiensis.
Neuraminidase activity in acanthamoeba species trophozoites and cysts.
Cytomegalovirus Infections
Approved Antiviral Drugs over the Past 50 Years.
Deafness
A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs.
Deficiency Diseases
Human beta-galactosidase and alpha-neuraminidase deficient mucolipidosis: genetic complementation analysis of the neuraminidase deficiency.
Mucolipidosis I: studies of sialidase activity and a prenatal diagnosis.
Dehydration
Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.
Delirium
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Dementia
Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies.
Sialidase (alpha-n-acetyl neuraminidase) deficiency: the enzyme defect in an adult with macular cherry-red spots and myoclonus without dementia.
Dengue
Carbosilane glycodendrimers.
Desialylation of platelets induced by Von Willebrand Factor is a novel mechanism of platelet clearance in dengue.
Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection.
Surface charge of dengue virus hemagglutinins prepared from infected mouse brains.
Dental Caries
[The determination of sialidase activity in the blood serum and saliva]
Dental Plaque
Neuraminidase activity in human dental plaque fluid.
Occurrence of haemophili in dental plaque and their association with neuraminidase activity.
Diabetes Complications
Decreased sialidase activity in mononuclear leucocytes of type 1 diabetic subjects: relationship to diabetic complications and glycaemic control.
Diabetes Insipidus
The map of chromosome 20.
Diabetes Mellitus
Acidic and neutral sialidase in the erythrocyte membrane of type 2 diabetic patients.
Antiviral therapy for influenza : a clinical and economic comparative review.
Sialic acid content and sialidase activity of polymorphonuclear leucocytes in diabetes mellitus.
[Analysis of sialic acid-related substances. 1. Platelet sialidase and blood sialic acid analysis, with special reference to the fluctuations in diabetes mellitus]
Diabetes Mellitus, Type 1
Target antigen of islet cell antibody in Japanese insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Acidic and neutral sialidase in the erythrocyte membrane of type 2 diabetic patients.
Acidic and neutral sialidase in the erythrocytes of patients with type 2 diabetes: an answer to comments by Richard et al.
Acidic and neutral sialidase in the erythrocytes of patients with Type 2 diabetes: influence on erythrocyte lifespan.
Measurement of sialic acid and acute phase reactant proteins in sera of patients with diabetic nephropathy.
Diabetic Nephropathies
Significance of serum and urine neuraminidase activity and serum and urine level of sialic acid in diabetic nephropathy.
Diphtheria
Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin.
Interaction of transferrin, haptoglobin and other serum proteins with neuraminidase of diphtheria toxin.
Modification of the cell surface with neuraminidase increases the sensitivities of cells to diphtheria toxin and Pseudomonas aeruginosa exotoxin.
Reaction of diphtheria toxin neuraminidase with human transferrin.
Treatment of FL cells with neuraminidase stimulating the sensitivities to diphtheria toxin and ricin toxin [proceedings]
[The effect of neuraminidase of C. diphtheriae on the functional capacity of the peritoneal exudate cells of guinea pigs to diphtheria bacilli]
Disseminated Intravascular Coagulation
Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.
DNA Virus Infections
Highlights in the development of new antiviral agents.
Dwarfism
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
The map of chromosome 20.
Dysostoses
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
[Case of mucolipidosis type I with a primary alpha-D-neuraminidase deficiency]
Eczema
Neuraminidase production by Propionibacterium acnes-strains isolated from patients with acne vulgaris, seborrheic eczema and healthy subjects.
Encephalitis
Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.
Encephalomyelitis, Venezuelan Equine
Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
[Inhibition of the infectivity of enveloped viruses while retaining the specific biological activity of the viral proteins]
Endocarditis
Metabolism of glycoprotein-derived sialic acid and N-acetylglucosamine by Streptococcus oralis.
Endocarditis, Subacute Bacterial
Neuraminidase production by a Streptococcus sanguis strain associated with subacute bacterial endocarditis.
Endometrial Neoplasms
Human monoclonal antibody (HMST-1) against lacto-series type 1 chain and expression of the chain in uterine endometrial cancers.
Immunohistochemical localization of blood group substances in normal and neoplastic endometrial tissues--with special reference to type 1 core chain expression.
Thomsen-Friedenreich-related antigen in human endometrium. An immunohistochemical study employing the monoclonal antibody 49H.8. A preliminary report.
[Effects of Sialidase Inhibitor on Proliferation and Apoptosis of Endometrial Cancer Cells].
Endometriosis
Reduced ?-2,6 sialylation regulates cell migration in endometriosis.
Endotoxemia
Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1.
Enteritis
Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type A and C strains causing human intestinal disease.
Sialidase Production and Genetic Diversity in Clostridium perfringens Type A Isolated from Chicken with Necrotic Enteritis in Brazil.
Enterocolitis
Necrotising enterocolitis and neuraminidase-producing bacteria.
Enterocolitis, Necrotizing
Survey of neuraminidase production by Clostridium butyricum, Clostridium beijerinckii, and Clostridium difficile strains from clinical and nonclinical sources.
Ependymoma
Localization and significance of peanut agglutinin-binding sites on ependymoma cells.
Epilepsies, Myoclonic
The molecular genetic bases of the progressive myoclonus epilepsies.
Epilepsy
Diversity of sialidases found in the human body - A review.
[Two siblings with adult-onset sialidosis type I (cherry-red spot-myoclonus syndrome)]
Esophageal Neoplasms
Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo.
Exanthema
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
exo-alpha-sialidase deficiency
A case of neuraminidase deficiency associated with a partial beta-galactosidase defect. Clinical, biochemical and radiological studies.
A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine.
A comparative study of the accumulated sialic acid-containing oligosaccharides from cultured human galactosialidosis and sialidosis fibroblasts.
A point mutation in the neu1 promoter recruits an ectopic repressor, Nkx3.2 and results in a mouse model of sialidase deficiency.
A Sialidase-Deficient Porphyromonas gingivalis Mutant Strain Induces Less IL-1? and TNF? in epi4 Cells than the W83 Strain Through Regulation of the JNK Pathway.
Abnormal pattern electroretinograms with macular cherry-red spots: evidence for selective ganglion cell damage.
Acid alpha-neuraminidase deficiency: a nephropathic phenotype?
Adult mucolipidosis with beta-galactosidase and neuraminidase deficiencies.
Adult type beta-galactosidase and neuraminidase deficiency in three siblings.
Adult type GMl-gangliosidosis: a complementation study on somatic cell hybrids.
Adult type mucolipidosis with beta-galactosidase and sialidase deficiency. Histological and biochemical studies.
Adult type neuronal storage disease with neuraminidase deficiency.
An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca2+ dynamics.
Anesthetic management for mastectomy and total hysterectomy in a 49-year-old woman with type 1 sialidosis: a case report.
beta-Galactosidase and neuraminidase deficiency associated with angiokeratoma corporis diffusum.
Biochemical comparison of the dysmorphic type with the normosomatic type of sialidosis.
Biological consequences of neuraminidase deficiency in Newcastle disease virus.
Cardiovascular involvement in alpha-n-acetyl neuraminidase deficiency syndromes (sialidosis type I and II).
Cell disease: desialylation of beta-hexosaminidase and its effect on uptake by fibroblasts.
Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult.
Chronic GM1 gangliosidosis presenting as dystonia: II. Biochemical studies.
Clinical presentation of congenital sialidosis in a patient with a neuraminidase gene frameshift mutation.
Cloning and characterization of a sialidase from the murine histocompatibility-2 complex: low levels of mRNA and a single amino acid mutation are responsible for reduced sialidase activity in mice carrying the Neu1a allele.
Cloning of the cDNA and gene encoding mouse lysosomal sialidase and correction of sialidase deficiency in human sialidosis and mouse SM/J fibroblasts.
Comparative enzymology, biochemistry and pathophysiology of human exo-alpha-sialidases (neuraminidases).
Comparison of sialic acids excretion in spot urines and 24-hour-urines of children and adults.
Complementation analysis of human sialidase deficiency using natural substrates.
Complementation, cross correction, and drug correction studies of combined beta-galactosidase neuraminidase deficiency in human fibroblasts.
Diagnosis and Management of Type 1 Sialidosis: Clinical Insights from Long-Term Care of Four Unrelated Patients.
Diagnostics and Therapy of human diseases - Focus on sialidases.
Effect of the co-existence of galactosyl and phosphomannosyl residues on beta-hexosaminidase on the processing and transport of the enzyme in mucolipidosis I fibroblasts.
Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.
Electrophoretic analysis of glycoprotein enzymes in the sialidoses and mucolipidoses.
Electrophysiological studies of myoclonus in sialidosis type 2.
Enhanced proteolytic degradation of normal beta-galactosidase in the lysosomal storage disease with combined beta-galactosidase and neuraminidase deficiency.
Galactosialidosis: molecular heterogeneity among distinct clinical phenotypes.
Ganglioside GM1 metabolism in living human fibroblasts with beta-galactosidase deficiency.
Genetic heterogeneity in human neuraminidase deficiency.
Human beta-galactosidase and alpha-neuraminidase deficient mucolipidosis: genetic complementation analysis of the neuraminidase deficiency.
Human neuraminidase is a 60 kDa-processing product of prosaposin.
I-cell disease. A hypothesis for the structure of the carbohydrate recognition site on beta-D-N-acetylhexosaminidase.
Increased levels of sialic acid associated with a sialidase deficiency in I-cell disease (mucolipidosis II) fibroblasts.
Infantile lethal neuraminidase deficiency (sialidosis).
Infantile sialidosis: natural history in a preterm infant with two new pathogenic mutations and new ocular findings.
Infantile type 2 sialidosis in a Pakistani family--a clinical and biochemical study.
Isolated acid neuraminidase deficiency: a distinct lysosomal storage disease.
Isolation and structural characterization of sialic acid-containing storage material from mucolipidosis I (sialidosis) fibroblasts.
Km defect in neuraminidase of dysmorphic type sialidosis with and without beta-galactosidase deficiency.
Liver neuraminidase deficiency inherited as a single gene on mouse chromosome 17.
Lysosomal and plasma membrane ganglioside GM3 sialidases of cultured human fibroblasts. Differentiation by detergents and inhibitors.
Lysosomal sialidase deficiency in sialidosis with partial beta-galactosidase deficiency.
Lysosomal sialidase deficiency: increased ganglioside content in autopsy tissues of a sialidosis patient.
Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man.
Molecular heterogeneity in human beta-galactosidase and neuraminidase deficiency.
Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation.
Mucolipidosis I, the cherry red-spot--myoclonus syndrome and neuraminidase deficiency.
Mucolipidosis I: studies of sialidase activity and a prenatal diagnosis.
Mucolipidosis IV, a sialolipidosis due to ganglioside sialidase deficiency.
Mucolipidosis type IV: ganglioside sialidase deficiency.
Multimodality evoked potentials and EEG in a case of cherry red spot-myoclonus syndrome and alpha-neuraminidase deficiency (sialidosis type 1)
Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex.
Neuraminidase assay in cultured human fibroblasts: in situ versus in vitro procedures.
Neuraminidase deficiency and accumulation of sialic acid in lymphocytes in adult type sialidosis with partial beta-galactosidase deficiency.
Neuraminidase deficiency in the cherry red spot-myoclonus syndrome.
Neuraminidase deficiency in the mouse.
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
Neuraminidase deficiency presenting as a nephrosialidosis: the first case detected in Poland.
Neuraminidase deficiency presenting as non-immune hydrops fetalis.
Neuraminidase deficiency: case report and review of the phenotype.
Neuraminidase in cultured fibroblasts and leucocytes of homozygotes and heterozygotes for the mucolipidosis II gene (I-cell disease).
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre.
Neuropathological findings of an autopsy case of adult beta-galactosidase and neuraminidase deficiency.
Pathological study on a severe sialidosis (alpha-neuraminidase deficiency).
Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.
Polymorphisms of apolipoprotein C-III in two cases with sialidase deficiency.
Post-translational modification of enzymes: processing genes.
Prenatal diagnosis of congenital sialidosis.
Prenatal diagnosis of galactosialidosis.
Radioassay method of neuraminidase towards N-acetylneuraminosyl hexasaccharides.
Revertant analysis of a temperature-sensitive mutant of Newcastle disease virus with defective glycoproteins: implication of the fusion glycoprotein in cell killing and isolation of a neuraminidase-deficient hemagglutinating virus.
Sialidase (alpha-n-acetyl neuraminidase) deficiency: the enzyme defect in an adult with macular cherry-red spots and myoclonus without dementia.
Sialidase deficiency in adult-type neuronal storage disease.
Sialidase Deficiency in Porphyromonas gingivalis Increases IL-12 Secretion in Stimulated Macrophages Through Regulation of CR3, IncRNA GAS5 and miR-21.
Sialidosis (neuraminidase deficiency) types I and II: neuro-ophthalmic manifestations.
Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobilities of some enzymes known to be glycoproteins. 1. Clinical findings.
Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobility of some enzymes known to be glycoproteins. II. Enzymes studies.
Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia.
Sialidosis: a review of human neuraminidase deficiency.
Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder.
Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan.
Synthesis of 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid and detection of skin fibroblast neuraminidase in normal humans and in sialidosis.
The cherry red spot-myoclonus syndrome: a newly recognized inherited lysosomal storage disease due to acid neuraminidase deficiency.
The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene.
The structure of sialyl-glycopeptides of the O-glycosidic type, isolated from sialidosis (mucolipidosis I) urine.
Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency.
Turnover of beta-galactosidase in fibroblasts from patients with genetically different types of beta-galactosidase deficiency.
Ultrastructural and immunocytochemical study of skin fibroblasts from normal and sialidosis patients.
[Adult type beta-galactosidase and neuraminidase deficiency in 3 siblings]
[Anesthetic management of a boy with sialidosis]
[Excretion of sialoglycopeptides in mucolipidosis I]
[Genetic disorders of N-acetylneuraminic acid metabolism: sialurias and sialidoses]
[Mucolipidosis type I. Sialidosis due to alpha-2-6-neuraminidase deficiency with neurological symptoms]
[Mucolipidosis. biologic characteristics (author's transl)]
[Mucolipidosis: clinical and genetic aspects]
[Ocular findings in a peculiar type of mucolipidosis called nephrosialidosis]
[Primary neuraminidase deficiency with prenatal disclosure]
[Sialidosis due to alpha-2-6 neuraminidase deficiency: a heterogeneous group]
[Skin and conjunctival biopsies in adult type beta-galactosidase neuraminidase deficiency]
Eye Abnormalities
Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient.
Eye Diseases
Neuraminidase activity of blue eye disease porcine rubulavirus: Specificity, affinity and inhibition studies.
Eye Infections
Experimental ocular toxoplasmosis in genetically susceptible and resistant mice.
Fabry Disease
beta-Galactosidase and neuraminidase deficiency associated with angiokeratoma corporis diffusum.
[Angiokeratoma and fucosidosis. Immunohistochemical and ultrastructural study]
Fetal Death
[Prognostic value of neuraminidase activity in mammary gland secretion in fetal death]
Fibrosarcoma
Antitumor immunity. II. Viability, tumorigenicity, and immunogenicity of neuraminidase-treated tumor cells: effective immunization of animals with a tumor vaccine.
Effect of neuraminidase on growth of a 3-methylcholanthrene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice.
Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas.
Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells.
Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase.
Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. II. Intratumor injections of neuraminidase.
Sialylation of 3-Methylcholanthrene-Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting.
Soluble factors from murine and human tumors induce suppressor cells.
The combined effect of radiotherapy and neuraminidase-treated tumor cells on 3-methylcholanthrene-induced fibrosarcoma.
Foodborne Diseases
Antibiotic Sensitivity of Clostridium perfringens Isolated From Faeces in Tabriz, Iran.
The production of neuraminidase by food poisoning strains of Clostridium welchii (C. perfringens).
Foot-and-Mouth Disease
Multiplex primer prediction software for divergent targets.
Fowlpox
A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV.
Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV into chickens in the presence of antibody to NDV or FPV.
Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants.
Negligible effect of chicken cytokine IL-12 integration into recombinant fowlpox viruses expressing avian influenza virus neuraminidase N1 on host cellular immune responses.
Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes.
Protection of chickens from Newcastle disease and infectious laryngotracheitis with a recombinant fowlpox virus co-expressing the F, HN genes of Newcastle disease virus and gB gene of infectious laryngotracheitis virus.
Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene.
Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses.
Vaccination of chickens with a recombinant fowlpox virus containing the hemagglutinin-neuraminidase gene of Newcastle disease virus under the control of the fowlpox virus thymidine kinase promoter.
Friedreich Ataxia
Lysosomal enzymes in ataxia: discovery of two new cases of late onset hexosaminidase A and B deficiency (adult Sandhoff disease) in French Canadians.
Fructose Intolerance
Two-dimensional electrophoresis highlights haptoglobin beta chain as an additional biomarker of congenital disorders of glycosylation.
Fucosidosis
Human alpha-fucosidase. Single residual enzymatic form in fucosidosis.
Galactorrhea
[Prognostic value of neuraminidase activity in mammary gland secretion in fetal death]
Gallstones
Intestinal alkaline phosphatase in bile: evidence for an enterohepatic circulation.
Gangliosidoses
Complementation, cross correction, and drug correction studies of combined beta-galactosidase neuraminidase deficiency in human fibroblasts.
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Gangliosidoses, GM2
Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre.
Gangliosidosis, GM1
A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine.
Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis.
Biochemical comparison of the dysmorphic type with the normosomatic type of sialidosis.
Biochemical, immunological, and structural studies on a sphingolipid activator protein (SAP-1).
Carrier detection of sialidosis with partial beta-galactosidase deficiency by the assay of lysosomal sialidase in lymphocytes.
Chronic GM1 gangliosidosis presenting as dystonia: II. Biochemical studies.
Combined sialidase (neuraminidase) and beta-galactosidase deficiency. Clinical, morphological and enzymological observations in a patient.
GM1 gangliosidosis type 2 in two siblings.
Inherited lysosomal storage disease associated with deficiencies of beta-galactosidase and alpha-neuraminidase in sheep.
Km defect in neuraminidase of dysmorphic type sialidosis with and without beta-galactosidase deficiency.
Lysosomal multienzymatic complex-related diseases: a genetic study among Portuguese patients.
Lysosomal sialidase deficiency in sialidosis with partial beta-galactosidase deficiency.
Neuraminidase deficiency and accumulation of sialic acid in lymphocytes in adult type sialidosis with partial beta-galactosidase deficiency.
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Partial characterization and studies of fibroblast and leucocyte neuraminidase activities towards sialyloligosaccharides in adult sialidosis and mucolipidosis II and III.
Prenatal diagnosis of sialidosis with combined neuraminidase and beta-galactosidase deficiency.
Ultrastructural lesions of ovine GM1 gangliosidosis.
Gas Gangrene
Early diagnosis of clostridial gas gangrene using sialidase antibodies.
Sialidase activity in the sera of patients and rabbits with clostridial myonecrosis.
The production of neuraminidase by food poisoning strains of Clostridium welchii (C. perfringens).
[Neuraminidase as a pathogenic factor in gas gangrene infections with Clostridium perfringens]
Gastroenteritis
Insight into host cell carbohydrate-recognition by human and porcine rotavirus from crystal structures of the virion spike associated carbohydrate-binding domain (VP8*).
Gastrointestinal Diseases
NanI Sialidase Contributes to the Growth and Adherence of Clostridium perfringens Type F Strain F4969 in the Presence of Adherent Mucus.
Gaucher Disease
Carbohydrate mimetics and scaffolds: sweet spots in medicinal chemistry.
Combinatorial approaches to iminosugars as glycosidase and glycosyltransferase inhibitors.
Increased lung surfactant phosphatidylcholine in patients affected by lysosomal storage diseases.
Genetic Diseases, Inborn
A comparative study of the accumulated sialic acid-containing oligosaccharides from cultured human galactosialidosis and sialidosis fibroblasts.
A point mutation in the neu1 promoter recruits an ectopic repressor, Nkx3.2 and results in a mouse model of sialidase deficiency.
Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis.
Glioblastoma
Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cells.
Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins.
Sialidase NEU4 is involved in glioblastoma stem cell survival.
Glioma
alpha2,6-Sialyltransferase gene transfection into a human glioma cell line (U373 MG) results in decreased invasivity.
Biosynthesis and localization of gangliosides in cultured cells.
Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.
Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents.
Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells.
Overexpression of ST6GalNAcV, a ganglioside-specific alpha2,6-sialyltransferase, inhibits glioma growth in vivo.
Receptor-mediated uptake of beta-glucuronidase into primary astrocytes and C6 glioma cells from rat brain.
Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins.
[Sensitivity of human glial tumor cells of different grade of anaplasia to lysis due to natural killers depending on some characteristics of the glycoprotein structure of tumor cell membranes]
[The composition of glycosphingolipids and the effect of neuraminidase on cultured glioma cell lines]
Glomerulonephritis
Extracellular neuraminidase production of streptococci associated with acute nephritis.
Glomerular binding sites for peanut agglutinin in acute poststreptococcal glomerulonephritis.
Histological evidence of neuraminidase involvement in acute nephritis: desialized leukocytes infiltrate the kidney in acute post-streptococcal glomerulonephritis.
Neuraminidase activity and free sialic acid levels in the serum of patients with acute poststreptococcal glomerulonephritis.
Neuraminidase and free sialic acid levels in acute poststreptococcal glomerulonephritis.
Neuraminidase production by streptococci from patients with glomerulonephritis.
Streptococcal neuraminidase and acute glomerulonephritis.
The role of sialidase in the development of hypocomplementemia in postinfectious acute glomerulonephritis.
Viral infections, their influence on some parts of the immune system and glomerulonephritis development.
[Structure and properties of neuraminidase originating from various sources]
Glomerulonephritis, IGA
Activity of alpha2,6-sialyltransferase and its gene expression in peripheral B lymphocytes in patients with IgA nephropathy.
Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy.
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1.
Neuraminidase treatment abrogates the binding abnormality of IgA1 from IgA nephropathy patients and the differential charge distribution of its alpha-heavy chains.
Glomerulonephritis, Membranous
Expression of sialidase and dystroglycan in human glomerular diseases.
Graft vs Host Disease
Modification of graft-versus-host disease by neuraminidase treatment of donor cells. Decreased tolerogenicity of neuraminidase-treated cells.
Neuraminidase pretreatment of donor lymphocytes and graft-versus-host disease.
Granuloma
A role for Bacteroides fragilis neuraminidase in bacterial growth in two model systems.
The effect of orengedokuto on experimentally-inflamed rats.
Hearing Loss
A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs.
Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1- deficient mice.
[Morphological and functional alterations of ear in lysosomal neuraminidase gene deficient mouse]
Heart Failure
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Influenza-induced rhabdomyolysis after autologous peripheral blood stem cell transplantation for malignant lymphoma.
Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages.
Hemangioma
Phenotypic characterization of normal and neoplastic canine endothelial cells by lectin histochemistry.
Hemangiosarcoma
Phenotypic characterization of normal and neoplastic canine endothelial cells by lectin histochemistry.
Hematuria
Relationship between IgA1 lectin-binding specificities, mesangial C4d deposits and clinical phenotypes in IgA nephropathy.
Hemolytic-Uremic Syndrome
Determination of neuraminidase activity in serum or plasma. Relevance to the pathogenic diagnosis of hemolytic uremic syndrome.
Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: treatment by exchange transfusion.
High-resolution capillary zone electrophoresis and mass spectrometry for distinction of undersialylated and hypoglycosylated transferrin glycoforms in body fluids.
Streptococcus pneumoniae-induced hemolytic uremic syndrome: a case for early diagnosis.
The use of a rapid fluorogenic neuraminidase assay to differentiate acute Streptococcus pneumoniae-associated hemolytic uremic syndrome (HUS) from other forms of HUS.
[Neuraminidase induced hemolytic anemia. Experimental and clinical observations (author's transl)]
Hepatitis
Carbohydrate mimetics and scaffolds: sweet spots in medicinal chemistry.
Combinatorial approaches to iminosugars as glycosidase and glycosyltransferase inhibitors.
Hepatic infections. Part II. The effect of acute and chronic hepatitis B antigenaemia on the reaction to antibodies to sheep red cells (microbial antigens) and human T-activated cells (exposed autologous tissue antigens).
Heterologous T cell immunity in severe hepatitis C virus infection.
Hepatitis B
A functional hepatocyte nuclear factor 3 binding site is a critical component of the duck hepatitis B virus major surface antigen promoter.
A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus.
Approved Antiviral Drugs over the Past 50 Years.
Cell surface display of hepatitis B virus surface antigen by using Pseudomonas syringae ice nucleation protein.
Characterization of hepatitis B virus major surface antigen gene transcriptional regulatory elements in differentiated hepatoma cell lines.
Characterization of the hepatitis B virus major surface antigen promoter hepatocyte nuclear factor 3 binding site.
Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus.
Complex regulation of transcription from the hepatitis B virus major surface antigen promoter in human hepatoma cell lines.
CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Detection of hepatitis B virus DNA in hepatocellular carcinoma: analysis by hybridization with subgenomic DNA fragments.
Development of imaged capillary isoelectric focusing method and use of capillary zone electrophoresis in hepatitis B vaccine RECOMBIVAX HB®.
Hepatitis B virus core protein promotes the expression of neuraminidase 1 to facilitate hepatocarcinogenesis.
Influenza vaccine: progress in a vaccine that elicits a broad immune response.
Integrated hepatitis B virus DNA sequences specifying the major viral core polypeptide are methylated in PLC/PRF/5 cells.
Large hepatitis B surface antigen polypeptides of Dane particles with the receptor for polymerized human serum albumin.
Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
Mapping the major transcripts of ground squirrel hepatitis virus: the presumptive template for reverse transcriptase is terminally redundant.
Maturation of recombinant hepatitis B virus surface antigen particles.
Modulation of expression of the hepatitis B virus surface antigen gene by the viral X-gene product.
Oral hepatitis B vaccine candidates produced and delivered in plant material.
Overexpression of hepatitis B virus surface antigens including the preS1 region in a serum-free Chinese hamster ovary cell line.
Prediction of transmembrane segments in proteins utilising multiple sequence alignments.
Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment.
Regulation of secretion of the hepatitis B virus major surface antigen by the preS-1 protein.
Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor.
RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer.
The nature of polypeptides larger in size than the major surface antigen components of hepatitis b and like viruses in ground squirrels, woodchucks, and ducks.
The properties of an HBV surface antigen protein carrying the binding site for the receptor of hepatocytes--its formation of surface antigen particles and secretion from discrete cell lines.
Tree squirrel hepatitis B virus: antigenic and structural characterization.
Hepatitis B, Chronic
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Hepatitis C
Antiviral drugs: current state of the art.
Approved Antiviral Drugs over the Past 50 Years.
Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus.
Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques.
Development of anti-viral agents using molecular modeling and virtual screening techniques.
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Molecular strategies to inhibit the replication of RNA viruses.
Hepatitis, Chronic
Alpha-fetoprotein antibody-lectin enzyme immunoassay to characterize sugar chains for the study of liver diseases.
Hepatoblastoma
Characterization of hepatitis B virus major surface antigen gene transcriptional regulatory elements in differentiated hepatoma cell lines.
Interaction between desialylated hepatitis B virus and asialoglycoprotein receptor on hepatocytes may be indispensable for viral binding and entry.
Herpes Simplex
Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells.
Effect of neuraminidase on Fc and C3b receptors on rabbit corneal cells infected with herpes simplex virus.
Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role.
Neuraminidase reversal of resistance to lysis of herpes simplex virus-infected cells by antibody and complement.
Removal of N-linked carbohydrates decreases the infectivity of herpes simplex virus type 1.
Sialidase activity of oncogenic cells transformed by herpes simplex virus.
Herpes Zoster
Distribution of carbohydrates in the zona pellucida of human oocytes.
Glycohistochemistry of the zona pellucida of developing oocytes in the rabbit and hare.
Sialidases on mammalian sperm mediate deciduous sialylation during capacitation.
Sperm penetration of rabbit zona pellucida inhibited by treatment of ova with neuraminidase.
Structural characterization of the N-linked carbohydrate chains of the zona pellucida glycoproteins from bovine ovarian and fertilized eggs.
Variations in lectin-binding on the zona pellucida during oocyte growth in some wild ungulates.
Herpesviridae Infections
A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses.
Approved Antiviral Drugs over the Past 50 Years.
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.
Competitive Fitness of Influenza B Viruses with Neuraminidase Inhibitor-Resistant Substitutions in a Co-infection Model of the Human Airway Epithelium.
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.
Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015.
MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.
Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance.
Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.
Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Protection against influenza B virus infection by immunization with DNA vaccines.
Sequential Influenza B Viral Load and Susceptibility in Children Treated with Oseltamivir and Zanamivir.
The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
Histiocytic Sarcoma
[Mechanism of hyperferritinemia in a case of malignant histiocytosis]
Histiocytosis, Langerhans-Cell
Expression of sialylated Leu-M1 antigen in histiocytosis X.
HIV Infections
Approved Antiviral Drugs over the Past 50 Years.
Electrostatic Surface Properties of Blood and Semen Extracellular Vesicles: Implications of Sialylation and HIV-Induced Changes on EV Internalization.
Highlights in the development of new antiviral agents.
Pneumococcus virulence factor sialidase: a new direction in neuro-AIDS research?
Hodgkin Disease
Expression of sialylated Leu-M1 antigen in histiocytosis X.
Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.
Lectin activity as a marker for Hodgkin disease cells.
Homocystinuria
Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre.
Hydatidiform Mole, Invasive
Lectin binding in tissues from hydatidiform mole, invasive mole and choriocarcinoma to concanavalin-A, wheat germ agglutinin and peanut agglutinin.
Hydrocephalus
Ependymal denudation, aqueductal obliteration and hydrocephalus after a single injection of neuraminidase into the lateral ventricle of adult rats.
Hydrops Fetalis
Neuraminidase deficiency presenting as non-immune hydrops fetalis.
Sialidosis presenting as severe nonimmune fetal hydrops is associated with two novel mutations in lysosomal alpha-neuraminidase.
Hyperacusis
GM1 gangliosidosis type 2 in two siblings.
Hyperalgesia
Intraplantar injection of sialidase reduces mechanical allodynia during inflammatory pain.
Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice.
Reversal of neuropathic pain in diabetes by targeting glycosylation of CaV3.2 T-type calcium channels.
Targeting of CaV3.2 T-type calcium channels in peripheral sensory neurons for the treatment of painful diabetic neuropathy.
Hyperinsulinism
Effect of intracisternal insulin on plasma glucose and insulin in the dog.
Hypersensitivity
Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy.
Enhancement of delayed skin hypersensitivity by neuraminidase in cancer patients.
Prevention of suppression of alloreactive capacity following intravenous injection of neuraminidase-treated allogeneic cells by co-injection of agents competing for asialoglycoprotein receptor.
[Determination of ten stilbenes and their antioxidant activity of peony seed coat, seed kernel and seed coat extracts].
[Enhancement of the immune response to surface antigens of the influenza B virus as a result of their covalent binding with a synthetic polymer carrier]
Hypertension
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Recombinant neuraminidase pseudotyped baculovirus: a dual vector for delivery of Angiotensin II peptides and DNA vaccine.
Hyperthyroidism
Tissue sources of serum alkaline phosphatase in 34 hyperthyroid cats: a qualitative and quantitative study.
Hypervitaminosis A
[Enzymatic activity of glycoprotein catabolism in the organs of rats with hyper- and hypovitaminosis A]
Hypoglycemia
Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy.
Effect of intracisternal insulin on plasma glucose and insulin in the dog.
The Function of Sialidase Revealed by Sialidase Activity Imaging Probe.
The sialidase inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid is a glucose-dependent potentiator of insulin secretion.
Hypothyroidism
Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients.
Hormonal control of postnatal development of ileal neuraminidase and acid beta-galactosidase.
Idiopathic Pulmonary Fibrosis
Elevated Expression of NEU1 Sialidase in Idiopathic Pulmonary Fibrosis Provokes Pulmonary Collagen Deposition, Lymphocytosis, and Fibrosis.
Sialidase activity and antibodies to sialidase-treated autologous erythrocytes in bronchoalveolar lavages from patients with idiopathic pulmonary fibrosis or sarcoidosis.
Immune System Diseases
Detection of anti-red blood cell antibodies by treatment of the cells with neuraminidase.
Diagnostics and Therapy of human diseases - Focus on sialidases.
Infant, Newborn, Diseases
Correlation between the production of extracellular substances by type III group B streptococcal strains and virulence in a mouse model.
Infections
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.
?2-3 Sialic acid glycoconjugate loss and its effect on infection with Toxoplasma parasites.
A 65-kDa trypsin-sensible membrane cell protein as a possible receptor for dengue virus in cultured neuroblastoma cells.
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.
A chimeric respiratory syncytial virus fusion protein functionally replaces the F and HN glycoproteins in recombinant Sendai virus.
A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.
A functional network of intramolecular cross-reacting epitopes delays the elicitation of neutralizing antibodies to Trypanosoma cruzi trans-sialidase.
A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.
A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa.
A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations.
A new in vitro hemagglutinin inhibitor screening system based on a single-vesicle fusion assay.
A novel method for detection of Newcastle disease virus with a fluorescent sialidase substrate.
A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture.
A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
A plant extract of Ribes nigrum folium possesses anti-influenza virus activity in vitro and in vivo by preventing virus entry to host cells.
A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals.
A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus.
A rapid-plate hemagglutination assay for the detection of infectious bronchitis virus.
A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza.
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.
A review of avian influenza in different bird species.
A review of neuraminidase inhibitor susceptibility in influenza strains.
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.
A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus.
Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children.
Activation of brain endothelium by pneumococcal neuraminidase NanA promotes bacterial internalization.
Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008).
Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction.
Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India.
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.
Aminopeptidase-N-independent entry of porcine epidemic diarrhea virus into Vero or porcine small intestine epithelial cells.
An alternative route of infection for viruses: entry by means of the asialoglycoprotein receptor of a Sendai virus mutant lacking its attachment protein.
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
An enzymatic assay reveals that proteins destined for the apical or basolateral domains of an epithelial cell line share the same late Golgi compartments.
An influenza virus model for Trypanosoma cruzi infection: interactive roles for neuraminidase and lectin.
An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies.
Analysis of delays in the prescription of oseltamivir in hospitals and potential for improvement.
Anti N1 Cross-Protecting Antibodies Against H5N1 Detected in H1N1 Infected People.
Anti-influenza A virus activity of uridine derivatives of 2-deoxy sugars.
Anti-influenza drugs and neuraminidase inhibitors.
Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.
Anti-Neuraminidase Bioactives from Manggis Hutan (Garcinia celebica L.) Leaves: Partial Purification and Molecular Characterization.
Anti-SAG1 peptide antibodies inhibit the penetration of Toxoplasma gondii tachyzoites into enterocyte cell lines.
Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections.
Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection.
Antibody Determinants of Influenza Immunity.
Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial.
Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
Antibody to Trypanosoma cruzi neuraminidase enhances infection in vitro and identifies a subpopulation of trypomastigotes.
Antigen variability in Anaplasma phagocytophilum during chronic infection of a reservoir host.
Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection.
Antigenic variation and the murine immune response to Giardia lamblia.
Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions.
Antiviral Activity of Chrysin against Influenza Virus Replication via Inhibition of Autophagy.
Antiviral combinations for severe influenza.
Antiviral treatment of childhood influenza: an update.
Antivirals in the management of an influenza pandemic.
Application of sialidase antibodies for the diagnosis of clostridial infections.
Approved Antiviral Drugs over the Past 50 Years.
Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies.
Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection.
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China.
Attachment and infection to MA104 cells of avian rotaviruses require the presence of sialic acid on the cell surface.
Atypical antibody responses to influenza.
Autoimmune reactions against liver cells by syngeneic neuraminidase-treated lymphocytes.
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
Avian influenza viruses infect primary human bronchial epithelial cells unconstrained by sialic acid ?2,3 residues.
Avian influenza viruses that cause highly virulent infections in humans exhibit distinct replicative properties in contrast to human H1N1 viruses.
Avian paramyoxvirus-8 immunization reduces viral shedding after homologous APMV-8 challenge but fails to protect against Newcastle disease.
Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production.
Bacterial neuraminidase increases IL-8 production in lung epithelial cells via NF-kappaB-dependent pathway.
Bacterial neuraminidase inhibitory effects of prenylated isoflavones from roots of Flemingia philippinensis.
Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor.
Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.
Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
Beyond personal protective equipment: adjunctive methods for control of healthcare-associated respiratory viral infections.
Binding of bacteria to HEp-2 cells infected with influenza A virus.
Biochemical studies on the production of neuraminidase by environmental isolates of Vibrio cholerae non-O1 from Bulgaria.
BirdFlu2009: Avian Influenza and Human Health.
Both ?2,3- and ?2,6-linked sialic acids on o-linked glycoproteins act as functional receptors for porcine sapovirus.
Bovine coronavirus uses N-acetyl-9-O-acetylneuraminic acid as a receptor determinant to initiate the infection of cultured cells.
Capnocytophaga canimorsus: a human pathogen feeding at the surface of epithelial cells and phagocytes.
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes.
Cell surface alterations induced by vaccinia and Newcastle disease viruses (38486).
Cell-permeable probe for identification and imaging of sialidases.
Characteristics of human infection with avian influenza viruses and development of new antiviral agents.
Characterization of a novel chromosomal virulence locus involved in expression of a major surface flagellar sheath antigen of the fish pathogen Vibrio anguillarum.
Characterization of a recombinant Bacteroides fragilis sialidase expressed in Escherichia coli.
Characterization of canine parvovirus (CPV) interactions with 3201 T cells: involvement of GPI-anchored protein(s) in binding and infection.
Characterization of neuraminidase-resistant mutants derived from rotavirus porcine strain OSU.
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.
Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
Clinical Features of Bacterial Vaginosis in a Murine Model of Vaginal Infection with Gardnerella vaginalis.
Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016.
Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients.
Clinical, epidemiological and virological characteristics of the first detected human case of avian influenza A(H5N6) virus.
Cloning and characterization of sialidases with 2-6' and 2-3' sialyl lactose specificity from Pasteurella multocida.
Clostridium perfringens Sialidases: Potential Contributors to Intestinal Pathogenesis and Therapeutic Targets.
Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens.
Combination activity of neuraminidase inhibitor oseltamivir and ?-tocopherol in influenza virus A (H3N2) infection in mice.
Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection.
Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan.
Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections.
Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens.
Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.
Comparison of human, simian, and bovine rotaviruses for requirement of sialic acid in hemagglutination and cell adsorption.
Complement Decay-Accelerating Factor is a modulator of influenza A virus lung immunopathology.
Comprehensive Analysis and Characterization of Linear Antigenic Domains on HN Protein from Genotype VII Newcastle Disease Virus Using Yeast Surface Display System.
Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme.
Construction and comparison of different source neuraminidase candidate vaccine strains for human infection with Eurasian avian-like influenza H1N1 virus.
Continuous non-radioactive method for screening trypanosomal trans-sialidase activity and its inhibitors.
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein.
Correlation between levels of apoptosis, levels of infection and haemagglutinin receptor binding interaction of various subtypes of influenza virus: does the viral neuraminidase have a role in these associations.
Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.
Current usage and effectiveness of influenza medications and factors regarding the time taken to alleviate fever based on postcard questionnaire survey.
Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity.
DANCING WITH CHEMICAL FORMULAE OF ANTIVIRALS: A PANORAMIC VIEW (part 2).
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.
Deacetylation of sialic acid by esterases potentiates pneumococcal neuraminidase activity for mucin utilization, colonization and virulence.
Deficiency of Antigen-Specific B Cells Results in Decreased Trypanosoma cruzi Systemic but Not Mucosal Immunity Due to CD8 T Cell Exhaustion.
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.
Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus.
Desialylation by Edwardsiella tarda is the initial step in the regulation of its invasiveness.
Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding.
Desialylation of O-glycans on glycoprotein Ib? drives receptor signaling and platelet clearance.
Desialylation of peripheral blood mononuclear cells promotes growth of HIV-1.
Detailed genetic analysis of hemagglutinin-neuraminidase glycoprotein gene in human parainfluenza virus type 1 isolates from patients with acute respiratory infection between 2002 and 2009 in Yamagata prefecture, Japan.
Detection and Titration of Influenza A Virus Neuraminidase Inhibiting (NAI) Antibodies Using an Enzyme-Linked Lectin Assay (ELLA).
Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
Detection of Toxoplasma gondii soluble antigen, SAG-1(p30), antibody and immune complex in the cerebrospinal fluid of HIV positive or negative individuals.
Development and assessment of a new cage-like particle adjuvant.
Development and evaluation of a real-time nucleic acid sequence based amplification assay for rapid detection of influenza A.
Development of antibodies to neuraminidase of A2-Hong Kong and A2-Taiwan influenza viruses after administration of different Hong Kong vaccines and after natural infection in humans.
Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats.
Developmental disturbances in the hamster retina caused by a mutant of mumps virus.
Diagnostics and Therapy of human diseases - Focus on sialidases.
Differential antiviral and anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1 influenza A virus-infected cells.
Differential immune response in mice immunized with the A, R or C domain from TcSP protein of Trypanosoma cruzi or with the coding DNAs.
Differential infection of receptor-modified host cells by receptor-specific influenza viruses.
Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
Direct adverse effects of Sendai virus DI particles on virus budding and on M protein fate and stability.
Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase.
Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Discovery of Potent Neuraminidase Inhibitors Using a Combination of Pharmacophore-Based Virtual Screening and Molecular Simulation Approach.
Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation.
Distinct functions of antigenic sites of the HN glycoprotein of Sendai virus.
Diverse Epitope Specificity, Immunodominance Hierarchy, and Functional Avidity of Effector CD4 T Cells Established During Priming Is Maintained in Lung After Influenza A Virus Infection.
DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.
Drug resistance in influenza A virus: the epidemiology and management.
Dual Specificity of Human Plasma Lactose-Binding Immunoglobulin to Anomers of Terminal Galactose Enables Recognition of Desialylated Lipoprotein(a) and Xenoantigens.
Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues.
Dynamics of functional maturation and inactivation of HN glycoprotein in NDV-infected chick embryo fibroblasts.
Dynamics of viral growth, viral enzymatic activity, and antigenicity in murine lungs during the course of influenza pneumonia.
Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus.
Early oseltamivir after hospital admission is associated with shortened hospitalization: A five-year analysis of oseltamivir timing and clinical outcomes.
Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection.
Edible bird's nest extract inhibits influenza virus infection.
Effect of 4-amino-3-nitrobenzoic acid on the expression level of the trans-sialidase gene in Trypanosoma cruzi epimastigotes.
Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
Effect of sialidase fusion protein (DAS 181) on human metapneumovirus infection of Hep-2 cells.
Effect of various digestive enzymes on the interaction of Toxoplasma gondii with macrophages.
Effectiveness of neuraminidase inhibitors to prevent mortality in patients with laboratory-confirmed avian influenza A H7N9.
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity.
Effects of cell differentiation on replication of A/WS/33, WSN, and A/PR/8/34 influenza viruses in mouse brain cell cultures: biological and immunological characterization of products.
Effects of HA and NA glycosylation pattern changes on the transmission of avian influenza A(H7N9) virus in guinea pigs.
Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors.
Efficacy of a Cap-Dependent Endonuclease Inhibitor and Neuraminidase Inhibitors against H7N9 Highly Pathogenic Avian Influenza Virus Causing Severe Viral Pneumonia in Cynomolgus Macaques.
Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques.
Efficient infection of buffalo rat liver-resistant cells by encephalomyocarditis virus requires binding to cell surface sialic acids.
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-? for infection control and treatment.
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors.
Energy metabolic disorder is a major risk factor in severe influenza virus infection: Proposals for new therapeutic options based on animal model experiments.
Enhancement of rotavirus infectivity by saturated fatty acids.
Entry of equid herpesvirus 1 into CD172a+ monocytic cells.
Entry of influenza virus into a glycosphingolipid-deficient mouse skin fibroblast cell line.
Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.
Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.
EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo.
Establishment of Adequate Functional Cellular Immune Response in Chicks Is Age Dependent.
Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
Evaluation of BioStar FLU OIA assay for rapid detection of influenza A and B viruses in respiratory specimens.
Evaluation of different serologic markers for the early detection of avian influenza infection in chickens.
Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.
Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo.
Evidence for Deleterious Antigenic Imprinting in SARS-CoV-2 Immune Response.
Evolution of antigen variation in the tick-borne pathogen Anaplasma phagocytophilum.
Exosome-Driven Antigen Transfer for MHC Class II Presentation Facilitated by the Receptor Binding Activity of Influenza Hemagglutinin.
Experimental ocular toxoplasmosis in genetically susceptible and resistant mice.
Experimental validation and computational modeling of anti-influenza effects of quercetin-3-O-?-L-rhamnopyranoside from indigenous south African medicinal plant Rapanea melanophloeos.
Exploring cell tropism as a possible contributor to influenza infection severity.
Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.
Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A.
Expression of cDNA encoding the Sendai virus hemagglutinin-neuraminidase gene: characterization of wild-type and mutant gene products.
Expression of gangliosides as receptors at the cell surface controls infection of NCTC 2071 cells by Sendai virus.
First reported detection of influenza A (H1N1)pdm09 in turkeys in the United Kingdom.
Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
Fluorescent Neuraminidase Assay Based on Supramolecular Dye Capture After Enzymatic Cleavage.
Free energy study of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. From the Michaelis complex to the covalent intermediate.
Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses.
Fusion properties of cells infected with human parainfluenza virus type 3: receptor requirements for viral spread and virus-mediated membrane fusion.
Galectins regulate the inflammatory response in airway epithelial cells exposed to microbial neuraminidase by modulating the expression of SOCS1 and RIG1.
Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses.
Gardnerella vaginalis and Prevotella bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis.
Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling.
Genetic analysis of H9N2 avian influenza viruses circulated in broiler flocks: a case study in Iraq in 2014-2015.
Genetic analysis of influenza virus NS1 gene: a temperature-sensitive mutant shows defective formation of virus particles.
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.
Genetic vaccination against experimental infection with myotropic parasite strains of Trypanosoma cruzi.
Geniposide demonstrates anti-inflammatory and antiviral activity against pandemic A/Jiangsu/1/2009 (H1N1) influenza virus infection in vitro and in vivo.
Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase.
Group C rotavirus requires sialic acid for erythrocyte and cell receptor binding.
H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus pandemrix(®) -vaccination.
H9N2 Influenza Virus Infections in Human Cells Require a Balance between Neuraminidase Sialidase Activity and Hemagglutinin Receptor Affinity.
Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.
Hemagglutinin-specific cytotoxic T-cell response during influenza infection.
Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence.
Heterosubtypic immunity to influenza A virus infections in mallards may explain existence of multiple virus subtypes.
Heterotypic protective immune reactions in mice infected with distinct serotypes of human influenza virus.
High polymeric IgA content facilitates recognition of microbial polysaccharide-natural serum antibody immune complexes by immobilized human galectin-1.
High Seroprevalence of Toxoplasmosis Detected by RDT among the Residents of Seokmo-do (Island) in Ganghwa-Gun, Incheon City, Korea.
High- and low-density lipoproteins enhance infection of Trypanosoma cruzi in vitro.
High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses.
Highlights in the development of new antiviral agents.
Highly sensitive detection of influenza virus by boron-doped diamond electrode terminated with sialic acid-mimic peptide.
HLA Class I-T Cell Epitopes from trans-Sialidase Proteins Reveal Functionally Distinct Subsets of CD8 T Cells in Chronic Chagas Disease.
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Human and most animal rotavirus strains do not require the presence of sialic acid on the cell surface for efficient infectivity.
Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus.
Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces.
Human renal neuraminidase.
Hybrid- and complex-type N-glycans are not essential for Newcastle disease virus infection and fusion of host cells.
Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.
Hyphenated 3D-QSAR statistical model-drug repurposing analysis for the identification of potent neuraminidase inhibitor.
I-cell disease: intracellular desialylation of lysosomal enzymes using an influenza virus vector.
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection.
Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.
Identification of novel E347Q and G362K amino acid substitutions in HN neutralization epitope and major antigenic difference in novel sub-genotype VIIj isolates.
IFIT1 Expression Patterns Induced by H9N2 Virus and Inactivated Viral Particle in Human Umbilical Vein Endothelial Cells and Bronchus Epithelial Cells.
IL-10 inhibits neuraminidase-activated TGF-? and facilitates Th1 phenotype during early phase of infection.
Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections.
Immunity to influenza in ferrets. 13. Protection against influenza infection by serum antibody to homologous haemagglutinin or neuraminidase antigens.
Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice.
Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
Immunoelectron microscopic study of the detection of the glycoproteins of influenza and Sendai viruses in infected cells by the immunoperoxidase method.
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience.
Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza.
Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis.
Implication of Sialidases in Salmonella Infection: Genome Release of Sialidase Knockout Strains from Salmonella enterica Serovar Typhimurium LT2.
Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies.
Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection.
In planta transcriptome analysis reveals tissue-specific expression of pathogenicity genes and microRNAs during rice-Magnaporthe interactions.
In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir.
In situ molecular identification of the influenza A (H1N1) 2009 Neuraminidase in patients with severe and fatal infections during a pandemic in Mexico City.
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors.
In vivo production of neuraminidase by Pasteurella haemolytica A1 in goats after transthoracic challenge.
In vivo production of neuraminidase by Pasteurella haemolytica in market stressed cattle after natural infection.
In vivo production of neuraminidase by Pasteurella multocida A:3 in goats after transthoracic challenge.
Inactivation of influenza A virus via exposure to silver nanoparticle-decorated silica hybrid composites.
Increased resistance of vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity avian influenza virus.
Infection of bovine well-differentiated airway epithelial cells by Pasteurella multocida: actions and counteractions in the bacteria-host interactions.
Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.
Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids.
Infection of human airway epithelium by human and avian strains of influenza a virus.
Infection of the tracheal epithelium by infectious bronchitis virus is sialic acid dependent.
Infection with influenza A H1N1. 1. Production and persistence of antibody.
Infection with Listeria monocytogenes impairs sialic acid addition to host cell glycoproteins.
Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance.
Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice.
Infectious subvirion particles of reovirus type 3 Dearing exhibit a loss in infectivity and contain a cleaved sigma 1 protein.
Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201.
Influenza A and methicillin-resistant Staphylococcus aureus co-infection in rhesus macaques - A model of severe pneumonia.
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
Influenza and Stroke Risk: A Key Target Not to be Missed?
Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.
Influenza vaccines based on virus-like particles.
Influenza virus genetics.
Influenza virus partially counteracts restriction imposed by tetherin/BST-2.
Influenza virus proteins: identity, synthesis, and modification analyzed by two-dimensional gel electrophoresis.
Influenza virus resistance to antiviral agents: a plea for rational use.
Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Influenza viruses - antiviral therapy and resistance.
Influenza viruses and cell membranes.
Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children.
Influenza, respiratory syncytial virus and SARS.
Influenza.
Inhaled antimicrobial therapy: from cystic fibrosis to the flu.
Inhibition of H9N2 Virus Invasion into Dendritic Cells by the S-Layer Protein from L. acidophilus ATCC 4356.
Inhibition of influenza A virus infection by ginsenosides.
Inhibition of influenza A virus infection in vitro by peptides designed in silico.
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection.
Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir.
Intermittent treatment of severe influenza.
Intracellular synthesis of neuraminidase following infection of charioallantoic membranes with influenza virus.
Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
Invasive phenotype of Trypanosoma cruzi restricted to a population expressing trans-sialidase.
Isolation and characterisation of sialidase from a strain of Streptococcus oralis.
Isolation and characterization of influenza A viruses from wild ducks in northern Japan: appearance of HSW1 antigens in the Japanese duck population.
Isolation of Separate Ureaplasma Species From Endotracheal Secretions of Twin Patients.
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
JC Polyomavirus Uses Extracellular Vesicles To Infect Target Cells.
Kinetics of influenza A virus infection in humans.
Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses.
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Latex fetuin spheres as probes for influenza virus neuraminidase in productively and abortively infected cells.
Leukocyte infection by the granulocytic ehrlichiosis agent is linked to expression of a selectin ligand.
Levels of immunoglobulins and antibodies to haemaglutinin and neuraminidase of influenza virus in nasal secretions after natural infection.
Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
Limited role for CD4+ T-cell help in the initial priming of Trypanosoma cruzi-specific CD8+ T cells.
Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
Long-lasting antibodies detected by a trans-sialidase inhibition assay of sera from parasite-free, serologically cured chagasic patients.
Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.
Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase.
Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.
Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.
Lymphocyte blastogenic responses to influenza virus antigens after influenza infection and vaccination in humans.
M2 protein-a proton channel of influenza A virus.
Macaque proteome response to highly pathogenic avian influenza and 1918 reassortant influenza virus infections.
Mammalian glycosyltransferase expression allows sialoglycoprotein production by baculovirus-infected insect cells.
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Management of respiratory viral infections in hematopoietic cell transplant recipients.
Mapping of a B-cell epitope present in the neuraminidase of Trypanosoma cruzi.
Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus.
Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice.
Mechanism of cell invasion by Trypanosoma cruzi: importance of sialidase activity.
Mechanism of interference mediated by human parainfluenza virus type 3 infection.
Mechanism of rabies virus entry into CER cells.
Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Modified sialic acids on mucus and erythrocytes inhibit influenza A HA and NA functions.
Modifying clinical practices to manage influenza in children effectively.
Molecular and genetic characteristics of hemagglutinin and neuraminidase in Iranian 2009 pandemic influenza A(H1N1) viruses.
Molecular characterisation of a predominant antigenic region of Giardia lamblia variant surface protein H7.
Molecular characteristics of the human pandemic influenza A virus (H1N1).
Molecular characterization of the surface glycoprotein genes of an H5N1 influenza virus isolated from a human in Guangdong, China.
Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus.
Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs.
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Molecular strategies to inhibit the replication of RNA viruses.
Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013.
Monoclonal antibodies against Trypanosoma cruzi neuraminidase reveal enzyme polymorphism, recognize a subset of trypomastigotes, and enhance infection in vitro.
Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.
Mucin-like glycoprotein genes are closely linked to members of the trans-sialidase super-family at multiple sites in the Trypanosoma cruzi genome.
Multiple clusters of A(H1N1)pdm09 virus circulating in severe cases of influenza during the 2010-2011 season: a phylogenetic and molecular analysis of the neuraminidase gene.
Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN.
NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
Naringenin suppresses Edwardsiella tarda infection in GAKS cells by NanA sialidase inhibition.
Necrotizing pneumonia caused by nanC-carrying serotypes is associated with pneumococcal haemolytic uraemic syndrome in children.
NEU1 Sialidase Regulates the Sialylation State of CD31 and Disrupts CD31-driven Capillary-like Tube Formation in Human Lung Microvascular Endothelia.
Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against Pseudomonas aeruginosa lung infection.
Neuraminidase activity of blue eye disease porcine rubulavirus: Specificity, affinity and inhibition studies.
Neuraminidase activity of influenza virus-infected cells: localization and properties.
Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.
Neuraminidase decreases in vitro adherence of slime-forming coagulase-negative staphylococci to biosynthetic ovine collagen vascular graft.
Neuraminidase enhances the initial steps of human T-cell leukemia virus type 1 replication.
Neuraminidase from a bacterial source enhances both HIV-1-mediated syncytium formation and the virus binding/entry process.
Neuraminidase Gene Variations in Influenza A(H1N1)pdm09 Virus among Patients Admitted to Refferal Pulmonary Hospital, Tehran, Iran in 2009-2013.
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
Neuraminidase inhibitor therapy in a military population.
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Neuraminidase Inhibitors and Influenza Infection.
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.
Neuraminidase inhibitors for preventing and treating influenza in children.
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.
Neuraminidase inhibitors for treatment of influenza A and B infections.
Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19.
Neuraminidase produces a decrease of adherence of slime-forming Staphylococcus aureus to gelatin-impregnated polyester fiber graft fabric: an experimental study.
Neuraminidase treatment of respiratory syncytial virus-infected cells or virions, but not target cells, enhances cell-cell fusion and infection.
Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection.
Neuraminidase-deficient Sendai virus HN mutants provide protection from homologous superinfection.
Neuraminidase-producing oral mitis group streptococci potentially contribute to influenza viral infection and reduction in antiviral efficacy of zanamivir.
NEUTRALIZING ANTIBODIES TO TYPE A INFLUENZA VIRUSES IN SHOREBIRDS AT DELAWARE BAY, NEW JERSEY, USA.
New approaches to influenza chemotherapy. Neuraminidase inhibitors.
Newcastle disease virus (NDV) vaccine based on immunization with avian cells expressing the NDV hemagglutinin-neuraminidase glycoprotein.
Newcastle disease virus F and HN proteins contribute to its macrophage host range.
Novel baculovirus expression vectors that provide sialylation of recombinant glycoproteins in lepidopteran insect cells.
Novel correlates of protection against pandemic H1N1 influenza A virus infection.
Nucleotide and predicted amino acid sequence analysis of the fusion protein and hemagglutinin-neuraminidase protein genes among Newcastle disease virus isolates. Phylogenetic relationships among the Paramyxovirinae based on attachment glycoprotein sequences.
Occasional review: influenza in COPD: pathogenesis, prevention, and treatment.
On the interaction of Trypanosoma cruzi neuraminidase and human lipoproteins.
Optimization of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses.
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Oseltamivir for treatment and prophylaxis of influenza infection.
Oseltamivir therapy in two low birth-weight premature infants born to women with H1N1 influenza.
Oseltamivir use in pregnancy: Risk of birth defects, preterm delivery, and small for gestational age infants.
Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation.
Over-expression of mammalian sialidase NEU3 reduces Newcastle disease virus entry and propagation in COS7 cells.
Pandemic preparedness: Toward a universal influenza vaccine.
Parasite-host glycan interactions during Trypanosoma cruzi infection: trans-Sialidase rides the show.
Pathogenesis and pathology of blackleg in ruminants: the role of toxins and neuraminidase. A short review.
Pathogenesis and Transmission of Genetically Diverse Swine-Origin H3N2 Variant Influenza A Viruses from Multiple Lineages Isolated in the United States, 2011-2016.
Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.
Peramivir and its use in H1N1 influenza.
Peramivir binding affinity with influenza A neuraminidase and research on its mutations using an induced-fit docking approach.
Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections.
Periodic appearance of a predominant variant antigen type during a chronic Giardia lamblia infection in a mouse model.
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.
Persistent infection with human parainfluenza virus 3 in CV-1 cells: analysis of the role of defective interfering particles.
Phylogenetic analysis of human influenza A/H3N2 viruses isolated in 2015 in Germany indicates significant genetic divergence from vaccine strains.
PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.
Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease.
Plant polyphenolic complex inhibits the reproduction of influenza and herpes simplex viruses.
Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis.
Point mutations in the S protein connect the sialic acid binding activity with the enteropathogenicity of transmissible gastroenteritis coronavirus.
Porcine arterivirus infection of alveolar macrophages is mediated by sialic acid on the virus.
Positive selection on the H3 hemagglutinin gene of human influenza virus A.
Possible Reason for Cross-Species and Cross-Subtype Reassortment in Polymerase Basic Protein 2 from Influenza A Virus.
Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK.
Potent inhibition of bacterial neuraminidase activity by pterocarpans isolated from the roots of Lespedeza bicolor.
Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase.
Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care 'test-and-treat' strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol.
Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.
Pregnancy and H1N1 influenza: lessons to learn.
Prevalence of Capnocytophaga canimorsus in dogs and occurrence of potential virulence factors.
Preventing influenza: an overview of systematic reviews.
Prevention and control of influenza. Role of vaccine.
Prevention of influenza in the general population.
Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice.
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.
Prior infection of pigs with swine influenza viruses is a barrier to infection with avian influenza viruses.
Probing molecular level interaction of oseltamivir with H5N1-NA and model membranes by molecular docking, multinuclear NMR and DSC methods.
Production and characterization of a monoclonal antibody against the sialidase of Gardnerella vaginalis using a synthetic peptide in a MAP8 format.
Production of the 57 kDa major surface antigen by a non-agglutinating strain of the fish pathogen Renibacterium salmoninarum.
Productive penetration of rotavirus in cultured cells induces coentry of the translation inhibitor alpha-sarcin.
Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine.
Proposed biomolecular theory of fasting during fevers due to infection.
Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1).
Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.
Protection against lethal influenza with neuraminidase.
Protection of chickens against challenge with virulent influenza A viruses of Hav5 subtype conferred by prior infection with influenza A viruses of Hsw1 subtype.
Protective effect of fluvastatin on influenza virus infection.
Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.
Protective immunity and safety of a genetically modified influenza virus vaccine.
Proton transfer facilitated by ligand binding. An energetic analysis of the catalytic mechanism of Trypanosoma cruzi trans-sialidase.
Purification of the Porcine rubulavirus attachment protein by liquid isoelectric focusing.
Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.
Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors.
Rab11 regulates trafficking of trans-sialidase to the plasma membrane through the contractile vacuole complex of Trypanosoma cruzi.
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.
Rapid identification and isolation of neuraminidase inhibitors from mockstrawberry (Duchesnea indica Andr.) based on ligand fishing combined with HR-ESI-Q-TOF-MS.
Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection.
Recent Advances in the Structure-based Design of Neuraminidase Inhibitors as Anti-influenza Agents.
Recent progress and challenges in the discovery of new neuraminidase inhibitors.
Receptor specificities of human respiroviruses.
Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro.
Recombinant sialidase NanA (rNanA) cleaves ?2-3 linked sialic acid of host cell surface N-linked glycoprotein to promote Edwardsiella tarda infection.
Reduced glycosylation of human cell lines increases susceptibility to CD4-independent infection by human immunodeficiency virus type 2 (LAV-2/B).
Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.
Relative Roles of GM1 Ganglioside, N-Acylneuraminic Acids, and ?2?1 Integrin in Mediating Rotavirus Infection.
Reovirus preferentially infects the basolateral surface and is released from the apical surface of polarized human respiratory epithelial cells.
Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear Staphylococcus aureus bacteremia.
Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.
Retroviral infection of Syrian hamster BHK cells depends on age and susceptibility toward sialidase.
Review of Non-Bacterial Infections in Respiratory Medicine: Viral Pneumonia.
Risk factors for poor outcomes and therapeutic strategies for seasonal and pandemic influenza.
Role of Porcine Aminopeptidase N and Sialic Acids in Porcine Coronavirus Infections in Primary Porcine Enterocytes.
Role of sialic acids in feline enteric coronavirus infections.
Role of sialidase in Mycoplasma alligatoris-induced pulmonary fibroblast apoptosis.
Role of sialidase in the initial phase of infection with influenza virus.
Rotaviruses require basolateral molecules for efficient infection of polarized MDCKII cells.
RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza.
Safety and pharmacokinetics of oseltamivir at standard and high dosages.
Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling.
Secreted Alpha-N-Arabinofuranosidase B Protein Is Required for the Full Virulence of Magnaporthe oryzae and Triggers Host Defences.
Sendai virus infection in the brains of mice: distribution of viral antigens studied with monoclonal antibodies.
Sendai virus utilizes specific sialyloligosaccharides as host cell receptor determinants.
Serological response to Pasteurella multocida NanH sialidase in persistently colonized rabbits.
Seroprevalence of Toxoplasmosis Detected by RDT in Residents near the DMZ (demilitarized zone) of Cheorwon-gun, Gangwon-do, Korea.
Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic ?/California/07/2009(H1N1) influenza in healthy volunteers.
Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016.
Shikimic acid, a base compound for the formulation of swine/avian flu drug: statistical optimization, fed-batch and scale up studies along with its application as an antibacterial agent.
Sialic acid is a receptor determinant for infection of cells by avian Infectious bronchitis virus.
Sialic acid on herpes simplex virus type 1 envelope glycoproteins is required for efficient infection of cells.
Sialic acid removal by trans-sialidase modulates MMP-2 activity during Trypanosoma cruzi infection.
Sialidase activity in the sera of patients and rabbits with clostridial myonecrosis.
Sialidase as a target for inhibitors of influenza virus replication.
Sialidase fusion protein as inhibitor of infection by influenza virus.
Sialidase of Glaesserella parasuis Augments Inflammatory Response via Desialylation and Abrogation of Negative Regulation of Siglec-5.
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Simultaneous detection of avian influenza virus NP and H5 antibodies in chicken sera using a fluorescence microsphere immunoassay.
Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE.
Single radial complement fixation test for assaying antibody to influenza virus type-specific antigens.
Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells.
Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors.
Specific gangliosides function as host cell receptors for Sendai virus.
Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents.
Stigmasterol retards the proliferation and pathological features of Trypanosoma congolense infection in rats and inhibits trypanosomal sialidase in vitro and in silico.
Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.
Streptococcus pneumoniae Enhances Human Respiratory Syncytial Virus Infection In Vitro and In Vivo.
Streptococcus pneumoniae-induced haemolytic uraemic syndrome.
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines.
Study on the interaction of tamiflu and oseltamivir carboxylate with human serum albumin.
Substrate Specificity of Equine and Human Influenza A Virus Sialidase to Molecular Species of Sialic Acid.
Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin.
Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
Suppression subtractive hybridization and comparative expression of a pore-forming toxin and glycosyl hydrolase genes in Rhizoctonia solani during potato sprout infection.
Surface glycoproteins of influenza A H3N2 virus modulate virus replication in the respiratory tract of ferrets.
Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
Suspected Oseltamivir-induced bradycardia in a pediatric patient: A case report from King Abdullah Specialist Children's Hospital, Riyadh, Saudi Arabia.
Synthesis of influenza neuraminidase inhibitors.
Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by a Salmonella typhimurium vaccine strain.
Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses.
The action of Trypanosoma cruzi trans-sialidase on glycolipids and glycoproteins.
The Ashwell receptor mitigates the lethal coagulopathy of sepsis.
The bird flu: a new emerging pandemic threat and its pharmacological intervention.
The detection of influenza A virus antigens in cultured cells by enzyme-linked immunosorbent assay.
The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
The effects of monoclonal antibodies against the hemagglutinin-neuraminidase and fusion protein on the release of Sendai virus from infected cells.
The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir.
The evolutionary genetics and emergence of avian influenza viruses in wild birds.
The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence.
The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination.
The importance of black-pigmented gram-negative anaerobes in human infections.
The influence of 150-cavity binders on the dynamics of influenza a neuraminidases as revealed by molecular dynamics simulations and combined clustering.
The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation.
The Low-pH Resistance of Neuraminidase Is Essential for the Replication of Influenza A Virus in Duck Intestine following Infection via the Oral Route.
The management of influenza in people of working age.
The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation.
The neuraminidase of influenza virus.
The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.
The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.
The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
The role of sialidase in the development of hypocomplementemia in postinfectious acute glomerulonephritis.
The SA85-1.1 protein of the Trypanosoma cruzi trans-sialidase superfamily is a dominant T-cell antigen.
The subclass IgG responses of mice to influenza surface proteins formulated into liposomes.
The surface receptor is a major determinant of the cell tropism of influenza C virus.
The therapeutic potential of phytol towards Trypanosoma congolense infection and the inhibitory effects against trypanosomal sialidase.
The Trypanosoma cruzi trans-sialidase, through its COOH-terminal tandem repeat, upregulates interleukin 6 secretion in normal human intestinal microvascular endothelial cells and peripheral blood mononuclear cells.
The use of a radial haemolysis test for neuraminidase antibodies in the diagnosis of influenza A infection.
The use of enzyme-linked immunosorbent assay to determine the appearance, specificity and immunoglobulin class of antibodies to the structural proteins of influenza A virus in mice.
The use of sialidase therapy for respiratory viral infections.
The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.
Theiler's murine encephalomyelitis virus attachment to the gastrointestinal tract is associated with sialic acid binding.
Therapeutic options for the management of influenza.
Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein.
Thomsen-Friedenreich antigen exposure as a cause of Streptococcus pyogenes-associated hemolytic-uremic syndrome.
Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection.
Trans-sialidase inhibition assay detects Trypanosoma cruzi infection in different wild mammal species.
Trans-sialidase inhibition assay for the detection of Trypanosoma cruzi infection in blood donor samples from Argentina.
Translational regulation of influenza virus mRNAs.
Treating Influenza Infection, From Now and Into the Future.
Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection.
Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.
Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic.
Trypanosoma cruzi subverts host cell sialylation and may compromise antigen-specific CD8+ T cell responses.
Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia.
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes.
Trypanosoma cruzi: the effect of nitric oxide synthesis inhibition on the CD4 T cell response to the trans-sialidase superfamily.
Trypanosoma rangeli sialidase: lack of activity in stocks from Panama and other regions.
Ultrasensitive Fluorogenic Reagents for Neuraminidase Titration.
Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment.
Use of antigenic cartography in vaccine seed strain selection.
Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi).
Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines.
Use of trans-Sialidase inhibition assay in a population serologically negative for Trypanosoma cruzi but at a high risk of infection.
Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: Analysis of 1000 hospitalized children.
Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.
Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells.
Virulence in Trypanosoma cruzi infection correlates with the expression of a distinct family of sialidase superfamily genes.
Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3.
WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008.
Why do influenza virus subtypes die out? A hypothesis.
Wildlife surveillance associated with an outbreak of lethal H5N2 avian influenza in domestic poultry.
Zanamivir (Glaxo Wellcome).
[Analysis of decrease in sensitivity in influenza A (H5N1) avian and human strains to neuraminidase inhibitors]
[Antigenic and biochemical analysis of the proteins of influenza virus A/USSR/Alma-Ata/13/81 with hemagglutinin H1]
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
[Epidemiology, clinical picture, prevention and treatment of avian influenza.]
[Epitope analysis of mumps virus proteins in a persistent cell culture infection: changes in the hemagglutinin-neuraminidase polypeptide]
[Evaluation of Newcastle disease virus with derivated hemagglutinin-neuraminidase gene of mesogenic strain]
[Flow cytometry detection of erythrocyte antigens and antibodies. Technical aspects and new clinical applications]
[Homologous and heterologous antibody induction in influenzal infection and immunization]
[Immunity against Erysipelothrix rhusiopathiae infection by means of active immunization using homologous neuraminidase (author's transl)]
[In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
[Influenza type A (H5N1) virus infection]
[Influenza].
[Interaction between vaginal micro-environment alterations and HPV16 infection in cervical intraepithelial neoplasia].
[Neuraminidase as a pathogenic factor in gas gangrene infections with Clostridium perfringens]
[Neuraminidase as a pathogenicity factor in microbial infections (proceedings)]
[Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations]
[Neuraminidase neutralizing antibodies in pigs with chronic Erysipelothrix rhusiopathiae infection (author's transl)]
[Pneumococcal infections in children: hemolytic-uremic syndrome]
[Protective action of liposome-incorporated surface antigens of the influenza virus by different methods of immunization]
[Protective antigen of influenza virus]
[Role of antineuraminidase antibodies in protection against influenza]
[Role of neuraminidase from cholera vibrions in the pathogenesis of experimental cholera]
[The use of antiviral agents during an (impending) influenza pandemic]
[The virulence of Streptococcus pneumoniae strains--the causative agents of pneumococcal infection at different sites]
[Treatment for viral respiratory infections: Principles of action, strategies, and future prospects]
Infertility
[Prognostic value of neuraminidase activity in mammary gland secretion in fetal death]
Infertility, Male
Identification of novel putative causative genes and genetic marker for male sterility in Japanese cedar (Cryptomeria japonica D.Don).
Inflammatory Bowel Diseases
Degradation by bacterial enzymes of colonic mucus from normal subjects and patients with inflammatory bowel disease: the role of sialic acid metabolism and the detection of a novel O-acetylsialic acid esterase.
Histochemical demonstration of desialation and desulphation of normal and inflammatory bowel disease rectal mucus by faecal extracts.
Influenza in Birds
2D-SAR, Topomer CoMFA and molecular docking studies on avian influenza neuraminidase inhibitors.
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.
4-Methylumbelliferyl-alpha-glycosides of partially O-acetylated N-acetylneuraminic acids as substrates of bacterial and viral sialidases.
A 20-amino-acid deletion in the neuraminidase stalk and a five-amino-acid deletion in the NS1 protein both contribute to the pathogenicity of H5N1 avian influenza viruses in mallard ducks.
A complete molecular diagnostic procedure for applications in surveillance and subtyping of avian influenza virus.
A Computational Model for Docking of Noncompetitive Neuraminidase Inhibitors and Probing their Binding Interactions with Neuraminidase of Influenza Virus H5N1.
A cross-sectional serological survey of the Dutch commercial poultry population for the presence of low pathogenic avian influenza virus infections.
A heterologous neuraminidase subtype strategy for the differentiation of infected and vaccinated animals (DIVA) for avian influenza virus using an alternative neuraminidase inhibition test.
A neuraminidase activity-based microneutralization assay for evaluating antibody responses to influenza H5 and H7 vaccines.
A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.
A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase.
A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza.
A real-time TaqMan RT-PCR method for neuraminidase type 1 (N1) gene detection of H5N1 Eurasian strains of avian influenza virus.
A reverse transcription-PCR for subtyping of the neuraminidase of avian influenza viruses.
A sandwich ELISA for the detection of neuraminidase of avian influenza A(H7N9) virus.
Adaptive mutations of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of influenza A viruses.
Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase.
Amino acid residues at positions 222 and 227 of the hemagglutinin together with the neuraminidase determine binding of H5 avian influenza viruses to sialyl Lewis X.
Amino Acid Substitutions in PB1 of Avian Influenza Viruses Influence Pathogenicity and Transmissibility in Chickens.
Amino acid substitutions in the neuraminidase protein of an H9N2 avian influenza virus affect its airborne transmission in chickens.
An in situ Pt Staining Method for Simple, Stable, and Sensitive Pressure-based Bioassays.
An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses.
An outbreak of avian influenza subtype H9N8 among chickens in South Korea.
An overview of the epidemiology of avian influenza.
Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Antibody and T cell responses induced in chickens immunized with avian influenza virus N1 and NP DNA vaccine with chicken IL-15 and IL-18.
Antibody recognition of a highly conserved influenza virus epitope.
Antibody Titer Has Positive Predictive Value for Vaccine Protection against Challenge with Natural Antigenic-Drift Variants of H5N1 High-Pathogenicity Avian Influenza Viruses from Indonesia.
Antigenic relationship between the surface antigens of avian and equine influenze viruses.
Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease.
Assessing the efficacy of a recombinant H9N2 avian influenza virus-inactivated vaccine.
Attenuation of pathogenicity of fowl plague virus by recombination with other influenza A viruses nonpathogenic for fowl: nonexculsive dependence of pathogenicity on hemagglutinin and neuraminidase of the virus.
Authors' response: Sequencing bias for residue 28 of the neuraminidase of the recent highly pathogenic avian influenza virus A(H5N8).
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
Avian influenza A/H5N1 neuraminidase expressed in yeast with a functional head domain.
Avian Influenza Virus Glycoproteins Restrict Virus Replication and Spread through Human Airway Epithelium at Temperatures of the Proximal Airways.
Avian Influenza Virus with Hemagglutinin-Neuraminidase Combination H3N6, Isolated from a Domestic Pigeon in Guangxi, Southern China.
Avian Influenza Virus with Hemagglutinin-Neuraminidase Combination H8N8, Isolated in Russia.
Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses.
B cell epitopes in the intrinsically disordered regions of neuraminidase and hemagglutinin proteins of H5N1 and H9N2 avian influenza viruses for peptide-based vaccine development.
Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus.
Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and its Implication for Drug Design.
Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives.
Biosynthesis, intracellular transport and enzymatic activity of an avian influenza A virus neuraminidase: role of unpaired cysteines and individual oligosaccharides.
BirdFlu2009: Avian Influenza and Human Health.
Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?
Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy.
Characterisation of an avian influenza A virus isolated from a human--is an intermediate host necessary for the emergence of pandemic influenza viruses?
Characterization of a cold-sensitive (cs) recombinant between two influenza A strains.
Characterization of a new avian-like influenza A virus from horses in China.
Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules.
Characterization of H3 subtype avian influenza viruses isolated from poultry in Vietnam.
Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses.
Characterization of pseudoparticles paired with hemagglutinin and neuraminidase from highly pathogenic H5N1 influenza and avian influenza A (H7N9) viruses.
Characterization of virulent and avirulent A/chicken/Pennsylvania/83 influenza A viruses: potential role of defective interfering RNAs in nature.
Clinical and Pathologic Characterization of an Outbreak of Highly Pathogenic Avian Influenza H7N8 in Commercial Turkeys in Southern Indiana.
Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens.
Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance.
Comparative analysis of virulence of a novel, avian-origin H3N2 canine influenza virus in various host species.
Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus.
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Comparison of the pathogenesis of two genetically different H3N2 influenza A viruses in pigs.
Compatibility between haemagglutinin and neuraminidase drives the recent emergence of novel clade 2.3.4.4 H5Nx avian influenza viruses in China.
Complete Genome Sequence of a Novel Reassortant Avian Influenza H1N2 Virus Isolated from a Domestic Sparrow in 2012.
Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase.
Computational assay of Zanamivir binding affinity with original and mutant influenza neuraminidase 9 using molecular docking.
Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
Computational identification of reassortments in avian influenza viruses.
Computational Method for Classification of Avian Influenza A Virus Using DNA Sequence Information and Physicochemical Properties.
Computational Study of Dispersion and Extent of Mutated and Duplicated Sequences of the H5N1 Influenza Neuraminidase over the Period 1997-2008.
Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase.
Construction of Multilevel Structure for Avian Influenza Virus System Based on Granular Computing.
Construction of Recombinant Marek's Disease Virus (rMDV) Co-Expressing AIV-H9N2-NA and NDV-F Genes under Control of MDV's Own Bi-Directional Promoter.
Continuing evolution of highly pathogenic H5N1 viruses in Bangladeshi live poultry markets.
Control of highly pathogenic avian influenza in Quang Tri province, Vietnam: voices from the human-animal interface.
Conventional H5N9 vaccine suppresses shedding in specific-pathogen-free birds challenged with HPAI H5N1 A/chicken/Yamaguchi/7/2004.
Correction for Jeong et al., "In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility".
Could a deletion in neuraminidase stalk strengthen human tropism of the novel avian influenza virus H7N9 in China, 2013?
Cross-immunity and age patterns of influenza A(H5N1) infection.
Cytotoxic T cell lysis of target cells fused with liposomes containing influenza virus haemagglutinin and neuraminidase.
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.
Degenerate primers for PCR amplification and sequencing of the avian influenza A neuraminidase gene.
Deletions in the Neuraminidase Stalk Region of H2N2 and H9N2 Avian Influenza Virus Subtypes Do Not Affect Postinfluenza Secondary Bacterial Pneumonia.
Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant.
Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Detection and differentiation of four poultry diseases using asymmetric reverse transcription polymerase chain reaction in combination with oligonucleotide microarrays.
Detection of highly pathogenic zoonotic influenza virus H5N6 by reverse-transcriptase quantitative polymerase chain reaction.
Detection of NP, N3 and N7 antibodies to avian influenza virus by indirect ELISA using yeast-expressed antigens.
Determination of hemagglutinin and neuraminidase subtypes of avian influenza A viruses in urban pigeons by a new nested RT-PCR.
Development and evaluation of an avian influenza, neuraminidase subtype 1, indirect enzyme-linked immunosorbent assay for poultry using the differentiation of infected from vaccinated animals control strategy.
Development of a DIVA (Differentiating Infected from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza.
Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Diagnostics-in-a-Suitcase: Development of a portable and rapid assay for the detection of the emerging avian influenza A (H7N9) virus.
Different patterns of replication in influenza virus-infected KB cells.
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.
Direct and label-free influenza virus detection based on multisite binding to sialic acid receptors.
Discover binding pathways using the sliding binding-box docking approach: application to binding pathways of oseltamivir to avian influenza H5N1 neuraminidase.
Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design.
Drugs against Avian Influenza A Virus: Design of Novel Sulfonate Inhibitors of Neuraminidase N1.
Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues.
Effectiveness of neuraminidase inhibitors to prevent mortality in patients with laboratory-confirmed avian influenza A H7N9.
Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza.
Efficacy of a Cap-Dependent Endonuclease Inhibitor and Neuraminidase Inhibitors against H7N9 Highly Pathogenic Avian Influenza Virus Causing Severe Viral Pneumonia in Cynomolgus Macaques.
Efficacy of a high-yield attenuated vaccine strain wholly derived from avian influenza viruses by use of reverse genetics.
Efficacy of avian influenza neuraminidase-specific vaccines in chickens.
Efficacy of Neuraminidase Inhibitors against H5N6 Highly Pathogenic Avian Influenza Virus in a Nonhuman Primate Model.
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques.
Emergence and genetic variation of neuraminidase stalk deletions in avian influenza viruses.
Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic.
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease.
Enhancement of DNA vaccine efficacy by intracellular targeting strategies.
Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.
Enzymological characteristics of avian influenza A virus neuraminidase.
Establishment of Adequate Functional Cellular Immune Response in Chicks Is Age Dependent.
Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers.
Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
Evaluation of neuraminidase antigen based competitive enzyme-linked immunosorbent assay in chickens vaccinated with avian influenza inactivated vaccine.
Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
Evaluation of transmission route and replication efficiency of H9N2 avian influenza virus.
Evolutionary interactions between haemagglutinin and neuraminidase in avian influenza.
Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.
Field monitoring of avian influenza viruses: whole-genome sequencing and tracking of neuraminidase evolution using 454 pyrosequencing.
Full sequence analysis of hemagglutinin and neuraminidase genes and proteins of highly pathogenic avian influenza H5N1 virus detected in Iran, 2015.
Functional defects of fowl plague virus temperature-sensitive mutant having mutation in the neuraminidase.
Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Further studies on the role of neuraminidase and the mechanism of low pH dependence in influenza virus-induced membrane fusion.
Galactose-conjugates of the oseltamivir pharmacophore--new tools for the characterization of influenza virus neuraminidases.
Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.
Generation of a recombinant chickenized monoclonal antibody against the neuraminidase of H9N2 avian influenza virus.
Generation of highly productive and mammalian nonpathogenic recombinant H9N2 avian influenza viruses by optimization of 3'end promoter and NS genome.
Genetic analysis of a novel reassortant H11N9 Isolated from waterfowl in South Korea in 2016.
Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013.
Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro.
Genetic characterization of an H2N2 influenza virus isolated from a muskrat in Western Siberia.
Genetic characterization of H1N1, H1N2 and H3N2 swine influenza virus in Thailand.
Genetic Characterization of Highly Pathogenic Avian Influenza A(H5N8) Virus in Pakistani Live Bird Markets Reveals Rapid Diversification of Clade 2.3.4.4b Viruses.
Genome Sequence of an H9N2 Avian Influenza Virus Strain with Hemagglutinin-Neuraminidase Combination, Isolated from a Quail in Guangxi, Southern China.
Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture.
Graphical representation and numerical characterization of H5N1 avian flu neuraminidase gene sequence.
H9N2 Influenza Virus Infections in Human Cells Require a Balance between Neuraminidase Sialidase Activity and Hemagglutinin Receptor Affinity.
Haemagglutinin and neuraminidase characterization of low pathogenic H5 and H7 avian influenza viruses isolated from Northern pintails (Anas acuta) in Japan, with special reference to genomic and biogeographical aspects.
Hemagglutinin-Neuraminidase Balance Influences the Virulence Phenotype of a Recombinant H5N3 Influenza A Virus Possessing a Polybasic HA0 Cleavage Site.
High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses.
Highly Pathogenic and Low Pathogenic Avian Influenza H5 Subtype Viruses in Wild Birds in Ukraine.
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Highly pathogenic avian influenza viruses H5N2, H5N3, and H5N8 in Taiwan in 2015.
Human H7N9 avian influenza virus infection: a review and pandemic risk assessment.
Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin.
I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses.
Identification of a Divergent Avian Influenza H3N2 Virus from Domestic Ducks in France.
In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility.
Increased resistance of vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity avian influenza virus.
Independent-Trajectories Thermodynamic-Integration Free-Energy Changes for Biomolecular Systems: Determinants of H5N1 Avian Influenza Virus Neuraminidase Inhibition by Peramivir.
Influence of insertion site of the avian influenza virus haemagglutinin (HA) gene within the Newcastle disease virus genome on HA expression.
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.
Influenza neuraminidase as a vaccine antigen.
Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
Influenza virus: association of mouse-lung virulence with plaque formation in mouse kidney cells.
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.
Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid.
Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus.
Interaction of N-acetyl-4-epi-D-neuraminic acid with key enzymes of sialic acid metabolism.
Intranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in Mice.
Isolation and Characterization of Avian Influenza H9N2 Viruses from Different Avian Species in Pakistan 2016-17.
Isolation and characterization of influenza A viruses from wild ducks in northern Japan: appearance of HSW1 antigens in the Japanese duck population.
Isolation and phylogenetic characterization of haemagglutinin and neuraminidase genes of H9N2 low pathogenicity avian influenza virus isolated from commercial layers in India.
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Letter to the editor: Sequencing bias for residue 28 of the neuraminidase of the recent highly pathogenic avian influenza virus A(H5N8).
Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities.
MiR674 inhibits the neuraminidase-stimulated immune response on dendritic cells via down-regulated Mbnl3.
Molecular analysis of highly pathogenic avian influenza virus of subtype H5N1 isolated from wild birds and mammals in northern Germany.
Molecular cloning and analysis of the N5 neuraminidase subtype from an avian influenza virus.
Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus.
Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Monoclonal antibody based ELISA tests to detect antibodies against neuraminidase subtypes 1, 2 and 3 of avian influenza viruses in avian sera.
Mutation signature in neuraminidase gene of avian influenza H9N2/G1 in Egypt.
N1 neuraminidase of H5N1 avian influenza A virus complexed with sialic acid and zanamivir - A study by molecular docking and molecular dynamics simulation.
Negligible effect of chicken cytokine IL-12 integration into recombinant fowlpox viruses expressing avian influenza virus neuraminidase N1 on host cellular immune responses.
Neolignans from leaves of Miliusa mollis.
Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses.
Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks.
Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
Neuraminidase is essential for fowl plague virus hemagglutinin to show hemagglutinating activity.
Neuraminidase pharmacophore model derived from diverse classes of inhibitors.
Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice.
Neuraminidase subtyping of avian influenza viruses with PrimerHunter-designed primers and quadruplicate primer pools.
Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
Novel antiviral activity of neuraminidase inhibitors against an avian influenza A virus.
Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble.
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.
Novel post-translational modifications of the hemagglutinin and neuraminidase proteins of avian influenza virus expressed by Kluyveromyces lactis.
Novel reassortant highly pathogenic H5N2 avian influenza viruses in poultry in China.
Novel use of a N2-specific enzyme-linked immunosorbent assay for differentiation of infected from vaccinated animals (DIVA)-based identification of avian influenza.
On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Optimal attenuation of a PR8-derived mouse pathogenic H5N1 recombinant virus for testing antigenicity and protective efficacy in mice.
Oseltamivir activity against avian influenza H9N2 strain with different point mutations in their neuraminidase.
Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option?
Passive immune neutralization strategies for prevention and control of influenza A infections.
Persistence of avian influenza viruses in water.
Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.
Phylogenetic analysis of H and N2 genes of avian influenza viruses detected in Ireland between 2003 and 2007.
Phylogenetic analysis of hemagglutinin and neuraminidase genes of highly pathogenic avian influenza H5N1 Egyptian strains isolated from 2006 to 2008 indicates heterogeneity with multiple distinct sublineages.
Phylogenetic analysis of hemagglutinin, neuraminidase, and nucleoprotein genes of H9N2 avian influenza viruses isolated in Israel during the 2000-2005 epizootic.
Phylogenetic analysis of neuraminidase gene of H9N2 avian influenza viruses isolated from chicken in Iran during 2010-2011.
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses.
Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses.
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes.
Protective efficacy of the H5 inactivated vaccine against different highly pathogenic H5N1 avian influenza viruses isolated in China and Vietnam.
Proteome Response of Chicken Embryo Fibroblast Cells to Recombinant H5N1 Avian Influenza Viruses with Different Neuraminidase Stalk Lengths.
Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents.
QSAR analyses on avian influenza virus neuraminidase inhibitors using CoMFA, CoMSIA, and HQSAR.
R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses.
Rapid and highly sensitive neuraminidase subtyping of avian influenza viruses by use of a diagnostic DNA microarray.
Rapid molecular subtyping by reverse transcription polymerase chain reaction of the neuraminidase gene of avian influenza A viruses.
Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1.
Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys.
Receptor recognition mechanism of human influenza A H1N1 (1918), avian influenza A H5N1 (2004), and pandemic H1N1 (2009) neuraminidase.
Recognition of viral glycoproteins by influenza A-specific cross-reactive cytolytic T lymphocytes.
Review analysis and impact of co-circulating H5N1 and H9N2 avian influenza viruses in Bangladesh.
Role of domestic ducks in the emergence of a new genotype of highly pathogenic H5N1 avian influenza A viruses in Bangladesh.
Safety and pharmacokinetics of oseltamivir at standard and high dosages.
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Seasonal and pandemic influenza preparedness: science and countermeasures.
Selection of avian influenza A (H9N2) virus with reduced susceptibility to neuraminidase inhibitors oseltamivir and zanamivir.
Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase.
Sequence analysis of recent H7 avian influenza viruses associated with three different outbreaks in commercial poultry in the United States.
Sequence analysis of the neuraminidase genes of avian influenza A viruses isolated from live bird markets in the United States.
Sequence and phylogenetic analysis of neuraminidase genes of H9N2 avian influenza viruses isolated from commercial broiler chicken in Iran (2008 and 2009).
Sequence of the neuraminidase gene of an avian influenza A virus (A/parrot/ulster/73, H7N1).
Shikimic Acid Production in Escherichia coli: From Classical Metabolic Engineering Strategies to Omics Applied to Improve Its Production.
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.
Sialivac: An intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry.
Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses.
Simultaneous detection of four different neuraminidase types of avian influenza A H5 viruses by multiplex reverse transcription PCR using a GeXP analyser.
Simultaneous Differentiation of the N1 to N9 Neuraminidase Subtypes of Avian Influenza Virus by a GeXP Analyzer-Based Multiplex Reverse Transcription PCR Assay.
Simultaneous genotyping of all hemagglutinin and neuraminidase subtypes of avian influenza viruses by use of padlock probes.
Single Electrode Genosensor for Simultaneous Determination of Sequences Encoding Hemagglutinin and Neuraminidase of Avian Influenza Virus (AIV) type H5N1.
Single PA mutation as a high yield determinant of avian influenza vaccines.
Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.
Spatiotemporal analysis of the genetic diversity of seal influenza A(H10N7) virus, Northwestern Europe.
Specific antibody response of mice after immunization with COS-7 cell derived avian influenza virus (H5N1) recombinant proteins.
Spot-scan imaging of microcrystals of an influenza neuraminidase-antibody fragment complex.
Studies with avian influenza A viruses: serological relations of the haemagglutinin and neuraminidase antigens of ten virus isolates.
Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
Substrate specificity of avian influenza H5N1 neuraminidase.
Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir.
Susceptibility of Chickens to Low Pathogenic Avian Influenza (LPAI) Viruses of Wild Bird- and Poultry-Associated Subtypes.
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
SYBR green-based real-time reverse transcription-PCR for typing and subtyping of all hemagglutinin and neuraminidase genes of avian influenza viruses and comparison to standard serological subtyping tests.
Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.
The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children.
The Appropriate Combination of Hemagglutinin and Neuraminidase Prompts the Predominant H5N6 Highly Pathogenic Avian Influenza Virus in Birds.
The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling.
The Emergence and Decennary Distribution of Clade 2.3.4.4 HPAI H5Nx.
The fit of codon usage of human-isolated avian influenza A viruses to human.
The molecular characterizations of surface proteins hemagglutinin and neuraminidase from recent H5Nx avian influenza viruses.
The Neuraminidase Stalk Deletion Serves as Major Virulence Determinant of H5N1 Highly Pathogenic Avian Influenza Viruses in Chicken.
The neuraminidases of the virulent and avirulent A/Chicken/Pennsylvania/83 (H5N2) influenza A viruses: sequence and antigenic analyses.
The origin and virulence of the 1918 "Spanish" influenza virus.
The Short Stalk Length of Highly Pathogenic Avian Influenza H5N1 Virus Neuraminidase Limits Transmission of Pandemic H1N1 Virus in Ferrets.
The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern.
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.
The virulence of the 1918 pandemic influenza virus: unraveling the enigma.
Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus.
Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic.
Truncation or Deglycosylation of the Neuraminidase Stalk Enhances the Pathogenicity of the H5N1 Subtype Avian Influenza Virus in Mallard Ducks.
Understanding the complex pathobiology of high pathogenicity avian influenza viruses in birds.
Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
Use of RT-PCR to Subtype N1 to N9 Neuraminidase Genes of Avian Influenza Viruses.
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers.
Variable impact of the hemagglutinin polybasic cleavage site on virulence and pathogenesis of avian influenza H7N7 virus in chickens, turkeys and ducks.
Viral neuraminidase and cellular ectosialyltransferase in human lymphoblastoid cells infected with influenza virus.
Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens.
Wildlife surveillance associated with an outbreak of lethal H5N2 avian influenza in domestic poultry.
[1H-NMR spectroscopy--a potent method for the determination of substrate specificity of sialidases (author's transl)]
[A preclinical trial of the reassortant influenza virus vaccine strain A/17/Quail/Hong Kong/97/84 (H9N2)].
[Change in the influenza virus upon multiplication in the presence of high concentrations of remantadine]
[Chitosan as an adjuvant for inactivated vaccines against avian influenza viruses]
[Distribution of avian influenza virus subtypes among domestic ducks in eastern China]
[Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].
[Effect of low pH values on the infectivity and neuraminidase activity of human and animal strains of influenza virus type A]
[Effect of neuraminidase treatment of chick embryo fibroblasts on the adsorption and reproduction of the fowl plague virus]
[Electrophoretic characteristics of the proteins and the preparative production of neuraminidase from the A/turkey/Wisconsin/66 (Hav6N2) strain of the avian influenza virus]
[Epidemiology, clinical picture, prevention and treatment of avian influenza.]
[Establishing a high-titer infectious avian influenza A (H5N1) pseudotyped viral particle].
[Factors that cause a change in the antigenic structure of of the influenza virus hemagglutinin]
[Fowl plague and avian influenza A viruses of poultry and birds. Diagnosis, control measures and practical experiences].
[Genetic characteristics of hemagglutinin and neuraminidase of avian influenza A (H7N9) virus in Guizhou province, 2014-2017].
[H-NMR spectroscopy. Specificity of microbial sialidases against complex substrates]
[Impact of avian influenza virus H5N1 neuraminidase mutations on the activity of neuraminidase and the sensibility to neuraminidase inhibitors].
[Influence of antibody-mediated immune pressure on neuraminidase gene mutations of avian influenza virus H9N2].
[Influenza type A (H5N1) virus infection]
[Molecular analysis of hemagglutinin and neuraminidase genes of avian influenza virus H5N6 subtype in the border of Yunnan Province from 2014 to 2015].
[Neuraminidase inhibitors and their potential use in the avian influenza pandemic]
[Neuraminidase inhibitors in prophylaxis and treatment of influenza]
[Optimization of the gene composition of influenza H5 virus hemagglutinin-containing reassortants and their efficacy in immune cross-protection experiments]
[Prediction of the B cell epitopes of hemagglutinin and neuraminidase of human infected avian influenza A H7N9 virus].
[Primary structure of the full-length DNA copy of the neuraminidase gene in the avian influenza virus of the N7 antigenic subtype]
[Properties of the influenza viruses isolated in 1976 from gulls in Astrakhan Province]
[Rapid detection of novel avian influenza virus subtype H7N9 by multiplex real-time RT-PCR].
[Relationship between eluting and neuraminidase activity of human, mammalian and avian influenza type A viruses]
[Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase]
Influenza, Human
-
"Late" Treatment With Neuraminidase Inhibitors for Severely Ill Patients With Influenza: Better Late Than Never?
"Will they just pack up and leave?" - attitudes and intended behaviour of hospital health care workers during an influenza pandemic.
'Flu' and structure-based drug design.
1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses.
2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus.
2009 H1N1 influenza: a twenty-first century pandemic with roots in the early twentieth century.
2009 update in prevention, evaluation, and outpatient treatment of influenza.
3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
3D-quantitative structure-activity relationship and antiviral effects of curcumin derivatives as potent inhibitors of influenza H1N1 neuraminidase.
4-(Acetylamino)-3-hydroxy-5-nitrobenzoic acid.
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.
5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication.
A 2 (N2) neuraminidase of the X-7 influenza virus recombinant: determination of molecular size and subunit composition of the active unit.
A 27-amino-acid deletion in the neuraminidase stalk supports replication of an avian H2N2 influenza A virus in the respiratory tract of chickens.
A 3D-RISM/RISM study of the oseltamivir binding efficiency with the wild-type and resistance-associated mutant forms of the viral influenza B neuraminidase.
A baculovirus dual expression vector derived from the Autographa californica nuclear polyhedrosis virus polyhedrin and p10 promoters: co-expression of two influenza virus genes in insect cells.
A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.
A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus.
A benzoic acid inhibitor induces a novel conformational change in the active site of Influenza B virus neuraminidase.
A binary QSAR model for classifying neuraminidase inhibitors of influenza A viruses (H1N1) using the combined minimum redundancy maximum relevancy criterion with the sparse support vector machine.
A brief introduction to the avian influenza virus.
A brief review of influenza virus infection.
A broad spectrum, one-step reverse-transcription PCR amplification of the neuraminidase gene from multiple subtypes of influenza A virus.
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.
A cell-free assay for the insertion of a viral glycoprotein into the plasma membrane.
A changing trend in diagnostic methods of Influenza A (H3N2) virus in human: a review.
A Chemically Programmed Antibody Is a Long-Lasting and Potent Inhibitor of Influenza Neuraminidase.
A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region.
A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility--North Carolina and South Carolina, 2010-2011.
A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus.
A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses.
A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
A competitive-inhibition radioimmunoassay for influenza virus envelope antigens.
A complete analysis of HA and NA genes of influenza A viruses.
A comprehensive deep sequencing strategy for full-length genomes of influenza A.
A Computational Assay that Explores the Hemagglutinin/Neuraminidase Functional Balance Reveals the Neuraminidase Secondary Site as a Novel Anti-Influenza Target.
A Computational Model for Docking of Noncompetitive Neuraminidase Inhibitors and Probing their Binding Interactions with Neuraminidase of Influenza Virus H5N1.
A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase.
A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.
A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.
A cost-benefit analysis of testing for influenza A in high-risk adults.
A Cost-Effectiveness Analysis of Neuraminidase Inhibitors for Influenza Virus Infections in an Adult-Outpatient Setting in Japan.
A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.
A designer drug against influenza: the NA inhibitor oseltamivir (Tamiflu).
A distinct lineage of influenza A virus from bats.
A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin.
A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.
A dual-functional molecular strategy for in situ suppressing and visualizing of neuraminidase in aqueous solution using iridium(iii) complexes.
A Dynamic, Supramolecular View on the Multivalent Interaction between Influenza Virus and Host Cell.
A fluorometric procedure for measuring the neuraminidase activity: its application to the determination of this activity in influenza and parainfluenza viruses.
A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.
A generic system for the expression and purification of soluble and stable influenza neuraminidase.
A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens.
A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.
A high-throughput screening system targeting the nuclear export pathway via the third nuclear export signal of influenza A virus nucleoprotein.
A human cell polarity protein Lgl2 regulates influenza A virus nucleoprotein exportation from nucleus in MDCK cells.
A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus.
A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.
A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model.
A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment.
A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
A microplate assay for sialidase activity using plant lectin binding to N-acetyllactosamine.
A microplate-based screening assay for neuraminidase inhibitors.
A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens.
A model-based assessment of oseltamivir prophylaxis strategies to prevent influenza in nursing homes.
A molecular mechanism for the low-pH stability of sialidase activity of influenza A virus N2 neuraminidases.
A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains.
A Monte Carlo sampling method of amino acid sequences adaptable to given main-chain atoms in the proteins.
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.
A multiplex real-time PCR assay for detection of oseltamivir-resistant strains of influenza virus.
A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein.
A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations.
A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.
A neuraminidase activity-based microneutralization assay for evaluating antibody responses to influenza H5 and H7 vaccines.
A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines.
A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.
A new in vitro hemagglutinin inhibitor screening system based on a single-vesicle fusion assay.
A new method for detection of pandemic influenza virus using High Resolution Melting analysis of the neuraminidase gene.
A new method for the purification of the influenza A virus neuraminidase.
A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.
A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action.
A new series of C3-aza carbocyclic influenza neuraminidase inhibitors: synthesis and inhibitory activity.
A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group.
A novel approach to antiviral therapy for influenza.
A novel aqueous extract from rice fermented with Aspergillus oryzae and Saccharomyces cerevisiae possesses an anti-influenza A virus activity.
A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro.
A novel genotyping and quantitative analysis of neuraminidase inhibitor-resistance associated mutations in influenza A viruses by single nucleotide polymorphism analysis.
A Novel I221L Substitution in Neuraminidase Confers High-Level Resistance to Oseltamivir in Influenza B Viruses.
A novel influenza virus neuraminidase inhibitor AV5027.
A novel lamprey antibody sequence to multimerize and increase the immunogenicity of recombinant viral and bacterial vaccine antigens.
A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains.
A novel lung explant model for the ex vivo study of efficacy and mechanisms of anti-influenza drugs.
A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particles.
A novel mutation in the neuraminidase gene of the 2009 pandemic H1N1 influenza A virus confers multidrug resistance.
A Novel Natural Influenza A H1N1 Virus Neuraminidase Inhibitory Peptide Derived from Cod Skin Hydrolysates and Its Antiviral Mechanism.
A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus.
A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.
A novel small molecule displays two different binding modes during inhibiting H1N1 influenza A virus neuraminidases.
A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture.
A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
A phospha-oseltamivir-biotin conjugate as a strong and selective adhesive for the influenza virus.
A plasmid-based reverse genetics system for influenza A virus.
A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding.
A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs.
A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals.
A preliminary panorama of the diversity of N1 subtype influenza viruses.
A previously unrecognized influenza B virus glycoprotein from a bicistronic mRNA that also encodes the viral neuraminidase.
A probable model of the inhibitory action of ceruloplasmin on the multiplication of some myxo- and paramyxoviruses.
A proline-based neuraminidase inhibitor: DFT studies on the zwitterion conformation, stability and formation.
A QSAR classification model for neuraminidase inhibitors of influenza A viruses (H1N1) based on weighted penalized support vector machine.
A QSAR study on influenza neuraminidase inhibitors.
A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
A randomized study of standard versus double dose oseltamivir for treating influenza in the community.
A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza.
A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination.
A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
A rapid LC-MS/MS quantification of peramivir using a simple and inexpensive sample precipitation: application to PK.
A re-examination of the single radial haemolysis technique for the assay of influenza anti-neuraminidase antibodies in human sera.
A reassortant between influenza A viruses (H7N2) synthesizing an enzymatically inactive neuraminidase at 40 degrees which is not incorporated into infectious particles.
A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site.
A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA.
A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
A review of avian influenza in different bird species.
A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.
A review of neuraminidase inhibitor susceptibility in influenza strains.
A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.
A rigid bicyclic platform for the generation of conformationally locked neuraminidase inhibitors.
A robust quantitative structure-activity relationship modelling of influenza neuraminidase a/PR/8/34 (H1N1) inhibitors based on the rank-bridge estimator.
A Screening of Neuraminidase Inhibition Activities of Isoquinolone Alkaloids in Coptis chinensis Using Molecular Docking and Pharmacophore Analysis.
A secondary sialic Acid binding site on influenza virus neuraminidase: fact or fiction?
A sensitive and specific ELISA immunocapture assay for rapid quantitation of influenza A/H3N2 neuraminidase protein.
A Sero-Survey of Subtype H3 Influenza A Virus Infection in Dogs and Cats in Japan.
A seven-segmented influenza A virus expressing the influenza C virus glycoprotein HEF.
A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies.
A sialosyl sulfonate as a potent inhibitor of influenza virus replication.
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.
A single cycle influenza virus coated in H7 haemagglutinin generates neutralizing antibody responses to haemagglutinin and neuraminidase glycoproteins and protection from heterotypic challenge.
A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.
A single sequence change destabilizes the influenza virus neuraminidase tetramer.
A single-radial haemolysis technique for measurement of antibody to influenza virus neuraminidase in equine sera.
A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis.
A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase.
A structural and energetics analysis of the binding of a series of N-acetylneuraminic-acid-based inhibitors to influenza virus sialidase.
A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs.
A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus.
A Sulfonozanamivir Analogue Has Potent Anti-influenza Virus Activity.
A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.
A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
A Synonymous Change in the Influenza A Virus Neuraminidase Gene Interferes with PCR-Based Subtyping and Oseltamivir Resistance Mutation Detection.
A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.
A topographic map of the enzyme active center and antigenic sites on the neuraminidase of influenza virus A/Tokyo/3/67 (H2N2).
A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus.
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
A Virtual Screening Approach For Identifying Plants with Anti H5N1 Neuraminidase Activity.
A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies.
A9?Deep sequencing analysis to investigate the importance of within host genetic diversity and evolution of influenza A viruses for the development of resistance against neuraminidase inhibitors.
Abnormal behavior during influenza in Japan during the last seven seasons: 2006-2007 to 2012-2013.
Absence of neuraminidase from influenza C virus.
Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans.
Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA.
ACP Journal Club. Review: Extended-duration chemoprophylaxis with neuraminidase inhibitors prevents symptomatic influenza.
ACP Journal Club. Review: Neuraminidase inhibitors relieve influenza symptoms and reduce laboratory-confirmed influenza in healthy adults.
Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza.
Action of influenza virus neuraminidase on gangliosides. Haemagglutinin inhibits viral neuraminidase.
Action of ortho- and paramyxovirus neuraminidase on gangliosides. Hydrolysis of ganglioside GM1 by Sendai virus neuraminidase.
Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
Active influenza virus neuraminidase is expressed in monkey cells from cDNA cloned in simian virus 40 vectors.
Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells.
Activity of Melaleuca alternifolia (tea tree) oil on Influenza virus A/PR/8: study on the mechanism of action.
Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.
Acyl amino acid derivatives as novel inhibitors of influenza neuraminidase.
Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
Adamantane and neuraminidase inhibitor resistance among circulating human influenza A viruses in Cuba during 2006-2010.
Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries.
Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008).
Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009.
Adaptation of influenza A viruses to cells expressing low levels of sialic acid leads to loss of neuraminidase activity.
Adaptation of the influenza neuraminidase and neuraminidase-inhibition assays to the microtitrator system.
Adaptive mutations of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of influenza A viruses.
Addition of a prominent epitope affects influenza A virus-specific CD8+ T cell immunodominance hierarchies when antigen is limiting.
Additional treatment with clarithromycin reduces fever duration in patients with influenza.
Adherence to Oseltamivir Guidelines during Influenza Pandemic, the Netherlands.
Adjunctive therapies and immunomodulatory agents in the management of severe influenza.
Adjustment of receptor-binding and neuraminidase substrate specificities in avian-human reassortant influenza viruses.
Administration of neuraminidase inhibitors for the treatment of Japanese patients infected with the novel influenza A (H1N1).
Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents.
Advancements in Host-Based Interventions for Influenza Treatment.
Advances in pharmacology. New treatments for influenza: neuraminidase inhibitors.
Advances in the Diagnosis and Management of Influenza.
Advances in the prophylaxis and treatment of influenza illness. Based on a presentation by Frederick G. Hayden, MD.
Advances in the structure-based design of the influenza A neuraminidase inhibitors.
Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
Affinity chromatography of influenza virus on immobilized alpha- and beta-ketosides of neuraminic acid derivatives.
Affinity of N-acetylneuraminic acid for influenza virus neuraminidase.
Affinity ranking of influenza neuraminidase mutants with monoclonal antibodies using an optical biosensor. Comparison with ELISA and slot blot assays.
Agathisflavone, a Biflavonoid from Anacardium occidentale L., Inhibits Influenza Virus Neuraminidase.
Allo-cross-reactivity of a human neuraminidase-specific T cell clone dependent on presentation of an endogenous B cell-specific antigen.
Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions.
Alternative base pairs attenuate influenza A virus when introduced into the duplex region of the conserved viral RNA promoter of either the NS or the PA gene.
Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials.
Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India.
Amino acid 316 of hemagglutinin and the neuraminidase stalk length influence virulence of H9N2 influenza virus in chickens and mice.
Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase.
Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase.
Amino acid sequence changes in antigenic variants of type A influenza virus N2 neuraminidase.
Amino acid sequence of the Pronase-released heads of neuraminidase subtype N2 from the Asian strain A/Tokyo/3/67 of influenza virus.
Amino acids responsible for the absolute sialidase activity of the influenza A virus neuraminidase: relationship to growth in the duck intestine.
Amino-terminal anchored surface display in insect cells and budded baculovirus using the amino-terminal end of neuraminidase.
AML1 protein interacts with influenza A virus neuraminidase and upregulates IFN-? response in infected mammalian cells.
Amplification of four genes of influenza A viruses using a degenerate primer set in a one step RT-PCR method.
An 18-amino acid deletion in an influenza neuraminidase.
An activity-integrated strategy of the identification, screening and determination of potential neuraminidase inhibitors from Radix Scutellariae.
An Amino Acid in the Stalk Domain of N1 Neuraminidase Is Critical for Enzymatic Activity.
An analysis of the role of neuraminidase in the receptor-binding activity of influenza B virus: the inhibitory effect of Zanamivir on haemadsorption.
An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac.
An effect of phloridzin on influenza virus elution and on neuraminidase activity.
An enzymatic assay for detection of viral entry.
An enzymatic assay reveals that proteins destined for the apical or basolateral domains of an epithelial cell line share the same late Golgi compartments.
An enzymatic virus-like particle assay for sensitive detection of virus entry.
An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex.
An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
An Infant Mouse Model of Influenza Virus Transmission Demonstrates the Role of Virus-Specific Shedding, Humoral Immunity, and Sialidase Expression by Colonizing Streptococcus pneumoniae.
An infectious bat-derived chimeric influenza virus harbouring the entry machinery of an influenza A virus.
An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice.
An influenza A(H5N8) virus isolated during an outbreak at a poultry farm in Russia in 2017 has an N294S substitution in the neuraminidase and shows reduced susceptibility to oseltamivir.
An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses.
An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir.
An influenza virus model for Trypanosoma cruzi infection: interactive roles for neuraminidase and lectin.
An inhibition test for identifying the neuraminidase antigen on influenza viruses.
An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies.
An integrated microfluidic system for rapid detection and multiple subtyping of influenza A viruses by using glycan-coated magnetic beads and RT-PCR.
An investigation of antigenic drift of neuraminidases of influenza A (H1N1) viruses.
An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza A Virus Subtype H7N9 and Protects Mice From Lethality.
An iron carbonyl approach to the influenza neuraminidase inhibitor oseltamivir.
An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice.
An NA-deficient 2009 pandemic H1N1 influenza virus mutant can efficiently replicate in cultured cells.
An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses.
An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults.
An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera.
An overview of influenza haemagglutinin and neuraminidase.
An overview of the epidemiology of avian influenza.
An update on the prevention of influenza in children and adolescents.
Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
Analyses of structural polypeptides of seven different isolates of influenza C virus.
Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation of drug unbinding and rebinding in simulation.
Analysis of delays in the prescription of oseltamivir in hospitals and potential for improvement.
Analysis of Glycosyl-Enzyme Intermediate Formation in the Catalytic Mechanism of Influenza Virus Neuraminidase Using Molecular Modeling.
Analysis of influenza A virus neuraminidase using lectin test and monoclonal antibodies.
Analysis of inhibitor binding in influenza virus neuraminidase.
Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.
Analysis of the binding of the Fab fragment of monoclonal antibody NC10 to influenza virus N9 neuraminidase from tern and whale using the BIAcore biosensor: effect of immobilization level and flow rate on kinetic analysis.
Analysis of the desialidation process of the haemagglutinin protein of influenza B virus: the host-dependent desialidation step.
Analysis of the Evolution of Pandemic Influenza A(H1N1) Virus Neuraminidase Reveals Entanglement of Different Phenotypic Characteristics.
Analysis of the hemagglutinin and neuraminidase genes of human Influenza A/H3N2 viruses circulating in iran between 2005 and 2007: antigenic and phylogenetic relationships to vaccine strains.
Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice.
Analysis of the signals for polarized transport of influenza virus (A/WSN/33) neuraminidase and human transferrin receptor, type II transmembrane proteins.
Analysis of the transmembrane domain of influenza virus neuraminidase, a type II transmembrane glycoprotein, for apical sorting and raft association.
Analysis of viral and cellular parameters which affect the fusion process of influenza viruses.
Analyzing swine sera for functional antibody titers against influenza A neuraminidase proteins using an enzyme-linked lectin assay (ELLA).
Ancestral and Compensatory Mutations that Promote Antiviral Resistance in Influenza N1 Neuraminidase Revealed by a Phylonumerics Approach.
Animal influenza virus neuraminidase: studies on dependence of some of its properties on its association with hemagglutinin.
Anomeric specificity and protein-substrate interactions support the 3D model for the hemagglutinin-neuraminidase from sendai virus.
Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV).
Anti-influenza A virus activity of uridine derivatives of 2-deoxy sugars.
Anti-Influenza Activity of an Ethyl Acetate Fraction of a Rhus verniciflua Ethanol Extract by Neuraminidase Inhibition.
Anti-influenza drugs: the development of sialidase inhibitors.
Anti-influenza effect of the major flavonoids from Salvia plebeia R.Br. via inhibition of influenza H1N1 virus neuraminidase.
Anti-Influenza Virus (H5N1) Activity Screening on the Phloroglucinols from Rhizomes of Dryopteris crassirhizoma.
Anti-influenza virus activities of flavonoids from the medicinal plant Elsholtzia rugulosa.
Anti-Influenza Virus Activity and Constituents. Characterization of Paeonia delavayi Extracts.
Anti-influenza virus activity of biflavonoids.
Anti-influenza virus activity of peramivir in mice with single intramuscular injection.
Anti-influenza virus phytochemicals from Radix Paeoniae Alba and characterization of their neuraminidase inhibitory activities.
Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.
Anti-neuraminidase antibodies: which substrate should be used to test their effect on influenza virus neuraminidase.
Anti-Neuraminidase Bioactives from Manggis Hutan (Garcinia celebica L.) Leaves: Partial Purification and Molecular Characterization.
Anti-pandemic influenza A(H1N1) virus potential of catechin and gallic acid.
Anti-Viral Inhibitor Binding to Influenza Neuraminidase by MALDI Mass Spectrometry.
Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry.
Antibody against influenza A2 virus neuraminidase in human sera.
Antibody against Microbial Neuraminidases Recognizes Human Sialidase 3 (NEU3): the Neuraminidase/Sialidase Superfamily Revisited.
Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.
Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase.
Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial.
Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98).
Antibody formation after vaccination with adsorbed and non-adsorbed A/New Jersey/8/76 influenza vaccines.
Antibody Neutralization of an Influenza Virus that Uses Neuraminidase for Receptor Binding.
Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination.
Antibody recognition of a highly conserved influenza virus epitope.
Antibody recognition of the influenza virus neuraminidase.
Antibody response in humans to neuraminidase of A2-Aichi-68 and B-Mass-66 influenza viruses.
Antibody response in man to influenza virus neuraminidase following influenza.
Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
Antibody-free digital influenza virus counting based on neuraminidase activity.
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice.
Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection.
Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies.
ANTIGENIC AND GENETIC CHARACTERIZATION OF INFLUENZA B VIRUSES IN 2012 FROM SLUMS, DHAKA, BANGLADESH.
Antigenic and genomic relation between human influenza A (H3N2) viruses circulating in Argentina during 1998 and the H3N2 vaccine component.
Antigenic characterisation of influenza B virus with a new microneutralisation assay: comparison to haemagglutination and sequence analysis.
Antigenic characterization of an H3N2 swine influenza virus isolated from pigs with proliferative and necrotizing pneumonia in Quebec.
Antigenic characterization of recombinant hemagglutinin proteins derived from different avian influenza virus subtypes.
Antigenic comparison of swine influenza virus isolates.
Antigenic Drift of Hemagglutinin and Neuraminidase in seasonal H1N1 influenza Viruses from Saudi Arabia in 2014-2015.
Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.
Antigenic relationship between the surface antigens of avian and equine influenze viruses.
Antigenic relationships among influenza virua A neuraminidase (N2) antigens by immunodiffusion and postinfection neutralization tests.
Antigenic structure and variation in an influenza virus N9 neuraminidase.
Antigenic variability in Neuraminidase protein of Influenza A/H3N2 vaccine strains (1968 - 2009).
Antigenic variation and the structure of influenza virus glycoproteins.
Antigenic variation of neuraminidase of human type A influenza (H3N2) viruses isolated in Berlin (West).
Antigenic, sequence, and crystal variation in influenza B neuraminidase.
Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins.
Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase.
Antineuraminidase antibody response of man to influenza virus neuraminidase N2: results obtained with an improved hemagglutination inhibition technique and an enzyme inhibition test.
Antipneumococcal activity of neuraminidase inhibiting artocarpin.
Antiviral Activities of Compounds from Aerial Parts of Salvia plebeia R. Br.
Antiviral activity of a synthesized shikonin ester against influenza A (H1N1) virus and insights into its mechanism.
Antiviral activity of antiserum specific for an influenza virus neuraminidase.
Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions.
Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
Antiviral Activity of Benzoic Acid Derivative NC-5 Against Influenza A Virus and Its Neuraminidase Inhibition.
Antiviral activity of chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of neuraminidase.
Antiviral Activity of Chrysin against Influenza Virus Replication via Inhibition of Autophagy.
Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition.
Antiviral Activity of Isoimperatorin Against Influenza A Virus in vitro and its Inhibition of Neuraminidase.
Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase.
Antiviral Activity of the Long Chain Pentraxin PTX3 against Influenza Viruses.
Antiviral activity of the plant extracts from Thuja orientalis, Aster spathulifolius, and Pinus thunbergii against influenza virus A/PR/8/34.
Antiviral adhesion molecular mechanisms for influenza: W. G. Laver's lifetime obsession.
Antiviral agents for influenza, hepatitis C and herpesvirus, enterovirus and rhinovirus infections.
Antiviral agents for influenza: a comparison of cost-effectiveness data.
Antiviral agents for treating influenza.
Antiviral agents: structural basis of action and rational design.
Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses.
Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline?
Antiviral combinations for severe influenza.
Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011.
Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016.
Antiviral drugs for viruses other than human immunodeficiency virus.
Antiviral drugs in current clinical use.
Antiviral drugs in influenza. An adjunct to vaccination in some situations.
Antiviral drugs in the immunocompetent host: part II. Treatment of influenza and respiratory syncytial virus infections.
Antiviral drugs: current state of the art.
Antiviral effect of flavonol glycosides isolated from the leaf of Zanthoxylum piperitum on influenza virus.
Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai.
Antiviral prophylaxis during pandemic influenza may increase drug resistance.
Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.
Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details.
Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers.
Antiviral resistance in influenza viruses: laboratory testing.
Antiviral resistance markers in influenza virus sequences in Mexico, 2000-2017.
Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007.
Antiviral strategies against influenza virus: towards new therapeutic approaches.
Antiviral strategies for pandemic and seasonal influenza.
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
Antiviral therapies on the horizon for influenza.
Antiviral therapy for influenza : a clinical and economic comparative review.
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Antiviral therapy of influenza.
Antiviral therapy: current options and challenges.
Antiviral therapy: respiratory infections, chronic hepatitis.
Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Antiviral treatment of childhood influenza: an update.
Antiviral treatment of influenza in South Korea.
Antiviral Treatments.
Antiviral use in healthcare workers-A systematic review.
Antivirals and resistance: influenza virus.
Antivirals and the control of influenza outbreaks.
Antivirals for influenza in healthy adults: systematic review.
Antivirals for influenza: historical perspectives and lessons learned.
Antivirals for influenza: strategies for use in pediatrics.
Antivirals for pandemic influenza.
Antivirals for the treatment and prevention of epidemic and pandemic influenza.
Antivirals in seasonal and pandemic influenza--future perspectives.
Antivirals in the management of an influenza pandemic.
Antivirals Targeting the Neuraminidase.
Antivirals targeting the polymerase complex of influenza viruses.
Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.
Antivirals used for influenza chemoprophylaxis.
Apical budding of a recombinant influenza A virus expressing a hemagglutinin protein with a basolateral localization signal.
Apical Trafficking Pathways of Influenza A Virus HA and NA via Rab17- and Rab23-Positive Compartments.
Apigenin suppresses influenza A virus-induced RIG-I activation and viral replication.
Apoptosis by influenza viruses correlates with efficiency of viral mRNA synthesis.
Application of a Seven-Target Pyrosequencing Assay To Improve the Detection of Neuraminidase Inhibitor-Resistant Influenza A(H3N2) Viruses.
Application of the single radial diffusion test for assay of antibody to influenza type A viruses.
Application of three duplex real-time PCR assays for simultaneous detection of human seasonal and avian influenza viruses.
Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions.
Approach to the involvement of influenza B neuraminidase in the cleavage of HA by host cell protease using low pH-induced cell fusion reaction.
Approaches and strategies for the treatment of influenza virus infections.
Approaches to antiviral chemotherapy for acute respiratory infections.
Approved Antiviral Drugs over the Past 50 Years.
Aptamers to hemagglutinin: a novel tool for influenza virus recognition and neutralization.
Are neuraminidase inhibitors effective for preventing and treating influenza in healthy adults and children?
Aromatic sialic acid analogues as potential inhibitors of influenza virus neuraminidase.
Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays.
Assays for functional binding of plasminogen to viral proteins.
Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.
Assembly of subtype 1 influenza neuraminidase is driven by both the transmembrane and head domains.
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Assessing the In Vitro Fitness of an Oseltamivir-Resistant Seasonal A/H1N1 Influenza Strain Using a Mathematical Model.
Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.
Assessing the susceptibility of highly pathogenic avian influenza H5N1 viruses to oseltamivir using embryonated chicken eggs.
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.
Assessment of Anti-Influenza Activity and Hemagglutination Inhibition of Plumbago indica and Allium sativum Extracts.
Assessment of immunity to influenza using artifical challenge of normal volunteers with influenza virus.
Assessment of influenza A neuraminidase (subtype N1) potency by ELISA.
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks.
Association of severe abnormal behavior and acetaminophen with/without neuraminidase inhibitors.
Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.
Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry.
Attachment of influenza C virus to human erythrocytes.
Attenuated influenza B virus recombinants obtained by crossing of B/England/2608/76 virus with a cold-adapted B/Leningrad/14/17/55 strain.
Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice.
Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.
Attenuation and phenotypic stability of influenza B/Texas/1/84 cold-adapted reassortant virus: studies in hamsters and chimpanzees.
Attenuation of an influenza A virus due to alteration of its hemagglutinin-neuraminidase functional balance in mice.
Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus.
Attenuation of influenza A virus by insertion of a foreign epitope into the neuraminidase.
Attenuation of pathogenicity of fowl plague virus by recombination with other influenza A viruses nonpathogenic for fowl: nonexculsive dependence of pathogenicity on hemagglutinin and neuraminidase of the virus.
Atypical antibody responses to influenza.
Aureonitol, a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin.
Aurintricarboxylic acid inhibits influenza virus neuraminidase.
Author Correction: Structural restrictions for influenza neuraminidase activity promote adaptation and diversification.
Auto-antibody dependent activation of the autologous classical complement pathway by guinea-pig red cells treated with influenza virus or neuraminidase: in vitro and in vivo study.
Automatic detection of rate change in large data sets with an unsupervised approach: the case of influenza viruses.
Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
Avian flu: isolation of drug-resistant H5N1 virus.
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
Avian influenza and pandemic influenza threat.
Avian influenza viruses infecting humans.
Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses.
Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process.
B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.
Bacterial and viral sialidases: contribution of the conserved active site glutamate to catalysis.
Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production.
Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor.
Bacterial pneumonia and pandemic influenza planning.
Baculovirus as an efficient vector for gene delivery into mosquitoes.
Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use.
Baculovirus-Produced Influenza Virus-like Particles in Mammalian Cells Protect Mice from Lethal Influenza Challenge.
Baicalein, Ethyl Acetate, and Chloroform Extracts of Scutellaria baicalensis Inhibit the Neuraminidase Activity of Pandemic 2009 H1N1 and Seasonal Influenza A Viruses.
Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus.
Balancing societal needs and regulatory certainty: the case study of peramivir in Japan.
Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone.
Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
Baloxavir marboxil treatment of nude mice infected with influenza A virus.
Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
Baloxavir marboxil: the new influenza drug on the market.
Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.
Basolateral sorting signals differ in their ability to redirect apical proteins to the basolateral cell surface.
Bat-derived influenza-like viruses H17N10 and H18N11.
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
Behaviour and control of influenza in institutions and small societies.
Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus.
Benzoic acid and pyridine derivatives as inhibitors of Trypanosoma cruzi trans-sialidase.
Benzoic acid inhibitors of influenza virus neuraminidase.
Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity.
Berberine-piperazine conjugates as potent influenza neuraminidase blocker.
Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
Beyond personal protective equipment: adjunctive methods for control of healthcare-associated respiratory viral infections.
Binding affinity of GM3 lactone for influenza virus.
Binding affinity of influenza virus N9 neuraminidase with Fab fragments of monoclonal antibodies NC10 and NC41.
Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and its Implication for Drug Design.
Binding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometry.
Binding of antibodies to isolated haemagglutinin and neuraminidase molecules of influenza virus observed in the electron microscope.
Binding of bacteria to HEp-2 cells infected with influenza A virus.
Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form.
Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
Bioactive compounds derived from the marine-derived fungus MCCC3A00951 and their influenza neuraminidase inhibition activity in vitro and in silico.
Bioassay of ferulic acid derivatives as influenza neuraminidase inhibitors.
Biochemical Methods for the Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en.
Bioinformatics studies of Influenza A hemagglutinin sequence data indicate recombination-like events leading to segment exchanges.
Biologic importance of neuraminidase stalk length in influenza A virus.
Biological and immunological properties of haemagglutinin and neuraminidase expressed from cloned cDNAs in prokaryotic and eukaryotic cells.
Biological and protective properties of immune sera directed to the influenza virus neuraminidase.
Biological properties of N-acyl and N-haloacetyl neuraminic acids: processing by enzymes of sialic acid metabolism, and interaction with influenza virus.
Bioluminescence-based neuraminidase inhibition assay for monitoring influenza drug susceptibility in clinical specimens.
Biophysical measurement of the balance of influenza a hemagglutinin and neuraminidase activities.
Biosensor-based epitope mapping of antibodies targeting the hemagglutinin and neuraminidase of influenza A virus.
Biotin-, fluorescein- and 'clickable' conjugates of phospha-oseltamivir as probes for the influenza virus which utilize selective binding to the neuraminidase.
BirdFlu2009: Avian Influenza and Human Health.
Birds, migration and emerging zoonoses: west nile virus, lyme disease, influenza A and enteropathogens.
Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.
Bivalent vaccine platform based on ca influenza virus vaccine elicits protective immunity against human adenoviruses.
Block deletions in the neuraminidase genes from some influenza A viruses of the N1 subtype.
Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza.
BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses.
Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs.
Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.
Broadly Protective CD8+ T Cell Immunity to Highly Conserved Epitopes Elicited by Heat Shock Protein gp96-Adjuvanted Influenza Monovalent Split Vaccine.
Broadly protective human antibodies that target the active site of influenza virus neuraminidase.
Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.
Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.
Bronchial reactivity in experimental infections with influenza virus.
Budding capability of the influenza virus neuraminidase can be modulated by tetherin.
Burden of influenza B virus infection and considerations for clinical management.
C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase.
C-Terminally tagged NA in replication-competent influenza A viruses reveals differences in glycan profiles between NA and HA.
Caffeic acid derivatives: a new type of influenza neuraminidase inhibitors.
Calcium is needed for the thermostability of influenza B virus neuraminidase.
Can an office practice telephonic response meet the needs of a pandemic?
Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?
Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles.
Carbocyclic influenza neuraminidase inhibitors possessing a C3-cyclic amine side chain: synthesis and inhibitory activity.
Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.
Carbohydrate mimetics and scaffolds: sweet spots in medicinal chemistry.
Carbosilane glycodendrimers.
Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.
Catalytic inactivation of influenza virus by iron oxide nanozyme.
Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).
Catalytic properties of the A/H3N2 influenza neuraminidases: influence of antigenic variations.
Catechin inhibiting the H1N1 influenza virus associated with the regulation of autophagy.
Catechin inhibition of influenza neuraminidase and its molecular basis with mass spectrometry.
Cationic Lipid/DNA Complex-Adjuvanted Influenza A Vaccination Induces Robust Cross-Protective Immunity.
CD4+ follicular regulatory T cells optimize the influenza virus-specific B cell response.
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Cell receptors for paramyxoviruses.
Cell surface transport, oligomerization, and endocytosis of chimeric type II glycoproteins: role of cytoplasmic and anchor domains.
Cell-mediated immune responses to the hemagglutinin and neuraminidase antigens of influenza A virus after immunization in humans.
Cell-permeable probe for identification and imaging of sialidases.
Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
Challenges and options in the management of viral infections after stem cell transplantation.
Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.
Changes in Hemagglutinin and Neuraminidase Genes of pH1N1 Influenza Virus Strains Collected from a North Indian Tertiary Care Hospital during 2015.
Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Changes in temperature-sensitivity of haemagglutinin and neuraminidase during adaptation of influenza virus to mice.
Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001-02, 2002-03, and 2003-04 seasons.
Changes in the Length of the Neuraminidase Stalk Region Impact H7N9 Virulence in Mice.
Changes in the neuraminidase of neurovirulent influenza virus strains.
Characterisation of an avian influenza virus nucleoprotein expressed in E. coli and in insect cells.
Characterisation of an ionisable group involved in binding and catalysis by sialidase from influenza virus.
Characterisation of influenza viruses isolated from turkeys in Great Britain during 1963--1977.
Characteristic of alkylated chalcones from Angelica keiskei on influenza virus neuraminidase inhibition.
Characteristics of a cell-free assay for the delivery of proteins to the plasma membrane.
Characteristics of cytotoxic T lymphocytes directed to influenza virus haemagglutinin elicited by immunization with muramyldipeptide-influenza liposome vaccine.
Characteristics of influenza HA-NA interdependence determined through a graphical technique.
Characterization and mutational analysis of haemagglutinin and neuraminidase of H3N2 and H1N1pdm09 human influenza A viruses in Egypt.
Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene.
Characterization of a 1980-swine recombinant influenza virus possessing H1 hemagglutinin and N2 neuraminidase similar to that of the earliest Hong Kong (H3N2) virus.
Characterization of a cold-sensitive (cs) recombinant between two influenza A strains.
Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus.
Characterization of a large cluster of influenza A(H1N1)pdm09 virus cross-resistant to oseltamivir and peramivir during the 2013/2014 influenza season in Japan.
Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.
Characterization of a newly emerged genetic cluster of H1N1 and H1N2 swine influenza virus in the United States.
Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls.
Characterization of a temperature-sensitive influenza B virus mutant defective in neuraminidase.
Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.
Characterization of contemporary 2010.1 H3N2 swine influenza A viruses circulating in United States pigs.
Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.
CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
Characterization of influenza virus neuraminidase with hemagglutinin activity and its comparison with that of viral neuraminidase.
Characterization of influenza virus-induced leukocyte adherence to human umbilical vein endothelial cell monolayers.
Characterization of mAb6-9-1 monoclonal antibody against hemagglutinin of avian influenza virus H5N1 and its engineered derivative, single-chain variable fragment antibody.
Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.
Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses.
Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses.
Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
Characterization of pseudoparticles paired with hemagglutinin and neuraminidase from highly pathogenic H5N1 influenza and avian influenza A (H7N9) viruses.
Characterization of recent H5 subtype avian influenza viruses from US poultry.
Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations.
Characterization of sialidase from an influenza A (H3N2) virus strain: kinetic parameters and substrate specificity.
Characterization of sialyltransferases from serum of normal and hepatoma Mc-29 bearing chickens.
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Characterization of temperature sensitive influenza virus mutants defective in neuraminidase.
Characterization of the 1918 "Spanish" influenza virus neuraminidase gene.
Characterization of the glycoproteins of bat-derived influenza viruses.
Characterization of the hemagglutinin and neuraminidase genes of recent influenza virus isolates from different avian species in Thailand.
Characterization of the hemagglutinin receptor specificity and neuraminidase substrate specificity of clinical isolates of human influenza A viruses.
Characterization of the neuraminidase genes from human influenza A viruses circulating in Iran from 2010 to 2015.
Characterization of the neuraminidase of the H1N1/09 pandemic influenza virus.
Characterization of the ribonucleoprotein and neuraminidase of influenza A viruses by immunodiffusion.
Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses.
Characterization of Variations in PB2, NS1, M, Neuraminidase and Hemagglutinin of Influenza A (H3N2) Viruses in Iran.
Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations.
Charged amino acid variability related to N-glyco -sylation and epitopes in A/H3N2 influenza: Hem -agglutinin and neuraminidase.
Chemical and antigenic characterization of the carbohydrate side chains of an Asian (N2) influenza virus neuraminidase.
Chemical insight into the emergence of influenza virus strains that are resistant to relenza.
Chemical probes for drug-resistance assessment by binding competition (RABC): oseltamivir susceptibility evaluation.
Chemoenzymatic site-specific labeling of influenza glycoproteins as a tool to observe virus budding in real time.
Chemoenzymatic Syntheses of Sialylated Oligosaccharides Containing C5-Modified Neuraminic Acids for Dual Inhibition of Hemagglutinins and Neuraminidases.
Chemoenzymatic synthesis of an N-acetylneuraminic acid analogue having a carbamoylmethyl group at C-4 as an inhibitor of sialidase from influenza virus.
Chemoenzymatic synthesis of neuraminic acid analogs structurally varied at C-5 and C-9 as potential inhibitors of the sialidase from influenza virus.
Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract.
Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin.
Chiropteran influenza viruses: flu from bats or a relic from the past?
Chromatofocusing of sialoglycoproteins.
Circulating pattern and genomic characteristics of influenza B viruses in Taiwan from 2003 to 2014.
Cirsimaritin inhibits influenza A virus replication by downregulating the NF-?B signal transduction pathway.
Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells.
Class I H-2d-restricted cytotoxic T lymphocytes recognize the neuraminidase glycoprotein of influenza virus subtype N1.
Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. Evidence that presentation of labile T cell determinants is favored by endogenous antigen synthesis.
ClassyFlu: classification of influenza A viruses with Discriminatively trained profile-HMMs.
Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan.
Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.
Clinical and Pathologic Characterization of an Outbreak of Highly Pathogenic Avian Influenza H7N8 in Commercial Turkeys in Southern Indiana.
Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and Innovations.
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation.
Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients.
Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.
Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
Clinical Efficacy of Peramivir in Adult Patients with Seasonal Influenza during the winter of 2012 in Japan.
Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States.
Clinical findings in 10 children with H275Y influenza A(H1N1)pdm09 virus infection.
Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy.
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
Clinical trials with a new influenza subunit vaccine in adults and children.
Clinical use of approved influenza antivirals: therapy and prophylaxis.
Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza.
Co-evolution analysis to predict protein-protein interactions within influenza virus envelope.
Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers.
Codon optimization of the major antigen encoding genes of diverse strains of influenza a virus.
Codon usage bias and recombination events for neuraminidase and hemagglutinin genes in Chinese isolates of influenza A virus subtype H9N2.
Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge.
Cold-adapted recombinant influenza A virus vaccines in seronegative young children.
Combating influenza with antiviral therapy in the pediatric population.
Combination activity of neuraminidase inhibitor oseltamivir and ?-tocopherol in influenza virus A (H3N2) infection in mice.
Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.
Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro.
Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model.
Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.
Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin.
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.
Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
Combinatorial effect of two E119V+I222L framework mutations in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.
Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection.
Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.
Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.
Combined MS/MS-NMR Annotation Guided Discovery of Iris lactea var. chinensis Seed as a Source of Viral Neuraminidase Inhibitory Polyphenols.
Combined quantum mechanics/molecular mechanics (QM/MM) simulations for protein-ligand complexes: free energies of binding of water molecules in influenza neuraminidase.
Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibition.
Combining Molecular Docking and Molecular Dynamics to Predict the Binding Modes of Flavonoid Derivatives with the Neuraminidase of the 2009 H1N1 Influenza A Virus.
Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
Comment on 'Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)"'.
Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.
Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.
Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016.
Community-acquired respiratory viruses.
Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity.
Comparable Fitness and Transmissibility between Oseltamivir-Resistant Pandemic 2009 and Seasonal H1N1 Influenza Viruses with the H275Y Neuraminidase Mutation.
Comparative analysis of virulence of a novel, avian-origin H3N2 canine influenza virus in various host species.
Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes.
Comparative Co-Evolution Analysis Between the HA and NA Genes of Influenza A Virus.
Comparative dynamics and distribution of influenza drug resistance acquisition to protein m2 and neuraminidase inhibitors.
Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.
Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.
Comparative evaluation of effectiveness of IAVchip DNA microarray in influenza A diagnosis.
Comparative in vitro analysis of inhibition of rhinovirus and influenza virus replication by mucoactive secretolytic agents and plant extracts.
Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections.
Comparative nucleotide sequences at the 3' end of the neuraminidase gene from eleven influenza type A viruses.
Comparative phyloinformatics of virus genes at micro and macro levels in a distributed computing environment.
Comparative sequence, antigenic and phylogenetic analysis of avian influenza (H9N2) surface proteins isolated in Pakistan between 1999 and 2008.
Comparative studies on influenza B virus. I. Biological properties and polypeptide composition of strains isolated in different years.
Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.
Comparative study of lymphocytes from individuals that were vaccinated and unvaccinated against the pandemic 2009-2011 H1N1 influenza virus in Southern Brazil.
Comparative study of the hemagglutinin and neuraminidase genes of influenza A virus H3N2, H9N2, and H5N1 subtypes using bioinformatics techniques.
Comparative study of the nucleotide bias between the novel H1N1 and H5N1 subtypes of influenza A viruses using bioinformatics techniques.
Comparative thermostability analysis of zoonotic and human influenza virus A and B neuraminidase.
Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens.
Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
Comparison of biological and physical properties of human and animal A(H1N1) influenza viruses.
Comparison of different cell substrates on the measurement of human influenza virus neutralizing antibodies.
Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Comparison of in vitro replication features of H7N3 influenza viruses from wild ducks and turkeys: potential implications for interspecies transmission.
Comparison of influenza virus hemagglutinin, neuraminidase and their antibody responses in infected patients.
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine.
Comparison of neuraminidase activity of influenza A virus subtype H5N1 and H1N1 using reverse genetics virus.
Comparison of neuraminidases of the same subtype but from different species using a new method of titration.
Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel.
Comparison of single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection: A phase III randomized, double-blind study.
Comparison of substrate specificities of sialidase activity between purified enzymes from influenza virus A (H1N1 and H3N2 subtypes) and B strains and their original viruses.
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Comparison of the antiviral effect of solid-state copper and silver compounds.
Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.
Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.
Comparison of the pathogenesis of two genetically different H3N2 influenza A viruses in pigs.
Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir.
Compensatory evolution of net-charge in influenza A virus hemagglutinin.
Competitive Cooperation of Hemagglutinin and Neuraminidase during Influenza A Virus Entry.
Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets.
Competitive Fitness of Influenza B Viruses with Neuraminidase Inhibitor-Resistant Substitutions in a Co-infection Model of the Human Airway Epithelium.
Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus.
Complete amino-acid sequence and carbohydrate content of the naturally occurring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant.
Complete nucleotide sequence of a human influenza neuraminidase gene of subtype N2 (A/Victoria/3/75).
Complete nucleotide sequence of the neuraminidase gene of human influenza virus A/WSN/33.
Complete nucleotide sequence of the neuraminidase gene of influenza B virus.
Complete nucleotide sequence of the neuraminidase gene of the human influenza virus A/Chile/1/83 (H1N1). Brief report.
Complex gel permeation assays for screening combinatorial libraries.
Complexity in influenza virus targeted drug design: interaction with human sialidases.
Complications of viral influenza.
Composition of Hemagglutinin and Neuraminidase Affects the Antigen Yield of Influenza A(H1N1)pdm09 Candidate Vaccine Viruses.
Comprehensive N-glycosylation analysis of the influenza A virus proteins HA and NA from adherent and suspension MDCK cells.
Comprehensive profiling of translation initiation in influenza virus infected cells.
Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase.
Computational analysis of proteome of H5N1 avian influenza virus to define T cell epitopes with vaccine potential.
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
Computational assay of Zanamivir binding affinity with original and mutant influenza neuraminidase 9 using molecular docking.
Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme.
Computational model for analyzing the evolutionary patterns of the neuraminidase gene of influenza A/H1N1.
Computational modeling and validation studies of 3-D structure of neuraminidase protein of H1N1 influenza A virus and subsequent in silico elucidation of piceid analogues as its potent inhibitors.
Computational studies of H5N1 influenza virus resistance to oseltamivir.
Computational studies of influenza a virus at three important targets: hemagglutinin, neuraminidase and m2 protein.
Computational studies of sialyllactones: methods and uses.
Computational Study of Dispersion and Extent of Mutated and Duplicated Sequences of the H5N1 Influenza Neuraminidase over the Period 1997-2008.
Computational Study of Drug Binding Affinity to Influenza A Neuraminidase Using Smooth Reaction Path Generation (SRPG) Method.
Computational Study of Interdependence Between Hemagglutinin and Neuraminidase of Pandemic 2009 H1N1.
Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase.
Computer-Guided Approach to Access the Anti-influenza Activity of Licorice Constituents.
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.
Conformational Free Energy Surface of alpha-N-Acetylneuraminic Acid: An Interplay Between Hydrogen Bonding and Solvation.
Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan.
Consensus QSAR model for identifying novel H5N1 inhibitors.
Conservation region finding for influenza A viruses by machine learning methods of N-linked glycosylation sites and B-cell epitopes.
Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies.
Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses.
Construction and comparison of different source neuraminidase candidate vaccine strains for human infection with Eurasian avian-like influenza H1N1 virus.
Construction of a convenient system for easily screening inhibitors of mutated influenza virus neuraminidases.
Construction of recombinant fusion protein of influenza, a virus neuraminidase and heat shock protein 70 gene: expression in baculovirus and bioactivity.
Contacts between influenza virus N9 neuraminidase and monoclonal antibody NC10.
Continuing challenges in influenza.
Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.
Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays.
Contribution of neuraminidase of influenza viruses to the sensitivity to sera inhibitors and reassortment efficiency.
Contribution to the standardization of influenza neuraminidase inhibition tests, based on enzyme- antienzyme kinetic studies.
Control of highly pathogenic avian influenza in Quang Tri province, Vietnam: voices from the human-animal interface.
Controlling influenza by inhibiting the virus's neuraminidase.
Cooperation between distinct viral variants promotes growth of H3N2 influenza in cell culture.
Coordinated Evolution of Influenza A Surface Proteins.
Core-6 fucose and the oligomerization of the 1918 pandemic influenza viral neuraminidase.
Correction: Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.
Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice.
Correlation Analyses on Binding Affinity of Sialic Acid Analogues and Antiinfluenza Drugs with Human Neuraminidase Using ab Initio MO Calculations on Their Complex Structures - LERE-QSAR Analysis (IV).
Correlation analyses on binding affinity of sialic acid analogues with influenza virus neuraminidase-1 using ab initio MO calculations on their complex structures.
Correlation between levels of apoptosis, levels of infection and haemagglutinin receptor binding interaction of various subtypes of influenza virus: does the viral neuraminidase have a role in these associations.
Corticosteroids as adjunctive therapy in the treatment of influenza.
Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.
Cost-effectiveness of newer treatment strategies for influenza.
Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults.
Critical care management of adults with community-acquired severe respiratory viral infection.
Critical interactions in binding antibody NC41 to influenza N9 neuraminidase: amino acid contacts on the antibody heavy chain.
Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
Cross-immunity and age patterns of influenza A(H5N1) infection.
Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.
Cross-protective immune responses elicited by live attenuated influenza vaccines.
Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.
Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase.
Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6.
Crystal structure of phage P22 tailspike protein complexed with Salmonella sp. O-antigen receptors.
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.
Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface.
Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site.
CrystalDock: a novel approach to fragment-based drug design.
Crystalline monoclonal fab fragment with specificity towards an influenza virus neuraminidase.
Crystallization and peptide maps of neuraminidase "heads" from H2N2 and H3N2 influenza virus strains.
Crystallization and preliminary X-ray analyses of two neuraminidases from influenza B virus strains B/Hong Kong/8/73 and B/Lee/40.
Crystallization and preliminary X-ray analysis of type B influenza virus neuraminidase complexed with antibody Fab fragments.
Crystallization and preliminary X-ray studies of influenza A virus neuraminidase of subtypes N5, N6, N8 and N9.
Crystals of antibodies complexed with influenza virus neuraminidase show isosteric binding of antibody to wild-type and variant antigens.
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Current and future antiviral therapy of severe seasonal and avian influenza.
Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses.
Current strategies for management of influenza in the elderly population.
Current usage and effectiveness of influenza medications and factors regarding the time taken to alleviate fever based on postcard questionnaire survey.
Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.
Cytotoxic T cell lysis of target cells fused with liposomes containing influenza virus haemagglutinin and neuraminidase.
DANCING WITH CHEMICAL FORMULAE OF ANTIVIRALS: A PANORAMIC VIEW (part 2).
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.
Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains.
Db-binding peptides from influenza virus: effect of non-anchor residues on stability and immunodominance.
Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium.
Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.
Defective ribosomal products are the major source of antigenic peptides endogenously generated from influenza A virus neuraminidase.
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.
Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus.
Defining the requirements for an antibody epitope on influenza virus neuraminidase: how tolerant are protein epitopes?
Deletion mutation in the signal anchor domain activates cleavage of the influenza virus neuraminidase, a type II transmembrane protein.
Deletions in the Neuraminidase Stalk Region of H2N2 and H9N2 Avian Influenza Virus Subtypes Do Not Affect Postinfluenza Secondary Bacterial Pneumonia.
Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses.
Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice.
Demonstration of antibodies to both hemagglutinin and neuraminidase antigens of H3N2 influenza A virus in domestic dogs.
Dependence of the activity of an influenza virus neuraminidase upon Ca2+.
Depression of luminol-enhanced chemiluminescence of guinea pig polymorphonuclear leukocytes by influenza virus with special reference to neuraminidase.
Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding.
Design and expression of a QconCAT protein to validate Hi3 protein quantification of influenza vaccine antigens.
Design and one-pot synthesis of 2-thiazolylhydrazone derivatives as influenza neuraminidase inhibitors.
Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
Design and Synthesis of 4-Alkyl-2-amino(acetamino)-6-aryl-1,3-thiazine Derivatives as Influenza Neuraminidase Inhibitors.
Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors.
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase.
Design of a mechanism-based probe for neuraminidase to capture influenza viruses.
Design of aromatic inhibitors of influenza virus neuraminidase.
Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.
Design of N-acetyl-6-sulfo-beta-d-glucosaminide-based inhibitors of influenza virus sialidase.
Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections.
Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Design of peptide epitope from the neuraminidase protein of influenza A and influenza B towards short peptide vaccine development.
Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors.
Design, synthesis and biological evaluation of "Multi-Site"-binding influenza virus neuraminidase inhibitors.
Design, synthesis and biological evaluation of honokiol derivatives as influenza neuraminidase inhibitors.
Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors.
Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.
Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors.
Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm.
Design, synthesis, and preliminary evaluation of new pyrrolidine derivatives as neuraminidase inhibitors.
Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores.
Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.
Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors.
Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors.
Design, Synthesis, Molecular Docking, and Biological Evaluation of New Emodin Anthraquinone Derivatives as Potential Antitumor Substances.
Desorption electrospray ionization reactions between host crown ethers and the influenza neuraminidase inhibitor oseltamivir for the rapid screening of Tamiflu((R)).
Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient.
Detection and characterization of type B influenza virus from influenza-like illness cases during the 2017-2018 winter influenza season in Beijing, China.
Detection and identification of human influenza viruses by the polymerase chain reaction.
Detection and isolation of highly pathogenic H5N1 avian influenza A viruses from blow flies collected in the vicinity of an infected poultry farm in Kyoto, Japan, 2004.
Detection and management of antiviral resistance for influenza viruses.
Detection and Titration of Influenza A Virus Neuraminidase Inhibiting (NAI) Antibodies Using an Enzyme-Linked Lectin Assay (ELLA).
Detection of a transient R292K mutation in Influenza A/H3N2 viruses shed for several weeks by an immunocompromised patient.
Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs.
Detection of antigenic variation in influenza virus neuraminidase by the ESSEN-NIT and the WHO standard procedure.
Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.
Detection of D151G/N mutations in the neuraminidase gene of influenza A (H3N2) viruses by real-time RT-PCR allelic discrimination assay.
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
Detection of evolutionarily distinct avian influenza a viruses in antarctica.
Detection of Hemagglutinin Variants of the Pandemic Influenza A (H1N1) 2009 Virus by Pyrosequencing.
Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Detection of influenza A virus neuraminidase and PB2 gene segments by one step reverse transcription polymerase chain reaction.
Detection of influenza B viruses with reduced sensitivity to neuraminidase inhibitor in Morocco during 2014/15 season.
Detection of influenza virus neuraminidase-specific antibodies by an enzyme-linked immunosorbent assay.
Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.
Detection of neuraminidase inhibitor-resistant influenza A (H1N1)pdm09 viruses obtained from influenza surveillance in Indonesia.
Detection of neuraminidase stalk motifs associated with enhanced N1 subtype influenza A virulence via Raman spectroscopy.
Detection of novel influenza A(H1N1) virus by real-time RT-PCR.
Detection of oseltamivir-resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test.
Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds.
Determinants of oligomeric structure in the chicken liver glycoprotein receptor.
Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate.
Determination of relative binding affinity of influenza virus N9 sialidases with the Fab fragment of monoclonal antibody NC41 using biosensor technology.
Determination of the novel sialic acid analog GG167 (GR121167X) in human urine by liquid chromatography: direct injection with column switching.
Determination of viral neuraminidase specificity for membrane-bound sialic acids by cell electrophoresis.
Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry.
Development and clinical testing of a simple, low-density gel element array for influenza identification, subtyping, and H275Y detection.
Development and evaluation of a real-time nucleic acid sequence based amplification assay for rapid detection of influenza A.
Development and fit-for-purpose verification of an LC-MS method for quantitation of hemagglutinin and neuraminidase proteins in influenza virus-like particle vaccine candidates.
Development and implementation of influenza a virus subtyping and detection of genotypic resistance to neuraminidase inhibitors.
Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
Development and testing of a de novo drug-design algorithm.
Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.
Development of 6E3 antibody-mediated SERS immunoassay for drug-resistant influenza virus.
Development of a high yield live attenuated H7N9 influenza vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.
Development of a multiplex probe combination-based one-step real-time reverse transcription-PCR for NA subtype typing of avian influenza virus.
Development of a novel real-time reverse-transcriptase PCR method for the detection of H275Y positive influenza A H1N1 isolates.
Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
Development of a real-time RT-PCR assay for detection of resistance to oseltamivir in influenza A pandemic (H1N1) 2009 virus using single nucleotide polymorphism probes.
Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Development of a surface plasmon resonance assay to measure the binding affinity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drug zanamivir.
Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus.
Development of an aqueous two-phase partitioning system for fractionating therapeutic proteins from tobacco extract.
Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques.
Development of anti-viral agents using molecular modeling and virtual screening techniques.
Development of antibodies to neuraminidase of A2-Hong Kong and A2-Taiwan influenza viruses after administration of different Hong Kong vaccines and after natural infection in humans.
Development of high-yield influenza B virus vaccine viruses.
Development of multiplex rt-PCR assays for rapid detection and subtyping of influenza type A viruses from clinical specimens.
Development of new stereodiverse diaminocyclitols as inhibitors of influenza virus neuraminidase.
Development of novel influenza virus vaccines and vectors.
Development of recombinant protein-based influenza vaccine. Expression and affinity purification of H1N1 influenza virus neuraminidase.
Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats.
Developments of subunit and VLP vaccines against influenza a virus.
Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
Diagnostic challenges in influenza.
Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes.
Diastereoselective tandem reactions of substituted 3-sulfolenes with bis-vinyl ketones leading to highly functionalized bicyclic and tricyclic frameworks.
Dietary Flavonoid Aglycones and Their Glycosides: Which Show Better Biological Significance?
Differences between influenza virus receptors on target cells of duck and chicken.
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Different patterns of replication in influenza virus-infected KB cells.
Different synthetic strategies of oseltamivir phosphate: a potent influenza neuraminidase inhibitor.
Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo.
Differential action of Aspergillus glycosidases on the hemagglutinating and neuraminidase activities of influenza and Newcastle disease viruses.
Differential effect of guanidine hydrochloride and heat on the haemagglutinin and neuraminidase of influenza viruses.
Differential effect of various inhibitors on four types of rat sialidase.
Differential expression of influenza N protein and neuraminidase antigenic determinants in Escherichia coli.
Differential expression of sialylglycoconjugates and sialidase activity in distinct morphological stages of Fonsecaea pedrosoi.
Differential release of sialic acid from normal and malignant cells by Vibrio cholerae neuraminidase or influenza virus neuraminidase.
Differential transport of Influenza A neuraminidase signal anchor peptides to the plasma membrane.
Differing epidemiological dynamics of influenza B lineages in Guangzhou, southern China, 2009-2010.
Difficulties in standardizing the neuraminidase content of influenza vaccines.
Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.
Diospyros anisandra phytochemical analysis and anti-hemagglutinin-neuraminidase activity on influenza AH1N1pdm09 virus.
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
Direct and label-free influenza virus detection based on multisite binding to sialic acid receptors.
Directed selection of amino acid changes in the influenza hemagglutinin and neuraminidase affecting protein antigenicity.
DISC ELECTROPHORESIS ANALYSIS OF SIALIDASE FROM INFLUENZA VIRUS.
Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.
Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase.
Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor.
Discovery of (E)-1-amino-4-phenylbut-3-en-2-ol derivatives as novel neuraminidase inhibitors.
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase.
Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors.
Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.
Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.
Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models.
Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.
Discovery of novel acylhydrazone neuraminidase inhibitors.
Discovery of Novel Neuraminidase Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
Discovery of Novel Pyrazole Derivatives as Potent Neuraminidase Inhibitors against Influenza H1N1 Virus.
Discovery of novel thiophene derivatives as potent neuraminidase inhibitors.
Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae.
Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design.
Disrupting the Conserved Salt Bridge in the Trimerization of Influenza A Nucleoprotein.
Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.
Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition.
Distribution of hemagglutinin and neuraminidase on influenza virions as revealed by immunoelectron microscopy.
Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies.
Divalent oseltamivir analogues as potent influenza neuraminidase inhibitors.
Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada.
Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity.
Divergent genetic evolution of hemagglutinin in influenza A H1N1 and A H1N2 subtypes isolated in the south-France since the winter of 2001-2002.
Diverse and Unexpected Roles of Human Monocytes/Macrophages in the Immune Response to Influenza Virus.
Diversity of sialidases found in the human body - A review.
DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors.
Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase.
Docking and 3D-QSAR investigations of pyrrolidine derivatives as potent neuraminidase inhibitors.
Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis.
Docking study of flavonoid derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
Does the availability of a neuraminidase inhibitor impair influenza vaccination? A report from Austria.
Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine.
Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus.
Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.
Drift of the sialyl-linkage specific recognition of the sialidase of influenza B virus isolates.
Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase.
Drug screening for influenza neuraminidase inhibitors.
Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution.
Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.
Drug under test: influenza--Relenza in daily practice. Experience during the influenza season 1999/2000.
Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases.
Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing.
Drugs against Avian Influenza A Virus: Design of Novel Sulfonate Inhibitors of Neuraminidase N1.
Drugs for Influenza Treatment: Is There Significant News?
Dual Acting Neuraminidase Inhibitors Open New Opportunities to Disrupt the Lethal Synergism between Streptococcus pneumoniae and Influenza Virus.
Dual oxidase 1 promotes antiviral innate immunity.
Duck and human pandemic influenza A viruses retain sialidase activity under low pH conditions.
Dynamic patterns of circulating influenza virus from 2005 to 2012 in Shandong Province, China.
Dynamic residue interaction network analysis of the oseltamivir binding site of N1 neuraminidase and its H274Y mutation site conferring drug resistance in influenza A virus.
Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008.
Dynamics of viral growth, viral enzymatic activity, and antigenicity in murine lungs during the course of influenza pneumonia.
Early administration of neuraminidase inhibitors in adult patients hospitalized for influenza does not benefit survival: a retrospective cohort study.
Early detection of influenza virus by using a fluorometric assay of infected tissue culture.
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.
Early oseltamivir after hospital admission is associated with shortened hospitalization: A five-year analysis of oseltamivir timing and clinical outcomes.
Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.
Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection.
Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment.
Echoes of 2009 H1N1 Influenza Pandemic in the COVID Pandemic.
Economic consequence of immediate testing for C-reactive protein and leukocyte count in new outpatients with acute infection.
Economic evaluations of neuraminidase inhibitors to control influenza.
Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore.
Edible bird's nest extract inhibits influenza virus infection.
Effect of a single inhalation of laninamivir octanoate in children with influenza.
Effect of a single mutation in neuraminidase on the properties of Influenza B virus isolates.
Effect of aloin on viral neuraminidase and hemagglutinin-specific T cell immunity in acute influenza.
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial.
Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus.
Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
Effect of blood group determinants on binding of human salivary mucous glycoproteins to influenza virus.
Effect of Ca++ on the stability of influenza virus neuraminidase.
Effect of cytochalasin B on the maturation of enveloped viruses.
Effect of dimethylsulfoxide (DMSO) on virus replication and maturation.
Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multi-season cohort study.
Effect of fever on hospital presentation, diagnosis, and treatment in patients with H1N1/09 influenza.
Effect of four neuraminidase inhibitors on influenza in Osaka, Japan: An eight-year survey.
Effect of glycosylation and glucose trimming inhibitors on the influenza A virus glycoproteins.
Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.
Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.
Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
Effect of modification of N-acetylneuraminic acid on the binding of glycoproteins to influenza virus and on susceptibility to cleavage by neuraminidase.
Effect of monoclonal anti-neuraminidase antibodies on the kinetic behavior of influenza virus neuraminidase.
Effect of neuraminidase antibody on Hong Kong influenza.
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Effect of neuraminidase on potency of inactivated influenza virus vaccines in mice.
Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.
EFFECT OF SIALIDASE ANTISERUM ON TOXICITY OF INFLUENZA VIRUS.
Effect of specific immunity to viral neuraminidase on subsequent influenza virus infection in man.
Effect of substitution of hemagglutinin-neuraminidase with influenza hemagglutinin on Sendai virus F protein mediated membrane fusion.
Effect of substrate aglycon on enzyme mechanism in the reaction of sialidase from influenza virus.
Effect of syngeneic anti-idiotypic antibody on influenza virus neuraminidase antibody response.
Effect of Tea Catechins on Influenza Infection and the Common Cold with a Focus on Epidemiological/Clinical Studies.
Effect of temperature on the order of electrophoretic migration of influenza virus neuraminidase and nucleoprotein genes in acrylamide gels lacking denaturing agents.
Effect of the fourth nucleotide at the 3' end of neuraminidase and matrix viral genomic RNA on the pathogenicity of influenza virus A/PR/8/34.
Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.
Effect of zanamivir on duration and resolution of influenza symptoms.
Effectiveness and role of zanamivir in the treatment of influenza infection.
Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.
Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons.
Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.
Effectiveness of neuraminidase inhibitors for preventing staff absenteeism during pandemic influenza.
Effectiveness of neuraminidase inhibitors for severe influenza.
Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.
Effects of Biomolecular Flexibility on Alchemical Calculations of Absolute Binding Free Energies.
Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus.
Effects of HA and NA glycosylation pattern changes on the transmission of avian influenza A(H7N9) virus in guinea pigs.
Effects of neuraminidase on airway reactivity in the guinea pig.
Effects of single-point amino acid substitutions on the structure and function neuraminidase proteins in influenza A virus.
Effects of site-specific mutation on structure and activity of influenza virus B/Lee/40 neuraminidase.
Effects of substitutions in the binding surface of an antibody on antigen affinity.
Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza.
Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.
Effects of windowing and zero-padding on Complex Resonant Recognition Model for protein sequence analysis.
Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study.
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors.
Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
Efficacy of a single intravenous dose of the neuraminidase inhibitor peramivir in the treatment of equine influenza.
Efficacy of hemagglutinin and neuraminidase antigens presented in ISCOMs as vaccine for influenza in turkeys.
Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
Efficacy of Neuraminidase Inhibitors against H5N6 Highly Pathogenic Avian Influenza Virus in a Nonhuman Primate Model.
Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks.
Efficient Method for the Preparation of Peracetylated Neu5Ac2en by Flash Vacuum Pyrolysis.
Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins.
Efficient synthesis of highly active phospha-isosteres of the influenza neuraminidase inhibitor oseltamivir.
Eight-plasmid system for rapid generation of influenza virus vaccines.
Electrochemical assay to detect influenza viruses and measure drug susceptibility.
Electron and X-ray diffraction studies of influenza neuraminidase complexed with monoclonal antibodies.
Electron microscopy of purified influenza virus neuraminidase.
Electroporation of influenza virus ribonucleoprotein complexes for rescue of the nucleoprotein and matrix genes.
Electrostatic complementarity at protein/protein interfaces.
Emerged HA and NA mutants of the pandemic influenza H1N1 viruses with increasing epidemiological significance in Taipei and Kaohsiung, Taiwan, 2009-10.
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-? for infection control and treatment.
Emergence of a young case infected with avian influenza A (H5N6) in Anhui Province, East China during the COVID-19 pandemic.
Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly receiving a suboptimal dose of antiviral prophylaxis.
Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors.
Emerging from the Shadow of Hemagglutinin: Neuraminidase Is an Important Target for Influenza Vaccination.
Emulsion-based adjuvants for influenza vaccines.
Enantioselective synthesis of antiinfluenza compound A-315675.
Endogenously-expressed influenza A M1 and NP proteins are efficiently presented by class-I and -II major histocompatibility complexes.
Enhanced Anti-influenza Agents Conjugated with Anti-inflammatory Activity.
Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.
Enhanced expression of secretable influenza virus neuraminidase in suspension mammalian cells by influenza virus nonstructural protein 1.
Enhanced growth of seed viruses for H5N1 influenza vaccines.
Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.
Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.
Enhanced Reliability of Avian Influenza Virus (AIV) and Newcastle Disease Virus (NDV) Identification Using Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry (MALDI-MS).
Enhanced replication of avian-origin H3N2 canine influenza virus in eggs, cell cultures and mice by a two-amino acid insertion in neuraminidase stalk.
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus.
Enhancement of neuraminidase activity with influenza virus by anti-influenza virus drug.
Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).
Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.
Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor.
Envelope Proteins Pertain with Evolution and Adaptive Mechanism of the Novel Influenza A/H1N1 in Humans.
Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards.
Environmental resistance development to influenza antivirals: a case exemplifying the need for a multidisciplinary One Health approach including physicians.
Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.
ENZYMATIC VARIANTS OF INFLUENZA VIRUS. III. FUNCTION OF NEURAMINIDASE IN THE VIRAL GROWTH CYCLE.
Enzymological characteristics of avian influenza A virus neuraminidase.
Enzymological heterogeneity of influenza B virus neuraminidase demonstrated by the fluorometric assay method.
Epidemiological and genetic characteristics of influenza virus and the effects of air pollution on laboratory-confirmed influenza cases in Hulunbuir, China, from 2010 to 2019.
Epidemiological and genetic characterization of pH1N1 and H3N2 influenza viruses circulated in MENA region during 2009-2017.
Epidemiological survey and genetic evolution of H3N2 subtype influenza viruses from stray dogs in Shanghai, China.
Epidemiological, Clinical and Virological Characteristics of Influenza B Virus from Patients at the Hospital Tertiary Care Units in Bangkok during 2011-2014.
Epidemiology and pathogenesis of influenza.
Epidemiology and virology of influenza illness. Based on a presentation by Arnold S. Monto, MD.
Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses.
Epitope analysis for influenza vaccine design.
Epitope mapping of diverse influenza Hemagglutinin drug candidates using HDX-MS.
Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies.
Epitope peptides of influenza H3N2 virus neuraminidase gene designed by immunoinformatics.
Epitope-targeting platform for broadly protective influenza vaccines.
EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo.
Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.
Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection.
Establishment and lineage replacement of H6 influenza viruses in domestic ducks in southern China.
Estimating influenza vaccine effectiveness in an outbreak when anti-viral medications were used as a control measure.
Estimating the Fitness Advantage Conferred by Permissive Neuraminidase Mutations in Recent Oseltamivir-Resistant A(H1N1)pdm09 Influenza Viruses.
Estimation of seroprevalence of the pandemic H1N1 2009 influenza virus using a novel virus-free ELISA assay for the detection of specific antibodies.
Estimation of the molecular weights of the polypeptide chains from the isolated hemagglutinin and neuraminidase subunits of influenza viruses.
Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography.
Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis.
Ethanolic Extract of Melia Fructus Has Anti-influenza A Virus Activity by Affecting Viral Entry and Viral RNA Polymerase.
Etiological diagnosis of influenza A virus by enzymatic radioimmunoassay.
European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS and ELN.
Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children.
Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.
Evaluation of a neuraminidase detection assay for the rapid detection of influenza A and B virus in children.
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase.
Evaluation of a Set of C9 N-acyl Neu5Ac2en Mimetics as Viral Sialidase Selective Inhibitors.
Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.
Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers.
Evaluation of BioStar FLU OIA assay for rapid detection of influenza A and B viruses in respiratory specimens.
Evaluation of diagnostic tests for influenza in a pediatric practice.
Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.
Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.
Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact.
Evaluation of Recombinant 2009 Pandemic Influenza A (H1N1) Viruses Harboring Zanamivir Resistance Mutations in Mice and Ferrets.
Evaluation of recombinant A/Victoria/3/75 (H3N2) influenza neuraminidase mutants as potential broad-spectrum subunit vaccines against influenza A.
Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates.
Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study.
Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo.
Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers.
Evaluation of the methodological quality of the Health Protection Agency's 2009 guidance on neuraminidase inhibitors.
Evaluation of the potential defensive strategy against Influenza A in cell line models.
Evaluation of three influenza neuraminidase inhibition assays for use in a public health laboratory setting during the 2011-2012 influenza season.
Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.
Evaluation of Twelve Real-Time Reverse Transcriptase PCR Primer-Probe Sets for Detection of Pandemic Influenza A/H1N1 2009 Virus.
Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus.
Evidence for Deleterious Antigenic Imprinting in SARS-CoV-2 Immune Response.
Evidence for influenza B virus lineage shifts and reassortants circulating in Thailand in 2014-2016.
Evidence for segment-nonspecific packaging of the influenza a virus genome.
Evidence for the contribution of the host species to the extent of antigenic variation of N1 influenza virus neuraminidase.
Evidence for wild waterfowl origin of H7N3 influenza A virus detected in captive-reared New Jersey pheasants.
Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.
Evidence of a cross-protective immune response to influenza A in the cotton rat model.
Evidence of a fixed internal gene constellation in influenza A viruses isolated from wild birds in Argentina (2006-2016).
Evidence of selection pressures of neuraminidase gene (NA) of influenza A virus subtype H5N1 on different hosts in Guangxi Province of China.
Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage.
Evolution and antigenic advancement of N2 neuraminidase of swine influenza A viruses circulating in the United States following two separate introductions from human seasonal viruses.
Evolution of influenza neuraminidase and the detection of antiviral resistant strains using mass trees.
Evolution of influenza viral neuraminidase (NA) revealed by large-scale sequence analysis.
Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
Evolution of surface and nonstructural-1 genes of influenza B viruses isolated in the Province of Québec, Canada, during the 1998-2001 period.
Evolution of the influenza virus neuraminidase gene during drift of the N2 subtype.
Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015.
Evolutional analysis of human influenza A virus N2 neuraminidase genes based on the transition of the low-pH stability of sialidase activity.
Evolutionarily conserved residues at an oligomerization interface of the influenza A virus neuraminidase are essential for viral survival.
Evolutionary analysis of human-origin influenza A virus (H3N2) genes associated with the codon usage patterns since 1993.
Evolutionary changes in influenza B are not primarily governed by antibody selection.
Evolutionary characterization of the six internal genes of H5N1 human influenza A virus.
Evolutionary dynamics of highly pathogenic avian influenza A/H5N1 HA clades and vaccine implementation in Vietnam.
Evolutionary dynamics of the N1 neuraminidases of the main lineages of influenza A viruses.
Evolutionary history and phylodynamics of influenza A and B neuraminidase (NA) genes inferred from large-scale sequence analyses.
Evolutionary interactions between haemagglutinin and neuraminidase in avian influenza.
Evolutionary pathways of N2 neuraminidases of swine and human influenza A viruses: origin of the neuraminidase genes of two reassortants (H1N2) isolated from pigs.
Evolutionary, genetic, structural characterization and its functional implications for the influenza A (H1N1) infection outbreak in India from 2009 to 2017.
Examining the use of antiviral prophylaxis for influenza outbreaks in residential aged care facilities in NSW, Australia.
Exosome-Driven Antigen Transfer for MHC Class II Presentation Facilitated by the Receptor Binding Activity of Influenza Hemagglutinin.
Experimental validation and computational modeling of anti-influenza effects of quercetin-3-O-?-L-rhamnopyranoside from indigenous south African medicinal plant Rapanea melanophloeos.
Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes.
Exploitation of the Catalytic Site and 150 Cavity for Design of Influenza A Neuraminidase Inhibitors.
Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role.
Exploring cell tropism as a possible contributor to influenza infection severity.
Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
Exploring the chemical space of influenza neuraminidase inhibitors.
Exploring the interactions of unsaturated glucuronides with influenza virus sialidase.
Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study.
Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.
Expression and Characterization of Recombinant, Tetrameric and Enzymatically Active Influenza Neuraminidase for the Setup of an Enzyme-Linked Lectin-Based Assay.
Expression of a foreign protein by influenza A virus.
Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system.
Expression of influenza neuraminidase in baculovirus-infected cells.
Expression of the influenza M2 protein in three different eukaryotic cell lines.
Expression, purification and characterization of low-glycosylation influenza neuraminidase in ?-1,6-mannosyltransferase defective Pichia pastoris.
Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.
Extraction of catalytically active neuraminidase of H5N1 influenza virus using thrombin proteolytic cleavage.
Factors promoting pathogenicity of influenza virus.
Fc? Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.
Fight against H1N1 Influenza A Virus: Recent Insights towards the Development of Druggable Compounds.
Filament-producing mutants of influenza A/Puerto Rico/8/1934 (H1N1) virus have higher neuraminidase activities than the spherical wild-type.
Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors.
Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews.
Finding a Maximum Common Subgraph from Molecular Structural Formulas through the Maximum Clique Approach Combined with the Ising Model.
First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection.
Fitness Costs for Influenza B Viruses Carrying Neuraminidase Inhibitor-Resistant Substitutions: Underscoring the Importance of E119A and H274Y.
Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
Fitness of neuraminidase inhibitor-resistant influenza A viruses.
Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus.
Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.
FLAN: a web server for influenza virus genome annotation.
Flavonoid glycosylation and biological benefits.
Flavonoids from Matteuccia struthiopteris and Their Anti-influenza Virus (H1N1) Activity.
Flocculation of influenza virus by a neuraminidase inhibitor, neuraminin, produced by Streptomyces sp.
Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals.
Fluorescent assays to quantitate enzymatic activities yielding as end product an aqueous-insoluble indigo-blue dye.
Fluorescent Neuraminidase Assay Based on Supramolecular Dye Capture After Enzymatic Cleavage.
Fluorometric assay for measurement of viral neuraminidase--application to the rapid detection of influenza virus in nasal wash specimens.
Fluorometric assay for the measurement of viral neuraminidase in influenza vaccines.
Fluorometric measurement of neuraminidase activity of influenza viruses.
FluTyper-an algorithm for automated typing and subtyping of the influenza virus from high resolution mass spectral data.
Force Spectroscopy Shows Dynamic Binding of Influenza Hemagglutinin and Neuraminidase to Sialic Acid.
Formation of virosomes from influenza subunits and liposomes.
Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase.
Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins.
Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.
Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.
Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011.
From the National Institutes of Health. Summary of a meeting on the origin of pandemic influenza viruses.
Full length sequencing of all nine subtypes of the neuraminidase gene of influenza A viruses using subtype specific primer sets.
Functional and structural analysis of influenza virus neuraminidase n3 offers further insight into the mechanisms of oseltamivir resistance.
Functional balance between haemagglutinin and neuraminidase in influenza virus infections.
Functional balance between neuraminidase and haemagglutinin in influenza viruses.
Functional balance between the hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 HA D222 variants.
Functional Balance of the Hemagglutinin and Neuraminidase Activities Accompanies the Emergence of the 2009 H1N1 Influenza Pandemic.
Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Functional reconstitution of the integral membrane proteins of influenza virus into phospholipid liposomes.
Functional significance of neuraminidase in the replication cycle of influenza viruses.
Functional significance of sialidase during influenza virus multiplication: an electron microscope study.
Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses.
Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors.
Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.
Further studies on the role of neuraminidase and the mechanism of low pH dependence in influenza virus-induced membrane fusion.
Fusion of enveloped viruses with sperm cells: interaction of Sendai, influenza, and Semliki Forest viruses with bull spermatozoa.
Galactose-conjugates of the oseltamivir pharmacophore--new tools for the characterization of influenza virus neuraminidases.
Galectins promote the interaction of influenza virus with its target cell.
Gene and protein sequence of an influenza neuraminidase with hemagglutinin activity.
General practitioners' management of influenza with or without neuraminidase inhibitors.
Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate.
Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.
Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.
Generation and Characterization of Recombinant Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors.
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.
Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Generation of live attenuated novel influenza A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs.
Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in the neuraminidase segment.
Generation of Stable Influenza Virus Hemagglutinin through Structure-Guided Recombination.
Genetic analysis and evaluation of the reassortment of influenza B viruses isolated in Taiwan during the 2004-2005 and 2006-2007 epidemics.
Genetic analysis of influenza A/H3N2 and A/H1N1 viruses circulating in Vietnam from 2001 to 2006.
Genetic analysis of neuraminidase gene of influenza A(H1N1)pdm09 virus circulating in Southwest India from 2009 to 2012.
Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013.
Genetic Analysis of the Neuraminidase (NA) Gene of Equine Influenza Virus (H3N8) from Epizootic of 2008-2009 in India.
Genetic ancestor of external antigens of pandemic influenza A/H1N1 virus.
Genetic and antigenic characterization of influenza A(H1N1)pdm09 in Yantai, China, during the 2009-2017 influenza season.
Genetic changes in influenza A(H3N2) viruses circulating during 2011 to 2013 in northern India (Lucknow).
Genetic characterisation of influenza A(H1N1)pdm09 viruses circulating in Assam, Northeast India during 2009-2015.
Genetic Characterisation of Influenza A(H1N1)pdm09 Viruses Circulating in Assam, Northeast India during 2009-2015.
Genetic characterisation of the influenza viruses circulating in Bulgaria during the 2019-2020 winter season.
Genetic characterization of an H2N2 influenza virus isolated from a muskrat in Western Siberia.
Genetic characterization of H3N2 influenza viruses isolated from pigs in North America, 1977-1999: evidence for wholly human and reassortant virus genotypes.
Genetic characterization of influenza virus circulating in Brazilian pigs during 2009 and 2010 reveals a high prevalence of the pandemic H1N1 subtype.
Genetic composition of a high-yielding influenza A virus recombinant: a vaccine strain against "Swine" influenza.
Genetic diversity of influenza A(H3N2) viruses in Northern Cameroon during the 2014-2016 influenza seasons.
Genetic diversity of the pandemic influenza A (H1N1) virus in Saudi Arabia.
Genetic engineering of live attenuated influenza viruses.
Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution.
Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season.
Genetic Predisposition To Acquire a Polybasic Cleavage Site for Highly Pathogenic Avian Influenza Virus Hemagglutinin.
Genetic relatedness between influenza A (H1N1) viruses isolated from humans and pigs.
Genetic relatedness of the neuramindase of influenza A strains Nav2, Nav3, and Nav6.
Genetic sequencing of influenza A (H1N1) pdm09 isolates from South India, collected between 2011 and 2015 to detect mutations affecting virulence and resistance to oseltamivir.
Genetic Sequencing of Influenza A (H1N1) pdm09 Isolates from South India, Collected between 2011 and 2015 to Detect Mutations Affecting Virulence and Resistance to Oseltamivir.
Genetic subtyping of influenza A viruses using RT-PCR with a single set of primers based on conserved sequences within the HA2 coding region.
Genetic tuning of the novel avian influenza A(H7N9) virus during interspecies transmission, China, 2013.
Genetic variability of the neuraminidase gene of influenza A(H1N1)pdm09 viruses circulating from the 2012/2013 to 2017/2018 season in Vojvodina Province, Serbia.
Genetic variation in neuraminidase genes of influenza A (H3N2) viruses.
Genome Stability of Pandemic Influenza A (H1N1) 2009 Based on Analysis of Hemagglutinin and Neuraminidase Genes.
Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases.
Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.
Genotypic evolution and epidemiological characteristics of H9N2 influenza virus in Shandong Province, China.
Genotyping of a nosocomial outbreak of pandemic influenza A/H1N1 2009.
GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets.
Global Assessment of Resistance to Neuraminidase Inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS).
Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus.
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase.
Glycan array analysis of influenza H1N1 binding and release.
Glycan binding and specificity of viral influenza neuraminidases by classical molecular dynamics and replica exchange molecular dynamics simulations.
Glycosylation and surface expression of the influenza virus neuraminidase requires the N-terminal hydrophobic region.
Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture.
Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs.
Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus.
Grid-enabled high-throughput in silico screening against influenza A neuraminidase.
GS-4104 (Gilead Sciences Inc).
GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains.
Guanidinobenzoic acid inhibitors of influenza virus neuraminidase.
Guanidinothiosialoside-Human Serum Albumin Conjugate Mimics mucin Barrier to Restrict Influenza Infection.
Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.
H1N1 influenza A virus neuraminidase modulates infectivity in mice.
H1N1 influenza virus-like particles: Physical degradation pathways and identification of stabilizers.
H1N1 novel influenza A in pregnant and immunocompromised patients.
H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus pandemrix(®) -vaccination.
H274Y's Effect on Oseltamivir Resistance: What Happens Before the Drug Enters the Binding Site.
H3N2 Canine Influenza Virus Infection in a Dog.
H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes.
H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies in humans that preferentially bind to oligomeric form of influenza hemagglutinin.
H9N2 Influenza Virus Infections in Human Cells Require a Balance between Neuraminidase Sialidase Activity and Hemagglutinin Receptor Affinity.
Haemagglutinin and neuraminidase sequencing delineate nosocomial influenza outbreaks with accuracy equivalent to whole genome sequencing.
HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy.
Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus.
HEL-Flu: an influenza virus containing the hen egg lysozyme epitope recognized by CD4+ T cells from mice transgenic for an alphabeta TCR.
Hemagglutinating and sialidase activities of subpopulations of influenza A viruses.
Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections.
Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
Hemagglutinin and neuraminidase genes of influenza B viruses circulating in Riyadh, Saudi Arabia during 2010-2011: Evolution and sequence analysis.
Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics.
Hemagglutinin and neuraminidase specific cell-mediated immune responses to influenza A virus following immunization in guinea pigs.
Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities.
Hemagglutinin specificity and neuraminidase coding capacity of neuraminidase-deficient influenza viruses.
Hemagglutinin stalk domain from H5N1 strain as a potentially universal antigen.
Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance.
Hemagglutinin-esterase-fusion (HEF) protein of influenza C virus.
Hemagglutinin-neuraminidase balance confers respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in ferrets.
Hemagglutinin-Neuraminidase Balance Influences the Virulence Phenotype of a Recombinant H5N3 Influenza A Virus Possessing a Polybasic HA0 Cleavage Site.
Hemagglutinin-neuraminidase protein of the paramyxovirus simian virus 5: nucleotide sequence of the mRNA predicts an N-terminal membrane anchor.
Hemolysis and fusion by influenza viruses with heat-inactivated neuraminidase activity.
Heterogeneity of neuraminidase genetic information in an H1N2 reassortant influenza virus [X-7 (F1)]. Brief report.
Heterogeneity of the cytotoxic response of thymus-derived lymphocytes after immunization with influenza viruses.
Heterologous T cell immunity in severe hepatitis C virus infection.
Heterologous viral protein interactions within licensed seasonal influenza virus vaccines.
Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice.
Heterosubtypic immunity to influenza A virus: where do we stand?
Heterotypic Neuraminidase Antibodies Against Different A(H1N1) Strains are Elicited after Seasonal Influenza Vaccination.
Heterotypic protective immune reactions in mice infected with distinct serotypes of human influenza virus.
High antiviral effects of hibiscus tea extract on the H5 subtypes of low and highly pathogenic avian influenza viruses.
High efficiency method of detection and isolation of neuraminidase inhibitor resistant influenza viruses by fluorescence sialidase imaging.
High genetic stability in MDCK-SIAT1 passaged human influenza viruses.
High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season.
High molecular weight constituents of cranberry interfere with influenza virus neuraminidase activity in vitro.
High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity.
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.
High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors.
High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde.
High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses.
High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines.
Highlights in the development of new antiviral agents.
Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations.
Highly lethal H5N1 influenza virus in asia: Genesis and options for control.
Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
Highly specific and rapid glycan based amperometric detection of influenza viruses.
Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.
Hospital Readmissions Among Children With H1N1 Influenza Infection.
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Host mediated variation and receptor binding specificity of influenza viruses.
Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza A(H1N1) viruses, Germany, 2007-8.
How antibodies recognize virus proteins.
How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency.
How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.
Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.
Human Clade 2.3.4.4 A/H5N6 Influenza Virus Lacks Mammalian Adaptation Markers and Does Not Transmit via the Airborne Route between Ferrets.
Human genetics and responses to influenza vaccination: clinical implications.
Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus.
Human influenza A (H1N2) viruses isolated from China.
Human influenza viral neuraminidases augment cell-mediated cytotoxicity in vitro.
Human influenza virus neuraminidase, but not hemagglutinin, induces murine macrophage interleukin 1 in vivo and in vitro.
Human monoclonal ScFv specific to NS1 protein inhibits replication of influenza viruses across types and subtypes.
Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein.
Human sera possess a limited antibody repertoire to influenza neuraminidase antigenic variants selected in vitro.
Human trachea primary epithelial cells express both sialyl(alpha2-3)Gal receptor for human parainfluenza virus type 1 and avian influenza viruses, and sialyl(alpha2-6)Gal receptor for human influenza viruses.
Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
Hydration of ligands of influenza virus neuraminidase studied by the fragment molecular orbital method.
Hydrophobic benzoic acids as inhibitors of influenza neuraminidase.
Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.
Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses.
Hyphenated 3D-QSAR statistical model-drug repurposing analysis for the identification of potent neuraminidase inhibitor.
I-cell disease: intracellular desialylation of lysosomal enzymes using an influenza virus vector.
I223R Mutation in Influenza A(H1N1)pdm09 Neuraminidase Confers Reduced Susceptibility to Oseltamivir and Zanamivir and Enhanced Resistance with H275Y.
Ia-transfected L-cell fibroblasts present a lysozyme peptide but not the native protein to lysozyme-specific T cells.
Identification and characterization of H2N3 avian influenza virus from backyard poultry and comparison with novel H2N3 swine influenza virus.
Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase.
Identification of a highly conserved H1 subtype-specific epitope with diagnostic potential in the hemagglutinin protein of influenza A virus.
Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Identification of a linear epitope on the haemagglutinin protein of pandemic A/H1N1 2009 influenza virus using monoclonal antibodies.
Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity.
Identification of amino acids in H9N2 influenza virus neuraminidase that are critical for the binding of two mouse monoclonal antibodies.
Identification of amino acids in the HA of H3 influenza viruses that determine infectivity levels in primary swine respiratory epithelial cells.
Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors.
Identification of coevolution sites and evolution history for neuraminidase of human influenza A viruses.
Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase.
Identification of Critical Residues in the Hemagglutinin and Neuraminidase of Influenza Virus H1N1pdm for Vaccine Virus Replication in Embryonated Chicken Eggs.
Identification of critical residues of influenza neuraminidase in viral particle release.
Identification of defects in the neuraminidase gene of four temperature-sensitive mutants of A/WSN/33 influenza virus.
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.
Identification of equine influenza virus infection in Asian wild horses (Equus przewalskii).
Identification of genetic determinants of influenza A virus resistance to adamantanes and neuraminidase inhibitors using biological microarray.
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
Identification of hemagglutinin and neuraminidase genes of influenza B virus.
Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
Identification of influenza A nucleoprotein as an antiviral target.
Identification of influenza A pandemic (H1N1) 2009 variants during the first 2009 influenza outbreak in Mexico City.
Identification of key residues involved in the neuraminidase antigenic variation of H9N2 influenza virus.
Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.
Identification of nonavid influenza A viruses containing human subtypes of hemagglutinin and neuraminidase isolated from poultry in Hong Kong.
Identification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screening.
Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method.
Identification of overlapping class I and class II H-2d-restricted T cell determinants of influenza virus N1 neuraminidase that require infectious virus for presentation.
Identification of Potential Inhibitors of H5N1 Influenza A Virus Neuraminidase by Ligand-Based Virtual Screening Approach.
Identification of pyrrolo[3,2-c]pyridin-4-amine compounds as a new class of entry inhibitors against influenza viruses in vitro.
Identification of residues that affect oligomerization and/or enzymatic activity of influenza virus H5N1 neuraminidase proteins.
Identification of single amino acid substitutions (SAAS) in neuraminidase from influenza a virus (H1N1) via mass spectrometry analysis coupled with de novo peptide sequencing.
Identification of Suitable Natural Inhibitor against Influenza A (H1N1) Neuraminidase Protein by Molecular Docking.
Identification of the 5'-Terminal Packaging Signal of the H1N1 Influenza A Virus Neuraminidase Segment at Single-Nucleotide Resolution.
IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection.
Imaging of influenza virus sialidase activity in living cells.
Imaging of Sialidase Activity and Its Clinical Application.
Iminosugars: Promising therapeutics for influenza infection.
Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes.
Immune response to influenza vaccination in an elderly population.
Immune response to influenza vaccine in hemodialysis patients with chronic renal failure.
Immune Responses to Adjuvanted H7N9 Split Antigen in Aged Mice.
Immunity to influenza in ferrets. 13. Protection against influenza infection by serum antibody to homologous haemagglutinin or neuraminidase antigens.
Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge.
Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge.
Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
Immunobiological properties of influenza A (H7N9) hemagglutinin and neuraminidase proteins.
Immunochemistry of variants of influenza virus hemagglutinin and neuraminidase.
Immunodominance of Antigenic Site B over Site A of Hemagglutinin of Recent H3N2 Influenza Viruses.
Immunoelectron microscopic study of the detection of the glycoproteins of influenza and Sendai viruses in infected cells by the immunoperoxidase method.
Immunoelectron microscopy of influenza A virus neuraminidase glycoprotein topography.
Immunogenic peptides of influenza virus subtype N1 neuraminidase identify a T-cell determinant used in class II major histocompatibility complex-restricted responses to infectious virus.
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets.
Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants.
Immunohistochemical Findings of an Autopsied Lung Specimen from a Patient with Pandemic Influenza (A/H1N1pdm) Virus Infection.
Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial.
Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience.
Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice.
Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
Immunologic studies on the influenza A virus nonstructural protein NS1.
Immunological consequences of infection and vaccination in South American trypanosomiasis.
Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.
Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis.
Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.
Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
Immunostimulating reconstituted influenza virosomes.
Impact assessment of the rational selection of training and test sets on the predictive ability of QSAR models.
Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.
Impact of a potential glycosylation site at neuraminidase amino acid 264 of influenza A/H9N2 virus.
Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy.
Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study.
Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein.
Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza.
Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.
Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors.
Impact of mutations at residue i223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients.
Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.
Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Impact of Oseltamivir Treatment on Influenza A and B Virus Dynamics in Human Volunteers.
Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an Individual Participant Data (IPD) meta-analysis.
Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.
Impact of tetramerization on the ligand recognition of N1 influenza neuraminidase via MMGBSA approach.
Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment.
Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility.
Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).
Impairment of the M-protein and unmasking of a superficial type-specific antigen by proteolytic treatment of influenza A virions with preservation of host-specific antigenicity.
Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.
Improved design of the annual influenza vaccine using epitope analysis.
Improved Transient Protein Expression by pFluNS1 Plasmid.
Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics.
Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34.
Improving influenza virus backbones by including terminal regions of MDCK-adapted strains on hemagglutinin and neuraminidase gene segments.
Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015.
In search of effective H1N1 neuraminidase inhibitor by molecular docking, antiviral evaluation and membrane interaction studies using NMR.
In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir.
In silico analysis of genes nucleoprotein, neuraminidase and hemagglutinin: A comparative study on different strains of influenza A (Bird Flu) virus sub-type H5N1.
In silico design of a multi-epitope peptide construct as a potential vaccine candidate for Influenza A based on neuraminidase protein.
In Silico Identification of the Potential Drug Resistance Sites over 2009 Influenza A (H1N1) Virus Neuraminidase.
In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1.
In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein.
In silico prediction of influenza vaccine effectiveness by sequence analysis.
In silico study of rotavirus VP7 surface accessible conserved regions for antiviral drug/vaccine design.
In silico study on multidrug resistance conferred by I223R/H275Y double mutant neuraminidase.
In situ molecular identification of the influenza A (H1N1) 2009 Neuraminidase in patients with severe and fatal infections during a pandemic in Mexico City.
In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.
In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
In vitro and in vivo activities of anti-influenza virus compound T-705.
In vitro and in vivo assay systems for study of influenza virus inhibitors.
In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.
In vitro and in vivo characterization of novel neuraminidase substitutions in influenza A(H1N1)pdm09 identified using Laninamivir-mediated in vitro selection.
In vitro and in vivo inhibitory effects of disodium cromoglycate on influenza virus infection.
In vitro anti-influenza A activity of interferon (IFN)-?1 combined with IFN-? or oseltamivir carboxylate.
In vitro Anti-viral Activity of Psoraleae Semen Water Extract against Influenza A Viruses.
In vitro antiviral effects and 3D QSAR study of resveratrol derivatives as potent inhibitors of influenza H1N1 neuraminidase.
In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients.
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
In vitro enhancement of human natural cell-mediated cytotoxicity by purified influenza virus glycoproteins.
In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.
In vitro evaluation of the antiviral activity of methylglyoxal against influenza B virus infection.
In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility.
In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors.
In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.
In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
In vivo anti-influenza virus activity of kampo (Japanese herbal) medicine "sho-seiryu-to" and its mode of action.
In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase.
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.
In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain.
In-silico structural analysis of the influenza A subtype H7N9 neuraminidase and molecular docking with different neuraminidase inhibitors.
In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors.
Inactivated Seasonal Influenza Vaccines Increase Serum Antibodies to the Neuraminidase of Pandemic Influenza A(H1N1) 2009 Virus in an Age-Dependent Manner.
Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
Inactivation and stability of viral diagnostic reagents treated by gamma radiation.
Inactivation of influenza B virus by normal guinea-pig serum.
Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016.
Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
Increase in titer of the naturally occurring human antibody to neuraminidase-treated lymphocytes after influenza.
Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation.
Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains.
Increased influenza A virus sialidase activity with N-acetyl-9-O-acetylneuraminic acid-containing substrates resulting from influenza C virus O-acetylesterase action.
Increased resistance of vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity avian influenza virus.
Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
Increasing appearance of reassortant influenza B virus in Taiwan from 2002 to 2005.
Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins.
Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus.
Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding.
Induction of long-term protective immune responses by influenza H5N1 virus-like particles.
Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.
Infection of human airway epithelium by human and avian strains of influenza a virus.
Infection of influenza virus neuraminidase-vaccinated mice with homologous influenza virus leads to strong protection against heterologous influenza viruses.
Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice.
Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104.
Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201.
Influenza A (H1N1) neuraminidase inhibitors from Vitis amurensis
Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies.
Influenza A and methicillin-resistant Staphylococcus aureus co-infection in rhesus macaques - A model of severe pneumonia.
Influenza A antibodies in Cervine animals.
Influenza A H1N1 pdm09-associated myocarditis during zanamivir therapy.
Influenza A H1N1 Virus 2009 Synthetic Hemagglutinin and Neuraminidase Peptides for Antibody Detection.
Influenza A H1N1pdm 2009 Virus in Paraguay: Nucleotide Point Mutations in Hemagglutinin and Neuraminidase Genes are not Associated with Drug Resistance.
Influenza A neuraminidase antibodies in children and young adults studied by serum absorption.
Influenza A neuraminidase antibody assay with sensitized erythrocytes.
Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase.
Influenza a virus encoding secreted gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins.
Influenza A virus enhances allergic histamine release. Effect of neuraminidase.
Influenza A virus enhances IgE-mediated histamine release from human basophil leukocytes. Examination of the effect of viral neuraminidase and haemagglutinin.
Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery.
Influenza A virus hemagglutinin and neuraminidase mutually accelerate their apical targeting through clustering of lipid rafts.
Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance.
Influenza A virus hemagglutinin containing basolateral localization signal does not alter the apical budding of a recombinant influenza A virus in polarized MDCK cells.
Influenza A Virus Hemagglutinin is Required for the Assembly of Viral Components Including Bundled vRNPs at the Lipid Raft.
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.
Influenza A virus hemagglutinin specific antibodies interfere with virion neuraminidase activity via two distinct mechanisms.
Influenza A Virus Infection of Intestinal Epithelial Cells Enhances the Adhesion Ability of Crohn's Disease Associated Escherichia coli Strains.
Influenza a virus n5 neuraminidase has an extended 150-cavity.
Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules.
Influenza A virus neuraminidase limits viral superinfection.
Influenza A virus neuraminidase protein enhances cell survival through interaction with CEACAM6.
Influenza A virus neuraminidase protein interacts with Hsp90, to stabilize itself and enhance cell survival.
Influenza A virus neuraminidase: regions of the protein potentially involved in virus-host interactions.
Influenza A virus nucleoprotein selectively decreases neuraminidase gene-segment packaging while enhancing viral fitness and transmissibility.
Influenza A virus survival in water is influenced by the origin species of the host cell.
Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice.
Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Influenza A viruses possessing type B hemagglutinin and neuraminidase: potential as vaccine components.
Influenza A viruses: combinations of hemagglutinin and neuraminidase subtypes isolated from animals and other sources.
Influenza A viruses: combinations of hemagglutinin and neuraminidase subtypes isolated from animals and other sources. Brief review.
Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.
Influenza A(H1N1)pdm09 virus: viral characteristics and genetic evolution.
Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
Influenza A/H4N2 mallard infection experiments further indicate zanamivir as less prone to induce environmental resistance development than oseltamivir.
Influenza and antiviral resistance: an overview.
Influenza and Community-acquired Pneumonia Interactions: The Impact of Order and Time of Infection on Population Patterns.
Influenza and influenza vaccination.
Influenza and other emerging respiratory viruses.
Influenza and Stroke Risk: A Key Target Not to be Missed?
Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity.
Influenza antiviral resistance in the Asia-Pacific region during 2011.
Influenza antiviral resistance testing in new york and wisconsin, 2006 to 2008: methodology and surveillance data.
Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season.
Influenza as a molecular walker.
Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface.
Influenza B virus BM2 protein is transported through the trans-Golgi network as an integral membrane protein.
Influenza B virus genome: assignment of viral polypeptides to RNA segments.
Influenza B virus neuraminidase can synthesize its own inhibitor.
Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.
Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11.
Influenza chemotherapy: a review of the present state of art and of new drugs in development.
Influenza diagnosis and treatment: a view from clinical practice.
Influenza epidemics: The role of allergists-immunologists.
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.
Influenza hemagglutinin and neuraminidase membrane glycoproteins.
Influenza Hemagglutinin and Neuraminidase: Yin?Yang Proteins Coevolving to Thwart Immunity.
Influenza in the acute hospital setting.
Influenza in the Emergency Department: Vaccination, Diagnosis, and Treatment: Clinical Practice Paper Approved by American Academy of Emergency Medicine Clinical Guidelines Committee.
Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.
Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.
Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors.
Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.
Influenza neuraminidase antibody patterns of man.
Influenza neuraminidase as a vaccine antigen.
Influenza Neuraminidase as a Vaccine Antigen.
Influenza neuraminidase as target for antivirals.
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.
Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity.
Influenza neuraminidase is delivered directly to the apical surface of MDCK cell monolayers.
Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors.
Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
Influenza neuraminidase.
Influenza neuraminidase: a druggable target for natural products.
Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.
Influenza Neuraminidase: Underrated Role in Receptor Binding.
Influenza Pathobiology and Pathogenesis in Avian Species.
Influenza pH1N1 Virus Accumulated H275Y Mutation in Neuraminidase during Propagation in MDCK Cells.
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
Influenza subtype identification with molecular methods.
Influenza treatment and prophylaxis with neuraminidase inhibitors: a review.
Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom.
Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding.
Influenza type B neuraminidase can replace the function of type A neuraminidase.
Influenza vaccination and antiviral therapy: is there a role for concurrent administration in the institutionalised elderly?
Influenza vaccine, anti-influenza drugs, and rapid diagnosis in Japan.
Influenza Vaccine: An effective preventive vaccine for developing countries.
Influenza vaccine: progress in a vaccine that elicits a broad immune response.
Influenza vaccines based on virus-like particles.
Influenza vaccines.
Influenza viral glycoproteins induced cell-mediated cytotoxicity by an interferon-independent mechanism.
Influenza Viral Load and Peramivir Kinetics after Single Administration and Proposal of Regimens for Peramivir Administration against Resistant Variants.
Influenza viral neuraminidase primes bacterial coinfection through TGF-?-mediated expression of host cell receptors.
Influenza viral neuraminidase: the forgotten antigen.
Influenza virus A(H1N1)pdm09 hemagglutinin polymorphism and associated disease in southern Germany during the 2010/11 influenza season.
Influenza virus antigens conjugated with a synthetic polyelectrolyte: a novel model of vaccines.
Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins.
Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins.
Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein.
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets.
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
Influenza virus changes cell-surface glycoproteins including major histocompatibility complex determinants on lymphocytes.
Influenza virus genetics.
Influenza virus glycoprotein-reactive human monoclonal antibodies.
Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape.
Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein.
Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles.
Influenza virus in ruminants: a review.
Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling.
Influenza virus infection of desialylated cells.
Influenza virus infection of mouse lymphoblasts alters the binding affinity of anti-H-2 antibody: requirement for viral neuraminidase.
Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections.
Influenza virus ISCOMs: antibody response in animals.
Influenza virus ISCOMs: biochemical characterization.
Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.
Influenza virus N-linked glycosylation and innate immunity.
Influenza virus neuraminidase (NA): a target for antivirals and vaccines.
Influenza virus neuraminidase activates latent transforming growth factor beta.
Influenza virus neuraminidase alters allogeneic T cell proliferation.
Influenza virus neuraminidase and the viral surface.
Influenza virus neuraminidase contributes to secondary bacterial pneumonia.
Influenza virus neuraminidase contributes to the dextran sulfate-dependent suppressive replication of some influenza A virus strains.
Influenza Virus Neuraminidase Engages CD83 and Promotes Pulmonary Injury.
Influenza virus neuraminidase inhibitors.
Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening.
Influenza virus neuraminidase inhibitory activity of phlorotannins from the edible brown alga Ecklonia cava.
Influenza virus neuraminidase regulates host CD8+ T-cell response in mice.
Influenza Virus Neuraminidase Structure and Functions.
Influenza virus neuraminidase with hemagglutinin activity.
Influenza virus neuraminidase.
Influenza virus neuraminidase: structure and function.
Influenza virus neuraminidase: structure, antibodies, and inhibitors.
Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic Acid receptors.
Influenza virus partially counteracts restriction imposed by tetherin/BST-2.
Influenza virus PB1 and neuraminidase gene segments can cosegregate during vaccine reassortment driven by interactions in the PB1 coding region.
Influenza virus proteins: identity, synthesis, and modification analyzed by two-dimensional gel electrophoresis.
Influenza virus resistance to antiviral agents: a plea for rational use.
Influenza virus resistance to antiviral therapy.
Influenza virus resistance to neuraminidase inhibitors.
Influenza virus resistance to neuraminidase inhibitors: implications for treatment.
Influenza virus sialidase.
Influenza virus sialidase: a target for drug discovery.
Influenza virus sialidase: effect of calcium on steady-state kinetic parameters.
Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans.
Influenza Virus Uses Its Neuraminidase Protein to Evade the Recognition of Two Activating NK Cell Receptors.
Influenza virus-like particle vaccines.
Influenza virus-like particles as a new tool for vaccine immunogenicity testing: Validation of a neuraminidase neutralizing antibody assay.
Influenza virus-like particles as pandemic vaccines.
Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Influenza virus-like particles harboring H9N2 HA and NA proteins induce a protective immune response in chicken.
Influenza virus-related critical illness: prevention, diagnosis, treatment.
Influenza virus: an NMR study of mechanisms involved in infection.
Influenza virus: association of mouse-lung virulence with plaque formation in mouse kidney cells.
Influenza viruses - antiviral therapy and resistance.
Influenza viruses differ in recognition of 4-O-acetyl substitution of sialic acid receptor determinant.
Influenza viruses from avian and porcine sources and their possible role in the origin of human pandemic strains.
Influenza viruses in animal wildlife populations.
Influenza viruses resistant to neuraminidase inhibitors.
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.
Influenza viruses with receptor-binding n1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice.
Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children.
Influenza viruses: basic biology and potential drug targets.
Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design.
Influenza's Newest Trick.
Influenza, respiratory syncytial virus and SARS.
Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity.
Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
Influenza.
Influenza. Cost of illness and considerations in the economic evaluation of new and emerging therapies.
Influenza. Past, present, and future.
Influenza: epidemiology, clinical features, therapy, and prevention.
Influenza: evolving strategies in treatment and prevention.
Influenza: its antigenic variation and ecology.
Influenza: propagation, quantification, and storage.
Influenza: vaccination and treatment.
Inhaled antimicrobial therapy: from cystic fibrosis to the flu.
Inherent Serum Inhibition of Influenza Virus Neuraminidases.
Inhibiting Viral Polymerase and Neuraminidase in Treating Influenza.
Inhibition effect of flavonoid compounds against neuraminidase expressed in Pichia pastoris.
Inhibition of cellular invasive parameters in influenza A virus-infected MDCK and Vero cells by a nutrient mixture.
Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways.
Inhibition of Influenza A Virus Infection by Fucoidan Targeting Viral Neuraminidase and Cellular EGFR Pathway.
Inhibition of influenza A virus infection in vitro by peptides designed in silico.
Inhibition of influenza A virus sialidase activity by sulfatide.
Inhibition of influenza viral neuraminidase activity by collectins.
Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812).
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Inhibition of influenza virus replication by plant-derived isoquercetin.
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action.
Inhibition of influenza virus sialidase and anti-influenza virus activity by plant flavonoids.
Inhibition of mouse liver sialidase by plant flavonoids.
Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design.
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.
Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion.
Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Inhibition of sialidase activity as a therapeutic approach.
Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position.
Inhibition of viral group-1 and group-2 neuraminidases by oseltamivir: A comparative structural analysis by the ScrewFit algorithm.
Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.
Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo.
Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus.
Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.
Inhibitory Effect and Possible Mechanism of Action of Patchouli Alcohol against Influenza A (H2N2) Virus.
Inhibitory effect of microalgae and cyanobacteria extracts on influenza virus replication and neuraminidase activity.
Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase.
Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.
Insights from QM/MM Modeling the 3D Structure of the 2009 H1N1 Influenza A Virus Neuraminidase and Its Binding Interactions with Antiviral Drugs.
Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Intact Glycopeptide Analysis of Influenza A/H1N1/09 Neuraminidase Revealing the Effects of Host and Glycosite Location on Site-Specific Glycan Structures.
Intact sphingomyelin biosynthetic pathway is essential for intracellular transport of influenza virus glycoproteins.
Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus.
Integrating sequence variation and protein structure to identify sites under selection.
Intensive care management of influenza-associated pulmonary aspergillosis.
Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5.
Interaction of C1q and mannan-binding lectin with viruses.
Interaction of Hsp40 with influenza virus M2 protein: implications for PKR signaling pathway.
Interaction of influenza virus proteins with planar bilayer lipid membranes. I. Characterization of their adsorption and incorporation into lipid bilayers.
Interactions of protein antigens with antibodies.
Intercontinental circulation of human influenza A(H1N2) reassortant viruses during the 2001-2002 influenza season.
Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics.
Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity.
Interferon induction by influenza virus: significance of neuraminidase.
Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir.
Intergenic HA-NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes.
Intermittent treatment of severe influenza.
Interspecies transmission of influenza viruses.
Intra-host viral variability in children clinically infected with H1N1 (2009) pandemic influenza.
Intracellular synthesis of neuraminidase following infection of charioallantoic membranes with influenza virus.
Intragastric delivery of recombinant Lactococcus lactis displaying ectodomain of influenza matrix protein 2 (M2e) and neuraminidase (NA) induced focused mucosal and systemic immune responses in chickens.
Intrahost emergent dynamics of oseltamivir-resistant virus of pandemic influenza A (H1N1) 2009 in a fatally immunocompromised patient.
Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.
Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.
Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses.
Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
Intravenous peramivir for treatment of influenza in hospitalized patients.
Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice.
Introduction of foreign sequences into the genome of influenza A virus.
Introduction of site-specific mutations into the genome of influenza virus.
Introductions and evolution of human-origin seasonal influenza a viruses in multinational swine populations.
Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1.
Investigation of genetic variation: Neuraminidase gene of influenza A virus H1N1/pdm09, Shiraz, Iran (2015-2016).
Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations.
Investigation of the binding and cleavage characteristics of N1 neuraminidases from avian, seasonal, and pandemic influenza viruses using saturation transfer difference nuclear magnetic resonance.
Involvement of periodontopathic anaerobes in aspiration pneumonia.
Involvement of Periodontopathic Anaerobes in Aspiration Pneumonia.
Involvement of the mannose receptor in infection of macrophages by influenza virus.
In Vitro Evaluation of Synergistic Inhibitory Effects of Neuraminidase Inhibitors and Methylglyoxal Against Influenza Virus Infection.
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors against clinical isolates of the influenza viruses circulating in the 2010-2011 to 2014-2015 Japanese influenza seasons.
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2015-16 season: Comparison with the 2010-11 to 2014-15 seasons.
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2016-17 season: Comparison with the 2010-11 to 2015-16 seasons.
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2017-18 season: Comparison with the 2010-11 to 2016-17 seasons.
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2018-19 season: Comparison with the 2010-11 to 2017-18 seasons.
Iota-carrageenan is a potent inhibitor of influenza A virus infection.
Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study.
Is the influenza vaccine effective in decreasing infection, hospitalization, pneumonia, and mortality in healthy adults?
Isocorilagin, isolated from Canarium album (Lour.) Raeusch, as a potent neuraminidase inhibitor against influenza A virus.
Isoelectric focusing studies of A2-1957 influenza neuraminidase and its subunits.
Isolation and characterization of a transfectant influenza B virus altered in RNA segment 6.
Isolation and characterization of influenza A viruses from wild ducks in northern Japan: appearance of HSW1 antigens in the Japanese duck population.
Isolation and characterization of influenza a viruses from wild free-flying ducks in Hokkaido, Japan.
Isolation and characterization of influenza virus recombinants with high and low neuraminidase activity. Use of 2-(3'-methoxyphenyl)-n-acetylneuraminic acid to identify cloned populations.
Isolation and genetic characterization of avian influenza viruses and a Newcastle disease virus from wild birds in Barbados: 2003-2004.
Isolation from birds of influenza viruses with human neuraminidase.
Isolation of a biologically active soluble form of the hemagglutinin-neuraminidase protein of Sendai virus.
Isolation of a low molecular weight sialidase (neuraminidase) from influenza virus.
Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin.
Isolation of biologically active components from rabies and other envelope viruses.
Isolation of influenza A virus from budgerigars and its serological characterization.
Isolation of neuraminidase from the WSN strain of influenza virus.
Isolation of novel triple-reassortant swine H3N2 influenza viruses possessing the hemagglutinin and neuraminidase genes of a seasonal influenza virus in Vietnam in 2010.
Isolation, sequencing and phylogenetic analysis of the hemagglutinin, neuraminidase and nucleoprotein genes of the Chilean equine influenza virus subtypes H7N7 and H3N8.
Isometrically invariant and allosterically aware description of deformable macromolecular surfaces: Application to the viral neuraminidase.
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Japanese Surveillance Systems and Treatment for Influenza.
John F. Enders lecture 2006: antivirals for influenza.
Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target.
Key amino acid residues of neuraminidase involved in influenza A virus entry.
Kinetic studies on the sialidase of three influenza B and three influenza A virus strains.
Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza.
Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus.
Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland.
Kinetics of influenza A virus infection in humans.
Kinetics of Neuraminidase Action on Glycoproteins by 1D and 2D NMR.
Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses.
L-Ficolin Binds to the Glycoproteins Hemagglutinin and Neuraminidase and Inhibits Influenza A Virus Infection Both in vitro and in vivo.
La balance HA-NA des virus influenza A(H1N1).
Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines.
Labeling of influenza viruses with synthetic fluorescent and biotin-labeled lipids.
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.
Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice.
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Laninamivir Octanoate and Artificial Surfactant Combination Therapy Significantly Increases Survival of Mice Infected with Lethal Influenza H1N1 Virus.
Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone.
Large outbreak of swine influenza in southern Japan caused by reassortant (H1N2) influenza viruses: its epizootic background and characterization of the causative viruses.
Late diagnosis of influenza in adult patients during a seasonal outbreak.
Latex fetuin spheres as probes for influenza virus neuraminidase in productively and abortively infected cells.
Lattice-translocation defects in specific crystals of the catalytic head domain of influenza neuraminidase.
Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses.
Length variations in the NA stalk of an H7N1 influenza virus have opposite effects on viral excretion in chickens and ducks.
Levels of immunoglobulins and antibodies to haemaglutinin and neuraminidase of influenza virus in nasal secretions after natural infection.
Limited effect of recombinant human mannose-binding lectin on the infection of novel influenza A (H7N9) virus in vitro.
Lipid-dependence of target membrane stability during influenza viral fusion.
Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
Live attenuated H5N1 vaccine with H9N2 internal genes protects chickens from infections by both Highly Pathogenic H5N1 and H9N2 Influenza Viruses.
Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.
Live bivalent vaccine for parainfluenza and influenza virus infections.
Live cold-adapted influenza A vaccine produced in Vero cell line.
Live Imaging of Virus-Infected Cells by Using a Sialidase Fluorogenic Probe.
Live temperature-sensitive equine influenza virus vaccine: generation of the virus and efficacy in hamsters.
Live tissue culture influenza vaccine for oral administration. I. Specific immune response to monovaccine A (H3N2) in volunteers.
Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets.
Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
Localization of the Ts defect in two Ts mutants of influenza A virus: evidence for the occurrence of intracistronic complementation between Ts mutants of influenza A virus coding for the neuraminidase and nucleoprotein polypeptides.
Locally Acquired Human Infection with Swine-Origin Influenza A(H3N2) Variant Virus, Australia, 2018.
Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase.
Location on the evolutionary trees of the non-structural protein (NS) and neuraminidase (NA) genes of late human influenza A (H2N2) viruses: parental viruses of the NS and NA genes of Hong Kong influenza A (H3N2) viruses.
Locking the 150-cavity open: in silico design and verification of influenza neuraminidase inhibitors.
Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care.
Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection.
Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.
Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
Longitudinal sampling is required to maximize detection of intrahost A/H3N2 virus variants.
Loss of enzyme activity in a site-directed mutant of influenza neuraminidase compared to expressed wild-type protein.
Loss of glycosylation at Asn144 alters the substrate preference of the N8 influenza A virus neuraminidase.
Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
Low Pathogenic Avian Influenza Viruses in Wild Migratory Waterfowl in a Region of High Poultry Production, Delmarva, Maryland.
Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.
Low-pathogenicity avian influenza virus (H6N2) in chickens in California, 2000-02.
Low-pH Stability of Influenza A Virus Sialidase Contributing to Virus Replication and Pandemic.
Lymphocyte responses to hemagglutinin and neuraminidase subunits of influenza virus.
M2 protein-a proton channel of influenza A virus.
Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models.
Magnetic beads-based neuraminidase enzyme microreactor as a drug discovery tool for screening inhibitors from compound libraries and fishing ligands from natural products.
Mallards and highly pathogenic avian influenza ancestral viruses, northern Europe.
Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea.
Management of influenza in patients with asthma or chronic obstructive pulmonary disease.
Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance.
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Management of respiratory viral infections in hematopoietic cell transplant recipients.
Management of viral infections in immunocompromised cancer patients.
Managing influenza: amantadine, rimantadine and beyond.
Manipulation of neuraminidase packaging signals and hemagglutinin residues improves the growth of A/Anhui/1/2013 (H7N9) influenza vaccine virus yield in eggs.
Many human RNA viruses show extraordinarily stringent selective constraints on protein evolution.
Mapping of the influenza virus genome: identification of the hemagglutinin and the neuraminidase genes.
Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites.
Masking terminal neo-epitopes of linear peptides through glycosylation favours immune responses towards core epitopes producing parental protein bound antibodies.
Mass Spectrometric Characterization of Narcolepsy-Associated Pandemic 2009 Influenza Vaccines.
Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan.
Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice.
Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus.
Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.
Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice.
MD simulation of the interaction between sialoglycans and the second sialic acid binding site of influenza A virus N1 neuraminidase.
Measurement of antibodies to influenza virus neuraminidase by an enzyme-linked immunosorbent assay.
Measurement of antibody to influenza virus neuraminidase by single radial hemolysis in agarose gels.
Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.
Measures for control of influenza.
Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay.
Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assay.
Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Mechanism of 150-cavity formation in influenza neuraminidase.
Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase.
Mechanism of attenuation of a chimeric influenza A/B transfectant virus.
Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins.
Mechanism of protection against influenza A virus by DNA vaccine encoding the hemagglutinin gene.
Mechanism-Based Covalent Neuraminidase Inhibitors with Broad Spectrum Influenza Antiviral Activity.
Mechanisms of antiviral resistance in influenza neuraminidase revealed by a mass spectrometry based phylonumerics approach.
Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities.
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.
Mesoscale All-Atom Influenza Virus Simulations Suggest New Substrate Binding Mechanism.
Metabolic Oligosaccharide Engineering with Alkyne Sialic Acids Confers Neuraminidase Resistance and Inhibits Influenza Reproduction.
Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.
Method for Sequencing the Whole Genome of the Highly Pathogenic Avian Influenza A(H5N6) Virus.
MF59 adjuvant: the best insurance against influenza strain diversity.
MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
Microglial activation by microbial neuraminidase through TLR2 and TLR4 receptors.
Microsecond Molecular Dynamics Simulations of Influenza Neuraminidase Suggest a Mechanism for the Increased Virulence of Stalk-Deletion Mutants.
Mild to moderate influenza activity in Europe and the detection of novel A(H1N2) and B viruses during the winter of 2001-02.
Mismatched hemagglutinin and neuraminidase specificities in recent human H3N2 influenza viruses.
Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Mobile imaging platform for digital influenza virus counting.
Mobility-Based Quantification of Multivalent Virus-Receptor Interactions: New Insights Into Influenza A Virus Binding Mode.
Modeling the effects of drug resistant influenza virus in a pandemic.
Modeling the paramyxovirus hemagglutinin-neuraminidase protein.
Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season.
Modification of infectious bursal disease virus antigen VP2 for cell surface location fails to enhance immunogenicity.
Modified sialic acids on mucus and erythrocytes inhibit influenza A HA and NA functions.
Modifying clinical practices to manage influenza in children effectively.
Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo.
Modulation of murine macrophage responses stimulated with influenza glycoproteins.
Molecular analysis of hemagglutinin, neuraminidase, matrix genes provide insight into the genetic diversity of seasonal H3N2 human influenza a viruses in Bangladesh during July-August, 2012.
Molecular analysis of isolates from influenza B outbreaks in the U.S. and Nepal, 2005.
Molecular and genetic characteristics of hemagglutinin and neuraminidase in Iranian 2009 pandemic influenza A(H1N1) viruses.
Molecular and phylogenetic analyses of influenza B viruses isolated from pediatric inpatients in South Korea during the 2011-2012 winter season.
Molecular and phylogenetic analysis and vaccine strain match of human influenza A(H3N2) viruses isolated in Northern Greece between 2004 and 2008.
Molecular and phylogenetic analysis of haemagglutinin and neuraminidase sequences from recent human influenza type A (H3N2) viral isolates in Southern Greece.
Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations.
Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.
Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
Molecular characteristics of the human pandemic influenza A virus (H1N1).
Molecular characterization of neuraminidase genes of influenza A(H3N2) viruses circulating in Southwest India from 2009 to 2013.
Molecular Characterization of Seasonal Influenza A and B from Hospitalized Patients in Thailand in 2018-2019.
Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand.
Molecular characterization of the hemagglutinin and neuraminidase genes of H5N1 influenza A viruses isolated from poultry in Vietnam from 2004 to 2005.
Molecular characterization of the influenza A(H1N1)pdm09 isolates collected in the 2015-2016 season and comparison of HA mutations detected in Turkey since 2009.
Molecular cloning and analysis of the N5 neuraminidase subtype from an avian influenza virus.
Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus.
Molecular docking analysis of zanamavir with haem agglutinin neuraminidase of human para influenza virus type 3.
Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3-alpha] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
Molecular docking of potential inhibitors for influenza H7N9.
Molecular Docking, 3D-QSAR studies and in-silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors.
Molecular epidemiology and evolution of A(H1N1)pdm09 and H3N2 virus during winter 2012-2013 in Beijing, China.
Molecular epidemiology and evolution of influenza A and B viruses during winter 2013-2014 in Beijing, China.
Molecular epidemiology and genetic characterization of influenza B virus in Lebanon during 2016-2018.
Molecular epidemiology and glycomics of swine influenza viruses circulating in commercial swine farms in the southeastern and midwest United States.
Molecular Epidemiology of a novel re-assorted epidemic strain of equine influenza virus in Pakistan in 2015-16.
Molecular epidemiology of influenza A virus infection in Cyprus in four consecutive seasons (2009 pandemic-2013).
Molecular evolution and characterization of hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 viruses isolated in Beijing, China, during the 2017-2018 and 2018-2019 influenza seasons.
Molecular evolution of the hemagglutinin and neuraminidase genes of pandemic (H1N1) 2009 influenza viruses in Sendai, Japan, during 2009-2011.
Molecular findings from influenza A(H1N1)pdm09 detected in patients from a Brazilian equatorial region during the pandemic period.
Molecular footprints of selective pressure in the neuraminidase gene of currently circulating human influenza subtypes and lineages.
Molecular hybridization with DNA probes as a laboratory diagnosis test for influenza viruses: further investigations on the possibilities of the method.
Molecular markers of influenza B lineages and clades.
Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs.
Molecular modeling of sialyloligosaccharide fragments into the active site of influenza virus N9 neuraminidase.
Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase.
Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis.
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Molecular point-of-care testing for influenza to improve early neuraminidase inhibitor treatment and outcomes in hospitalised adults.
Molecular prediction of oseltamivir efficiency against probable influenza A (H1N1-2009) mutants: molecular modeling approach.
Molecular simulation study of the binding mechanism of [?-PTi2W10O40]7- for its promising broad-spectrum inhibitory activity to FluV-A neuraminidase.
Molecular strategies to inhibit the replication of RNA viruses.
Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013.
Molecular-level simulation of pandemic influenza glycoproteins.
Monitoring genetic diversity of influenza A(H1N1)pdm09 virus circulating during the post-pandemic period in Turkey.
Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity.
Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons.
Monoclonal antibodies against avian paramyxovirus-3: antigenic mapping and functional analysis of the haemagglutinin-neuraminidase protein and the characterization of nonspecific monoclonal antibodies.
Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.
Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.
Monomeric inhibitors of influenza neuraminidase enhance the hemagglutination inhibition activities of polyacrylamides presenting multiple C-sialoside groups.
Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.
Morin Hydrate Inhibits Influenza Virus entry into Host Cells and Has Anti-inflammatory Effect in Influenza-infected Mice.
Morphology of the isolated hemagglutinin and neuraminidase subunits of influenza virus.
Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants.
Mouse Saliva Inhibits Transit of Influenza Virus to the Lower Respiratory Tract by Efficiently Blocking Influenza Virus Neuraminidase Activity.
Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs.
Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection.
Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets.
Multidrug-Resistant Pandemic (H1N1) 2009 Infection in Immunocompetent Child.
Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic.
Multiple clusters of A(H1N1)pdm09 virus circulating in severe cases of influenza during the 2010-2011 season: a phylogenetic and molecular analysis of the neuraminidase gene.
Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).
Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.
Multiple viral introductions: molecular characterization of influenza B virus in Wenzhou, Zhejiang, China, from 2011 to 2014 based on hemagglutinin and neuraminidase genes.
Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies.
Multiplex primer prediction software for divergent targets.
Multiplex Reverse Transcription-PCR for Simultaneous Surveillance of Influenza A and B Viruses.
Multiplex rt-PCR and indirect immunofluorescence assays for detection and subtyping of human influenza virus in Tunisia.
Multiscale Simulations Examining Glycan Shield Effects on Drug Binding to Influenza Neuraminidase.
Multivalent Affinity Profiling: Direct Visualization of the Superselective Binding of Influenza Viruses.
Multivalent S-sialoside protein conjugates block influenza hemagglutinin and neuraminidase.
Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.
Murine TH response to influenza virus: recognition of hemagglutinin, neuraminidase, matrix, and nucleoproteins.
Mutants of an influenza A reassortant which are cold-sensitive (cs) as well as temperature-sensitive (ts): on the role of the neuraminidase activity for influenza virus infection.
Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme.
Mutation of neuraminidase cysteine residues yields temperature-sensitive influenza viruses.
Mutation of the 2(nd) Sialic Acid-Binding Site Resulting in Reduced Neuraminidase Activity Preceded Emergence of H7N9 Influenza A Virus.
Mutation of the second sialic acid-binding site of influenza A virus neuraminidase drives compensatory mutations in hemagglutinin.
Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
Mutational analysis of the signal-anchor domain of influenza virus neuraminidase.
Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Mutations at highly conserved residues in influenza A(H1N1)pdm09 virus affect neuraminidase activity.
Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses.
Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir).
Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.
Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic.
Mutations in the cytoplasmic tail of influenza A virus neuraminidase affect incorporation into virions.
Mutations in the ectodomain of newcastle disease virus fusion protein confer a hemagglutinin-neuraminidase-independent phenotype.
Mutations in the Neuraminidase-Like Protein of Bat Influenza H18N11 Virus Enhance Virus Replication in Mammalian Cells, Mice, and Ferrets.
Mutations in the nonconserved noncoding sequences of the influenza A virus segments affect viral vRNA formation.
Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
N-Glycosylation Fingerprinting of Viral Glycoproteins by xCGE-LIF.
N-Linked Glycan Sites on the Influenza A Virus Neuraminidase Head Domain Are Required for Efficient Viral Incorporation and Replication.
N-Linked Glycosylation Plays an Important Role in Budding of Neuraminidase Protein and Virulence of Influenza Viruses.
N1 neuraminidase of H5N1 avian influenza A virus complexed with sialic acid and zanamivir - A study by molecular docking and molecular dynamics simulation.
N1 neuraminidase of influenza virus A/FPV/Rostock/34 has haemadsorbing activity.
N9 neuraminidase complexes with antibodies NC41 and NC10: empirical free energy calculations capture specificity trends observed with mutant binding data.
N? gas plasma inactivates influenza virus mediated by oxidative stress.
NA proteins of influenza A viruses H1N1/2009, H5N1, and H9N2 show differential effects on infection initiation, virus release, and cell-cell fusion.
NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
Nanomicroarray and multiplex next-generation sequencing for simultaneous identification and characterization of influenza viruses.
Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season.
Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Natural cases of 2009 pandemic H1N1 Influenza A virus in pet ferrets.
Natural infection with influenza A (H3N2). The development, persistance and effect of antibodies to the surface antigens.
Natural Products as Promising Therapeutics for Treatment of Influenza Disease.
NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets.
Neuraminidase activity and specificity of influenza A virus are influenced by haemagglutinin-receptor binding.
Neuraminidase Activity and The Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus.
Neuraminidase activity is not the cause of influenza virus-induced neutrophil dysfunction.
Neuraminidase activity of blue eye disease porcine rubulavirus: Specificity, affinity and inhibition studies.
Neuraminidase activity of influenza virus-infected cells: localization and properties.
Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.
Neuraminidase Amino Acid Sequences of Influenza A/H3N2 and B Viruses Isolated from Influenza Patients in the 2014/15 Japanese Influenza Season.
Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses.
Neuraminidase and resistance to influenza.
Neuraminidase and resistance to vaccination with live influenza A2 Hong Kong vaccines.
Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis.
Neuraminidase antibodies and H5N1: geographic-dependent influenza epidemiology could determine cross-protection against emerging strains.
Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.
Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding.
Neuraminidase as an enzymatic marker for detecting airborne Influenza virus and other viruses.
Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.
Neuraminidase assay of influenza vaccines.
Neuraminidase characterisation reveals very low levels of antiviral resistance and the presence of mutations associated with reduced antibody effectiveness in the Irish influenza 2018/2019 season.
Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.
Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.
Neuraminidase from Influenza A and B Viruses is Susceptible to the Compound 4-(4-Phenyl-1H-1,2,3-Triazol-1-yl)-2,2,6,6-Tetramethylpiperidine-1- Oxyl.
Neuraminidase from influenza virus A (H3N2): specificity towards several substrates and procedure of activity determination.
Neuraminidase gene from the early Asian strain of human influenza virus, A/RI/5-/57 (H2N2).
Neuraminidase gene homology contributes to the protective activity of influenza vaccines prepared from the influenza virus library.
Neuraminidase Gene Variations in Influenza A(H1N1)pdm09 Virus among Patients Admitted to Refferal Pulmonary Hospital, Tehran, Iran in 2009-2013.
Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection.
Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks.
Neuraminidase in avin influenza A virus antigenically related to that of human A0 and A1 subtypes.
Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type.
Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies.
Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues.
Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children.
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Neuraminidase inhibitor resistance in influenza viruses.
Neuraminidase inhibitor resistance in influenza: a clinical perspective.
Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.
Neuraminidase inhibitor susceptibility and evolutionary analysis of human influenza B isolates from three Asian countries during 2012-2015.
Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999.
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
Neuraminidase inhibitor therapy in a military population.
Neuraminidase Inhibitor Zanamivir Ameliorates Collagen-Induced Arthritis.
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo.
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.
Neuraminidase Inhibitors and Influenza Infection-Reply.
Neuraminidase Inhibitors and Influenza Infection.
Neuraminidase inhibitors and relief of influenza symptoms.
Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
Neuraminidase inhibitors and their role in avian and pandemic influenza.
Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials.
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.
Neuraminidase inhibitors as anti-influenza virus agents.
Neuraminidase inhibitors as antiviral agents.
Neuraminidase inhibitors as antivirals.
Neuraminidase inhibitors beneficial for treatment and prevention of influenza in children.
Neuraminidase inhibitors for critically ill children with influenza.
Neuraminidase inhibitors for influenza A and B: antivirals need to be protected from adverse conditions to retain effectiveness.
Neuraminidase inhibitors for influenza A and B: PROSE may be as useful as POEMs.
Neuraminidase inhibitors for influenza A and B: study showed benefits of treatment are marginal.
Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance.
Neuraminidase inhibitors for influenza complications--Authors' reply.
Neuraminidase inhibitors for influenza complications.
Neuraminidase inhibitors for influenza in healthy adults: what we don't know.
Neuraminidase inhibitors for influenza treatment and prevention in healthy adults.
Neuraminidase inhibitors for influenza.
Neuraminidase inhibitors for influenza: a call for better research.
Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
Neuraminidase inhibitors for influenza: fully evaluating benefits and harms.
Neuraminidase inhibitors for influenza: methods change, principles don't.
Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).
Neuraminidase inhibitors for preventing and treating influenza in children.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: a Cochrane review.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.
Neuraminidase inhibitors for the treatment and prevention of influenza.
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.
Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials.
Neuraminidase inhibitors for treatment of equine influenza - when all else fails?
Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.
Neuraminidase inhibitors for treatment of influenza A and B infections.
Neuraminidase inhibitors for treatment of influenza.
Neuraminidase Inhibitors from the Fruiting Body of Phellinus igniarius.
Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study.
Neuraminidase Inhibitors in Influenza Treatment and Prevention?Is It Time to Call It a Day?
Neuraminidase inhibitors in patients with underlying airways disease.
Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy.
Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice.
Neuraminidase inhibitors in the treatment of influenza A and B--overview and case reports.
Neuraminidase inhibitors produce a small reduction in duration of seasonal influenza in children and reduce transmission in affected households, but effects on serious complications unclear.
Neuraminidase inhibitors reduce nitric oxide production in influenza virus-infected and gamma interferon-activated RAW 264.7 macrophages.
Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
Neuraminidase inhibitors take bite out of influenza.
Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Neuraminidase inhibitors: progress in the management of influenza.
Neuraminidase inhibitors: zanamivir and oseltamivir.
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.
Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
Neuraminidase mutations conferring resistance to oseltamivir in influenza A(H7N9) viruses.
Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.
Neuraminidase of Influenza A Virus Binds Lysosome-Associated Membrane Proteins Directly and Induces Lysosome Rupture.
Neuraminidase of influenza virus reveals a flower-like head.
Neuraminidase Receptor Binding Variants of Human Influenza A(H3N2) Viruses due to Substitution of Aspartic acid 151 in the Catalytic Site - Role in Virus Attachment?
Neuraminidase Resistant Sialosides for the Detection of Influenza Viruses.
Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice.
Neuraminidase subtyping of human influenza a viruses by RT-PCR and its application to clinical isolates.
Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection.
Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Neuraminidase-inhibition assay for the identification of influenza A virus neuraminidase subtype or neuraminidase antibody specificity.
Neuraminidase-inhibition assay for the identification of influenza A virus neuraminidase virus subtype or neuraminidase antibody specificity.
Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.
Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site.
Neuraminidase-mediated, NKp46-dependent immune-evasion mechanism of influenza viruses.
Neuraminidase-producing oral mitis group streptococci potentially contribute to influenza viral infection and reduction in antiviral efficacy of zanamivir.
Neuraminidase-specific antibody responses are generated in naive and vaccinated newborn nonhuman primates following virus infection.
Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.
Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae.
Neuraminidase: Another Piece of the Influenza Vaccine Puzzle.
Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody.
Neutralizing and neuraminidase antibodies correlate with protection against influenza during a late season A/H3N2 outbreak among unvaccinated military recruits.
New Antivirals and Drug Resistance.
New approaches to influenza chemotherapy. Neuraminidase inhibitors.
New aspects of influenza viruses.
New avian influenza A virus subtype combination H5N7 identified in Danish mallard ducks.
New crystalline forms of neuraminidase of type B human influenza virus.
New ganglioside analogs that inhibit influenza virus sialidase.
New genotype of avian influenza H5N1 viruses isolated from tree sparrows in China.
New insights into the nonconserved noncoding region of the subtype-determinant hemagglutinin and neuraminidase segments of influenza A viruses.
New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors.
New point of care test is highly specific but less sensitive for influenza virus A and B in children and adults.
New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.
New stilbenoid with inhibitory activity on viral neuraminidases from Erythrina addisoniae.
New world bats harbor diverse influenza A viruses.
New, azide-free transformation of epoxides into 1,2-diamino compounds: synthesis of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu).
New, efficient synthesis of oseltamivir phosphate (Tamiflu) via enzymatic desymmetrization of a meso-1,3-cyclohexanedicarboxylic acid diester.
New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions.
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
Newer influenza antivirals, biotherapeutics and combinations.
NH2-terminal hydrophobic region of influenza virus neuraminidase provides the signal function in translocation.
Nitazoxanide: a first-in-class broad-spectrum antiviral agent.
Non-neutralizing Antibodies Directed at Conservative Influenza Antigens.
Non-sialate inhibitor of influenza A/WSN/33 neuraminidase.
Nonlinkage of neurovirulence exclusively to viral hemagglutinin or neuraminidase in genetic recombinants of A-NWS (HON1) influenza virus.
Nosocomial influenza in children.
Novel 3,4-disubstituted-Neu5Ac2en derivatives as probes to investigate flexibility of the influenza virus sialidase 150-loop.
Novel alpha- and beta-amino acid inhibitors of influenza virus neuraminidase.
Novel antiviral activity of neuraminidase inhibitors against an avian influenza A virus.
Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.
Novel correlates of protection against pandemic H1N1 influenza A virus infection.
Novel fucolipids of human adenocarcinoma: disialosyl Lea antigen (III4FucIII6NeuAcIV3NeuAcLc4) of human colonic adenocarcinoma and the monoclonal antibody (FH7) defining this structure.
Novel hemagglutinin-based influenza virus inhibitors.
Novel influenza A viruses isolated from Canadian feral ducks: including strains antigenically related to swine influenza (Hsw1N1) viruses.
Novel linear polymers bearing thiosialosides as pendant-type epitopes for influenza neuraminidase inhibitors.
Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies.
Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode.
Novel oral anti-influenza drug candidate AV5080.
Novel oral anti-influenza prodrug candidate AV5075S.
Novel oseltamivir-resistant mutations distant from the active site of influenza B neuraminidase.
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.
Novel Piperine compound AB05 (N-5-(3,4-dimethoxyphenyl) -2E,4E pentadienylpiperidine) inhibits H1N1 influenza virus propagation in vitro.
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.
Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.
Novel strategies for prevention and treatment of influenza.
Novel swine influenza A/H1N1 and the phase six pandemic.
NS-gene based phylogenetic analysis of equine influenza viruses isolated in Poland.
Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses.
Nucleotide and deduced amino acid sequence of the influenza neuraminidase genes of two equine serotypes.
Nucleotide sequence of the influenza virus A/USSR/90/77 neuraminidase gene.
Nucleotide sequences of the neuraminidase genes of influenza A/Leningrad/134/57 (H2N2) virus and two of its live, attenuated, cold-adapted variants.
Observations on the relationship between hemagglutinin and neuraminidase of influenza viruses.
Oligonucleotide microchip for subtyping of influenza A virus.
On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9.
On the penetration mechanism of influenza viruses.
On the role of electrostatic interactions in the design of protein-protein interfaces.
On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
On three-dimensional holographic vector of atomic interaction field analysis for influenza neuraminidase inhibitors.
Optimal Charges in Lead Progression: A Structure-Based Neuraminidase Case Study.
Optimization of a Quantitative Micro-neutralization Assay.
Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.
Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations.
Optimization of small molecule drugs binding to highly polar target sites: lessons from the discovery and development of neuraminidase inhibitors.
Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.
Optimizing antiviral therapy for influenza: understanding the evidence.
Optimizing viral protein yield of influenza virus strain A/Vietnam/1203/2004 by modification of the neuraminidase gene.
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.
Oral clarithromycin enhances airway IgA immunity through induction of IgA class switching recombination and B-cell activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus.
Oral Delivery of a Novel Attenuated Salmonella Vaccine Expressing Influenza A Virus Proteins Protects Mice against H5N1 and H1N1 Viral Infection.
Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958.
Origins and Evolutionary Genomics of the Novel Swine-Origin Influenza A (H1N1) Virus in Humans -Past and Present Perspectives.
Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations.
Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs.
Ortho- and paramyxoviruses from migrating feral ducks: characterization of a new group of influenza A viruses.
Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex.
Oseltamivir (TamifluTM) is a substrate of PEPT1.
Oseltamivir and Abnormal Behaviors: True or Not?
Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.
Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan.
Oseltamivir exposure in pregnancy and the risk of specific birth defects.
Oseltamivir for influenza.
Oseltamivir for treatment and prophylaxis of influenza infection.
Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors.
Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets.
Oseltamivir pharmacology in young children: a commentary.
Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses.
Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.
Oseltamivir resistance during treatment of influenza A (H5N1) infection.
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.
Oseltamivir Resistance in Influenza A(H6N2) Caused by an R292K Substitution in Neuraminidase Is Not Maintained in Mallards without Drug Pressure.
Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study.
Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient.
Oseltamivir susceptibility in south-western France during the 2007-8 and 2008-9 influenza epidemics and the ongoing influenza pandemic 2009.
Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
Oseltamivir use in adolescents and adults: clinical and economic considerations.
Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice.
Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
Oseltamivir-Associated Supraventricular Tachycardia in an Infant.
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
Oseltamivir-Resistant Influenza A (H1N1) Virus Strain with an H274Y Mutation in Neuraminidase Persists without Drug Pressure in Infected Mallards.
Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients.
Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.
Oseltamivir-resistant influenza A(H1N1) 2009 virus in Greece during the post-pandemic 2010-2011 season.
Oseltamivir-resistant influenza A(H1N1) pdm09 virus: first reported case from India.
Oseltamivir-resistant influenza A(H1N1)pdm09 virus in southern Brazil.
Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14.
Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance.
Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 Season.
Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan.
Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
Oseltamivir-resistant influenza viruses get by with a little help from permissive mutations.
Oseltamivir-resistant influenza viruses isolated in South Korea from 2005 to 2010.
Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea.
Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets.
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets.
Oseltamivir-resistant seasonal A(H1N1) and A(H1N1)pdm09 influenza viruses from the 2007/2008 to 2012/2013 season in Nara Prefecture, Japan.
Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
Oseltamivir.
Oseltamivir: a clinical and pharmacological perspective.
Oseltamivir: a review of its use in influenza.
Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation.
Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1.
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors.
Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.
Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.
Pandemic influenza H1N1 2009, innate immunity, and the impact of immunosenescence on influenza vaccine.
Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects.
Pandemic influenza: is an antiviral response realistic?
Pandemic Swine H1N1 Influenza Viruses with Almost Undetectable Neuraminidase Activity Are Not Transmitted via Aerosols in Ferrets and Are Inhibited by Human Mucus but Not Swine Mucus.
Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option?
Panorama phylogenetic diversity and distribution of Type A influenza virus.
Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors.
Parvovirus infection of cells by using variants of the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains.
Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant.
Patchouli alcohol: in vitro direct anti-influenza virus sesquiterpene in Pogostemon cablin Benth.
Pathogenesis and Transmission of Genetically Diverse Swine-Origin H3N2 Variant Influenza A Viruses from Multiple Lineages Isolated in the United States, 2011-2016.
Pathogenic studies and antigenic and sequence comparisons of A/equine/Alaska/1/91 (H3N8) influenza virus.
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus.
Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.
Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice.
Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.
PEPT1-mediated prodrug strategy for oral delivery of peramivir.
Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.
Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza.
Peramivir and its use in H1N1 influenza.
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.
Peramivir binding affinity with influenza A neuraminidase and research on its mutations using an induced-fit docking approach.
Peramivir conjugates as orally available agents against influenza H275Y mutant.
Peramivir for the treatment of influenza.
Peramivir injection in the treatment of acute influenza: a review of the literature.
Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections.
Peramivir: A Review in Uncomplicated Influenza.
Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
Peramivir: an intravenous neuraminidase inhibitor.
Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment.
Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected].
Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.
Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.
Perspectives on antiviral use during pandemic influenza.
Phage surface presentation and secretion of antibody fragments using an adaptable phagemid vector.
Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing.
Pharmacoeconomics of Antiviral Therapy for Influenza in a Japanese Hospital Setting.
Pharmacokinetic behavior of peramivir in the plasma and lungs of rats after trans-nasal aerosol inhalation and intravenous injection.
Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.
Pharmacokinetic Properties of Anti-Influenza Neuraminidase Inhibitors.
Pharmacokinetic Properties ofAnti-Influenza Neuraminidase Inhibitors.
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
Pharmacokinetics of oseltamivir in young and very elderly subjects.
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
Pharmacokinetics of Peramivir in an Adolescent Patient Receiving Continuous Venovenous Hemodiafiltration.
Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
Pharmacological activities and structure-modification of resveratrol analogues.
Pharmacophore model of influenza neuraminidase inhibitors--a systematic review.
Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors.
Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.
Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382).
Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.
Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
Phenolic compounds from Eurycorymbus cavaleriei.
Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects.
Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.
Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
Phenotypic expression of HA-NA combinations in human-avian influenza A virus reassortants.
Photodegradation and inhibition of drug-resistant influenza virus neuraminidase using anthraquinone-sialic acid hybrids.
Phylogenetic analysis of hemagglutinin and neuraminidase genes of H9N2 viruses isolated from migratory ducks.
Phylogenetic analysis of neuraminidase gene of H9N2 influenza viruses prevalent in chickens in China during 1995-2002.
Phylogenetic analysis of the N8 neuraminidase gene of influenza A viruses.
Phylogenetic analysis of the neuraminidase gene of pandemic H1N1 influenza A virus circulating in the South American region.
Phylogenetic analysis of the neuraminidase segment gene of Influenza A/H1N1 strains isolated from Monastir Region (Tunisia) during the 2017-2018 outbreak.
Phylogenetic relationships of the HA and NA genes between vaccine and seasonal influenza A(H3N2) strains in Korea.
Phylogenetic, molecular and drug-sensitivity analysis of HA and NA genes of human H3N2 influenza A viruses in Guangdong, China, 2007-2011.
PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.
Plant expression systems for production of hemagglutinin as a vaccine against influenza virus.
Plant polyphenolic complex inhibits the reproduction of influenza and herpes simplex viruses.
Plant-produced recombinant influenza A vaccines based on the M2e peptide.
Plant-Produced Recombinant Influenza Vaccine Based on Virus-Like HBc Particles Carrying an Extracellular Domain of M2 Protein.
Plasmin-mediated activation of pandemic H1N1 influenza virus hemagglutinin independent of the viral neuraminidase.
Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase.
Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus.
Plasmodium falciparum lacks sialidase and trans-sialidase activity.
Plasticity of 150-loop in influenza neuraminidase explored by Hamiltonian replica exchange molecular dynamics simulations.
Plasticity of the 340-Loop in Influenza Neuraminidase Offers New Insight for Antiviral Drug Development.
Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
PNA FIT-Probes for the Dual Color Imaging of Two Viral mRNA Targets in Influenza H1N1 Infected Live Cells.
Pneumococcal Neuraminidase A (NanA) Promotes Biofilm Formation and Synergizes with Influenza A Virus in Nasal Colonization and Middle Ear Infection.
Pneumococcal surface protein A contributes to secondary Streptococcus pneumoniae infection after influenza virus infection.
Polarization of allogeneic T-cell responses by influenza virus-infected dendritic cells.
Polyclonal B-cell activation by influenza A/Texas virus-specific human T-cell clones.
Polymerase-assisted fluorescence resonance energy transfer (FRET) assay for simultaneous detection of binary viral sequences.
Polyphenolic glycosides isolated from Pogostemon cablin (Blanco) Benth. as novel influenza neuraminidase inhibitors.
Polyunsaturated fatty acids from Phyllocaulis boraceiensis mucus block the replication of influenza virus.
Polyuridylated mRNA synthesized by a recombinant influenza virus is defective in nuclear export.
Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers.
Population dynamics at neuraminidase position 151 of influenza A (H1N1)pdm09 virus in clinical specimens.
Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza.
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
Population pharmacokinetics of peramivir in healthy volunteers and influenza patients.
Population-wide emergence of antiviral resistance during pandemic influenza.
Porous gold nanoparticles for attenuating infectivity of influenza A virus.
Positive selection on hemagglutinin and neuraminidase genes of H1N1 influenza viruses.
Positive selection on the H3 hemagglutinin gene of human influenza virus A.
Possible Reason for Cross-Species and Cross-Subtype Reassortment in Polymerase Basic Protein 2 from Influenza A Virus.
Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK.
Post-Exposure Prophylaxis for Influenza in Pediatric Wards: Oseltamivir or Zanamivir After Rapid Antigen Detection.
Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors.
Postreassortment changes in a model system: HA-NA adjustment in an H3N2 avian-human reassortant influenza virus.
Postreassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match.
Potency of an inactivated influenza vaccine prepared from A/duck/Hong Kong/960/1980 (H6N2) against a challenge with A/duck/Vietnam/OIE-0033/2012 (H6N2) in mice.
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.
Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin.
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.
Potential benefits and limitations of various strategies to mitigate the impact of an influenza pandemic.
Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design.
Potential for hepatic and renal dysfunction during influenza B infection, convalescence, and after induction of secondary viremia.
Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza.
Potentiation of the immune response to influenza virus subunit vaccines.
Practising evidence-based occupational health in workers' groups: how to prevent sickness absence caused by influenza.
Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care 'test-and-treat' strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol.
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses.
Pre-existing anti-neuraminidase antibodies are associated with shortened duration of influenza A (H1N1)pdm virus shedding and illness in naturally infected adults.
Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit.
Predicting Influenza Antigenicity by Matrix Completion With Antigen and Antiserum Similarity.
Predicting the emergence of H3N2 influenza viruses reveals contrasted modes of evolution of HA and NA antigens.
Predicting the host of influenza viruses based on the word vector.
Prediction of Biological Functions on Glycosylation Site Migrations in Human Influenza H1N1 Viruses.
Prediction of epitopes in hemagglutinin and neuraminidase proteins of influenza A virus H5N1 strain: a clue for diagnostic and vaccine development.
Prediction of mutations in H1 neuraminidases from North America influenza A virus engineered by internal randomness.
Prediction of the Inhibition of Influenza Virus Neuraminidase Various Strains by Means of a Generalized Model Constructed Using the Data on the Position of Known Ligands.
Prediction of zanamivir efficiency over the possible 2009 Influenza A (H1N1) mutants by multiple molecular dynamics simulations and free energy calculations.
Predictors of Influenza Diagnosis Among Patients With Laboratory-Confirmed Influenza.
Predictors of mortality and length of stay in hospitalized cases of 2009 influenza A (H1N1): Experiences of a tertiary care center.
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.
Pregnancy and H1N1 influenza: lessons to learn.
Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study.
Preliminary crystallographic analysis of neuraminidase N2 from a new influenza A virus.
Preliminary crystallographic data for influenza virus neuraminidase "heads".
Preparation and characterization of a purified influenza virus neuraminidase vaccine.
Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine.
Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine.
Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration.
Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus.
Preparation of influenza B virus recombinant strains.
Preparation of influenza virosome vaccine with muramyldipeptide derivative B30-MDP.
Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein.
Preparation-conditioned changes of the antigenicity of influenza virus neuraminidases.
Preparing for the 2020-2021 influenza season.
Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic.
Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.
Prescription of neuraminidase inhibitors for influenza.
Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission.
Prevalence and risk factors for H1N1 and H3N2 influenza A virus infections in Minnesota turkey premises.
Prevalence and subtypes of Influenza A Viruses in Wild Waterfowl in Norway 2006-2007.
Prevalence of epistasis in the evolution of influenza a surface proteins.
Prevention and early treatment of influenza in healthy adults.
Prevention and treatment of influenza in immunocompromised patients.
Prevention of influenza in the general population.
Primarily oseltamivir resistant influenza A (H1N1pdm09) virus evolving into a multi-drug resistant virus carrying H275Y and I223R neuraminidase substitutions.
Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice.
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.
Primer development to obtain complete coding sequence of HA and NA genes of influenza A/H3N2 virus.
Principles of rational classification and nomenclature of human influenza A viruses.
Principles of selective inactivation of viral genome. I. UV-induced inactivation of influenza virus.
Prion Protein is a Novel Modulator of Influenza: Potential Implications for Anti-Influenza Therapeutics.
Probable association of plaque size with neuraminidase subtype among H3N2 influenza A viruses. Brief report.
Probing molecular level interaction of oseltamivir with H5N1-NA and model membranes by molecular docking, multinuclear NMR and DSC methods.
Probing the effect of quercetin 3-glucoside from Dianthus superbus L against influenza virus infection- In vitro and in silico biochemical and toxicological screening.
Probing the Neuraminidase Activity of Influenza Virus Using a Cytolysin A Protein Nanopore.
Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
Production of neuraminidase in cell monolayers infected with influenza virus.
Professional oral care reduces influenza infection in elderly.
Professional oral health care by dental hygienists reduced respiratory infections in elderly persons requiring nursing care.
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors.
Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine.
Progress in the Development of Universal Influenza Vaccines.
Progress of small molecular inhibitors in the development of anti-influenza virus agents.
Progress on baculovirus-derived influenza vaccines.
Prolonged Influenza Virus Infection during Lymphocytopenia and Frequent Detection of Drug-Resistant Viruses.
Prolonged shedding of amantadine- and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant.
Prolonged shedding of influenza A(H1N1)v virus: two case reports from France 2009.
Promising Anti-influenza Properties of Active Constituent of Withania somnifera Ayurvedic Herb in Targeting Neuraminidase of H1N1 Influenza: Computational Study.
Properties of influenza C virus grown in cell culture.
Properties of the erythrocyte receptors for influenza C virus.
Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation.
Prophylaxis and treatment of influenza virus infection.
Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1).
Prospective Cohort Study Comparing Seasonal and H1N1(2009)-Pandemic Influenza Virus Illnesses in HIV-Infected Children During 2009.
Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir.
Protease-Activated Receptor 2 Agonist as Adjuvant: Augmenting Development of Protective Memory CD8 T Cell Responses Induced by Influenza Virosomes.
Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents.
Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model.
Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.
Protection against influenza B virus infection by immunization with DNA vaccines.
Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.
Protection against lethal influenza with neuraminidase.
Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes.
Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.
Protection of chickens against challenge with virulent influenza A viruses of Hav5 subtype conferred by prior infection with influenza A viruses of Hsw1 subtype.
Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase.
Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective interfering virus.
Protection of mice with recombinant influenza virus neuraminidase.
Protective effect of a polyvalent influenza DNA vaccine in pigs.
Protective effect of fluvastatin on influenza virus infection.
Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.
Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model.
Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice.
Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
Protective Immunity Afforded by Inactivated H5N1 (NIBRG-14) Vaccine Requires Antibodies against Both Hemagglutinin and Neuraminidase in Mice.
Protective immunity against influenza H5N1 virus challenge in chickens by oral administration of recombinant Lactococcus lactis expressing neuraminidase.
Protective immunity and safety of a genetically modified influenza virus vaccine.
Protein-lipid interactions critical to replication of the influenza A virus during infection.
Proteinquakes in the Evolution of Influenza Virus Hemagglutinin (A/H1N1) under Opposing Migration and Vaccination Pressures.
Proteolytic activation of the 1918 influenza virus hemagglutinin.
Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity.
Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.
Pterocarpans and flavanones from Sophora flavescens displaying potent neuraminidase inhibition.
Pterodontic acid isolated from Laggera pterodonta suppressed RIG-I/NF-KB/STAT1/Type I interferon and programmed death-ligand 1/2 activation induced by influenza A virus in vitro.
Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir.
Punctuated evolution of influenza virus neuraminidase (A/H1N1) under opposing migration and vaccination pressures.
Punicalagin is a neuraminidase inhibitor of influenza viruses.
Purification and properties of cloned Salmonella typhimurium LT2 sialidase with virus-typical kinetic preference for sialyl alpha 2----3 linkages.
Purification of antibodies to influenza A virus structural proteins by affinity chromatography, and their participation in haemagglutination-inhibition, neutralization and enzyme-linked immunosorbent assay.
Purification of haemagglutinin and neuraminidase from influenza virus strain 3QB and isolation of a peptide from an antigenic region of haemagglutinin.
Purification of membrane proteins in SDS and subsequent renaturation.
Purification of neuraminidase from influenza viruses by affinity chromatography.
Purification of viral neuraminidase from inclusion bodies produced by recombinant Escherichia coli.
Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans.
Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.
Purified viral neuraminidase vaccine to control influenza.
Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.
Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents.
Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: the hydrophobic side chain influences type A subtype selectivity.
QSAR model for predicting neuraminidase inhibitors of influenza A viruses (H1N1) based on adaptive grasshopper optimization algorithm.
QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors.
QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences.
Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.
Quantification of influenza virus structural proteins using rocket immunoelectrophoresis.
Quantification of Multivalent Interactions between Sialic Acid and Influenza A Virus Spike Proteins by Single-Molecule Force Spectroscopy.
Quantification of peramivir (a novel anti-influenza drug) in human plasma by hydrophilic interaction chromatography/tandem mass spectrometry.
Quantification of peramivir in dog plasma by liquid chromatography/tandem mass spectrometry employing precolumn derivatization.
Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.
Quantification of Viral Proteins of the Avian H7 Subtype of Influenza Virus: An Isotope Dilution Mass Spectrometry Method Applicable for Producing more Rapid Vaccines in the Case of an Influenza Pandemic.
Quantifying relative within-host replication fitness in influenza virus competition experiments.
Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays.
Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction.
Quantitative predictions of binding free energy changes in drug-resistant influenza neuraminidase.
Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors.
Radiation inactivation analysis of influenza virus reveals different target sizes for fusion, leakage, and neuraminidase activities.
Radioimmunoassay of influenza A virus haemagglutinin. I. Preparation and properties of radioactive 125I-labelled bromelain-released haemagglutinin.
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.
Randomized Trials of a Neuraminidase Inhibitor to Prevent Influenza.
Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis.
Rapid detection of influenza A neuraminidase subtypes by cDNA amplification coupled to a simple DNA enzyme immunoassay.
Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR.
Rapid detection of the S247N neuraminidase mutation in influenza A(H1N1)pdm09 virus by one-step duplex RT-PCR assay.
Rapid diagnostics: the detection of neuraminidase activity as a technology for high-specificity targets.
Rapid Differentiation of Seasonal and Pandemic H1N1 Influenza through Proteotyping of Viral Neuraminidase with Mass Spectrometry.
Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.
Rapid enzymologic anti-neuraminidase antibody microtest.
Rapid Fluorescent Detection Assay for Human Parainfluenza Viruses.
Rapid identification and isolation of neuraminidase inhibitors from mockstrawberry (Duchesnea indica Andr.) based on ligand fishing combined with HR-ESI-Q-TOF-MS.
Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis.
Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay.
Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses.
Rapid molecular subtyping by reverse transcription polymerase chain reaction of the neuraminidase gene of avian influenza A viruses.
Rapid multiplex reverse transcription-PCR typing of influenza A and B virus, and subtyping of influenza A virus into H1, 2, 3, 5, 7, 9, N1 (human), N1 (animal), N2, and N7, including typing of novel swine origin influenza A (H1N1) virus, during the 2009 outbreak in Milwaukee, Wisconsin.
Rapid preparation of mutated influenza hemagglutinins for influenza virus pandemic prevention.
Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.
Rates of evolution of the retroviral oncogene of Moloney murine sarcoma virus and of its cellular homologues.
Rational design of potent sialidase-based inhibitors of influenza virus replication.
Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1.
Re-assorted pandemic (H1N1) 2009 influenza A virus discovered from pigs in Germany.
Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children.
Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children.
Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
Real-time influenza surveillance in Germany--results of a pilot project.
Reassortant Eurasian Avian-Like Influenza A(H1N1) Virus from a Severely Ill Child, Hunan Province, China, 2015.
Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys.
Reassortment and evolution of current human influenza A and B viruses.
Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature.
Reassortment and interspecies transmission of North American H6N2 influenza viruses.
Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009.
Reassortment between Avian H5N1 and Human Influenza Viruses Is Mainly Restricted to the Matrix and Neuraminidase Gene Segments.
Reassortment patterns of avian influenza virus internal segments among different subtypes.
Recent advances in anti-influenza agents with neuraminidase as target.
Recent Advances in Neuraminidase Inhibitor Development as Anti-influenza Drugs.
Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery.
Recent Advances in the Structure-based Design of Neuraminidase Inhibitors as Anti-influenza Agents.
Recent advances in the study, prevention, and treatment of infectious diseases.
Recent anti-influenza strategies in multivalent sialyloligosaccharides and sialylmimetics approaches.
Recent evolution of equine influenza and the origin of canine influenza.
Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses.
Recent Patents on development of nucleic acid-based antiviral drugs against seasonal and pandemic influenza virus infections.
Recent progress and challenges in the discovery of new neuraminidase inhibitors.
Recent progress in anti-influenza chemotherapy.
Recent progress in rational drug design of neuraminidase inhibitors.
Recent strategies in the search for new anti-influenza therapies.
Receptor binding properties of the influenza virus hemagglutinin as a determinant of host range.
Receptor recognition mechanism of human influenza A H1N1 (1918), avian influenza A H5N1 (2004), and pandemic H1N1 (2009) neuraminidase.
Recognition of dual targets by a molecular beacon-based sensor: subtyping of influenza A virus.
Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes.
Recognition of viral hemagglutinins by NKp44 but not by NKp30.
Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants.
Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus.
Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
Recombinant Influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines.
Recombinant Influenza Virus Carrying the Respiratory Syncytial Virus (RSV) F85-93 CTL Epitope Reduces RSV Replication in Mice.
Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes.
Recombinant influenza-virus vaccines. IV. Segregation of antigenic and some biological properties of Influenza virus neuraminidase by recombination.
Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
Recombinant neuraminidase pseudotyped baculovirus: a dual vector for delivery of Angiotensin II peptides and DNA vaccine.
Recombinant neuraminidase vaccine protects against lethal influenza.
Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge.
Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro.
Recommendations for Treatment with Neuraminidase Inhibitors in Emergency Department Patients Infected with Influenza Virus.
Recommended hospital preparations for future cases and outbreaks of novel influenza viruses.
Reconstitution of functional influenza virus envelopes and fusion with membranes and liposomes lacking virus receptors.
Reconstructing disease outbreaks from genetic data: a graph approach.
Reconstructing the household transmission of influenza in the suburbs of Tokyo based on clinical cases.
Recovery of Drug-Resistant Influenza Virus from Immunocompromised Patients: A Case Series.
Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.
Red cells bound to influenza virus N9 neuraminidase are not released by the N9 neuraminidase activity.
Reduced Effectiveness of Oseltamivir in Children Infected With Oseltamivir-Resistant Influenza A(H1N1) Viruses With His275Tyr Mutation.
Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice.
Reduced sensitivity of influenza A (H5N1) to oseltamivir.
Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.
Reducing antibiotic use in influenza: challenges and rewards.
Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
Reduction in Sympathetic Nerve Activity as a Possible Mechanism for the Hypothermic Effect of Oseltamivir, an Anti-influenza Virus Drug, in Normal Mice.
Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.
Reduction of neuraminidase activity exacerbates disease in 2009 pandemic influenza virus-infected mice.
Reductive amination assistance for quantification of oseltamivir phosphate and oseltamivir carboxylate by HPLC-MS/MS.
Redundancy of signal and anchor functions in the NH2-terminal uncharged region of influenza virus neuraminidase, a class II membrane glycoprotein.
Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants.
Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex.
Regulation of primary metabolic pathways in oyster mushroom mycelia induced by blue light stimulation: accumulation of shikimic Acid.
Relation of sialidase of influenza A viruses to viral particles as determined by electron microscopy.
Relationship between surface antigens of two variants of influenza A (H3N2) virus, as revealed by hemagglutination inhibition, kinetic neutralization, and neuraminidase inhibition.
Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.
Release of influenza virus neuraminidase by caseinase C of Streptomyces albus G.
Release of neuraminidase from hemagglutinins caused by treatment of influenza viruses with ether. (Brief report).
Remarkable Structural Diversity of N-Glycan Sulfation on Influenza Vaccines.
Remote-site stimulation of influenza antibodies in monkeys following intestinal stimulation.
REMOVED: Physicochemical properties of the potent influenza neuraminidase inhibitor, peramivir (BCX-1812).
Replacement of neuraminidase inhibitor susceptible influenza A(H1N1) with resistant phenotype in 2008 and circulation of susceptible influenza A and B viruses during 2009-2013, South Africa.
Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro.
Replication of H9 influenza viruses in the human ex vivo respiratory tract, and the influence of neuraminidase on virus release.
Replication of influenza B virus: biological functions of viral neuraminidase.
Repository of Eurasian influenza A virus hemagglutinin and neuraminidase reverse genetics vectors and recombinant viruses.
Rescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinity.
Rescue of influenza B virus from eight plasmids.
Rescue of synthetic RNAs into thogoto and influenza A virus particles using core proteins purified from Thogoto virus.
Residue 41 of the Eurasian avian-like swine influenza a virus matrix protein modulates virion filament length and efficiency of contact transmission.
Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza.
Resistance Mutation R292K Is Induced in Influenza A(H6N2) Virus by Exposure of Infected Mallards to Low Levels of Oseltamivir.
Resistance of influenza viruses to neuraminidase inhibitors--a review.
Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
Resistant influenza A viruses in children treated with oseltamivir: descriptive study.
Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study.
Respiratory syncytial virus envelope glycoprotein (G) has a novel structure.
Respiratory viral infections in adults.
Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.
Respiratory viral infections in the elderly.
Respiratory viral infections occurring after hematopoietic stem cell transplantation.
Respiratory viruses predisposing to bacterial infections: role of neuraminidase.
Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine.
Response to: Recommendations for Treatment with Neuraminidase Inhibitors in Emergency Department Patients Infected with Influenza Virus.
Restricted infectivity of a human-Lineage H3N2 influenza A virus in pigs is hemagglutinin and neuraminidase gene dependent.
Retrospective Analysis of the Equine Influenza Virus A/Equine/Kirgizia/26/1974 (H7N7) Isolated in Central Asia.
Reverse design of an influenza neutralizing spiky nano-inhibitor with a dual mode of action.
Reverse-transcription polymerase chain reaction/pyrosequencing to characterize neuraminidase H275 residue of influenza A 2009 H1N1 virus for rapid and specific detection of the viral oseltamivir resistance marker in a clinical laboratory.
Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
Review of the use of neuraminidase inhibitors for prophylaxis of influenza.
Review: Neuraminidase inhibitors reduce symptomatic influenza; oseltamivir does not reduce hospitalizations.
Review: Oseltamivir relieves symptoms but does not reduce hospitalizations in influenza.
Rigid, specific, and discrete gold nanoparticle/antibody conjugates.
Risk factors for poor outcomes and therapeutic strategies for seasonal and pandemic influenza.
RNA Polymerase II Inhibitors Dissociate Antigenic Peptide Generation from Normal Viral Protein Synthesis: A Role for Nuclear Translation in Defective Ribosomal Product Synthesis?
Role of Neuraminidase in Influenza A(H7N9) Receptor Binding.
Role of neuraminidase in influenza virus-induced apoptosis.
Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.
Role of neuraminidase in the morphogenesis of influenza B virus.
Role of neuraminidase inhibitor chemoprophylaxis in controlling nosocomial influenza: an observational study.
Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses.
Role of phosphatidylserine exposure and sugar chain desialylation at the surface of influenza virus-infected cells in efficient phagocytosis by macrophages.
Role of Pneumococcal NanC in the Severe Disease of Streptococcus pneumoniae Superinfection with Influenza.
Role of proteases in the release of porcine epidemic diarrhea virus from infected cells.
Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study.
Role of secondary sialic acid binding sites in influenza N1 neuraminidase.
Role of sialic acid in infection with vesicular stomatitis virus.
Role of sialidase in the initial phase of infection with influenza virus.
Role of surface glycoproteins in influenza virus pyrogenicity.
Role of the Innate Cytokine Storm Induced by the Influenza A Virus.
Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding.
Role of viral glycoproteins in haemolysis by influenza B virus.
Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.
Roles of neuraminidase in the initial stage of influenza virus infection.
RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza.
RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson.
SA11 rotavirus is specifically inhibited by an acetylated sialic acid.
Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses.
Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15.
Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection.
Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.
Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children.
Safety and pharmacokinetics of oseltamivir at standard and high dosages.
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.
Safety of neuraminidase inhibitors for influenza.
Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model.
Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.
SARS-CoV-2 and influenza: a comparative overview and treatment implications.
Scoring binding affinity of multiple ligands using implicit solvent and a single molecular dynamics trajectory: application to influenza neuraminidase.
Scoring ensembles of docked protein:ligand interactions for virtual lead optimization.
Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs.
Screening for H7N9 influenza A by matrix gene-based real-time reverse-transcription PCR.
Screening for Neuraminidase Inhibitory Activity in Traditional Chinese Medicines Used to Treat Influenza.
Screening of influenza mutations using base-specific cleavage and MALDI mass spectrometry.
Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines.
Seasonal Human Influenza: Treatment Options.
Seasonality of influenza A(H3N2) virus: a Hong Kong perspective (1997-2006).
Second sialic acid-binding site of influenza A virus neuraminidase: binding receptors for efficient release.
Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza A virus.
Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
Selection and analysis of antigenic variants of the neuraminidase of N2 influenza viruses with monoclonal antibodies.
Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes.
Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors.
Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
Selective incorporation of influenza virus RNA segments into virions.
Selective removal of neuraminidase from influenza A 2 viruses.
Selective solubilization of hemagglutinin and neuraminidase from influenza viruses.
Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase.
Separation of hemagglutinin and neuraminidase from influenza virus membrane by column displacement electrophoresis (isotachophoresis) with preservation of their activities.
Sequence analysis of haemagglutinin and neuraminidase of H1N1 strain from a patient coinfected with Mycobacterium tuberculosis.
Sequence and crystallization of influenza virus B/Beijing/1/87 neuraminidase.
Sequence and phylogenetic analyses of neuraminidase gene of Iranian seasonal influenza H1N1 viruses from 2005-2009 and corresponding vaccine strains.
Sequence and structure alignment of Paramyxoviridae attachment proteins and discovery of enzymatic activity for a morbillivirus hemagglutinin.
Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase.
Sequence of the influenza A/Udorn/72 (H3N2) virus neuraminidase gene as determined from cloned full-length DNA.
Sequence of the N2 neuraminidase from influenza virus A/NT/60/68.
Sequence of the neuraminidase gene of an avian influenza A virus (A/parrot/ulster/73, H7N1).
Sequence of the neuraminidase gene of influenza virus A/Tokyo/3/67 and previously uncharacterized monoclonal variants.
Sequence variation at the 3' end of the neuraminidase gene from 39 influenza type A viruses.
Sequential Influenza B Viral Load and Susceptibility in Children Treated with Oseltamivir and Zanamivir.
Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor.
Serological studies with purified neuraminidase antigens of influenza B viruses.
Serum amyloid p is a sialylated glycoprotein inhibitor of influenza a viruses.
Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic ?/California/07/2009(H1N1) influenza in healthy volunteers.
Seven new cassane furanoditerpenes from the seeds of Caesalpinia minax.
Severe abnormal behavior incidence after administration of neuraminidase inhibitors using the national database of medical claims.
Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016.
Severe, critical and fatal cases of 2009 H1N1 influenza in China.
Shedding of the Pandemic Swine-Origin Influenza A Virus (H1N1) after Oseltamivir Administration.
Sheng Jiang San, a traditional multi-herb formulation, exerts anti-influenza effects in vitro and in vivo via neuraminidase inhibition and immune regulation.
Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors.
Shikimic Acid Production in Escherichia coli: From Classical Metabolic Engineering Strategies to Omics Applied to Improve Its Production.
Sialic acid is a receptor determinant for infection of cells by avian Infectious bronchitis virus.
Sialic acid is cleaved from glycoconjugates at the cell surface when influenza virus neuraminidases are expressed from recombinant vaccinia viruses.
Sialic acid is incorporated into influenza hemagglutinin glycoproteins in the absence of viral neuraminidase.
Sialidase activity and related properties of influenza A2 viruses.
Sialidase Activity in Human Blood Serum Has a Distinct Seasonal Pattern: A Pilot Study.
Sialidase activity in rimantadine-resistant and -sensitive influenza A viruses.
Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication.
Sialidase and protease activities of commercial (RDE) receptor destroying enzyme products used for the (HI) hemagglutination inhibition test of influenza viruses]
Sialidase as a target for inhibitors of influenza virus replication.
Sialidase assay by luminescence in the low picomole-range of sialic acid. Its application to the measurement of this activity in influenza virus.
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.
Sialidase fusion protein as inhibitor of infection by influenza virus.
Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.
Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone.
Sialidases in biological systems.
Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses.
Sialoglycoproteins that bind influenza A virus and resist viral neuraminidase in different animal sera.
Sialylatin of glycoproteins of murine mammary tumor virus, murine leukemia virus, and Mason-Pfizer monkey virus.
Signal-processing-based bioinformatics approach for the identification of influenza A virus subtypes in Neuraminidase genes.
Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways.
Simple and rapid separation of ortho- and paramyxovirus glycoproteins.
Simple test for detection of virus neuraminidase and antineuraminidase using lectins (lectin-neuraminidase test system).
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes.
Simpterpenoid A, a Meroterpenoid with a Highly Functionalized Cyclohexadiene Moiety Featuring gem-Propane-1,2-dione and Methylformate Groups, from the Mangrove-Derived Penicillium simplicissimum MA-332.
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Simultaneous detection of hemagglutinin and neuraminidase genes of novel influenza A (H7N9) by duplex real-time reverse transcription polymerase chain reaction.
Simultaneous detection of oseltamivir- and amantadine-resistant influenza by oligonucleotide microarray visualization.
Simultaneous purification of influenza haemagglutinin and neuraminidase proteins by immunochromatography.
Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry.
Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE.
Single assay for simultaneous detection and differential identification of human and avian influenza virus types, subtypes, and emergent variants.
Single Electrode Genosensor for Simultaneous Determination of Sequences Encoding Hemagglutinin and Neuraminidase of Avian Influenza Virus (AIV) type H5N1.
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus.
Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-0 (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium.
Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.
Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.
Site-directed mutagenesis of a conserved hexapeptide in the paramyxovirus hemagglutinin-neuraminidase glycoprotein: effects on antigenic structure and function.
Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design.
Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism.
Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.
Skin vaccination with dissolvable microneedle patches incorporating influenza neuraminidase and flagellin protein nanoparticles induces broad immune protection against multiple influenza viruses.
Slow-binding inhibition of sialidase from influenza virus.
Small Variations Between Species/Subtypes Attributed to Reassortment Evidenced from Polymerase Basic Protein 1 with Other Seven Proteins from Influenza A Virus.
SNP Discrimination by Tolane-Modified Peptide Nucleic Acids: Application for the Detection of Drug Resistance in Pathogens.
Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.
Solid-phase synthesis of mimosine tetrapeptides and their inhibitory activities on neuraminidase and tyrosinase.
Soluble Proteins Induce Strong CD8+ T Cell and Antibody Responses through Electrostatic Association with Simple Cationic or Anionic Lipopeptides That Target TLR2.
Soluble recombinant influenza vaccines.
Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase.
Spatiotemporal analysis of the genetic diversity of seal influenza A(H10N7) virus, Northwestern Europe.
Specific Mutations in the PB2 Protein of Influenza A Virus Compensate for the Lack of Efficient Interferon Antagonism of the NS1 Protein of Bat Influenza A-Like Viruses.
Specific Sites of N-Linked Glycosylation on the Hemagglutinin of H1N1 Subtype Influenza A Virus Determine Sensitivity to Inhibitors of the Innate Immune System and Virulence in Mice.
Specific subtyping of influenza A virus using a recombinant hemagglutinin protein expressed in baculovirus.
Specificity of neuraminidase activity from influenza viruses isolated in different hosts tested with novel substrates.
Specificity of the N1 and N2 sialidase subtypes of human influenza A virus for natural and synthetic gangliosides.
Spotlight on zanamivir in influenza.
Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine.
Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal.
Spread of predominant neuraminidase and hemagglutinin co-mutations in the influenza A/H3N2 virus genome.
Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor.
Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase.
Stability of neuraminidase in inactivated influenza vaccines.
Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.
Steps in maturation of influenza A virus neuraminidase.
Stereoisomers of oseltamivir - synthesis, in silico prediction and biological evaluation.
Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents.
Stereospecific synthesis of a GS 4104 metabolite: determination of absolute stereochemistry and influenza neuraminidase inhibitory activity.
Stimulation of cytotoxic T cells by liposomes containing influenza virus or its components.
Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.
Stimulation of phagocytosis of influenza virus-infected cells through surface desialylation of macrophages by viral neuraminidase.
Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase.
Strain identification of commercial influenza vaccines by mass spectrometry.
Strain-specific antiviral activity of iminosugars against human influenza A viruses.
Strain-specific differences in the effect of influenza A virus neuraminidase on vector-expressed hemagglutinin.
Strategies to alleviate original antigenic sin responses to influenza viruses.
Structural analysis of a designed inhibitor complexed with the hemagglutinin-neuraminidase of Newcastle disease virus.
Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
Structural and composition of the N2 neuraminidase of influenza virus. Effect of carbohydrate content on the validity of molecular weight estimations.
Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus.
Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle disease virus hemagglutinin-neuraminidase protein: receptor recognition is dependent on neuraminidase activity.
Structural and functional-group tuning in the design of neuraminidase inhibitors.
Structural basis for a class of nanomolar influenza A neuraminidase inhibitors.
Structural basis for influence of viral glycans on ligand binding by influenza hemagglutinin.
Structural basis of antigenic variation: studies of influenza virus neuraminidase.
Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies.
Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.
Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers.
Structural characterization of the 1918 influenza virus H1N1 neuraminidase.
Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases.
Structural insights into the design of novel anti-influenza therapies.
Structural modification on rupestonic acid leads to highly potent inhibitors against influenza virus.
Structural restrictions for influenza neuraminidase activity promote adaptation and diversification.
Structural similarity between binding sites in influenza sialidase and isocitrate dehydrogenase: implications for an alternative approach to rational drug design.
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Structure and diversity of influenza virus neuraminidase.
Structure and functions of influenza virus neuraminidase.
Structure determination of the 1918 H1N1 neuraminidase from a crystal with lattice-translocation defects.
Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding.
Structure of an escape mutant of glycoprotein N2 neuraminidase of influenza virus A/Tokyo/3/67 at 3 A.
Structure of an Influenza A virus N9 neuraminidase with a tetrabrachion-domain stalk.
Structure of an influenza neuraminidase-diabody complex by electron cryomicroscopy and image analysis.
Structure of influenza virus N7: the last piece of the neuraminidase "jigsaw" puzzle.
Structure of influenza virus neuraminidase B/Lee/40 complexed with sialic acid and a dehydro analog at 1.8-A resolution: implications for the catalytic mechanism.
Structure of quinoprotein methylamine dehydrogenase at 2.25 A resolution.
Structure of the catalytic and antigenic sites in influenza virus neuraminidase.
Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus.
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution.
Structure of the lysosomal sphingolipid activator protein 1 by homology with influenza virus neuraminidase.
Structure of the neuraminidase gene in human influenza virus A/PR/8/34.
Structure prediction and analysis of neuraminidase sequence variants.
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors.
Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
Structure-based virtual screening of influenza virus RNA polymerase inhibitors from natural compounds: Molecular dynamics simulation and MM-GBSA calculation.
Structure-guided design of a novel class of benzyl-sulfonate inhibitors for influenza virus neuraminidase.
Structures of aromatic inhibitors of influenza virus neuraminidase.
Studies on adaptation of influenza virus replicated at low temperature.IV. Sensitivity of neuraminidase and hemagglutinin to some proteolytic enzymes, detergents and chemical agents.
Studies on mutation lesions and physiology of fowl plague virus ts mutants.
Studies on neuraminidase from influenza virus A(H3N2) obtained by two procedures.
Studies on synthesis and structure-activity relationship (SAR) of derivatives of a new natural product from marine fungi as inhibitors of influenza virus neuraminidase.
STUDIES ON THE NEURAMINIDASE OF INFLUENZA VIRUS. II. ADDITIONAL PROPERTIES OF THE ENZYMES FROM THE ASIAN AND PR 8 STRAINS.
Studies on the Bioactive Flavonoids Isolated from Pithecellobium clypearia Benth.
Studies on the development of the charge heterogeneity of the influenza virus glycoproteins.
Studies on the inhibitory effect of concanavalin A on the neuraminidase activity of influenza A virus strains.
Studies on the neuraminidase of influenza virus. I. Separation and some properties of the enzyme from Asian and PR8 strains.
Studies on the role of myxovirus neuraminidase in virus-cell receptors interaction by means of direct determination of sialic acid split from cells. I. Experiments on influenza virus-RBC cell system.
Studies on the size, chemical composition, and partial sequence of the neuraminidase (NA) from type A influenza viruses show that the N-terminal region of the NA is not processed and serves to anchor the NA in the viral membrane.
Studies with cross-linking reagents on the oligomeric form of the paramyxovirus fusion protein.
Study of immunogenicity of recombinant proteins based on hemagglutinin and neuraminidase conservative epitopes of Influenza A virus.
Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines.
Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden.
Study of several genetic markers of two recombinants derived from autochthonous influenza virus type A strains.
Study of specific oligosaccharide structures related with swine flu (H1N1) and avian flu, and tamiflu as their remedy.
Study on molecular mechanism and 3D-QSAR of influenza neuraminidase inhibitors.
Study on the interaction of tamiflu and oseltamivir carboxylate with human serum albumin.
Study on the Mechanisms of Active Compounds in Traditional Chinese Medicine for the Treatment of Influenza Virus by Virtual Screening.
Subclinical influenza virus a infections in pigs exhibited at agricultural fairs, Ohio, USA, 2009-2011.
Substituent effects on the binding of natural product anthocyanidin inhibitors to influenza neuraminidase with mass spectrometry.
Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
Substrate Binding by the Second Sialic Acid-Binding Site of Influenza A Virus N1 Neuraminidase Contributes to Enzymatic Activity.
Substrate specificity and inhibitor studies of a membrane-bound ganglioside sialidase isolated from human brain tissue.
Substrate specificity of avian influenza H5N1 neuraminidase.
Substrate Specificity of Equine and Human Influenza A Virus Sialidase to Molecular Species of Sialic Acid.
Substrate, inhibitor, or antibody stabilizes the Glu 119 Gly mutant influenza virus neuraminidase.
Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.
Subtype identification of the novel A H1N1 and other human influenza A viruses using an oligonucleotide microarray.
Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin.
Subtyping of influenza neuraminidase using mass spectrometry.
Successful treatment of influenza A virus by oseltamivir in bone marrow transplant recipients.
Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody.
Sulfation of the N-linked oligosaccharides of influenza virus hemagglutinin: temporal relationships and localization of sulfotransferases.
Superoxide anion production in influenza protein-activated NADPH oxidase of human polymorphonuclear leukocytes.
Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.
Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
Supply of Neuraminidase Inhibitors Related to Reduced Influenza A (H1N1) Mortality during the 2009-2010 H1N1 Pandemic: An Ecological Study.
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study.
Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.
Suppression of influenza A virus nuclear antigen production and neuraminidase activity by a nutrient mixture containing ascorbic acid, green tea extract and amino acids.
Suppression of influenza virus infection by an N-thioacetylneuraminic acid acrylamide copolymer resistant to neuraminidase.
Surface expression of influenza virus neuraminidase, an amino-terminally anchored viral membrane glycoprotein, in polarized epithelial cells.
Surface glycoproteins of influenza A H3N2 virus modulate virus replication in the respiratory tract of ferrets.
Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages.
Surveillance for antiviral resistance among influenza viruses circulating in Algeria during five consecutive influenza seasons (2009-2014).
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.
Surveillance of antiviral resistance markers in Argentina: detection of E119V neuraminidase mutation in a post-treatment immunocompromised patient.
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Survey of compliance with oseltamivir phosphate therapy in Japan.
Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.
Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Susceptibility of Highly Pathogenic H5N1 Influenza Viruses to the Neuraminidase Inhibitor Oseltamivir Differs in vitro and in a Mouse Model.
Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1.
Susceptibility of influenza viruses circulating in Western Saudi Arabia to neuraminidase inhibitors.
Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Suspected Oseltamivir-induced bradycardia in a pediatric patient: A case report from King Abdullah Specialist Children's Hospital, Riyadh, Saudi Arabia.
Swine Influenza Virus (H1N2) Characterization and Transmission in Ferrets, Chile.
Swine-origin influenza A (H3N2) virus infection in two children--Indiana and Pennsylvania, July-August 2011.
Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants.
Syncytium formation and HIV-1 replication are both accentuated by purified influenza and virus-associated neuraminidase.
Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro.
Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives.
Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.
Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.
Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir.
Synthesis and Biological Evaluation of NH2-Sulfonyl Oseltamivir Analogues as Influenza Neuraminidase Inhibitors.
Synthesis and biological evaluation of oseltamivir analogues from shikimic acid.
Synthesis and evaluation of 1,4,5,6-tetrahydropyridazine derivatives as influenza neuraminidase inhibitors.
Synthesis and evaluation of a new series of substituted acyl(thio)urea and thiadiazolo [2,3-a] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
Synthesis and evaluation of influenza A viral neuraminidase candidate inhibitors based on a bicyclo[3.1.0]hexane scaffold.
Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility.
Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.
Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain.
Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase.
Synthesis and processing of the influenza virus neuraminidase, a type II transmembrane glycoprotein.
Synthesis of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified at the C-4 and C-9 positions and their behaviour towards sialidase from influenza virus and pig liver membrane.
Synthesis of a carbocyclic sialic acid analogue for the inhibition of influenza virus neuraminidase.
Synthesis of a cluster-forming sialylthio-D-galactose fullerene conjugate and evaluation of its interaction with influenza virus hemagglutinin and neuraminidase.
Synthesis of a tetrasubstituted bicyclo [2.2.2] octane as a potential inhibitor of influenza virus sialidase.
Synthesis of an influenza neuraminidase inhibitor intermediate via a highly diastereoselective coupling reaction.
Synthesis of an STnThr analogue, structurally based on a TnThr antigen mimetic.
Synthesis of bromoindolyl 4,7-di-O-methyl-Neu5Ac: specificity toward influenza A and B viruses.
Synthesis of influenza neuraminidase inhibitors.
Synthesis of novel N-acetylneuraminic acid derivatives as substrates for rapid detection of influenza virus neuraminidase.
Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.
Synthesis of screening substrates for the directed evolution of sialic acid aldolase: towards tailored enzymes for the preparation of influenza A sialidase inhibitor analogues.
Synthesis of sialoglycopolypeptide for potentially blocking influenza virus infection using a rat alpha2,6-sialyltransferase expressed in BmNPV bacmid-injected silkworm larvae.
Synthesis of tetrasubstituted bicyclo[3.2.1]octenes as potential inhibitors of influenza virus sialidase.
Synthesis of transition-state analogues as potential inhibitors of sialidase from Influenza virus.
Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Synthetic inhibitors of Vibrio cholerae neuraminidase and neuraminidases of some influenza virus strains.
Synthetic long oligonucleotides to generate artificial templates for use as positive controls in molecular assays: drug resistance mutations in influenza virus as an example.
Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors.
Systematic evaluation of suspension MDCK cells, adherent MDCK cells, and LLC-MK2 cells for preparing influenza vaccine seed virus.
Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening.
Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
Systematic review of influenza resistance to the neuraminidase inhibitors.
Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza.
Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
Systematic syntheses of influenza neuraminidase inhibitors: a series of carbosilane dendrimers uniformly functionalized with thioglycoside-type sialic acid moieties.
T cell mediated protection against lethal 2009 pandemic H1N1 influenza infection in a mouse model.
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.
T-cell immunity to influenza A viruses.
Tailor made sialidase inhibitors home in on influenza virus.
Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses.
Tamiphosphor monoesters as effective anti-influenza agents.
Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries.
Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: clinical and economic impact.
Targeting a cluster of arginine residues of neuraminidase to avoid oseltamivir resistance in influenza A (H1N1): a theoretical study.
Targeting Antigens for Universal Influenza Vaccine Development.
Targets for the induction of protective immunity against influenza a viruses.
Targets of anti-influenza chemotherapy other than neuraminidase and proton pump.
Temperature optima of neuraminidase activity of influenza viruses.
Temperature-sensitive mutants of influenza A virus: evaluation of the A/Victoria/75-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers.
Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen.
Tethered neuraminidase inhibitors that bind an influenza virus: a first step towards a diagnostic method for influenza.
Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase.
TH cells primed during influenza virus infection provide help for qualitatively distinct antibody responses to subsequent immunization.
The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid.
The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site.
The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets.
The 2nd sialic acid-binding site of influenza A virus neuraminidase is an important determinant of the hemagglutinin-neuraminidase-receptor balance.
The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study.
The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery.
The accuracy and timeliness of neuraminidase inhibitor dispensing data for predicting laboratory-confirmed influenza.
The amino-terminal region of the neuraminidase protein from avian H5N1 influenza virus is important for its biosynthetic transport to the host cell surface.
The aminoshikimic acid pathway in bacteria as source of precursors for the synthesis of antibacterial and antiviral compounds.
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.
The antigenic relationship of the neuraminidase of Hong Kong virus to that of other human strains of influenza A virus.
The Appropriate Combination of Hemagglutinin and Neuraminidase Prompts the Predominant H5N6 Highly Pathogenic Avian Influenza Virus in Birds.
The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys.
The battle against influenza: The role of neuraminidase inhibitors in children.
The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic.
The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling.
The bird flu: a new emerging pandemic threat and its pharmacological intervention.
The canyon hypothesis.
The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance.
The carbohydrate chains of influenza virus hemagglutinin.
The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice.
The complete neuraminidase of influenza A/PR8/34 (H0N1) is not detectable in its recombinant virus.
The complete nucleotide sequence of the influenza virus neuraminidase gene of A/NJ/8/76 strain and its evolution by segmental duplication and deletion.
The control of influenza: antivirals as an adjunct to vaccines.
The cotranslational maturation program for the type II membrane glycoprotein influenza neuraminidase.
The cytoplasmic tail of influenza A virus neuraminidase (NA) affects NA incorporation into virions, virion morphology, and virulence in mice but is not essential for virus replication.
The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly.
The cytoplasmic tail of the neuraminidase protein of influenza A virus does not play an important role in the packaging of this protein into viral envelopes.
The cytoplasmic tails of the influenza virus spike glycoproteins are required for normal genome packaging.
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses using a real-time RT-PCR assay.
The difference in thermostability of haemagglutinin and neuraminidase of two variants of influenza A2 virus.
The distribution of neuraminidase among the cytoplasmic membranes of HeLa cells infected with an influenza virus.
The disulphide bonds of an Asian influenza virus neuraminidase.
The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.
The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.
The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine.
The effect of ceruloplasmin on the multiplication and on some biological and physico-chemical characteristics of influenza virus A/PR8/34 (H0N1) cultivated in chorioallantoic membrane fragments. Note 2. Modifications occurring in the course of serial passages.
The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.
The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
The effect of phospholipase C on influenza viruses: limited release of "soluble" V-antigens and of neuraminidase.
The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
The effect of virus particle size on chemiluminescence induction by influenza and Sendai viruses in mouse spleen cells.
The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.
The emergency use authorization of peramivir IV: a view from the manufacturer.
The epitope regions of H1-subtype influenza A, with application to vaccine efficacy.
The equilibrium constant for the interaction between a monoclonal Fab fragment and an influenza virus neuraminidase.
The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle?
The evolutionary dynamics of influenza A virus adaptation to mammalian hosts.
The evolutionary genetics and emergence of avian influenza viruses in wild birds.
The evolutionary pattern of glycosylation sites in influenza virus (H5N1) hemagglutinin and neuraminidase.
The first isolation of swine H1N1 influenza viruses from pigs in Thailand.
The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
The H275Y Neuraminidase Mutation of the Pandemic A/H1N1 Influenza Virus Lengthens the Eclipse Phase and Reduces Viral Output of Infected Cells, Potentially Compromising Fitness in Ferrets.
The hemagglutinins of the human influenza viruses A and B recognize different receptor microdomains.
The Homologous Tripartite Viral RNA Polymerase of A/Swine/Korea/CT1204/2009(H1N2) Influenza Virus Synergistically Drives Efficient Replication and Promotes Respiratory Droplet Transmission in Ferrets.
The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination.
The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors.
The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant.
The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
The impact of case diagnosis coverage and diagnosis delays on the effectiveness of antiviral strategies in mitigating pandemic influenza A/H1N1 2009.
The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.
The importance of antineuraminidase antibodies in resistance to influenza A and immunologic memory for their synthesis.
The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients.
The influence of 150-cavity binders on the dynamics of influenza a neuraminidases as revealed by molecular dynamics simulations and combined clustering.
The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus.
The influenza A virus PB2, PA, NP, and M segments play a pivotal role during genome packaging.
The influenza pandemic of 2009: lessons and implications.
The influenza virus haemagglutinin gene: cloning and characterisation of a double-stranded DNA copy.
The influenza virus neuraminidase protein transmembrane and head domains have coevolved.
The influenza virus neuraminidase.
The influenza viruses.
The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity.
The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.
The Interferon-Inducible Proteoglycan Testican-2/SPOCK2 Functions as a Protective Barrier against Virus Infection of Lung Epithelial Cells.
The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase.
The Little Ice Age and the emergence of influenza A.
The low potential for drug interactions with zanamivir.
The Low-pH Resistance of Neuraminidase Is Essential for the Replication of Influenza A Virus in Duck Intestine following Infection via the Oral Route.
The low-pH stability discovered in neuraminidase of 1918 pandemic influenza A virus enhances virus replication.
The m segment of the 2009 pandemic influenza virus confers increased neuraminidase activity, filamentous morphology, and efficient contact transmissibility to a/puerto rico/8/1934-based reassortant viruses.
The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines.
The management of influenza in people of working age.
The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccines.
The medicinal potential of influenza virus surface proteins: hemagglutinin and neuraminidase.
The Medicinal Potential of Natural products for the Development of Anti-influenza Agents.
The N-terminal domain of PA from bat-derived influenza-like virus H17N10 has endonuclease activity.
The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity.
The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
The Neuraminidase Inhibitor Oseltamivir Is Effective Against A/Anhui/1/2013 (H7N9) Influenza Virus in a Mouse Model of Acute Respiratory Distress Syndrome.
The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain.
The neuraminidase of bat influenza viruses is not a neuraminidase.
The neuraminidase of influenza virus.
The neuraminidase yield-reduction bioassay of human other interferons.
The neuraminidases of the virulent and avirulent A/Chicken/Pennsylvania/83 (H5N2) influenza A viruses: sequence and antigenic analyses.
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures.
The Next Wave of Influenza Drugs.
The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.
The novel swine-origin H1N1 influenza A virus riddle: is it a domestic bird H1N1-derived virus?
The origin and virulence of the 1918 "Spanish" influenza virus.
The Origin of Novel Avian Influenza A (H7N9) and Mutation Dynamics for Its Human-To-Human Transmissible Capacity.
The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.
The pathogenesis of influenza in humans.
The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs.
The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.
The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.
The polypeptides of influenza virus. 3. Identification of the hemagglutinin, neuraminidase and nucleocapsid proteins.
The polypeptides of influenza virus. VI. Composition of the neuraminidase.
The position 4 nucleotide at the 3' end of the influenza virus neuraminidase vRNA is involved in temporal regulation of transcription and replication of neuraminidase RNAs and affects the repertoire of influenza virus surface antigens.
The potential for multidrug-resistant influenza.
The potential impact of neuraminidase inhibitor resistant influenza.
The potential of neuraminidase as an antigen for nasal vaccines to increase cross-protection against influenza viruses.
The preparation and properties of 14 C-carboxamidomethylated subunits from A 2 -1957 influenza neuraminidase.
The public health policy implications of understanding metabiosis.
The R292K Mutation That Confers Resistance to Neuraminidase Inhibitors Leads to Competitive Fitness Loss of A/Shanghai/1/2013 (H7N9) Influenza Virus in Ferrets.
The rapid identification of human influenza neuraminidase N1 and N2 subtypes by ELISA.
The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses.
THE REACTION OF RECEPTOR GLYCOPROTEIN WITH INFLUENZA VIRUS AND NEURAMINIDASE: AN ELECTRON MICROSCOPIC STUDY.
The reappearance of Victoria lineage influenza B virus in Brazil, antigenic and molecular analysis.
The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen.
The relative amount of an influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment.
The role of antigen in the localization of naive, acutely activated, and memory CD8(+) T cells to the lung during influenza pneumonia.
The role of antigenically different virus neuraminidases as structures implicated in receptor-binding processes.
The role of balanced haemagglutinin-neuraminidase activity in the genesis of transmissible neuraminidase inhibitor-resistant variants in seasonal and novel pandemic influenza A H1N1 viruses.
The role of cell surface expression of influenza virus neuraminidase in induction of human lymphocyte apoptosis.
The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.
The role of hemagglutinin in the inhibition of neuraminidase activity of influenza virus by concanavalin A. Brief Report.
The role of live influenza vaccines in children.
The Role of Neuraminidase Inhibitors in the Treatment and Prevention of Influenza.
The role of oseltamivir in the treatment and prevention of influenza in children.
The role of sialidase in influenza virus infection.
The role of the neuraminidase of the infecting virus in the production of noninfectious (von Magnus) influenza virus.
The signal anchor and stem regions of the beta-galactoside alpha 2,6-sialyltransferase may each act to localize the enzyme to the Golgi apparatus.
The significance of influenza virus neuraminidase in immunity.
The size and shape of influenza virus neuraminidase.
The special neuraminidase stalk-motif responsible for increased virulence and pathogenesis of H5N1 influenza A virus.
The structural relationship of sialidase to the influenza virus surface.
The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody.
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.
The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor.
The structures of Salmonella typhimurium LT2 neuraminidase and its complexes with three inhibitors at high resolution.
The subclass IgG responses of mice to influenza surface proteins formulated into liposomes.
The surface receptor is a major determinant of the cell tropism of influenza C virus.
The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor.
The threat of avian influenza H5N1: 'do we have the tools for the job'?
The treatment of influenza with antiviral drugs.
The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication.
The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.
The use of a radial haemolysis test for neuraminidase antibodies in the diagnosis of influenza A infection.
The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.
The value of neuraminidase inhibition antibody titers in influenza seroepidemiology.
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews.
The virulence of the 1918 pandemic influenza virus: unraveling the enigma.
The war against influenza: discovery and development of sialidase inhibitors.
Theoretical analysis of the neuraminidase epitope of the Mexican A H1N1 influenza strain, and experimental studies on its interaction with rabbit and human hosts.
Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.
Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation.
Therapeutic options for the management of influenza.
Thiosialoside clusters using carbosilane dendrimer core scaffolds as a new class of influenza neuraminidase inhibitors.
Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection.
Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin.
Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus.
Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial.
Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards.
Three-dimensional structure of a complex of antibody with influenza virus neuraminidase.
Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid.
Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus.
Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase.
Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution.
Three-dimensional structures of influenza virus neuraminidase-antibody complexes.
Three-dimensional structures of single-chain Fv-neuraminidase complexes.
Three-dimensional window analysis for detecting positive selection at structural regions of proteins.
TMPRSS2 activates hemagglutinin-esterase glycoprotein of influenza C virus.
Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity.
Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines.
Total synthesis of A-315675: a potent inhibitor of influenza neuraminidase.
Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.
Towards a universal influenza vaccine: different approaches for one goal.
Towards the electrochemical diagnostic of influenza virus: development of a graphene-Au hybrid nanocomposite modified influenza virus biosensor based on neuraminidase activity.
Transfer of the hemagglutinin activity of influenza virus neuraminidase subtype N9 into an N2 neuraminidase background.
Transforming growth factor-?: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis.
Translational regulation of influenza virus mRNAs.
Transmembrane domain of influenza virus neuraminidase, a type II protein, possesses an apical sorting signal in polarized MDCK cells.
Transmission of avian influenza A viruses among species in an artificial barnyard.
Transmission of influenza A in families.
Transport of an influenza virus vaccine formulation (iscom) in Caco-2 cells.
Transport of influenza A virus neuraminidase (NA) to host cell surface is regulated by ARHGAP21 and Cdc42.
Transport of influenza virus envelope proteins from the Golgi complex to the apical plasma membrane in MDCK cells: pH-controlled interaction with a cycling receptor is not involved.
Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses.
Traveling waves in a model of influenza A drift.
Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results.
Treating and preventing influenza in aged care facilities: a cluster randomised controlled trial.
Treating Influenza With Neuraminidase Inhibitors: What Is the Evidence?
Treatment and prevention of influenza: Swedish recommendations.
Treatment and prophylaxis of influenza and the problem of resistance to neuraminidase inhibitors.
Treatment of community-acquired lower respiratory tract infections during pregnancy.
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.
Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.
Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection.
Treatment of influenza with neuraminidase inhibitors.
Treatment of influenza with neuraminidase inhibitors: virological implications.
Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.
Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral.
Treatment of Severe Cases of Pandemic (H1N1) 2009 Influenza: Review of Antivirals and Adjuvant Therapy.
Treatment options for H5N1: lessons learned from the H1N1 pandemic.
Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09.
Treatment with neuraminidase inhibitors for high-risk patients with influenza: why is adherence to antiviral treatment recommendations so low?
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Triabodies: single chain Fv fragments without a linker form trivalent trimers.
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice.
Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice.
Triplet entropy analysis of hemagglutinin and neuraminidase sequences measures influenza virus phylodynamics.
Trypanosoma vivax, stock V953: inhibitory effect of type A influenza virus anti-HAV8 serum on in vitro neuraminidase (sialidase) activity.
Two evolutionary strategies of influenza viruses to escape host non-specific inhibitors: alteration of hemagglutinin or neuraminidase specificity.
Two neuraminidase inhibitors for treatment of influenza.
Type A influenza virus surveillance in free-flying, nonmigratory ducks residing on the eastern shore of Maryland.
Type A influenza viruses in waterfowl in Ohio and implications for domestic turkeys.
Type C influenza virus.
Type II transmembrane domain hydrophobicity dictates the cotranslational dependence for inversion.
Type- and subtype-specific RT-PCR assays for avian influenza A viruses (AIV).
Typing and subtyping of influenza viruses in clinical samples by PCR.
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic.
U13???C13 mutation in the variable region of the NA gene 3'UTR of H9N2 influenza virus influences the replication and transcription of NA and enhances virus infectivity.
Ubiquitous reassortments in influenza a viruses.
Ultrasensitive detection of drug-resistant pandemic 2009 (H1N1) influenza A virus by rare-variant-sensitive high-resolution melting-curve analysis.
Ultrasensitive detection of rare mutations using next-generation targeted resequencing.
Ultrasensitive Fluorogenic Reagents for Neuraminidase Titration.
Un-"ESCRT"-ed Budding.
Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
Understanding the Influenza A H1N1 2009 Pandemic.
Unexpected platelets elevation in a patient with idiopathic thrombocytopenia treated with oseltamivir for influenza infection.
Unique ability of pandemic influenza to downregulate the genes involved in neuronal disorders.
Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
Unique Directional Motility of Influenza C Virus Controlled by Its Filamentous Morphology and Short-Range Motions.
Universal Anti-Neuraminidase Antibody Inhibiting all Influenza A Subtypes.
Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011.
Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice.
Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines.
Unsaturated N-acetyl- D-glucosaminuronic acid glycosides as inhibitors of influenza virus sialidase.
Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment.
Unusual diffraction of type B influenza virus neuraminidase crystals.
Update on influenza and other viral pneumonias.
Upper respiratory tract infections.
Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus.
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes.
Use of antiviral prophylaxis in influenza outbreaks in long term care facilities.
Use of HDEL-tagged Trichoderma reesei mannosyl oligosaccharide 1,2-alpha-D-mannosidase for N-glycan engineering in Pichia pastoris.
Use of hemagglutinin and neuraminidase amplicon-based high-throughput sequencing with variant analysis to detect co-infection and resolve identical consensus sequences of seasonal influenza in a university setting.
Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance.
Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09.
Use of lentiviral pseudotypes as an alternative to reassortant or Triton X-100-treated wild-type Influenza viruses in the neuraminidase inhibition enzyme-linked lectin assay.
Use of neuraminidase inhibitors for prophylaxis and treatment of pandemic influenza: summary of a Faculty of Public Health meeting.
Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies.
Use of Neuraminidase Inhibitors for Treatment of Severe Influenza: Times Are Changing.
Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.
Use of neuraminidase inhibitors to combat pandemic influenza.
Use of oseltamivir in Dutch nursing homes during the 2004-2005 influenza season.
Use of Oseltamivir to control influenza complications after bone marrow transplantation.
Use of semiconductor-based oligonucleotide microarrays for influenza a virus subtype identification and sequencing.
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers.
Use of the DNA flow-thru chip, a three-dimensional biochip, for typing and subtyping of influenza viruses.
Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines.
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1: Preparation and characterization of disrupted virions.
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Using Support Vector Machine (SVM) for Classification of Selectivity of H1N1 Neuraminidase Inhibitors.
Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility.
Vaccination of an adolescent group with A (H3N2) + A(HSW1N1) bivaccine before an A (H1N1) influenza epidemic.
Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice.
Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody.
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses.
Vaccine approaches conferring cross-protection against influenza viruses.
Vaccine production in Neurospora crassa.
Vaccine-associated enhanced respiratory disease is influenced by hemagglutinin and neuraminidase in whole inactivated influenza virus vaccines.
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
Validation of a fully integrated microfluidic array device for influenza a subtype identification and sequencing.
Variability among the neuraminidase, non-structural 1 and PB1-F2 proteins in the influenza A virus genome.
Variable ligand- and receptor-binding hot spots in key strains of influenza neuraminidase.
Variation in the divalent cation requirements of influenza a virus N2 neuraminidases.
Variation in the membrane-insertion and "stalk" sequences in eight subtypes of influenza type A virus neuraminidase.
Variation of influenza A (H3N2) viruses isolated in the G.D.R. during 1969-1980 epidemics.
VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: Analysis of 1000 hospitalized children.
Vigna radiata (L.) R. Wilczek Extract Inhibits Influenza A Virus by Targeting Viral Attachment, Penetration, Assembly, and Release.
Viral burden, inflammatory milieu and CD8+ T-cell responses to influenza virus in a second-generation thiazolide (RM-5061) and oseltamivir combination therapy study.
Viral infections in immunocompromised patients: what's new with respiratory viruses?
Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS).
Viral neuraminidase and cellular ectosialyltransferase in human lymphoblastoid cells infected with influenza virus.
Viral neuraminidase treatment of dendritic cells enhances antigen-specific CD8(+) T cell proliferation, but does not account for the CD4(+) T cell independence of the CD8(+) T cell response during influenza virus infection.
Viral pneumonia.
Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors.
Virological characterization of influenza H1N1pdm09 in Vietnam, 2010-2013.
Virological Methods for the Generation and Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en.
Virological monitoring of influenza activity and influenza-like illness in the epidemic season 2011-2012 in poland.
Virological surveillance and phylogenetic analysis of the PB2 genes of influenza viruses isolated from wild water birds flying from their nesting lakes in Siberia to Hokkaido, Japan in autumn.
Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, Spain.
Virosome engineering of colloidal particles and surfaces: bioinspired fusion to supported lipid layers.
Virtual screening approach to identifying influenza virus neuraminidase inhibitors using molecular docking combined with machine-learning-based scoring function.
Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach.
Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells.
Virus enhances histamine release from human basophils.
Virus isolations from pet birds submitted for importation into the United States.
Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia.
Virus yield-reduction assays for interferon with the influenza virus neuraminidase assay.
Virus-cell interactions in the induction of type 1 interferon by influenza virus in mouse spleen cells.
Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
Virus-like particles as universal influenza vaccines.
Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens.
What adaptive changes in hemagglutinin and neuraminidase are necessary for emergence of pandemic influenza virus from its avian precursor?
What does the molecular structure of viruses tell us about viral functions?
What happened after the initial global spread of pandemic human influenza virus A (H1N1)? A population genetics approach.
WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008.
Whole-Genome Phylogenetic Analysis of Influenza B/Phuket/3073/2013-Like Viruses and Unique Reassortants Detected in Malaysia between 2012 and 2014.
Why do influenza virus subtypes die out? A hypothesis.
Why was the 1918 influenza pandemic so lethal? The possible role of a neurovirulent neuraminidase.
Wildlife surveillance associated with an outbreak of lethal H5N2 avian influenza in domestic poultry.
Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
Yu Ping Feng San, an Ancient Chinese Herbal Decoction, Induces Gene Expression of Anti-viral Proteins and Inhibits Neuraminidase Activity.
Zanamivir (Glaxo Wellcome).
Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza.
Zanamivir for the prevention of influenza in adults and children age 5 years and older.
Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial.
Zanamivir in the treatment of influenza.
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
Zanamivir.
Zanamivir: a rational approach to influenza B.
Zanamivir: a review of clinical safety.
Zanamivir: a review of its use in influenza.
Zanamivir: an influenza virus neuraminidase inhibitor.
Zanamivir: an update of its use in influenza.
Zanamivir: from drug design to the clinic.
ZstatFlu-II test: a chemiluminescent neuraminidase assay for influenza viral diagnostics.
Zwitterionic structures: from physicochemical properties toward computer-aided drug designs.
[ Influenza virus proteins modulate hemostasis in vitro and in vivo ]
[A compact microarray for sub-typing of influenza A virus].
[A comparative study of the neuraminidase activity of 2 strains of influenza A2 type virus]
[A field experiment with neuraminidase influenza vaccine (author's transl)]
[A mechanism for limiting reproduction influenza A virus reassortants with incomplete functional compatibility of hemagglutinin and neuraminidase gene products]
[A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients].
[A new influenza subunit vaccine: reactogenicity and antigenicity in comparison to split and whole virus vaccines (author's transl)]
[A study on the standard of influenza neuraminidase inhibition assay].
[Ability of the influenza viruses and their envelope proteins to stimulates endothelial cells apoptosis in vitro].
[Access to research data: a light at the end of the tunnel?].
[Accessing the features of surface neuraminidase (N1) of influenza A virus presenting on the platforms for anti-NA Abs screening].
[Action of antiviral substances on influenza viruses through the inhibition of neuraminidase production]
[Active neuraminidase constituents of Polygonum cuspidatum against influenza A(H1N1) influenza virus].
[Adaptation of freshly isolated strains of influenza viruses. I. Neuraminidase activity]
[Advances in antiviral chemotherapy]
[Amantadine]
[An analysis on genetic characteristics of hemagglutinin and neuraminidase of type B influenza viruses in Guangzhou in 2006]
[An analysis on HA, NA gene/protein evolution and the variability of antigenicity sites of influenza A (H7N9) virus].
[An inhibitor of influenza virus neuraminidase isolated from Staphylococcus aureus]
[Analysis of decrease in sensitivity in influenza A (H5N1) avian and human strains to neuraminidase inhibitors]
[Analysis of etiology of four pandemic influenza A (H1N1) virus outbreaks in Shandong province, in 2009].
[Analysis of HA and NA Genes of Influenza A H1N1 Virus in Yunnan Province during 2009-2014].
[Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan].
[Analysis of the antigenic properties of strains of influenza virus that caused the epidemic of 1974-1975]
[Analysis of the antigenic specificity of the neuraminidases of influenza B viruses isolated in different years]
[Analysis of the Genetic Evolution of Neuraminidases of Influenza A Subtype N9 Viruses].
[Analysis of the Neuraminidase Amino Acid Sequences of Influenza A/H1N1pdm09, A/H3N2, and B Viruses Isolated from Influenza Patients in the 2013/14 Japanese Influenza Season].
[Anti-virals for influenza virus infection]
[Antibody response to hemagglutinin and neuraminidase induced by an influenza subunit vaccine (author's transl)]
[Antigen production for the influenza virus neuraminidase activity inhibition reaction]
[Antigenic and biochemical analysis of the proteins of influenza virus A/USSR/Alma-Ata/13/81 with hemagglutinin H1]
[Antigenic and biological characteristics of influenza virus A strains isolated in 1985]
[Antigenic and biological characteristics of the A (H1N1) strains that caused the 1977--1978 epidemic]
[Antigenic characteristics of chicken influenza viruses]
[Antigenic characterization of hemagglutinin and neuraminidase in strains of influenza B virus isolated in Italy in the years 1962, 1967 and 1971]
[Antigenic drift of current influenza A viruses]
[Antigenic heterogeneity of influenza virus B neuraminidases]
[Antigenic properties of influenza virus type A inactivated by ultraviolet irradiation]
[Antigenic relationships of strains of the epidemic virus H1N1 isolated in November-December 1977 in the USSR to inluenza viruses of human and animal origin]
[Antigenic specificity of neuraminidase and structure of neuraminidase gene of influenza A(H1N1) serotype Hsw1N1 viruses isolated from man and animals]
[Antineuraminidase activity of inactivated influenza vaccines in elderly people]
[Antineuraminidase serum antibodies in natural influenza A and immunization with influenza vaccines]
[Antiviral agents in influenza--current recommendations. Anti-influenza agents are not a substitution for but a complement to vaccination]
[Antiviral treatment of influenza in humans]
[Antivirals for influenza]
[Assessment of the antiviral activity of 2HCl*H-His-Rim compound compared to the anti-influenza drug Arbidol for influenza caused by A/duck/Novosibirsk/56/05 (H5N1) (Influenza A virus, Alphainfluenzavirus, Orthomyxoviridae).]
[Assessment of the sensitivity of immunoprecipitation for the serodiagnosis of influenzal-bacterial pneumonias]
[Avian influenza virus]
[Biological characteristics of influenza B viruses isolated during influenza B epidemics in 1976-1977]
[Biological consequences of breaks and reunions of disulfide bonds in influenza virus proteins]
[Biological properties and genome structure of recombinant strains of influenza A virus differing in their degree of human virulence]
[Biological properties of the agents of the influenza epidemic of 1972-1973 in Leningrad and other cities of the Soviet Union]
[Changes in cell membrane fluidity evoked by removal of influenza virus receptors with neuraminidase]
[Changes in the antigenicity of influenza virus neuraminidases due to various methods of preparation]
[Characteristics of complete genome of pandemic A/H1N1/2009 influenza virus isolated in Fujian Province, China].
[Characteristics of isolating influenza virus hemagglutinin using purified bromelin]
[Characteristics of measuring the neuraminidase activity and total protein in influenza virus preparations of an allantoic nature]
[Characteristics of neuraminidase N1 from human influenza A viruses]
[Chemical Constituents from Leaves of Acanthus ilicifolius and Their Anti-influenza Virus Activities].
[Chitosan as an adjuvant for inactivated vaccines against avian influenza viruses]
[Circulation of the influenza A virus of H13 serosubtype among seagulls in the Northern Caspian (1979-1985)]
[Classical fowl plague and milder influenza infections in birds and mammals]
[Clinical characteristic of the elderly in influenza infection]
[Clinical Characteristics of Adult Onset RSV Infection During Two Consecutive Winter Seasons].
[Clinical evaluation of an immunochromatography test for rapid diagnosis of influenza]
[Clinical evaluation of rapid diagnostic kit detecting separately influenza A and B viruses]
[Clinical features and outcome in 84 patients with influenza pneumonia]
[Clinical studies on influenza neuraminidase inhibiting antibody]
[Cold-adapted strain of A/Leningrad/134/47/57 (H2N2)--a special attenuation donor of live influenza vaccine for children and the isolation of its recombinants]
[Comparative characteristics of epidemic strains of the influenza virus B isolated in 1980-1981]
[Comparative immunogenicity studies of cultural and peptide influenza vaccines].
[Comparative study of the RNA and proteins of antigenically similar human and animal influenza A viruses]
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
[Comparison of the synonymous and non-synonymous substitution rates in various regions of the neuraminidase and hemagglutinin genes of the influenza A virus]
[Complement fixation, hemagglutination inhibition and neuraminidase inhibition reactions in the seroepidemiologic evaluation of an influenza A epidemic]
[Complex study of population immunity to 3 influenza A virus antigens]
[Contemporary threat of influenza virus infection]
[Contribution of neuraminidase of influenza viruses to the sensitivity to the serum inhibitors and reassortment efficiency].
[Contribution to the antigenic study of influenza viruses in animals. I.--Neuraminidase of the equine influenza viruses (author's transl)]
[Contribution to the antigenic study of influenza viruses in animals. II.--Antibodies, antineuraminidase in horse: conditions of apparition and importance (author's transl)]
[Control of hospital infection of influenza: administration of neuraminidase inhibitor and cohort isolation of influenza patients]
[Control of subunit influenza vaccines]
[Controversies about neuraminidase inhibitor. Is the influenza drug less effective than assumed?]
[Creation of a generalized model prediction of inhibition of neuraminidase of influenza virus of various strains].
[Critical review of anti-influenza drugs]
[Design, synthesis and activity of a new type of influenza virus N1 neuraminidase inhibitors].
[Determination of standard conditions for the influenza virus neuraminidase inhibition test]
[Determination of the antigenic specificity of the neuraminidase of influenza viruses]
[Determination of the neuraminidase specificity of influenza A and B viruses using a modified lectin test]
[Development of a real-time reverse transcriptase PCR assay for detection of E119V amino acid change in neuraminidase of influenza A (H3N2) using the TaqMan-MGB probe].
[Differentiating markers of virulent and attenuated (cold-adapted) strains of influenza A virus]
[Disulfide maturation of the glycoproteins of influenza virus hemagglutinin and neuraminidase in infected cells]
[DNA vaccination via in vivo electroporation can elicit specific immune response against highly pathogenic H5N1 influenza viral structural antigens in mice]
[Editorial: The role of neuraminidase in immunity against influenza]
[Effect of heat treatment on influenza virus neuraminidase activity]
[Effect of inhibitors of protein synthesis on neuraminidase and hemaglutinin of the influenza virus]
[Effect of low pH values on the infectivity and neuraminidase activity of human and animal strains of influenza virus type A]
[Effect of physicochemical factors on influenza virus neuraminidase]
[Effect of ultraviolet irradiation and formalin on the antigenic properties of the hemagglutinin and neuraminidase from the influenza A/-Victoria/72 virus]
[Effects of Maxing Shigan Decoction Decocted by Different Methods and Its Drug Containing Serum on Neuraminidase Activity of Influenza A Virus].
[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].
[Efficacy of inhaled zanamivir in the treatment and prevention of influenza]
[Elaboration of immune stimulating lipid-saponin subunit antigen carrier based on glycolipid monogalactosyldiacylglycerol from sea macrophytes and triterpene glycosides from Cucumaria japonica].
[Electrophoretic motility of RNA of recombinant influenza virus strains X-7 and X-9]
[Eluting and neuraminidase activity of inhibitor-resistant strains of influenza A2 virus]
[Enhancement of the immune response to surface antigens of the influenza B virus as a result of their covalent binding with a synthetic polymer carrier]
[Enzyme activity of the neuraminidase from various strains of the influenza A virus]
[Epidemiology, clinical picture, prevention and treatment of avian influenza.]
[Establishment of a cell-based 2009 H1N1 influenza neuraminidase inhibitors evaluation system].
[Etiological and molecular characteristics of pandemic influenza A (H1N1) virus during 2009-2010 in Shandong Province].
[Evaluation of Chinese traditional patent medicines against influenza virus in vitro].
[Evaluation of rapid detection kit using neuraminidase activity of influenza virus]
[Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
[Evaluation of the rapid detection test for influenza A and B viruses using neuraminidase activity]
[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].
[Evolutionary analysis of neuraminidase gene of A/H7N9 influenza virus].
[Expression and mutagenesis of genes coding for protein synthesis in the influenza virus]
[Expression of NA of influenza virus and C3d fusion gene in replication-defective recombinant adenovirus and its immune efficacy analysis].
[Expression of neuraminidase gene of influenza virus H1N1 in baculovirus-expression system].
[Factors that cause a change in the antigenic structure of of the influenza virus hemagglutinin]
[Favipiravir, a new concept of antiviral drug against influenza viruses].
[Formation and protective functions of antibodies to neuraminidase of the influenza A virus]
[Formation of antibodies against neuraminidase of A/California/07/2009 (H1N1) influenza virus after immunization with live monovalent influenza vaccine].
[French general practitioners' perceptions and use of neuraminidase inhibitors during the pandemic A(H1N1)2009 influenza].
[Function of neuraminidase of influenza virus and anti influenza compounds by its inhibition]
[Functional interactions of the influenza virus glycoproteins]
[Generation high yield vaccine strain wholly derived from avian influenza viruses by reverse genetics]
[Genetic characteristics of hemagglutinin and neuraminidase of avian influenza A (H7N9) virus in Guizhou province, 2014-2017].
[Genetic characteristics of influenza A/H3N2 virus neuraminidase gene: a survey from 2010 to 2012 in Qinghai Province, China].
[Genetic markers and their interrelationships in influenza viruses. 3. The interrelationship between virulence and sensitivity to serum inhibitors, neuraminidase and eluting activity]
[Genetic variability of isolates of pandemic influenza A virus H1N1 isolated in Russia in 2009].
[Genetic variation of the hemagglutinin and neuraminidase of influenza B viruses isolated in Ningbo during 2010-2012].
[Genetic variation of the hemagglutinin and neuraminidase of influenza B viruses isolated in Zhejiang province during 1999 - 2010.]
[Genome composition analysis of the reassortant influenza viruses used in seasonal and pandemic live attenuated influenza vaccine].
[Geriatrics]
[Heat sensitivity of haemagglutinin and neuraminidase of influenza A-strains]
[Heterogeneity of an influenza virus population in the manifestation of biological functions (author's transl)]
[High-yield reassortant virus containing hemagglutinin and neuraminidase genes of pandemic influenza A/Moscowl/01/2009 (H1N1) virus].
[Homologous and heterologous antibody induction in influenzal infection and immunization]
[Humoral and cellular immunity in influenza virus infection]
[Hypothermic Action of Oseltamivir Not Dependent on Its Anti-influenza Virus Action].
[Immunogenic activity of the influenza virus dependent on ne uraminidase (author's transl)]
[Immunogenic activity of the viral hemagglutinin and neuraminidase from live and inactivated influenza vaccines]
[Immunologic analysis of the antigenic properties of neuraminidase from drift-variants of influenza virus B]
[Immunologic characteristics of the neuraminidase of influenza A viruses serologic subtype 2]
[Immunologic response of mice to influenza virus strains with different neuraminidase activity]
[Immunological analysis of the surface components of the influenza virus similar to the serovariant A (Hsw1N1) isolated in Alma-Ata 1984-1985]
[In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
[Incidence of circulating antibodies against hemagglutinin and neuraminidase of influenza viruses in the epidemic season 1991/92 in Poland]
[Influence of normal inhibitors of allantoic fluid on hemagglutinin and sialidase in influenza virus]
[Influenza A pneumonia]
[Influenza A, pregnancy and neuraminidase inhibitors.]
[Influenza and other viral respiratory infections]
[Influenza in children]
[Influenza inhibitor of the host serum RNAse]
[Influenza vaccination in dialysis patients]
[Influenza vaccination: antibodies against hemagglutinin and neuraminidase after administration of common Al2O3 and Al(OH)3 vaccines in man]
[Influenza virus neuraminidase and its role in anti-influenzal immunity]
[Influenza--always present among us]
[Influenza: a current medical problem]
[Influenza: Whats new?]
[Influenza]
[Influenza].
[Inhibition of the infectivity of enveloped viruses while retaining the specific biological activity of the viral proteins]
[Inhibitory activity of blood group antigens M and N in inhibition of virus hemagglutination reactions of influenza viruses]
[Inter-species transmission of the influenza virus]
[Isolation and crystallization of neuraminidase of the influenza B virus strain B/Leningrad/179/86]
[Isolation of preparative amounts of influenza virus neuraminidase by affinity chromatography]
[Isolation of surface antigens of influenza virus A/Hong Kong 1/68 (H3N2) by density gradient fractionation with a new carboxypolypeptidase (author's transl)]
[Lipid raft and influenza virus--viral glycoproteins on a raft]
[Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza. II. Neuraminidase inhibiting antibodies (author's transl)]
[Maturation of the hemagglutinin and neuraminidase polypeptides of the influenza virus in infected cells]
[Mechanism of the modifying effect of neuraminidase of the influenza virus on the development of Rauscher leukemia]
[Mechanism underlying the anterograde transport of the influenza A virus transmembrane proteins and genome in host cytoplasm].
[Method for evaluating the neuraminidase activity of receptordestroying enzyme (RDE) compounds using the influenza virus.]
[Molecular and genetic analysis of influenza A viruses isolated in Russia, based on the neuraminidase and M2 protein gene sequence]
[Molecular characterization of human influenza viruses--a look back on the last 10 years]
[Molecular genetic analysis of a cold-adapted donor attenuation strain for a pediatric liver influenza vaccine, of recombinants based on it and of isolates from vaccinated children]
[Molecular genetic studies of the susceptibility of epidemic influenza A(H1N1) virus strains isolated in the 2006-2009 seasons in Russia to oseltamivir (Tamiflu)].
[Molecular mechanism of the variation of influenza virus hemagglutinin and neuraminidase, and their recognition of sialylglycoconjugates]
[Monitoring of the sensitivity of epidemic influenza virus strains isolated in Russia to etiotropic chemical agents]
[Mutations in the genes coding for hemagglutinin and neuraminidase in cold-adapted variants of the influenza virus A/Leningrad/134/57 (H2N2)]
[Mutations in the Neuraminidase Gene of the Epidemic Influenza Virus Strain Isolated in the 2012-2013 Season and Improvement of a PCR Assay for the Detection of Influenza Virus].
[Neuraminidase activity of inactivated influenza vaccines]
[Neuraminidase antigenic erythrocytic diagnostic agent in determining antibodies to the neuraminidase of influenza A viruses]
[Neuraminidase inhibitor for treatment of influenza A and B]
[Neuraminidase inhibitor permitted. The first pill against influenza]
[Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically]
[Neuraminidase inhibitors against influenza]
[Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations]
[Neuraminidase inhibitors and risk of H5N1 influenza]
[Neuraminidase inhibitors in prophylaxis and treatment of influenza]
[Neuraminidase inhibitors in the general practice management of influenza: who prescribe them, when and with which results?]
[Neuraminidase inhibitors in therapy of influenza]
[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza]
[Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
[Neuraminidase of influenza virus]
[Neuraminidase-Inhibiting Antibodies to Avian Influenza Virus Subtypes in Human Sera (author's transl)]
[Oligonucleotide microarray for subtyping of influenza virus A neuraminidase].
[Oral neuraminidase inhibitor and an early warning system. New weapons against influenza]
[Oseltamivir resistance depends on the position 273 amino acid of neuraminidase of the type A influenza virus (H1N1), circulating in human population].
[Peculiarity of reassortment of current wild type influenza viruses with master donor viruses for live influenza vaccine].
[Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza]
[Perspectives of antiviral drugs used on influenza].
[pH-dependent hemolytic and neuraminidase activity of remantadine-sensitive and -resistant variants of influenza virus]
[pH-dependent rearrangements in the influenza A virus].
[Pharmaco-economics of anti-influenza vaccinations]
[Pharmacoeconomic evaluation of oseltamivir as prophylaxis against influenza infection]
[Phylogenetic analysis based on hemagglutinin and neuraminidase genes between swine influenza virus and human influenza A/H3N2 virus strains isolated in Zhejiang province]
[Phylogenetic analysis of human/swine/avian gene reassortant H1N2 influenza A virus isolated from a pig in China]
[Prediction of inhibition of influenza virus neuraminidase of various strains by using a generalized model constructed using the data on the position of known ligands].
[Prediction of selective inhibition of neuraminidase from various influenza virus strains by potential inhibitors].
[Preliminary results of the comparative study of the hemagglutinin and neuraminidase antigens of strains of influenza virus A isolated in Leningrad in 1972-1973]
[Preparative isolation of neuraminidase from influenza viruses A (Singapore) 1-57, A (Hongkong) 1-68 and A (Leningrad) 99-71]
[Preparative method of isolating influenza virus glycoproteins]
[Present and future in a development of new anti-influenza drugs]
[Present data on influenza virus isolated from ducks and chickens, and influenza virus C. Anti-influenza drugs]
[Prevention and care management of influenza infection in institutions for the elderly and high risk groups]
[Prevention and treatment of influenza]
[Primary structure of a full-size DNA copy of the influenza virus A/Kiev/59/79 (H1N1) neuraminidase gene]
[Primary structure of the full-length DNA copy of the neuraminidase gene in the avian influenza virus of the N7 antigenic subtype]
[Properties of current influenza A (H1N1) virus strains and the characteristics of the epidemics they induce]
[Properties of the influenza viruses isolated in 1976 from gulls in Astrakhan Province]
[Protective action of liposome-incorporated surface antigens of the influenza virus by different methods of immunization]
[Purification of neuraminidase from influenza virus on an immunosorbent]
[Radioimmunological analysis of the neuraminidase of influenza virus subtype N2]
[Rapid detection tests for viruses available in pediatric clinics]
[Reaction of influenza viruses with thymus-dependent lymphocytes]
[Recognition mechanisms of receptor sialooligosaccharides by influenza virus hemagglutinin and sialidase]
[Recombinant viruses of poultry as vector vaccines against fowl plague]
[Reduction of the functional match of influenza virus hemagglutinin and neuraminidase after reassortation of genes]
[Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase]
[Research progress in molecular determinants of neuraminidase, polymerase basic protein 2 and nonstructural protein 1, related to virulence of influenza A virus--a review].
[Research progress of anti-influenza virus agents].
[Research progress of neuraminidase inhibitors for anti-influenza]
[Resistance in influenza viruses]
[Respiratory viruses: epidemiologic features, clinical impact, and management]
[Role of antineuraminidase antibodies in protection against influenza]
[Role of carbohydrates in the manifestation of the hemagglutinating and neuraminidase activities of the influenza virus]
[Role of influenza virus sialidase]
[Role of neuraminidase in pathogenesis of influenza]
[Role of neuraminidase inhibitors for the treatment of influenza A virus infections]
[Screening based on response surface methodology of multi-fractions traditional Chinese medicine with anti-influenza virus neuraminidase activity: take shuanghuanglian injection as an example].
[Sensitivity of influenza A2 virus to the non-specific alpha-inhibitor of Francis (the thermoresistance of the sialidase of several variants of influenza A2 virus)]
[Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]
[Serological study of the neuraminidase activity of cholera filtrate and influenza virus]
[Significance of the neuraminidase inhibitor oseltamivir for the management of seasonal influenza]
[Specific serum against influenza virus neuraminidase]
[Speed and intensity of the immune response to the administration of inactivated influenza vaccine in relation to neuraminidase activity]
[Structure and function of influenza virus neuraminidase]
[Studies of adaptation of influenza viruses to their replication in low temperature. I. Biological properties]
[Studies on sialidase and esterase in influenza viruses]
[Studies on the adaptation of freshly isolated strains of influenza virus. 3. Comparative determination of neuraminidase activity]
[Studies on the determination of neuraminidase subtypes of influenza A viruses using ovomucoid]
[Study of the virus carrier state in chicken influenza]
[Study on immunogenicity of a recombinant adenovirus vaccine containing neuraminidase gene of H5N1 influenza virus (A/Anhui/1/2005) in mice]
[Study on the role of influenza viral neuraminidase in the early stages of the growth cycle by means fo quantitative hemadsorption (author's transl)]
[Successive isolation of hemagglutinin and neuraminidase from influenza virus A/Kransnodar/101/59 (H2N2) using bromelain]
[Susceptibility of human influenza A (H3N2) viruses to neuraminidase inhibitors isolated during 2011-2012 in China].
[Susceptibility of Influenza B Viruses to Neuraminidase Inhibitors Isolated during 2013-2014 Influenza Season in Mainland China].
[Synthesis, cloning and determination of the primary structure of a full-size DNA copy of the neuraminidase gene from influenza virus type A subtype H1N1]
[The 2001/2002 influenza season and the vaccine composition for the 2002/2003 season]
[The antigenic specificity of the hemagglutinin and neuraminidase of influenza B virus reproducing in different cell systems]
[The characteristics of various substrates in the determination of neuraminidase activity in influenza virus]
[The immunomodulating action of the surface antigens of the influenza A virus in experimental staphylococcal infection]
[The induction by the influenza virus A/H1N1 (serovariant Hsw1N1) and its glycoproteins of congenital pathology in mice]
[The mechanisms of the antiviral action of the bora-adamantane derivative preparation BG-12]
[The model of prediction of the inhibition of neuraminidases of influenza A and B based on a reduced set of energy terms].
[The nature of amino acid substitution in antigenic drift of hemagglutinin N3 and neuraminidase N2 from the influenza virus]
[The rapid detection kit based on neuraminidase activity of influenza virus]
[The receptor destroying enzyme of influenza viruses. The role of the receptor destroying enzyme on the budding and the release of influenza viruses from the host cells]
[The smaller number of influenza patients with neuropsychiatric events had taken oseltamivir beforehand]
[The structure and function of the HE protein of influenza C virus]
[The structure of carbohydrate chains of hemagglutinin and neuraminidase of influenza virus B/Leningrad/179/86]
[The structure of oligosaccharide fragments of glycoproteins from influenza virus A/Krasnodar/101/59/(H2N2)--heavy and light chains of hemagglutinin and neuraminidase]
[The threatening influenza pandemic: a national store ofoseltamivir is a waste of money]
[The use of antiviral agents during an (impending) influenza pandemic]
[The use of enzymes for searching for biologically active compounds]
[The use of rapid tests for individual diagnosis of influenza]
[The use of the Soviet detergents dezintegron-O and dezintegron-B for the solubilization of influenza virus glycoproteins]
[Two recombinant adenovirus vaccine candidates containing neuraminidase Gene of H5N1 influenza virus (A/Anhui/1/2005) elicited effective cell-mediated immunity in mice]
[Universal influenza vaccines: developments, prospects for use].
[Using antibiotics in case of influenza]
[Using neuraminidase inhibitors in prevention and treatment of influenza]
[Vaccination of infants and schoolchildren with an influenza subunit vaccine (author's transl)]
[Variability of influenza A2 viruses in nature]
[Variation of influenza viruses and their recognition of the receptor sialo-sugar chains]
[Various sides of influenza. Part II--epidemiology, influenza surveillance and prophylaxis]
[Virological impact of stalk region of neuraminidase in influenza A/Anhui/1/05 (H5N1) and A/Ohio/07/2009 (H1N1) viruses].
[What is current opinion of antiviral therapy for the flu in 2001?]
Insulin Resistance
A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.
Adverse Effects of Oseltamivir Phosphate Therapy on the Liver of LDLR-/- Mice Without Any Benefit on Atherosclerosis and Thrombosis.
Elastin-derived peptides, new regulators of insulin resistance development in mice.
Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice.
NEU3 sialidase as a marker of insulin sensitivity: Regulation by fatty acids.
Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice.
New role for ceramide in hypoxia and insulin resistance.
Intellectual Disability
Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient.
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
Intestinal Diseases
Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type A and C strains causing human intestinal disease.
Ischemic Stroke
Sialic acid and sialidase activity in acute stroke.
Keratitis
Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection.
Kidney Calculi
Human renal neuraminidase.
Kidney Failure, Chronic
Immune response to influenza vaccine in hemodialysis patients with chronic renal failure.
Kidney Neoplasms
Arylamidase from human renal cancer tissue in comparison with normal kidney and placental enzymes.
Kyphosis
[Case of mucolipidosis type I with a primary alpha-D-neuraminidase deficiency]
Laboratory Infection
Serum neuraminidase activity and hematological alterations in acute human Chagas' disease.
Leber Congenital Amaurosis
Altered expression of ?-galactosidase-1-like protein 3 (Glb1l3) in the retinal pigment epithelium (RPE)-specific 65-kDa protein knock-out mouse model of Leber's congenital amaurosis.
Leishmaniasis
The Role of Sialic Acids in the Establishment of Infections by Pathogens, With Special Focus on Leishmania.
Leishmaniasis, Visceral
Trans-sialidase neutralizing antibodies detection in Trypanosoma cruzi infected domestic reservoirs.
Leprosy, Lepromatous
Macrophage membrane alterations in leprosy as determined by change in sialic acid level.
Leprosy, Tuberculoid
Macrophage membrane alterations in leprosy as determined by change in sialic acid level.
Leukemia
Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies.
Cationic anticancer drugs and their modes of action.
Characterization of a 75,000 mol. wt glycoprotein synthesized by guinea-pig T-lymphocytes: a possible homologue of Lyt-1 antigen.
Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis.
Human leukemia cells and mature lymphocytes induce platelet aggregation after removal of cell surface sialic acid.
Human T-cell leukemia-associated cell surface glycoprotein GP37: studies with three monoclonal antibodies and a rabbit antiserum.
Immune response-associated antigens on mouse leukemia cells. I. Detection of Ia antigens on GRSL cells.
Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
Membrane type sialidase inhibits the megakaryocytic differentiation of human leukemia K562 cells.
Monoclonal antibodies to carbohydrate antigens in autologous bone marrow transplantation.
Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study.
New monoclonal antibodies SN3, SN3a, and SN3b directed to sialic acid of glycoprotein on human non-T leukemia cells.
Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes.
Sialylatin of glycoproteins of murine mammary tumor virus, murine leukemia virus, and Mason-Pfizer monkey virus.
Stimulation of sialidase activity during cell differentiation of human promyelocytic leukemia cell line HL-60.
The presence of anti-leukoblast antibodies as complement fixation agents in leukemia patients imm-nized with leukoblats treated with neuraminidase and radiation.
[Establishing a high-titer infectious avian influenza A (H5N1) pseudotyped viral particle].
[Evaluation of leukemogenic and immunogenic properties of leukemic cells modified by neuraminidase of non-cholera Vibrios on the model of Rauscher leukemia]
[Inhibiting effect of cholera vibrio neuraminidase in Rauscher mouse leukemia]
[Inhibitory effect of combined administration of neuraminidase and interferon in mice with Rauscher leukemia]
[Mechanism of the modifying effect of neuraminidase of the influenza virus on the development of Rauscher leukemia]
Leukemia L1210
Cationic anticancer drugs and their modes of action.
Immunogenicity of leukemia L1210 cells after neuraminidase treatment.
Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.
Leukemia, Erythroblastic, Acute
A novel series of anti-human glycophorin A (CD235a) antibodies defining five extra- and intracellular epitopes.
Biogenesis of glycophorin A in K562 human erythroleukemia cells.
Evidence for sialidase activity in K 562 cells: inhibition by adriamycin treatment.
Monoclonal antibodies recognizing normal and retrovirus-transformed chicken hematopoietic cells.
Synthesis of sialoglycoconjugates during dimethylsulfoxide-induced erythrodifferentiation of friend leukemia cells.
Transport of surface mannose 6-phosphate receptor to the Golgi complex in cultured human cells.
Tunicamycin modulates binding of 125I-erythropoietin to Friend erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia.
Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
Sodium periodate stimulation of normal and chronic lymphocytic leukemia lymphocytes. II. The use of neuraminidase and trypsin to probe the nature of the response.
Leukemia, Lymphoid
Glomerular antigens in severe hereditary nephrosis.
Leukemia, Megakaryoblastic, Acute
Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regeneration of membrane sialic acid after neuraminidase treatment of leukemic granulocytes.
Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3.
Leukemia, Myeloid
FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis(x) hapten.
Monoclonal antibodies to carbohydrate antigens in autologous bone marrow transplantation.
Leukemia, Myeloid, Acute
Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies.
Detection of the granulocyte-specific antigen 3-fucosyl-N-acetyl-lactosamine on leukemic cells after neuraminidase treatment.
Monoclonal antibodies to carbohydrate antigens in autologous bone marrow transplantation.
Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris.
Leukemia, T-Cell
Neuraminidase enhances the initial steps of human T-cell leukemia virus type 1 replication.
Leukemoid Reaction
The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation.
The Sialidase NanS Enhances Non-TcsL Mediated Cytotoxicity of Clostridium sordellii.
Leukostasis
Recruitment of murine neutrophils in vivo through endogenous sialidase activity.
Lipidoses
A new form of ovine GM1-gangliosidosis.
Liver Abscess
Entamoeba histolytica: identification of a major surface antigen in liver abscess pus using a monoclonal antibody.
Liver Cirrhosis
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
Co-expression of X-hapten-like antigen and antigen YH206 on mucin molecules.
Intestinal variant alkaline phosphatase in plasma in disease.
[Hemostatic studies on acquired abnormal fibrinogenemia in severe liver diseases and umbilical cord blood]
Liver Diseases
Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase.
Effect of ethanol on sialidase activity of peripheral lymphocytes.
Neuraminidase activity in human peripheral lymphocytes: its increase in chronic active liver disease.
[Structure and properties of neuraminidase originating from various sources]
Liver Diseases, Alcoholic
Effect of ethanol on sialidase activity of peripheral lymphocytes.
Liver Neoplasms
Therapeutic targeting of liver cancer with a recombinant DNA vaccine containing the hemagglutinin-neuraminidase gene of Newcastle disease virus via apoptotic-dependent pathways.
Liver Neoplasms, Experimental
The impact of neuraminidase on apoptosis in cultures of blood lymphocytes isolated from rats bearing morris hepatoma.
Lung Injury
Influenza Virus Neuraminidase Engages CD83 and Promotes Pulmonary Injury.
Lung Neoplasms
An altered lectin binding to mucus glycoprotein in goblet cells of human tracheobronchial epithelium among former mustard-gas workers.
Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.
Expression of CD44 variants in lung cancer and its relationship to hyaluronan binding.
Isolation of small cell lung cancer-associated antigen from human brain.
Monoclonal antibody that distinguishes small-cell lung cancer from non-small-cell lung cancer.
Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
Noncatalytic Endosialidase Enables Surface Capture of Small-Cell Lung Cancer Cells Utilizing Strong Dendrimer-Mediated Enzyme-Glycoprotein Interactions.
P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.
Lupus Erythematosus, Systemic
Desialylation of dying cells with catalytically active antibodies possessing sialidase activity facilitates their clearance by human macrophages.
Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study.
[Immunoenzyme analysis and complement fixation test used for detection of antibodies to neuraminidase in patients with systemic lupus erythematosus]
Lupus Nephritis
Expression of sialidase and dystroglycan in human glomerular diseases.
Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice.
The role of neuraminidase 1 (NEU1) in cytokine release by primary mouse mesangial cells and disease outcomes in murine lupus nephritis.
Lymphatic Metastasis
Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion.
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Lymphocytosis
Elevated Expression of NEU1 Sialidase in Idiopathic Pulmonary Fibrosis Provokes Pulmonary Collagen Deposition, Lymphocytosis, and Fibrosis.
Lymphogranuloma Venereum
Effect of polycations, polyanions and neuraminidase on the infectivity of trachoma-inclusin conjunctivitis and lymphogranuloma venereum organisms HeLa cells: sialic acid residues as possible receptors for trachoma-inclusion conjunction.
Lymphoma
Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction.
Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma.
Cell surface sialic acid influences tumor cell recognition in the mixed lymphocyte reaction.
Combination of cytokine-induced killer and dendritic cells pulsed with antigenic ?-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.
Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: Regulatory roles of cell surface glycans.
Glycosidases from the interferon producing lymphoid cell line Namalva and from three other lymphoid cell lines.
Inhibition of human anti-Gd cold agglutinins by sialyllactose.
Modification of blood-borne arrest properties of lymphoma cells by inhibitors of protein glycosylation suggests the existence of endogenous lectins.
Neuraminidase "unmasking" and failure of trypsin to "unmask" -D-galactose-like sites on erythrocyte, lymphoma, and normal and virus-transformed fibroblast cell membranes.
Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes.
Radiation-induced lymphoblastic lymphomas/leukemias and sarcomas of mice express conserved, immunogenic 44-kilodalton oncofetal antigen.
Regulatory roles of cell surface sialylation in sphingolipid-induced cell death in human B cell lymphoma.
Regulatory roles of cell surface sialylation in susceptibility to sphingomyelinase in human diffuse large B cell lymphoma.
Sialic acids linked to glycoconjugates of Fas regulate the caspase-9-dependent and mitochondria-mediated pathway of Fas-induced apoptosis in Jurkat T cell lymphoma.
Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia.
Sialylation by ?-galactoside ?-2,6-sialyltransferase and N-glycans regulate cell adhesion and invasion in human anaplastic large cell lymphoma.
The effect of specific glycosidases on Ricinus communis agglutinin binding to cell surfaces of two tumor sublines. A comparative flow-cytometric study.
[Comparative study of gangliosides from murine B- and T-lymphomas.]
[Immunogenicity of L5178Y cells modified by different reagents]
[Structure of lymphoma gangliosides in EL-4 mice]
[The morphofunctional characteristics of lymphoma NK/LY cells treated with concanavalin A and Vibrio cholerae neuraminidase]
[Transplantability and immunogenicity in mice of lymphoma Nk/Ly cells modified by concanavalin A and neuraminidase]
Lymphoma, B-Cell
Caspase-dependent drug-induced apoptosis is regulated by cell surface sialylation in human B-cell lymphoma.
Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma.
Cell surface sialic acid influences tumor cell recognition in the mixed lymphocyte reaction.
Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.
Phaseolus vulgaris leukoagglutinating lectin-binding reactivity in human diffuse large B-cell lymphoma and its relevance to the patient's clinical outcome: lectin histochemistry and lectin blot analysis.
Regulatory roles of cell surface sialylation in sphingolipid-induced cell death in human B cell lymphoma.
Regulatory roles of cell surface sialylation in susceptibility to sphingomyelinase in human diffuse large B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Caspase-dependent drug-induced apoptosis is regulated by cell surface sialylation in human B-cell lymphoma.
Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.
Phaseolus vulgaris leukoagglutinating lectin-binding reactivity in human diffuse large B-cell lymphoma and its relevance to the patient's clinical outcome: lectin histochemistry and lectin blot analysis.
Regulatory roles of cell surface sialylation in sphingolipid-induced cell death in human B cell lymphoma.
Regulatory roles of cell surface sialylation in susceptibility to sphingomyelinase in human diffuse large B cell lymphoma.
Lymphoma, Large-Cell, Anaplastic
Sialylation by ?-galactoside ?-2,6-sialyltransferase and N-glycans regulate cell adhesion and invasion in human anaplastic large cell lymphoma.
Lymphoma, Non-Hodgkin
Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
Lymphoma, T-Cell
Sialic acids linked to glycoconjugates of Fas regulate the caspase-9-dependent and mitochondria-mediated pathway of Fas-induced apoptosis in Jurkat T cell lymphoma.
Lysosomal Storage Diseases
A case of galactosialidosis with a homozygous Q49R point mutation.
A case of galactosialidosis with novel mutations of the protective protein/cathepsin a gene: diagnosis prompted by trophoblast vacuolization on placental examination.
A case of galactosialidosis.
A new heterozygous compound mutation in the CTSA gene in galactosialidosis.
A Turkish case of galactosialidosis with a new homozygous mutation in CTSA gene.
An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca2+ dynamics.
Cathepsin A deficiency in galactosialidosis: studies of patients and carriers in 16 families.
Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Chemical chaperone treatment for galactosialidosis: Effect of NOEV on ?-galactosidase activities in fibroblasts.
Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene.
Clinical presentation of congenital sialidosis in a patient with a neuraminidase gene frameshift mutation.
Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I.
Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Enhanced proteolytic degradation of normal beta-galactosidase in the lysosomal storage disease with combined beta-galactosidase and neuraminidase deficiency.
Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
Infantile sialidosis: natural history in a preterm infant with two new pathogenic mutations and new ocular findings.
Inheritance of an ovine lysosomal storage disease associated with deficiencies of beta-galactosidase and alpha-neuraminidase.
Inherited lysosomal storage disease associated with deficiencies of beta-galactosidase and alpha-neuraminidase in sheep.
Inhibition of CatA: an emerging strategy for the treatment of heart failure.
Intermittent enzyme replacement therapy prevents Neu1 deficiency.
Interspecific genetic complementation analysis of human and sheep fibroblasts with beta-galactosidase deficiency.
Isolated acid neuraminidase deficiency: a distinct lysosomal storage disease.
Lectin histochemistry of an ovine lysosomal storage disease with deficiencies of beta-galactosidase and alpha-neuraminidase.
Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation.
Molecular pathology of galactosialidosis in a patient affected with two new frameshift mutations in the cathepsin A/protective protein gene.
New mutations in two Dutch patients with early infantile galactosialidosis.
Optical coherence tomography features in a case of Type I sialidosis.
Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis.
Sialidosis presenting as severe nonimmune fetal hydrops is associated with two novel mutations in lysosomal alpha-neuraminidase.
Sialidosis type I presenting with a novel mutation and advanced neuroimaging features.
Sialidosis type I: ophthalmological findings.
The cherry red spot-myoclonus syndrome: a newly recognized inherited lysosomal storage disease due to acid neuraminidase deficiency.
Transient neonatal hyperparathyroidism: a presenting feature of sialidosis type II.
Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.
Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients.
Ultrastructural lesions of ovine GM1 gangliosidosis.
Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1- deficient mice.
[Screening methods for the diagnosis of lysosomal storage disease]
Macular Degeneration
Comparison of lectin binding of drusen, RPE, Bruch's membrane, and photoreceptors.
Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration.
Malaria
A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein.
Analysis of Erythrocyte Invasion Mechanisms of Plasmodium falciparum Clinical Isolates Across 3 Malaria-Endemic Areas in Ghana.
Applying biotin-streptavidin binding for iscom (immunostimulating complex) association of recombinant immunogens.
Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form.
Erythrocyte invasion and merozoite ligand gene expression in severe and mild Plasmodium falciparum malaria.
High titres of anti-T antibodies and other haemagglutinins in human malaria.
Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity.
Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide.
Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria.
Merozoite surface protein-1 genetic diversity in Plasmodium malariae and Plasmodium brasilianum from Brazil.
Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from Plasmodium falciparum circumsporozoite protein as antigens.
Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.
Plasmodium falciparum heterochromatin protein 1 marks genomic loci linked to phenotypic variation of exported virulence factors.
Population genomics of the immune evasion (var) genes of Plasmodium falciparum.
Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection.
Rapid antigen diversification through mitotic recombination in the human malaria parasite Plasmodium falciparum.
T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites.
The human immune response against the major merozoite surface antigen of Plasmodium falciparum.
The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area.
Malnutrition
Neonatal undernutrition and short term administration of hydrocortisone and thyroxine: effects on rat brain hydrolases.
Marek Disease
Adenovirus-mediated co-expression of the TRAIL and HN genes inhibits growth and induces apoptosis in Marek's disease tumor cell line MSB-1.
Cell-mediated immunity to tumor antigen in Marek's disease: susceptibility of effector cells to antithymocyte serum and enhancement of cytotoxic activity by Vibrio cholerae neuraminidase.
Mastocytoma
Induction of lymphocyte cytotoxicity by modification of the effector or target cells with periodate or with neuraminidase and galactose oxidase.
Some effects of neuraminidase on the in vitro interactions between spleen and mastocytoma (P815) cells.
The effect of neuraminidase on the sensitivity of tumor cells toward lysis by antibody and complement or by sensitized lymphocytes.
Measles
Bioinformatic and immunological analysis reveals lack of support for measles virus related mimicry in Crohn's disease.
Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Glycosylation of measles virus haemagglutinin protein in infected cells.
Individual N-Glycans Added at Intervals along the Stalk of the Nipah Virus G Protein Prevent Fusion but Do Not Block the Interaction with the Homologous F Protein.
Overexpression of human virus surface glycoprotein precursors induces cytosolic unfolded protein response in Saccharomyces cerevisiae.
Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
Secretion of immunoglobulins by human lymphocytes after infection with influenza virus.
Single genotype of measles virus is dominant whereas several genotypes of mumps virus are co-circulating.
The neuraminidase of measles virus.
The predicted primary structure of the measles virus hemagglutinin.
Melanoma
A correlation between cell surface sialyltransferase, sialic acid, and glycosidase activities and the implantability of B16 murine melanoma.
CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells.
Cell surface glycoproteins of human tumor cell lines: unusual characteristics of malignant melanoma.
Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
Correlation between plasminogen activator activity of immunizing tumor cells and complement-mediated cytotoxic antibodies secreted by cloned hybrid cells.
Cytotoxicity reactions during immunotherapy of melanoma with neuraminidase altered autologous tumor cells.
Demonstration of carbohydrate structures in malignant melanoma tyrosinase.
Differing lectin-binding patterns of malignant melanoma and nevocellular and Spitz nevi.
Electrophoretic heterogeneity of pigmented hamster melanoma cells.
Electrophoretic profile of tyrosinase treated with neuraminidase in various subcellular fractions from mouse melanoma.
Enzymatic susceptibility and spontaneous release of human melanoma tumor-associated antigens.
Identification of a structure on human melanoma cells recognized by CTL exhibiting anomalous killer cell function.
Inhibition of b16 melanoma metastasis by administration of g(m3)- or gg3- liposomes - blocking adhesion of melanoma-cells to endothelial-cells (antiadhesion therapy) via inhibition of g(m3)-gg3cer or g(m3)-laccer interaction.
Membrane sialidase NEU3 is highly expressed in human melanoma cells promoting cell growth with minimal changes in the composition of gangliosides.
Organization and neuraminidase susceptibility of sialic acid residues in human melanoma cell lines with different heterotransplantabilities in nude mice.
Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells.
Proceedings: Increase in antigenicity of syngeneic murine melanoma by neuraminidase.
Prolonged inhibition of protein and glycoprotein synthesis in tumor cells treated with muconomycin A.
Simultaneous silencing of lysophosphatidylcholine acyltransferases 1-4 by nucleic acid nanoparticles (NANPs) improves radiation response of melanoma cells.
The surface glycoproteins of a mouse melanoma growing in culture and as a solid tumor in vivo.
Uncoupling of chondroitin sulfate glycosaminoglycan synthesis by brefeldin A.
Melanoma, Experimental
Comparative study of sialidase activity and G(M3) content in B16 melanoma variants with different metastatic potential.
Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells.
Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA.
Memory Disorders
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Meningitis
Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein.
Effect of pneumococcal neuraminidase on canine cerebral cortex in experimental meningitis.
Experimental pneumococcal meningitis. Effects of neuraminidase and other pneumococcal constituents on cerebrospinal fluid in the intact dog.
The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease.
Meningitis, Bacterial
Neuraminidase activity in bacterial meningitis.
Purification and properties of a bacteriophage-induced endo-N-acetylneuraminidase specific for poly-alpha-2,8-sialosyl carbohydrate units.
Meningitis, Pneumococcal
A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs.
Experimental pneumococcal meningitis. Effects of neuraminidase and other pneumococcal constituents on cerebrospinal fluid in the intact dog.
Histochemical demonstration of neuraminidase effects in pneumococcal meningitis.
Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.
Meningoencephalitis
Neuraminidase activity in acanthamoeba species trophozoites and cysts.
The substantia nigra is a major target for neurovirulent influenza A virus.
Mesothelioma
Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1.
Mesothelioma, Malignant
Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Diffuse malignant peritoneal mesothelioma in a young woman with a high serum level of CA125.
Metabolic Diseases
Comparison of sialic acids excretion in spot urines and 24-hour-urines of children and adults.
[Inherited metabolic diseases caused by the genetic defect of protective protein/cathepsin A and lysosomal sialidase]
Monoclonal Gammopathy of Undetermined Significance
Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Mouth Neoplasms
"Aberrant sialylation plays a significant role in oral squamous cell carcinoma progression".
Role of aberrant glycosylation enzymes in oral cancer progression.
Salivary glyco-sialylation changes monitors oral carcinogenesis.
Mucocutaneous Lymph Node Syndrome
[Analysis of blood neuraminidase activities and free sialic acid, with special reference to the fluctuations in Kawasaki disease]
Mucolipidoses
A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine.
A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.
A point mutation in the neu-1 locus causes the neuraminidase defect in the SM/J mouse.
A sialidosis type I cohort and a quantitative approach to multimodal ophthalmic imaging of the macular cherry-red spot.
Abnormal pattern electroretinograms with macular cherry-red spots: evidence for selective ganglion cell damage.
Acidic sialidase activity is aberrant in obese and diabetic mice.
Activated sialidase activity in transformed lymphocytes by Epstein-Barr (EB) virus of sialidosis type I (cherry-red spot-myoclonus syndrome).
Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase.
Adult mucolipidosis with beta-galactosidase and neuraminidase deficiencies.
Adult type mucolipidosis with beta-galactosidase and sialidase deficiency. Histological and biochemical studies.
An activator protein of oligosaccharide sialidase.
An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca2+ dynamics.
Anesthetic management for mastectomy and total hysterectomy in a 49-year-old woman with type 1 sialidosis: a case report.
Bergmeister's papilla in a young patient with type 1 sialidosis: case report.
beta-Galactosidase deficient-type mucolipidosis: a complementation study of neuraminidase in somatic cell hybrids.
Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Biochemical study of sialidosis type I in a Russian family.
Cardiovascular involvement in alpha-n-acetyl neuraminidase deficiency syndromes (sialidosis type I and II).
Carrier detection of sialidosis with partial beta-galactosidase deficiency by the assay of lysosomal sialidase in lymphocytes.
Catalytically defective ganglioside neuraminidase in mucolipidosis IV.
Cell disease: desialylation of beta-hexosaminidase and its effect on uptake by fibroblasts.
Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis.
Characterization of the mouse lysosomal sialidase promoter.
Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex.
Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult.
Cleavage of oligosaccharides by rat kidney sialidase. Influence of substrate structure.
Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene.
Clinical Exome Sequencing Enables Congenital Sialidosis Type II Diagnosis in Two Siblings Presenting with Unreported Clinical Features from a Rare Homozygous Sequence Variant p.(Tyr370Cys) in NEU1.
Clinical presentation of congenital sialidosis in a patient with a neuraminidase gene frameshift mutation.
Clinical variability of type II sialidosis by C808T mutation.
Cloning of the cDNA and gene encoding mouse lysosomal sialidase and correction of sialidase deficiency in human sialidosis and mouse SM/J fibroblasts.
Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis.
Coincident neuraminidase and aspartoacylase deficiency associated with chromosome 9Q paracentric inversion in a Saudi family.
Comparative enzymology, biochemistry and pathophysiology of human exo-alpha-sialidases (neuraminidases).
Comparison of sialic acids excretion in spot urines and 24-hour-urines of children and adults.
Compound heterozygous mutations in the neuraminidase 1 gene in type 1 sialidosis: A case report and review of literature.
Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I.
Crystal structure of the human cytosolic sialidase Neu2. Evidence for the dynamic nature of substrate recognition.
Deficiency of methylumbelliferyl-alpha-Neuraminic acid neuraminidase in the sialidoses and mucolipidosis II and III.
Deficiency of neuraminidase in the sialidoses and the mucolipidoses.
Deficit in neuraminidase associated with mucolipidosis II (I-cell disease).
Degradation of gangliosides by the lysosomal sialidase requires an activator protein.
Diagnosis and Management of Type 1 Sialidosis: Clinical Insights from Long-Term Care of Four Unrelated Patients.
Diagnostics and Therapy of human diseases - Focus on sialidases.
Effect of the co-existence of galactosyl and phosphomannosyl residues on beta-hexosaminidase on the processing and transport of the enzyme in mucolipidosis I fibroblasts.
Effects of neuraminidase of the phenotype of sindbis virus grown in fibroblasts obtained from patients with I-cell disease.
Electrophoretic analysis of glycoprotein enzymes in the sialidoses and mucolipidoses.
Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Establishment and characterization of Neu1-knockout zebrafish and its abnormal clinical phenotypes.
Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis.
Exclusion of NEU1 and PPGB from candidate genes for a lysosomal storage disease in Japanese Black cattle
Exclusion of NEU1 and PPGB from candidate genes for a lysosomal storage disease in Japanese Black cattle.
Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression.
Fundus autofluorescence and optical coherence tomography of a macular cherry-red spot in a case report of sialidosis.
Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties.
Ganglioside sialidase distribution in mucolipidosis type IV cultured fibroblasts.
Generation of human induced pluripotent stem cells (hIPSCs) from sialidosis types I and II patients with pathogenic neuraminidase 1 mutations.
Generation of novel induced pluripotent stem cell (iPSC) line from a 16-year-old sialidosis patient with NEU-1 gene mutation.
Genetic heterogeneity in human neuraminidase deficiency.
Human beta-galactosidase and alpha-neuraminidase deficient mucolipidosis: genetic complementation analysis of the neuraminidase deficiency.
I-cell disease. A hypothesis for the structure of the carbohydrate recognition site on beta-D-N-acetylhexosaminidase.
I-cell disease: intracellular desialylation of lysosomal enzymes using an influenza virus vector.
Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient.
Identification of a homozygous deletion of the NEU1 gene in a patient with type II sialidosis presenting isolated fetal ascites and central nervous system hypoplasia.
Increased levels of sialic acid associated with a sialidase deficiency in I-cell disease (mucolipidosis II) fibroblasts.
Increased lung surfactant phosphatidylcholine in patients affected by lysosomal storage diseases.
Infantile sialidosis: natural history in a preterm infant with two new pathogenic mutations and new ocular findings.
Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail.
Km defect in neuraminidase of dysmorphic type sialidosis with and without beta-galactosidase deficiency.
Lysosomal and plasma membrane ganglioside GM3 sialidases of cultured human fibroblasts. Differentiation by detergents and inhibitors.
Lysosomal localization of Japanese medaka (Oryzias latipes) Neu1 sialidase and its highly conserved enzymatic profiles with human.
Lysosomal multienzymatic complex-related diseases: a genetic study among Portuguese patients.
Lysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assembly.
Lysosomal sialidase deficiency in sialidosis with partial beta-galactosidase deficiency.
Lysosomal sialidase deficiency: increased ganglioside content in autopsy tissues of a sialidosis patient.
Metabolic disorders characterized by angiokeratomas and neurologic dysfunction.
Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells.
Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein.
Molecular pathology of NEU1 gene in sialidosis.
Mucolipidosis I (acid neuraminidase deficiency). Three cases and delineation of the variability of the phenotype.
Mucolipidosis I, the cherry red-spot--myoclonus syndrome and neuraminidase deficiency.
Mucolipidosis I--a sialidosis.
Mucolipidosis I: studies of sialidase activity and a prenatal diagnosis.
Mucolipidosis IV, a sialolipidosis due to ganglioside sialidase deficiency.
Mucolipidosis type IV: ganglioside sialidase deficiency.
Multimodality evoked potentials and EEG in a case of cherry red spot-myoclonus syndrome and alpha-neuraminidase deficiency (sialidosis type 1)
Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex.
Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.
Neuraminidase activities in sialidosis and mucolipidosis.
Neuraminidase activity in liver and brain from patients with I-cell disease.
Neuraminidase activity in the mucolipidoses (types I, II and III) and the cherry-red spot myoclonus syndrome.
Neuraminidase deficiency and accumulation of sialic acid in lymphocytes in adult type sialidosis with partial beta-galactosidase deficiency.
Neuraminidase deficiency in the cherry red spot-myoclonus syndrome.
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
Neuraminidase deficiency presenting as non-immune hydrops fetalis.
Neuraminidase deficiency: case report and review of the phenotype.
Neuraminidase in cultured fibroblasts and leucocytes of homozygotes and heterozygotes for the mucolipidosis II gene (I-cell disease).
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Neuraminidase studies in sialidosis.
Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.
Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes.
Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis.
Novel mutations in the neuraminidase-1 (NEU1) gene in two patients of sialidosis in India.
Oligosaccharide and ganglioside neuraminidase activities of mucolipidosis I (sialidosis) and mucolipidosis II (I-cell disease) fibroblasts.
Optical coherence tomography features in a case of Type I sialidosis.
Partial characterization and studies of fibroblast and leucocyte neuraminidase activities towards sialyloligosaccharides in adult sialidosis and mucolipidosis II and III.
Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis.
Pathological study on a severe sialidosis (alpha-neuraminidase deficiency).
Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.
Prenatal diagnosis and fetal pathology in a Turkish family harboring a novel nonsense mutation in the lysosomal alpha-N-acetyl-neuraminidase (sialidase) gene.
Prenatal diagnosis of sialidosis with combined neuraminidase and beta-galactosidase deficiency.
Radioassay method of neuraminidase towards N-acetylneuraminosyl hexasaccharides.
Short-term, high dose enzyme replacement therapy in sialidosis mice.
Sialidase in brain and fibroblasts in three patients with different types of sialidosis.
Sialidosis and galactosialidosis: chromosomal assignment of two genes associated with neuraminidase-deficiency disorders.
Sialidosis presenting as severe nonimmune fetal hydrops is associated with two novel mutations in lysosomal alpha-neuraminidase.
Sialidosis Type 1 with a Novel Mutation in the Neuraminidase-1 (NEU1) Gene.
Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobilities of some enzymes known to be glycoproteins. 1. Clinical findings.
Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobility of some enzymes known to be glycoproteins. II. Enzymes studies.
Sialidosis type 2 (acid neuraminidase deficiency): clinical and biochemical features of a further case.
Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia.
Sialidosis type I presenting with a novel mutation and advanced neuroimaging features.
Sialidosis type I: ophthalmological findings.
Sialidosis: a review of human neuraminidase deficiency.
Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder.
Sialidosis: delineation of subtypes by neuraminidase assay.
Sialidosis: the cherry-red spot--myoclonus syndrome.
Splice donor site mutation in the lysosomal neuraminidase gene causing exon skipping and complete loss of enzyme activity in a sialidosis patient.
Stimulation of GM3 ganglioside sialidase activity by an activator protein in patients with mucolipidosis IV and controls.
Studies on sialidoses: GM3 ganglioside sialidase in human leucocytes.
Studies on the sialidoses: properties of human leucocyte neuraminidases.
Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan.
Synthesis of 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid and detection of skin fibroblast neuraminidase in normal humans and in sialidosis.
The cherry red spot-myoclonus syndrome: a newly recognized inherited lysosomal storage disease due to acid neuraminidase deficiency.
The identification of lysosomal ganglioside sialidase in human cells.
The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene.
The molecular genetic bases of the progressive myoclonus epilepsies.
The structure of sialyl-glycopeptides of the O-glycosidic type, isolated from sialidosis (mucolipidosis I) urine.
The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis.
Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.
Transient neonatal hyperparathyroidism: a presenting feature of sialidosis type II.
Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A.
Two genetically different MU-NANA neuraminidases in human leucocytes.
Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.
Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview.
Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients.
Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1- deficient mice.
[A new type of sialidosis with kidney disease: nephrosialidosis. I. Clinical, radiological and nosological study]
[Anesthetic management of a boy with sialidosis]
[Genetic disorders of N-acetylneuraminic acid metabolism: sialurias and sialidoses]
[Morphological and functional alterations of ear in lysosomal neuraminidase gene deficient mouse]
[Mucolipidosis type I. Sialidosis due to alpha-2-6-neuraminidase deficiency with neurological symptoms]
[Prenatal diagnosis of sialidosis, a defect of the lysosomal enzyme neuraminidase]
[Primary neuraminidase deficiency with prenatal disclosure]
[Sialidosis due to alpha-2-6 neuraminidase deficiency: a heterogeneous group]
[Sialidosis type I. Two cases in a family]
[Studies on sialidosis and mucolipidosis. Properties of neuraminidase in cultured skin fibroblasts]
[Two siblings with adult-onset sialidosis type I (cherry-red spot-myoclonus syndrome)]
Mucopolysaccharidoses
Decreased ganglioside neuraminidase activity in fibroblasts from mucopolysaccharidosis patients. Inhibition of the activity in vitro by sulfated glycosaminoglycans and other compounds.
GM1 gangliosidosis type 2 in two siblings.
Mucopolysaccharidosis III
Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID.
Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre.
Mucopolysaccharidosis IV
An Autophagic Vacuolar Myopathy-Like Disorder Presenting as Non-Immune Hydrops in a Female Fetus.
An autophagic vacuolar myopathy-like disorder presenting as nonimmune hydrops in a female fetus.
Partial deficiency of glycoprotein neuraminidase in some patients with Morquio disease type A.
Multiple Myeloma
Antibody-mediated sialidase activity in blood serum of patients with multiple myeloma.
Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Desialylation of dying cells with catalytically active antibodies possessing sialidase activity facilitates their clearance by human macrophages.
Mumps
A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.
A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.
Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity.
Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein.
Amino acid substitution at position 464 in the haemagglutinin-neuraminidase protein of a mumps virus Urabe strain enhanced the virus growth in neuroblastoma SH-SY5Y cells.
Analysis of the fusion protein gene of the porcine rubulavirus LPMV: comparative analysis of paramyxovirus F proteins.
Antibody responses to mumps virus proteins in natural mumps infection and after vaccination with live and inactivated mumps virus vaccines.
Antigenic relationships between six genotypes of the small hydrophobic protein gene of mumps virus.
Are cases of mumps in vaccinated patients attributable to mismatches in both vaccine T-cell and B-cell epitopes? An immunoinformatic analysis.
Biological characteristics of genetic variants of Urabe AM9 mumps vaccine virus.
Complete nucleotide sequence of the hemagglutinin-neuraminidase (HN) mRNA of mumps virus and comparison of paramyxovirus HN proteins.
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein.
Disruption of the Dimer-Dimer Interaction of the Mumps Virus Attachment Protein Head Domain, Aided by an Anion Located at the Interface, Compromises Membrane Fusion Triggering.
Establishment of cell lines stably expressing mumps virus glycoproteins.
Expression of mumps virus glycoproteins in mammalian cells from cloned cDNAs: both F and HN proteins are required for cell fusion.
Functional consequences of attenuating mutations in the haemagglutinin neuraminidase, fusion and polymerase proteins of a wild-type mumps virus strain.
Functional properties and genetic relatedness of the fusion and hemagglutinin-neuraminidase proteins of a mumps virus-like bat virus.
Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine.
Genomic characterization of mumps viruses from a large-scale mumps outbreak in Arkansas, 2016.
Hemagglutinin-neuraminidase (HN) amino acid alterations in neutralization escape mutants of Kilham mumps virus.
Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.
Hemagglutinin-neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore.
Identification of amino acids involved in the sialidase activity of the mumps virus hemagglutinin-neuraminadase protein.
Identification of an amino acid that defines the fusogenicity of mumps virus.
Intracellular maturation of mumps virus hemagglutinin-neuraminidase glycoprotein: conformational changes detected with monoclonal antibodies.
Intracellular processing of mumps virus glycoproteins.
Large-Scale Expression and Purification of Mumps Virus Hemagglutinin-Neuraminidase for Structural Analyses and Glycan-Binding Assays.
Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein.
Mechanisms of temperature sensitivity of attenuated Urabe mumps virus.
Molecular characterization of two genotypes of mumps virus circulated in Korea during 1998-2001.
Mumps virus infection of the developing mouse brain--appearance of structural virus proteins demonstrated with monoclonal antibodies.
Mumps Virus Matrix, Fusion, and Nucleocapsid Proteins Cooperate for Efficient Production of Virus-Like Particles.
Neuraminidase activity and antigenicity of the egg adapted strains of mumps virus.
Novel polyvalent live vaccine against varicella-zoster and mumps virus infections.
Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain.
Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps virus Urabe vaccine strain.
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.
Overexpression of human virus surface glycoprotein precursors induces cytosolic unfolded protein response in Saccharomyces cerevisiae.
Postembedding immunocytochemical localization of paramyxovirus antigens by light and electron microscopy.
Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence.
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.
Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
Recombinant mumps viruses expressing the batMuV fusion glycoprotein are highly fusion-active and neurovirulent.
Selection of mutants of mumps virus with altered structure and pathogenicity by passage in vivo.
Selective inactivation of hemagglutinin and neuraminidase on mumps virus.
Sequence analysis of F, SH, and HN genes among mumps virus strains in Japan.
Sequence determination of the mumps virus HN gene.
Simple detection of mumps virus neuraminidase and anti-neuraminidase with the lectin neuraminidase test.
Simple differentiation method of mumps Hoshino vaccine strain from wild strains by reverse transcription loop-mediated isothermal amplification (RT-LAMP).
Simple test for detection of virus neuraminidase and antineuraminidase using lectins (lectin-neuraminidase test system).
Single amino acid changes in the mumps virus HN and L proteins are associated with neuroattenuation.
Single genotype of measles virus is dominant whereas several genotypes of mumps virus are co-circulating.
Some properties of mumps virus neuraminidase.
Structural basis for Glycan-receptor binding by mumps virus hemagglutinin-neuraminidase.
Structure-function analysis of two variants of mumps virus hemagglutinin-neuraminidase protein.
Substrate specificity of the neuraminidase of different mumps virus strains.
The reactions of monoclonal antibodies with structural proteins of mumps virus.
The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease.
Transcripts of simian virus 41 (SV41) matrix gene are exclusively dicistronic with the fusion gene which is also transcribed as a monocistron.
Variability of hemagglutinin-neuraminidase and nucleocapsid protein of vaccine and wild-type mumps virus strains.
[Epitope analysis of mumps virus proteins in a persistent cell culture infection: changes in the hemagglutinin-neuraminidase polypeptide]
[Evaluation of immunoblotting method for the detection of antibodies to mumps virus]
[Genetic characteristics on the small hydrophobic protein and hemagglutinin-neuraminidase genes of mumps virus in Yunnan province, China from 2007 to 2009.]
[The rapid detection kit based on neuraminidase activity of influenza virus]
Muscular Dystrophies
Decreased surface sialic acid content is a sensitive indicator of muscle damage.
Myocardial Infarction
Functional Metabolomics Characterizes a Key Role for
Plasma sialidase activity in acute myocardial infarction.
Serum total and lipid-bound sialic acid levels following acute myocardial infarction.
Myocarditis
Influenza A H1N1 pdm09-associated myocarditis during zanamivir therapy.
Myoclonus
Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis.
Adult type GMl-gangliosidosis: a complementation study on somatic cell hybrids.
Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult.
Electrophysiological studies of myoclonus in sialidosis type 2.
Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies.
Neuraminidase activity in the mucolipidoses (types I, II and III) and the cherry-red spot myoclonus syndrome.
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.
Sialidase (alpha-n-acetyl neuraminidase) deficiency: the enzyme defect in an adult with macular cherry-red spots and myoclonus without dementia.
[Two siblings with adult-onset sialidosis type I (cherry-red spot-myoclonus syndrome)]
Myotonic Dystrophy
Carbohydrate composition of erythrocyte membranes and glycosidase activities in serum in patients with myotonic dystrophy, limb-girdle dystrophy and congenital myotonia.
Nasopharyngeal Carcinoma
A study of glycoconjugates in nasopharyngeal carcinoma with correlation to clinical transformation.
Neoplasm Metastasis
A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas.
A successful liver metastasis model in mice with neuraminidase treated colon 26.
Altered saccharide sequences in two groups of patients with metastatic prostatic carcinoma.
Clustering of murine lung metastases reflects fractal nonuniformity in regional lung blood flow.
Comparative study of sialidase activity and G(M3) content in B16 melanoma variants with different metastatic potential.
Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4.
Defensive role of pleural mesothelial cell sialomucins in tumor metastasis.
Differences in lectin binding in tissue sections of human and murine malignant tumors and their metastases.
ELEVATION OF LIVER NEURAMINIDASE ACTIVITY IN THE TUMOR-BEARING HOST. A BIOCHEMICAL APPROACH TO THE MECHANISM OF CANCER INVASION AND METASTASIS FORMATION.
Establishment and characterization of Neu1-knockout zebrafish and its abnormal clinical phenotypes.
Inhibition of b16 melanoma metastasis by administration of g(m3)- or gg3- liposomes - blocking adhesion of melanoma-cells to endothelial-cells (antiadhesion therapy) via inhibition of g(m3)-gg3cer or g(m3)-laccer interaction.
Inhibition of liver metastases from neuraminidase-treated colon 26 cells by an anti-Thomsen-Friedenreich-specific monoclonal antibody.
LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway.
Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion.
Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells.
Prevention of experimental liver metastases by D-galactose.
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.
Role of aberrant glycosylation enzymes in oral cancer progression.
Salivary glyco-sialylation changes monitors oral carcinogenesis.
Significance of platelets in an antimetastatic activity of bacterial lipopolysaccharide.
Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA.
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Variation of leukocyte neuraminidase with Duke stage in patients with adenocarcinoma of the colon and rectum.
[Pseudomyxoma peritonei: a case with multiple metastases. Ultrastructural study and chemical analysis of the mucoid substance]
[Successful liver metastasis model with neuraminidase treated colon 26 adenocarcinoma via portal vein: preliminary report]
Neoplasms
A biotechnological tool for glycoprotein desialylation based on immobilized neuraminidase from Clostridium perfringens.
A Chemical Biology Solution to Problems with Studying Biologically Important but Unstable 9-O-Acetyl Sialic Acids.
A comparative study of peanut agglutinin and amaranthin binding to human urinary bladder tumor glycoproteins.
A correlation between cell surface sialyltransferase, sialic acid, and glycosidase activities and the implantability of B16 murine melanoma.
A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells.
A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas.
A novel method for detection of Newcastle disease virus with a fluorescent sialidase substrate.
A trial of adjuvant combination chemoimmunotherapy for stage III carcinoma of stomach.
Aberrant expression of sialidase and cancer progression.
Accessibility of plasma membrane sialoglycoconjugates of Novikoff tumor cells to exogenous neuraminidase and proteases.
Acidic sialidase activity is aberrant in obese and diabetic mice.
Action of pronase and neuraminidase on the electrophoretic mobility of erythrocytes from normal cats and those with spontaneous tumours.
Activation of host lymphocytes cultured with cancer cells treated with neuraminidase.
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.
Adenovirus-mediated co-expression of the TRAIL and HN genes inhibits growth and induces apoptosis in Marek's disease tumor cell line MSB-1.
Adverse Effects of Oseltamivir Phosphate Therapy on the Liver of LDLR-/- Mice Without Any Benefit on Atherosclerosis and Thrombosis.
Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the alpha1,2-fucosyltransferase gene.
An alteration in tumor histocompatibility induced by neuraminidase.
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
Analysis of carbohydrate composition and sialidase activity in oral secretions of patients with tumors in the upper aerodigestive tract.
Analysis of human tumor associated Thomsen-Friedenreich antigen.
Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.
Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo.
Antitumor immune response following injection of neuraminidase-treated sarcoma cells.
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity.
Approaches to effective tumor immunotherapy with cells and the enzyme neuraminidase.
Assessment of lectin binding for prognosis in endometrial carcinoma.
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China.
Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.
Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
Blocking of lymphokine activated killer (LAK) cell mediated cytotoxicity by cell-sized beads bearing tumor cell proteins.
Carbohydrate mimetics and scaffolds: sweet spots in medicinal chemistry.
Cell surface modification in the treatment of experimental cancer: neuraminidase or concanavalin A.
Cell-mediated immunity to tumor antigen in Marek's disease: susceptibility of effector cells to antithymocyte serum and enhancement of cytotoxic activity by Vibrio cholerae neuraminidase.
Cells of rhabdomyosarcoma PA-23 tumor clones with high and low metastatic potential differ by activity of lysosomal sialidase.
Cervicovaginal cytokines, sialidase activity and bacterial load in reproductive-aged women with intermediate vaginal flora.
Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
Characterization of seminoma-derived placental-like alkaline phosphatase.
Characterization of the lymphokine responsible for migration-inhibitory activity against tumor cells.
Characterization of variant gamma-glutamyl transpeptidase produced by pancreatocholangiocarcinoma cell lines in a protein-free, chemically defined medium.
CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway.
Chitinase 3-like-1 deficient donor splenocytes accentuated the pathogenesis of acute graft-versus-host diseases through regulating T cell expansion and type I inflammation.
Clinical and experimental studies on inflammatory mediators during AIDS-associated Pneumocystis carinii pneumonia.
Cloning, Expression, and Characterization of Capra hircus Golgi ?-Mannosidase II.
Combination chemoimmunotherapy for advanced gastric carcinoma.
Combination of cytokine-induced killer and dendritic cells pulsed with antigenic ?-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.
Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
Combinatorial approaches to iminosugars as glycosidase and glycosyltransferase inhibitors.
Combined immunostimulation (Propionibacterium avidum KP 40) and anticoagulation (heparin) prevents metastatic lung and liver colonization in mice.
Combined use of BCG and neuraminidase in experimental tumor immunotherapy.
Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4.
Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer.
Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions. Functional activation of Fc gamma RII by treatment with proteases or neuraminidase.
Curcumin's effects on sialic acid level and sialidase activity in Ehrlich ascites tumor bearing mice.
Cytotoxicity reactions during immunotherapy of melanoma with neuraminidase altered autologous tumor cells.
Defensive role of pleural mesothelial cell sialomucins in tumor metastasis.
Deregulation of sialidases in human normal and tumor tissues.
Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin.
Design, Synthesis, Molecular Docking, and Biological Evaluation of New Emodin Anthraquinone Derivatives as Potential Antitumor Substances.
Detection of 4-O-acetyl-N-glycolylneuraminyl lactosylceramide as one of tumor-associated antigens in human colon cancer tissues by specific antibody.
Diagnostics and Therapy of human diseases - Focus on sialidases.
Differences between the O-acetylated sialic acids of the epithelial mucins of human colonic tumors and normal controls: a correlative chemical and histochemical study.
Differences in expression of oligosaccharide determinants by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer.
Differences in lectin binding in tissue sections of human and murine malignant tumors and their metastases.
Differences in the isoelectric focusing patterns of gamma-glutamyl transpeptidase from normal and cancerous rat mammary tissue.
Differences in the peripheries of Lewis lung tumor cells growing in different sites in the mouse.
Differential expression of alpha2,6-sialyltransferase in colon tumors recognized by a monoclonal antibody.
Dimethyl sulfoxide (DMSO) increases expression of sialyl Lewis x antigen and enhances adhesion of human gastric carcinoma (NUGC4) cells to activated endothelial cells.
Distribution of mucosubstances in adenoid cystic carcinoma.
Diversity of sialidases found in the human body - A review.
Effect of enzymic removal of cell surface constituents on metastatic colonisation potential of mouse mammary tumour cells.
Effect of neuraminidase and papain treatment on lectin-induced agglutination of Novikoff tumor cells and assay of lectin receptor activity of the glycopeptides released from the cell surface by papain.
Effectiveness of neuraminidase in experimental immunotherapy of two murine pulmonary carcinomas.
Effects of neuraminidase on apoptosis of blood lymphocytes in rats with implanted Morris tumor.
ELEVATION OF LIVER NEURAMINIDASE ACTIVITY IN THE TUMOR-BEARING HOST. A BIOCHEMICAL APPROACH TO THE MECHANISM OF CANCER INVASION AND METASTASIS FORMATION.
Elicitation of anti-viral cytotoxic T lymphocytes with purified viral and H-2 antigens.
Emphasis on peanut lectin as a marker for granular cells.
Endothelial cell membrane vesicles in the study of organ preference of metastasis.
Enhancement of delayed skin hypersensitivity by neuraminidase in cancer patients.
Establishment and characterization of Neu1-knockout zebrafish and its abnormal clinical phenotypes.
Exosomes Secreted by HeLa Cells Shuttle on Their Surface the Plasma Membrane-Associated Sialidase NEU3.
Experimental cancer immunotherapy: modification of tumor cells to increase immunogenicity.
Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in E. Coli for Cancer Immunotherapy.
Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.
Factors involved in the cytotoxicity of normal guinea pig serum for cells of murine tumor TA3 sublines treated with neuraminidase.
Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas.
Failure of neuraminidase treatment to influence tumorigenicity or immunogenicity of syngeneically transplanted rat tumour cells.
Flow cytometric evaluation of Thomsen-Friedenreich antigen on transitional cell cancer using monoclonal antibody.
Functional role of platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants.
Functional studies of H-2k-like epitopes on DTIC treated and untreated L1210 (H-2d) clones.
Further studies on the effect of neuraminidase on tumor cell transplantability.
Genes that mediate breast cancer metastasis to the brain.
Glycosphingolipid expression on murine L1-fibrosarcoma cells: analysis of clonal in vivo and in vitro selected sublines with different lung colonisation potential.
GM3 and cancer.
Hepatocyte-tumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti-H-2 antibody.
Histochemistry of mucin secreting components in mucoepidermoid and adenosquamous carcinoma of the oesophagus.
Human macrophage responses to vaccine strains of influenza virus: synthesis of viral proteins, interleukin-1 beta, interleukin-6, tumour necrosis factor-alpha and interleukin-1 inhibitor.
Human sialidase as a cancer marker.
Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids.
Humoral reponse to neuraminidase-treated tumor cells.
Hyperviscosity syndrome in disseminated breast adenocarcinoma.
Identification of internally sialylated carbohydrate tumor marker candidates, including Sda/CAD antigens, by focused glycomic analyses utilizing the substrate specificity of neuraminidase.
Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium.
Immuno-therapy of methyl cholanthrene induced and spontaneous tumors in mice by use of tumor vaccine, neuraminidase and BCG.
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Immunological differential diagnosis of human brain tumours.
Immunological properties of and neuraminidase action on aminopeptidases and arylamidases in human normal and cancer tissues.
Immunoprophylaxis and therapy of grafted rat colonic carcinoma.
Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells.
Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy.
In vivo tumor cell adhesion in the pulmonary microvasculature is exclusively mediated by tumor cell - endothelial cell interaction.
Increased binding and killing of neuraminidase-galactose oxidase-treated tumor cells by normal macrophages.
Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma.
Increased sialidase activity in serum of cancer patients: Identification of sialidase and inhibitor activities in human serum.
Increased tumor immunity in mice inoculated with muconomycin A-treated B16 melanoma cells.
Increased tumorigenicity of polyploid Ehrlich variants during growth in vivo is associated with karyotypic changes.
Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus.
Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Inhibition of DNA synthesis by a small-cell lung carcinoma-derived protein.
Inhibition of growth of rat Yoshida sarcoma using a neuraminidase treated tumour vaccine.
Inhibition of tumor cell adhesion to lymph nodes by laminin-related peptide and neuraminidase.
Interaction of high or low metastatic related tumor lines with normal or lymphokine-activated syngeneic peritoneal macrophages: in vitro analysis of tumor cell binding and cytostasis.
Ionizing radiations increase the activity of the cell surface glycohydrolases and the plasma membrane ceramide content.
Isoenzyme-Selective Inhibitors of Human Neuraminidases Reveal Distinct Effects on Cell Migration.
Isolation and characterization of Rana catesbeiana lectin and demonstration of the lectin-binding glycoprotein of rodent and human tumor cell membranes.
Lectin binding and expression of blood group-related antigens in carcinoma-in-situ and invasive carcinoma of urinary bladder.
Lectin binding in murine tumour lines with different malignant characteristics. Effect of enzyme (pronase, neuraminidase) treatment on lectin labelling.
Lectin binding sites related with rat ascites hepatoma cell adhesion.
Lectin binding to human gastric adenocarcinomas and adjacent tissues.
Lectin histochemistry as a predictor of dysplasia grade in colorectal adenomas.
Lectin histochemistry of normal and neoplastic nasopharyngeal epithelium.
Lectin potentiation of BCG-contact-mediated antitumor action.
Letter: Effect of neuraminidase on tumor development and growth.
LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway.
Localization of glycoconjugates on the surfaces of pronephric tumor cells in vitro.
Low mobility T cells in the peripheral blood of cancer patients: surface modification and mobility.
Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion.
Lymphoblastic lymphoma of convoluted or acid phosphatase type-a tumor of T precursor cells.
Lymphocyte blastogenic response to autologous tumor cells pretreated with neuraminidase in patients with gastric carcinoma.
Lymphocyte neuraminidase activity in cancer patients.
Macrophage-mediated tumor cytotoxicity: role of macrophage surface sialic acid.
Management of viral infections in immunocompromised cancer patients.
Metastatic cancer cell attachment to endothelium is promoted by endothelial glycocalyx sialic acid degradation.
Metastatic sarcoma. Combined surgical and immunotherapeutic approach. Neuraminidase treated tumor cells as tumor vaccine.
Modification of sialidase levels and sialoglycoconjugate pattern during erythroid and erytroleukemic cell differentiation.
Modification of the immunologic properties of the cell surface.
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium.
Modulation of K562 cells with sodium butyrate. Association of impaired NK susceptibility with sialic acid and analysis of other parameters.
Modulation of the immunosuppressive effects of splenic macrophages in Fischer rats bearing adenocarcinoma 13762.
Molecular characteristics of the human pandemic influenza A virus (H1N1).
Monoclonal antibodies to the human mammary gland: III. Monoclonal antibody LICR-LON-M18 identifies impaired expression and excess sialylation of the I(Ma) cell-surface antigen by primary breast carcinoma cells.
MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 ?1,6-N-acetylglucosaminyltransferase and ?-galactoside ?2,3-sialyltransferase.
NEU3 sialidase strictly modulates GM3 levels in skeletal myoblasts C2C12 thus favoring their differentiation and protecting them from apoptosis.
Neuraminidase 1 regulates proliferation, apoptosis and the expression of Cadherins in mammary carcinoma cells.
Neuraminidase and concanavalin A in the experimental immunotherapy of cancer.
Neuraminidase and regression of solid tumors.
Neuraminidase and tumor immunotherapy.
Neuraminidase effect on the growth of a transplantable nickel sulfide-induced rat tumor.
Neuraminidase immunotherapy of tumors in man.
Neuraminidase induced immunospecific destruction of transplantable experimental tumors.
Neuraminidase sensitive antigenic determinants of plasma cell tumor membrane glycoproteins.
Neuraminidase treated cells and their role in cancer immunotherapy.
Neuraminidase-mediated augmentation of in vitro immune response of patients with solid tumors.
Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.
Newcastle Disease Virus Hemagglutinin Neuraminidase as a Potential Cancer Targeting Agent.
Observations on the effect of neuraminidase on the distribution of intravenously injected Walker tumor cells in rats.
On the lysosomal occurrence and the properties of the neuraminidase of rat liver and of Ehrlich ascites tumor cells.
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.
Oseltamivir-conjugated polymeric micelles prepared by RAFT living radical polymerization as a new active tumor targeting drug delivery platform.
Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells.
Overexpression of ST6GalNAcV, a ganglioside-specific alpha2,6-sialyltransferase, inhibits glioma growth in vivo.
Oxyresveratrol: Structural Modification and Evaluation of Biological Activities.
P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.
Peanut lectin: a histochemical marker for phaeochromocytomas.
Phosphatidic acid-mediated activation and translocation to the cell surface of sialidase NEU3, promoting signaling for cell migration.
Placental-like alkaline phosphatase in malignant and benign ovarian tumors.
Plasma membrane-associated sialidase as a crucial regulator of transmembrane signalling.
Plasma membrane-associated sialidase confers cancer initiation, promotion and progression.
Platelet aggregating material (PAM) of two virally-transformed tumors: SV3T3 mouse fibroblast and PW20 rat renal sarcoma. Role of cell surface sialylation.
Possible immunological action of Vibrio cholerae neuraminidase (VCN) in tumor immunotherapy.
Possible mechanism of inhibition of experimental pulmonary metastasis of mouse colon adenocarcinoma 26 sublines by a sialic acid: nucleoside conjugate.
Potentiation of epidermal growth factor-mediated oncogenic transformation by sialidase NEU3 leading to Src activation.
Precision glycocalyx editing as a strategy for cancer immunotherapy.
Prevention of experimental liver metastases by D-galactose.
Proton NMR examination of tumor cells of high or low metastatic potential.
Proximity Ligation-Based Fluorogenic Imaging Agents for Neuraminidases.
Pseudopsammoma bodies in meningotheliomatous meningioma. A histochemical and ultrastructural study.
Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine.
Recognition of a high molecular weight glycoprotein (HMW-GP) associated with rat colon cancer cells by rat monoclonal antibodies.
Regeneration of the surface glycoproteins of a transplantable mouse tumor cell after treatment with neuraminidase.
Regression of established methylcholanthrene tumors by intratumor injections of Vbrio cholerae neuraminidase.
Related glycoproteins from normal secretory and malignant breast cells. Purification and initial comparative characterizations.
Role of plasma-membrane-bound sialidase NEU3 in clathrin-mediated endocytosis.
Roles of plasma membrane-associated sialidase NEU3 in human cancers.
Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia.
Sequential combination chemoimmunotherapy for various malignant tumors: clinical and laboratory results.
Sialic acid metabolism in rats undergoing chemically-induced mammary gland carcinogenesis in specific dietary states.
Sialidase activity in mouse neuroblastoma cell lines.
Sialidase and malignancy: a minireview.
Sialidase of Glaesserella parasuis Augments Inflammatory Response via Desialylation and Abrogation of Negative Regulation of Siglec-5.
Sialidase significance for cancer progression.
Sialoglycoconjugates in primary and recurrent mixed tumors of lacrimal glands.
Sialyl Lewisx-dependent binding of human monocyte-derived dendritic cells to selectins.
Sialyl ligands facilitate lymphocyte accumulation during inflammation of the central nervous system.
Sialylatin of glycoproteins of murine mammary tumor virus, murine leukemia virus, and Mason-Pfizer monkey virus.
Sialylation facilitates self-assembly of 3D multicellular prostaspheres by using cyclo-RGDfK(TPP) peptide.
Sialylation of 3-Methylcholanthrene-Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting.
Sialylation: an Avenue to Target Cancer Cells.
Significance of glycosylation patterns of rat Zajdela ascitic hepatocellular carcinoma: effect of enzymatic removal of surface sialic acid on humoral response.
Significance of platelets in an antimetastatic activity of bacterial lipopolysaccharide.
Specific immunoprophylaxis in experimental tumour-host systems.
Specific lysis of human colon tumor cells by antibodies to CEA and isoantigen A: dependence on rabbit serum or neuraminidase.
Specific modifications of hepatoma cell-surface glycoproteins with enzymes. Effects on in vitro growth as investigated by the use of lectins.
Specificity of macrophage mediated cytotoxicity: role of target cell sialic acid.
Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines.
Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase.
Systematic analysis of the human tumor cell binding to human vs. murine E- and P-selectin under static vs. dynamic conditions.
T-antigen. A prognostic indicator of high recurrence index in transitional carcinoma of the bladder.
Targeting polysialic acid-abundant cancers using oncolytic adenoviruses with fibers fused to active bacteriophage borne endosialidase.
The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.
The binding of peroxidase-labelled lectins to human breast epithelium. IV--The reactivity of breast carcinomas to peanut, soy bean and Dolichos biflorus agglutinins.
The carbohydrate on human chorionic gonadotropin produced by cancer cells.
The combined effect of radiotherapy and neuraminidase-treated tumor cells on 3-methylcholanthrene-induced fibrosarcoma.
The comparison of different rosette assay systems for the determination of T-lymphocytes in patients with solid malignant tumors.
The effect of neuraminidase on the immunogenicity of the Landschütz ascites tumour: site and mode of action.
The effect of neuraminidase on the sensitivity of tumor cells toward lysis by antibody and complement or by sensitized lymphocytes.
The effect of trypsin and neuraminidase on the circulation and organ distribution of tumor cells.
The effects of inflammatory mediators, polyamines, antisera, neuraminidase and heparin on the cell-surface charge of BP8 tumour cells and allergised lymph-node cells.
The electrophoretic mobility of BP8 ascites tumour cells and allergized lymph-node cells after treatment with inflammatory mediators, ptomaines, polyamines, antisera and neuraminidase or heparin.
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
The immunotherapy of advanced human cancer with neuraminidase.
The impact of neuraminidase on apoptosis in cultures of blood lymphocytes isolated from rats bearing morris hepatoma.
The in vitro growth, heterotransplantation, and immunohistochemical characterization of the blastemal component of Wilms' tumor.
The influence of host immunity on the arrest of circulating cancer cells, and its modification by neuraminidase.
The modification of the growth characteristics of the Landschütz ascites tumour by neuraminidase.
The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling ?1 integrin internalization and recycling.
The Reed-Sternberg cell/lymphocyte rosette. I. Properties of rosettes formed between Hodgkin's cell lines and allogeneic lymphocytes.
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.
Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guérin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Thomsen-Friedenreich antigen in bladder cancer tissues detected by monoclonal antibody.
Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody: a possible marker of recurrence.
Thomsen-Friedenreich-related antigen in non-neoplastic ureter urothelium and transitional cell tumours of the urinary bladder. An immunohistochemical study employing the monoclonal antibody 49H.8.
Tissue and serum sialidase levels in breast cancer.
Tissue distribution, immunochemical characterization, and biosynthesis of 47D10, a tumor-associated surface glycoprotein.
Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma.
Transmembrane Peptides as Inhibitors of Protein-Protein Interactions: An Efficient Strategy to Target Cancer Cells?
Tumor necrosis factor-alpha induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic cells.
Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guérin and neuraminidase.
Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors.
Tumor therapy of neoplastic diseases with tumor cells and neuraminidase: experimental studies on chessboard vaccination in transplantation tumors.
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression.
Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase.
Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression.
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Use of the lectin from Amaranthus caudatus as a histochemical probe of proliferating colonic epithelial cells.
Variation of leukocyte neuraminidase with Duke stage in patients with adenocarcinoma of the colon and rectum.
Vase mini-exon usage by NCAM is not restricted to tumours of neuroectodermal origin.
Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
Visualization of sialidase activity in Mammalian tissues and cancer detection with a novel fluorescent sialidase substrate.
[Action of x-rays and neuraminidase on pinocytotic activity and microtubule-microfilament system of Ehrlich ascites tumor cells in monolayer culture (author's transl)]
[Antigenicity of a chemically induced neurogenic rat sarcoma (author's transl)]
[Antitumor effect of a tumor-cell neuraminidase vaccine]
[Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene]
[Distribution of lectin-receptors in normal, dysplastic and neoplastic cervical epithelium]
[Effect of intratumoral injection of bacterial and viral neuraminidase in rats]
[Effect of neuraminidase and x-rays (2 Gy and 8 Gy) on microvilli and membrane invaginations of Ehrlich ascites tumor cells in monolayer culture]
[Effects of treatment with neuraminidase on the immunogenicity of ATPC tumor cells]
[Expression of a cloned hemagglutinin-neuraminidase gene from Newcastle disease virus in murine myeloma cells]
[Glycohistochemical analysis of apoptotic bodies in eyelid tumor]
[Immunogenicity of L5178Y cells modified by different reagents]
[Immunotherapy of cancer--status and perspectives]
[Immunotherapy of malignant growths (author's transl)]
[Interaction between vaginal micro-environment alterations and HPV16 infection in cervical intraepithelial neoplasia].
[Lectin histochemistry in the kidney and renal tumors]
[Lectin histochemistry of choroidal malignant melanoma]
[Lymphocyte cytotoxicity against autologous tumor cells and the effect of interferon-beta on their activities. (1) Evaluation by modification of target tumor cells]
[MODIFICATIONS INDUCED BY NEURAMINIDASE ON THE ALPHA-1 GLYCOPROTEIN ISOLATED FROM YOSHIDA ACITES TUMOR.]
[Modulating effect of immunotherapy with modified tumor cells in transplantable lymphoma]
[Multidimensional Analysis of Hippocampal Excitatory Neurotransmission and Development of Analytical Tools for Glycans].
[Peanut lectin-binding sites in gastric carcinoma and the adjacent mucosa]
[Problems of cancer immunotherapy (author's transl)]
[Sensitivity of human glial tumor cells of different grade of anaplasia to lysis due to natural killers depending on some characteristics of the glycoprotein structure of tumor cell membranes]
[Studies on charge heterogeneity of arylsulfatase A from human lung cancer]
[Studies on platelet aggregation induced by human cultured carcinoma cell lines]
[The effect of vibrio-cholerae neuraminidase (VCN) on the NK activity of peripheral blood lymphocytes in patients with cancer]
[Use of the enzyme neuraminidase for immunotherapeutic treatment of chemically induced carcinogenesis]
Nephritis
Extracellular neuraminidase production of streptococci associated with acute nephritis.
Histological evidence of neuraminidase involvement in acute nephritis: desialized leukocytes infiltrate the kidney in acute post-streptococcal glomerulonephritis.
Neuraminidase activity and free sialic acid levels in the serum of patients with acute poststreptococcal glomerulonephritis.
Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis.
The role of neuraminidase in TLR4-MAPK signalling and the release of cytokines by lupus serum-stimulated mesangial cells.
Nephrosis
Altered glomerular permeability as a result of focal detachment of the visceral epithelium.
The prolonged thrombin time of nephrotic syndrome.
Nephrotic Syndrome
Effects of the aminonucleoside of puromycin on glomerular epithelial cells in vitro.
Renal neuraminidase. Characterization in normal rat kidney and measurement in experimentally induced nephrotic syndrome.
Nervous System Diseases
Molecular characterization of the hemagglutinin-neuraminidase gene of porcine rubulavirus isolates associated with neurological disorders in fattening and adult pigs.
Molecular heterogeneity in human beta-galactosidase and neuraminidase deficiency.
Nesidioblastosis
Peanut lectin binding sites in human foetal and neonatal pancreas.
Neurilemmoma
Lectin histochemistry of normal and neoplastic peripheral nerve sheath. 2. Lectin binding patterns of schwannoma and neurofibroma.
Neuroblastoma
Activation of acetyl- and butyrylcholinesterase by enzymatic removal of sialic acid from intact neuroblastoma and astroblastoma cells in culture.
Amino acid substitution at position 464 in the haemagglutinin-neuraminidase protein of a mumps virus Urabe strain enhanced the virus growth in neuroblastoma SH-SY5Y cells.
Biosynthesis and localization of gangliosides in cultured cells.
Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines.
Density-dependent changes in gangliosides and sialidase activity of murine neuroblastoma cells.
Desialylation of extracellular GD1a-neoganglioprotein suggests cell surface orientation of the plasma membrane-bound ganglioside sialidase activity in human neuroblastoma cells.
Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin.
Differential functional relevance of a plasma membrane ganglioside sialidase in cholinergic and adrenergic neuroblastoma cell lines.
Effects of cell surface ganglioside sialidase inhibition on growth control and differentiation of human neuroblastoma cells.
Effects of GM1 and 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (NeuAc2en) on neuroblastoma (Neuro 2a) and human glioma cells (U1242 MG).
Expression of the cluster 1 antigen (neural cell adhesion molecule) in neuroectodermal tumours.
Fluorescent cytochemical detection of sialidase activity using 5-bromo-4-chloroindol-3-yl-alpha- D- N-acetylneuraminic acid as the substrate.
Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture.
Glycan Chains of Gangliosides: Functional Ligands for Tissue Lectins (Siglecs/Galectins).
Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells.
Hydroxyl free radicals induce cell differentiation in SK-N-MC neuroblastoma cells.
Induced and spontaneous neuritogenesis are associated with enhanced expression of ganglioside GM1 in the nuclear membrane.
Induction of axonal differentiation by silencing plasma membrane-associated sialidase Neu3 in neuroblastoma cells.
Ionizing radiations increase the activity of the cell surface glycohydrolases and the plasma membrane ceramide content.
Modulation of neuritogenesis by ganglioside-specific sialidase (Neu 3) in human neuroblastoma NB-1 cells.
Molecular cloning and biochemical characterization of two novel Neu3 sialidases, neu3a and neu3b, from medaka (Oryzias latipes).
Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3.
NEU4L sialidase overexpression promotes ?-catenin signaling in neuroblastoma cells, enhancing stem-like malignant cell growth.
Oseltamivir Blocks Human Neuronal Nicotinic Acetylcholine Receptor-Mediated Currents.
P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.
Peanut lectin: a histochemical marker for phaeochromocytomas.
Role of plasma membrane ganglioside sialidase of human neuroblastoma cells in growth control and differentiation.
Selective ganglioside desialylation in the plasma membrane of human neuroblastoma cells.
Sialidase activity in mouse neuroblastoma cell lines.
Sialidase NEU4 is involved in glioblastoma stem cell survival.
Stimulation of neurite outgrowth in neuroblastoma cells by neuraminidase: putative role of GM1 ganglioside in differentiation.
Structural and functional characteristics of insulin receptors in rat neuroblastoma cells.
The plasma membrane ganglioside sialidase cofractionates with markers of lipid rafts.
[Surface charge of mouse neuroblastoma cells and changes during growth and morphologic differentiation of the cell population]
Neurofibroma
Lectin histochemistry of normal and neoplastic peripheral nerve sheath. 2. Lectin binding patterns of schwannoma and neurofibroma.
Neuroinflammatory Diseases
Microglia activated by microbial neuraminidase contributes to ependymal cell death.
Microglial activation by microbial neuraminidase through TLR2 and TLR4 receptors.
Microglial Morphometric Parameters Correlate With the Expression Level of IL-1?, and Allow Identifying Different Activated Morphotypes.
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Neuroinflammation induced by intracerebroventricular injection of microbial neuraminidase.
SVCT2 Expression and Function in Reactive Astrocytes Is a Common Event in Different Brain Pathologies.
Nevus
Differing lectin-binding patterns of malignant melanoma and nevocellular and Spitz nevi.
HMB-45 antibody demonstrates melanosome specificity by immunoelectron microscopy.
Newcastle Disease
'a'-Position-mutated and G4-mutated hemagglutinin-neuraminidase proteins of Newcastle disease virus impair fusion and hemagglutinin-neuraminidase-fusion interaction by different mechanisms.
2?-3,4-Unsaturated sialic acid derivatives: Synthesis optimization, and biological evaluation as Newcastle disease virus hemagglutinin-neuraminidase inhibitors.
A comparison of the onset of protection induced by Newcastle disease virus strain B1 and a fowl poxvirus recombinant Newcastle disease vaccine to a viscerotropic velogenic Newcastle disease virus challenge.
A differential scanning calorimetric study of Newcastle disease virus: identification of proteins involved in thermal transitions.
A mutation in the stalk of the newcastle disease virus hemagglutinin-neuraminidase (HN) protein prevents triggering of the F protein despite allowing efficient HN-F complex formation.
A novel chimeric oncolytic virus vector for improved safety and efficacy in hepatocellular carcinoma.
A novel method for detection of Newcastle disease virus with a fluorescent sialidase substrate.
A possible approach to enrich cDNA yields with full-length molecules.
A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV.
A single amino acid substitution in the haemagglutinin-neuraminidase protein of Newcastle disease virus results in increased fusion promotion and decreased neuraminidase activities without changes in virus pathotype.
A single amino acid substitution in the hemagglutinin-neuraminidase of Newcastle disease virus results in a protein deficient in both functions.
A temperature-sensitive mutant of Newcastle disease virus which is affected in both haemagglutinin-neuraminidase and matrix proteins.
A Y526Q mutation in the Newcastle disease virus HN protein reduces its functional activities and attenuates virus replication and pathogenicity.
Aberrant membrane insertion of a cytoplasmic tail deletion mutant of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.
Abnormal surface expression of sialoglycans on B lymphocyte cell lines from patients with carbohydrate deficient glycoprotein syndrome I A (CDGS I A).
Accidental persistent infection of cell lines by Newcastle disease virus, showing three unusual features--defective neuraminidase, temperature sensitivity and intranuclear inclusions.
Action of ortho- and paramyxovirus neuraminidase on gangliosides. Hydrolysis of ganglioside GM1 by Sendai virus neuraminidase.
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.
Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction.
Agglutination-separation reactions of red blood cells sensitized with Newcastle disease virus: quantities, agglutination characteristics, and serology of altered virus and HN spikes released following neuraminidase reactivation.
Alpha-2,6-sialylation of L-PHA reactive oligosaccharides and expression of N-acetylglucosaminyltransferase V in human diffuse large B cell lymphoma.
Amino acid esters substituted phosphorylated emtricitabine and didanosine derivatives as antiviral and anticancer agents.
Amino acid substitutions in a conserved region in the stalk of the Newcastle disease virus HN glycoprotein spike impair its neuraminidase activity in the globular domain.
Amino acid substitutions in the F-specific domain in the stalk of the newcastle disease virus HN protein modulate fusion and interfere with its interaction with the F protein.
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
Analysis of synonymous codon usage in Newcastle disease virus hemagglutinin-neuraminidase (HN) gene and fusion protein (F) gene.
Analysis of the protective effect of the haemagglutinin-neuraminidase protein in Newcastle disease virus infection.
Anomalous behaviour of Newcastle disease virus haemagglutinin-neuraminidase protein in Western blotting analysis of monoclonal antibody binding sites.
Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo.
Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV into chickens in the presence of antibody to NDV or FPV.
Antigenic validation of recombinant hemagglutinin-neuraminidase protein of Newcastle disease virus expressed in Saccharomyces cerevisiae.
Antitumor effect of the Newcastle disease viral hemagglutinin-neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells.
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity.
Antiviral action of interferon-beta on Newcastle disease virus: selectivity to the hemagglutinin-neuraminidase gene expression.
Attenuate Newcastle disease virus by codon modification of the glycoproteins and phosphoprotein genes.
Avian adeno-associated virus-based expression of Newcastle disease virus hemagglutinin-neuraminidase protein for poultry vaccination.
Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
Avian paramyoxvirus-8 immunization reduces viral shedding after homologous APMV-8 challenge but fails to protect against Newcastle disease.
Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.
Biological activities of monoclonal antibodies to the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus.
Biological consequences of neuraminidase deficiency in Newcastle disease virus.
Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein.
Biosynthesis of the O-glycosidically linked oligosaccharide chains of fetuin. Indications for an alpha-N-acetylgalactosaminide alpha 2 leads to 6 sialyltransferase with a narrow acceptor specificity in fetal calf liver.
Biosynthesis of Vicia graminea lectin- and Vicia unijuga lectin-binding glycoproteins in human tumor and nontumor cells and an estimation of its epitope structure.
Cells persistently infected with Newcastle disease virus. 3. Thermal stability of hemagglutinin and neuraminidase of a mutant isolated from persistently infected L cells.
Characterization of a carbohydrate epitope defined by the monoclonal antibody H185: sialic acid O-acetylation on epithelial cell-surface mucins.
Characterization of Newcastle disease virus envelope glycoproteins expressed in insect cells.
Characterization of Newcastle disease virus vaccines by biological properties and sequence analysis of the hemagglutinin-neuraminidase protein gene.
Characterization of terminal NeuNAcalpha2-3Galbeta1-4GlcNAc sequence in lipooligosaccharides of Neisseria meningitidis.
Chicken galectin-1B inhibits Newcastle disease virus adsorption and replication through binding to hemagglutinin-neuraminidase (HN) glycoprotein.
Chimeric Newcastle disease virus nucleocapsid with parts of viral hemagglutinin-neuraminidase and fusion proteins.
Chimeric Newcastle disease virus-vectored vaccine protects chickens against H9N2 avian influenza virus in the presence of pre-existing NDV immunity.
Cloning and expression of NDV hemagglutinin-neuraminidase cDNA in a baculovirus expression vector system.
Cloning and nucleotide sequence of Newcastle disease virus hemagglutinin-neuraminidase mRNA: identification of a putative sialic acid binding site.
Cloning of a novel alpha 2,3-sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups.
Co-expression of the Hemagglutinin and Neuraminidase by Heterologous Newcastle Disease Virus Vectors Protected Chickens against H5 Clade 2.3.4.4 HPAI Viruses.
Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens.
Comparative analysis of sialidase protein in velogenic and lentogenic strains of Newcastle disease virus.
Comparative characteristics of the Israeli Newcastle disease virus field strains by means of a wide panel of monoclonal antibodies against hemagglutinin-neuraminidase glycoprotein.
Conformationally sensitive antigenic determinants on the HN glycoprotein of Newcastle disease virus form with different kinetics.
Construction and expression of a single-chain variable fragment antibody against chicken DEC 205 for targeting the bacterial expressed hemagglutinin-neuraminidase of Newcastle disease virus.
Construction of a camelid VHH yeast two-hybrid library and the selection of VHH against haemagglutinin-neuraminidase protein of the Newcastle disease virus.
Construction of Recombinant Marek's Disease Virus (rMDV) Co-Expressing AIV-H9N2-NA and NDV-F Genes under Control of MDV's Own Bi-Directional Promoter.
Contribution of HN protein length diversity to Newcastle disease virus virulence, replication and biological activities.
Crystallization of Newcastle disease virus hemagglutinin-neuraminidase glycoprotein.
Decreased dependence on receptor recognition for the fusion promotion activity of L289A-mutated newcastle disease virus fusion protein correlates with a monoclonal antibody-detected conformational change.
Deduced amino acid sequences surrounding the fusion glycoprotein cleavage site and of the carboxyl-terminus of haemagglutinin-neuraminidase protein of the avirulent thermostable vaccine strain I-2 of Newcastle disease virus.
Detection and differentiation of four poultry diseases using asymmetric reverse transcription polymerase chain reaction in combination with oligonucleotide microarrays.
Determination of the disulfide bond arrangement of Newcastle disease virus hemagglutinin neuraminidase. Correlation with a beta-sheet propeller structural fold predicted for paramyxoviridae attachment proteins.
Development of a candidate vaccine for Newcastle disease virus by epitope display in the Cucumber mosaic virus capsid protein.
Different Origins of Newcastle Disease Virus Hemagglutinin-Neuraminidase Protein Modulate the Replication Efficiency and Pathogenicity of the Virus.
Differential action of Aspergillus glycosidases on the hemagglutinating and neuraminidase activities of influenza and Newcastle disease viruses.
Disulfide bond formation is a determinant of glycosylation site usage in the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.
Dynamic properties of Newcastle Disease Virus envelope and their relations with viral hemagglutinin-neuraminidase membrane glycoprotein.
E. coli expression and immunological assessment of expressed recombinant Newcastle disease virus hemagglutinin-neuraminidase protein in chickens.
Effect of inhibitors of proteases and glycosidases on functional lability of newly synthesized hemagglutinin-neuraminidase glycoprotein in avirulent NDV strain-infected cells.
Effects of the HN gene C-terminal extensions on the Newcastle disease virus virulence.
Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge.
Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants.
Engineered intermonomeric disulfide bonds in the globular domain of Newcastle disease virus hemagglutinin-neuraminidase protein: implications for the mechanism of fusion promotion.
Enhanced Reliability of Avian Influenza Virus (AIV) and Newcastle Disease Virus (NDV) Identification Using Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry (MALDI-MS).
Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa.
Estimation of Newcastle disease virus concentration by using a sandwich ELISA and measuring neuraminidase activity.
Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone.
Evaluation of the hemagglutination-inhibition assay using a baculovirus-expressed hemagglutinin-neuraminidase protein for detection of Newcastle disease virus antibodies.
Exoglycosidase purity and linkage specificity: assessment using oligosaccharide substrates and high-pH anion-exchange chromatography with pulsed amperometric detection.
Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in E. Coli for Cancer Immunotherapy.
Expression of a secreted version of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: its evaluation as a diagnostic reagent.
Expression of Hemagglutinin-Neuraminidase glycoprotein of Newcastle Disease Virus in agroinfiltrated Nicotiana benthamiana plants.
Flexibility of the head-stalk linker domain of paramyxovirus HN glycoprotein is essential for triggering virus fusion.
Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle disease virus: monoclonal antibodies to some sites prevent viral attachment.
Further characterization of the interaction between L-selectin and its endothelial ligands.
Fusion deficiency induced by mutations at the dimer interface in the Newcastle disease virus hemagglutinin-neuraminidase is due to a temperature-dependent defect in receptor binding.
Fusion mutants of Newcastle disease virus selected with monoclonal antibodies to the hemagglutinin-neuraminidase.
Fusogenic activity of reconstituted newcastle disease virus envelopes: a role for the hemagglutinin-neuraminidase protein in the fusion process.
Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals.
Glycosylation within an antigenic site on the HN glycoprotein of Newcastle disease virus interferes with its role in the promotion of membrane fusion.
GMP-140 binds to a glycoprotein receptor on human neutrophils: evidence for a lectin-like interaction.
Heat inactivation of the neuraminidase and haemagglutinin estimated in the agglutination-separation reactions using red blood cells sensitized with Newcastle disease virus.
Hemagglutinin-neuraminidase and fusion proteins of virulent Newcastle disease virus cooperatively disturb fusion-fission homeostasis to enhance mitochondrial function by activating the unfolded protein response of endoplasmic reticulum and mitochondrial stress.
Hemagglutinin-neuraminidase Sequence and Phylogenetic Analysis of Two Newcastle Disease Virus Isolated from Chickens in Iran.
High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules.
HN gene C-terminal extension of Newcastle disease virus is not the determinant of the enteric tropism.
HN Protein of Newcastle Disease Virus Induces Apoptosis Through SAPK/JNK Pathway.
HN protein of Newcastle disease virus sensitizes HeLa cells to TNF-?-induced apoptosis by downregulating NF-?B expression.
Identification and characterization of the Sda beta 1,4,N-acetylgalactosaminyltransferase from pig large intestine.
Identification of a potential neutralizing linear epitope of hemagglutinin-neuraminidase in Newcastle disease virus.
Identification of a variable epitope on the Newcastle disease virus hemagglutinin-neuraminidase protein.
Identification of amino acid residues important to the neuraminidase activity of the HN glycoprotein of Newcastle disease virus.
Identification of novel E347Q and G362K amino acid substitutions in HN neutralization epitope and major antigenic difference in novel sub-genotype VIIj isolates.
Identification of the amino acids residues involved in hemagglutinin-neuraminidase of Newcastle disease virus binding to sulfated Chuanmingshen violaceum polysaccharides.
Immunogenic properties of recombinant ectodomain of Newcastle disease virus hemagglutinin-neuraminidase protein expressed in Escherichia coli.
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.
Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes.
In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.
Increase in the Neuraminidase Activity of a Nonpathogenic Newcastle Disease Virus Isolate during Passaging in Chickens.
Individual N-Glycans Added at Intervals along the Stalk of the Nipah Virus G Protein Prevent Fusion but Do Not Block the Interaction with the Homologous F Protein.
Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240.
Induction of Immune Response in Animal Model Using Recombinant Anti-NDV Vaccine.
Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus.
Influence of insertion site of the avian influenza virus haemagglutinin (HA) gene within the Newcastle disease virus genome on HA expression.
Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites.
Integration of membrane proteins into the endoplasmic reticulum requires GTP.
Intracellular processing of the vesicular stomatitis virus glycoprotein and the Newcastle disease virus hemagglutinin-neuraminidase glycoprotein.
Intracellular synthesis of myxovirus neuraminidase in chick embryo cell monolayer culture. I. Neuraminidase activity, hemagglutinin synthesis, and content of cellbound sialic acid in Newcastle disease virus-infected cells.
Ionic dependence of the sialidase activity of hemagglutinin-neuraminidase glycoprotein in Newcastle disease virus membrane.
Isolation and characterization of defective interfering particle of Newcastle disease virus.
Killing Effects of IFN R-/- Mouse NK Cells Activated by HN Protein of NDV on Mouse Hepatoma Cells and Possible Mechanism with Syk and NF-?B.
Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus.
Mapping of three antigenic sites on the haemagglutinin-neuraminidase protein of Newcastle disease virus.
Maturation of the hemagglutinin-neuraminidase and fusion glycoproteins of two biologically distinct strains of Newcastle disease virus.
Mature, cell-associated HN protein of Newcastle disease virus exists in two forms differentiated by posttranslational modifications.
Membrane glycoproteins of Newcastle disease virus: nucleotide sequence of the hemagglutinin-neuraminidase cloned gene and structure/function relationship of predicted amino acid sequence.
Methanolic soluble fractions of lingzhi or reishi medicinal mushroom, Ganoderma lucidum (higher Basidiomycetes) extract inhibit neuraminidase activity in Newcastle disease virus (LaSota).
Modulation of the activities of HN protein of Newcastle disease virus by nonconserved cysteine residues.
Modulation of the neuraminidase activity of HN protein from Newcastle disease virus by substrate binding and conformational change: kinetic and thermal denaturation studies.
Molecular characterization of chicken-derived genotype VIId Newcastle disease virus isolates in China during 2005-2012 reveals a new length in hemagglutinin-neuraminidase.
Molecular characterization of hemagglutinin-neuraminidase fragment gene of Newcastle disease virus isolated from periodically-vaccinated farms.
Monoclonal antibodies as functional probes of the HN glycoprotein of Newcastle disease virus: antigenic separation of the hemagglutinating and neuraminidase sites.
Monoclonal antibodies identify a strain-specific epitope on the HN glycoprotein of Newcastle disease virus strain Australia-Victoria.
Monoclonal antibodies specific for the hemagglutinin-neuraminidase protein define neutralizing epitopes specific for Newcastle disease virus genotype 2.VII from Egypt.
Monoclonal antibodies to hemagglutinin-neuraminidase and fusion glycoproteins of Newcastle disease virus: relationship between glycosylation and reactivity.
Monoclonal antibody routinely used to identify avirulent strains of Newcastle disease virus binds to an epitope at the carboxy terminus of the hemagglutinin-neuraminidase protein and recognizes individual mesogenic and velogenic strains.
Mutated form of the Newcastle disease virus hemagglutinin-neuraminidase interacts with the homologous fusion protein despite deficiencies in both receptor recognition and fusion promotion.
Mutations in the Newcastle disease virus hemagglutinin-neuraminidase protein that interfere with its ability to interact with the homologous F protein in the promotion of fusion.
Neuraminidase as an enzymatic marker for detecting airborne Influenza virus and other viruses.
Neuraminidase content of strains of Newcastle disease virus which differ in virulence.
Neutralization map of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: domains recognized by monoclonal antibodies that prevent receptor recognition.
Neutralization of Newcastle disease virus by monoclonal antibodies to the hemagglutinin-neuraminidase glycoprotein: requirement for antibodies to four sites for complete neutralization.
Newcastle disease virus (NDV) vaccine based on immunization with avian cells expressing the NDV hemagglutinin-neuraminidase glycoprotein.
Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
Newcastle disease virus contains a linkage-specific glycoprotein sialidase. Application to the localization of sialic acid residues in N-linked oligosaccharides of alpha 1-acid glycoprotein.
Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.
Newcastle disease virus evolution. I. Multiple lineages defined by sequence variability of the hemagglutinin-neuraminidase gene.
Newcastle disease virus F and HN proteins contribute to its macrophage host range.
Newcastle Disease Virus Hemagglutinin Neuraminidase as a Potential Cancer Targeting Agent.
Newcastle disease virus neuraminidase primes neutrophils for stimulation by galectin-3 and formyl-Met-Leu-Phe.
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
Nucleotide and predicted amino acid sequence analysis of the fusion protein and hemagglutinin-neuraminidase protein genes among Newcastle disease virus isolates. Phylogenetic relationships among the Paramyxovirinae based on attachment glycoprotein sequences.
Nucleotide sequence and phylogenetic analysis of Newcastle disease virus isolates from recent outbreaks in Taiwan.
Nucleotide sequence of the envelope protein genes of a highly virulent, neurotropic strain of Newcastle disease virus.
Nucleotide sequence of the gene encoding the Newcastle disease virus hemagglutinin-neuraminidase protein and comparisons of paramyxovirus hemagglutinin-neuraminidase protein sequences.
Nucleotide sequence of the hemagglutinin-neuraminidase gene of Newcastle disease virus avirulent strain D26: evidence for a longer coding region with a carboxyl terminal extension as compared to virulent strains.
On the inhibition mechanism of the sialidase activity from Newcastle disease virus.
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.
Onset of protective immunity in chicks after vaccination with a recombinant herpesvirus of turkeys vaccine expressing Newcastle disease virus fusion and hemagglutinin-neuraminidase antigens.
Over-expression of mammalian sialidase NEU3 reduces Newcastle disease virus entry and propagation in COS7 cells.
Partial Antiviral Activities Detection of Chicken Mx Jointing with Neuraminidase Gene (NA) against Newcastle Disease Virus.
Pathotyping isolates of Newcastle disease virus using antipeptide antibodies to pathotype-specific regions of their fusion and hemagglutinin-neuraminidase proteins.
Positive selection in the hemagglutinin-neuraminidase gene of Newcastle disease virus and its effect on vaccine efficacy.
Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase.
Potential use of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus expressed in Rachiplusia nu larvae as an immunogen for chickens.
Preparation and diagnostic utility of a hemagglutination inhibition test antigen derived from the baculovirus-expressed hemagglutinin-neuraminidase protein gene of Newcastle disease virus.
Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle disease virus: identification of key amino acids involved in cell binding, catalysis, and fusion.
Prokaryotic recombinant hemagglutinin-neuraminidase protein enhances the humoral response and efficacy of commercial Newcastle disease vaccines in chickens.
Protection of chickens from Newcastle and Marek's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein.
Protection of chickens from Newcastle disease and infectious laryngotracheitis with a recombinant fowlpox virus co-expressing the F, HN genes of Newcastle disease virus and gB gene of infectious laryngotracheitis virus.
Protection of chickens from Newcastle disease with a recombinant baculovirus subunit vaccine expressing the fusion and hemagglutininneuraminidase proteins.
Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene.
Protective effect of individual glycoproteins of Newcastle disease virus expressed in insect cells: the fusion protein derived from an avirulent strain had lower protective efficacy.
Proteins of Newcastle disease virus envelope: interaction between the outer hemagglutinin-neuraminidase glycoprotein and the inner non-glycosylated matrix protein.
Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.
Rapid Fluorescent Detection Assay for Human Parainfluenza Viruses.
Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses.
Recombinant haemagglutinin neuraminidase antigen-based single serum dilution ELISA for rapid serological profiling of Newcastle disease virus.
Recombinant infectious bronchitis virus (IBV) H120 vaccine strain expressing the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) protects chickens against IBV and NDV challenge.
Recombinant infectious bursal disease virus expressing Newcastle disease virus (NDV) neutralizing epitope confers partial protection against virulent NDV challenge in chickens.
Recombinant Newcastle disease virus (NDV) La Sota expressing the haemagglutinin-neuraminidase protein of genotype VII NDV shows improved protection efficacy against NDV challenge.
Reducing agent-sensitive dimerization of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus correlates with the presence of cysteine at residue 123.
Regarding the specificity of Newcastle disease virus sialidase.
Regioselective transglycosylation in the synthesis of oligosaccharides: comparison of beta-galactosidases and sialidases of various origins.
Requirement for sialic acid on neutrophils in a GMP-140 (PADGEM) mediated adhesive interaction with activated platelets.
Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.
Retraction notice: Role of C596 in the C-terminal extension of the haemagglutinin-neuraminidase protein in replication and pathogenicity of a highly virulent Indonesian strain of Newcastle disease virus.
Retroviral expressed hemagglutinin-neuraminidase protein protects chickens from Newcastle disease virus induced disease.
Role of C596 in the C-terminal extension of the haemagglutinin-neuraminidase protein in replication and pathogenicity of a highly virulent Indonesian strain of Newcastle disease virus.
Role of carbohydrate processing and calnexin binding in the folding and activity of the HN protein of Newcastle disease virus.
Role of cotranslational disulfide bond formation in the folding of the hemagglutinin-neuraminidase protein of Newcastle disease virus.
Role of the cytoplasmic tail amino acid sequences of Newcastle disease virus hemagglutinin-neuraminidase protein in virion incorporation, cell fusion, and pathogenicity.
Role of the two sialic acid binding sites on the newcastle disease virus HN protein in triggering the interaction with the F protein required for the promotion of fusion.
Role of thiol/disulfide exchange in newcastle disease virus entry.
Role of untranslated regions of the hemagglutinin-neuraminidase gene in replication and pathogenicity of newcastle disease virus.
Screening and mechanistic study of key sites of the hemagglutinin-neuraminidase protein related to the virulence of Newcastle disease virus.
Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion.
Selection of unique antigenic variants of Newcastle disease virus with neutralizing monoclonal antibodies and anti-immunoglobulin.
Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model.
Sialidase, receptor-binding and fusion-promotion activities of Newcastle disease virus haemagglutinin-neuraminidase glycoprotein: a mutational and kinetic study.
Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction.
Strain-specific degradation of a viral glycoprotein in Newcastle disease virus-infected cells.
Structural analysis and functional role of the carbohydrate component of somatostatin receptors.
Structural analysis of a designed inhibitor complexed with the hemagglutinin-neuraminidase of Newcastle disease virus.
Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle disease virus hemagglutinin-neuraminidase protein: receptor recognition is dependent on neuraminidase activity.
Structural features unique to each of the three antigenic sites on the hemagglutinin-neuraminidase protein of Newcastle disease virus.
Structure and function of a membrane anchor-less form of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.
Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III.
Structure of the Newcastle disease virus hemagglutinin-neuraminidase (HN) ectodomain reveals a four-helix bundle stalk.
Structure of the ulster strain newcastle disease virus hemagglutinin-neuraminidase reveals auto-inhibitory interactions associated with low virulence.
Subunits of NDV. Hemagglutinin and neuraminidase subunits of Newcastle disease virus.
Syncytia generated by hemagglutinin-neuraminidase and fusion proteins of virulent Newcastle disease virus induce complete autophagy by activating AMPK-mTORC1-ULK1 signaling>.
Synergistic effects of adjuvants interferon-gamma and levamisole on DNA vaccination against infection with Newcastle disease virus.
T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Terminal glycosylation of bovine uroplakin III, one of the major integral-membrane glycoproteins of mammalian bladder.
The action of sialidases on substrates containing O-acetylsialic acids.
The attachment function of the Newcastle disease virus hemagglutinin-neuraminidase protein can be separated from fusion promotion by mutation.
The carboxyterminus of the hemagglutinin-neuraminidase of Newcastle disease virus is exposed at the surface of the viral envelope.
The comparative antigenic characterization of Newcastle disease virus strains isolated in Kenya and Kazakhstan.
The differences in significance of alpha 2,3Gal-linked and alpha 2,6GalNAc-linked sialic acid residues in blood group M- and N-related epitopes recognized by various monoclonal antibodies.
The fusion promotion activity of the NDV HN protein does not correlate with neuraminidase activity.
The hemagglutinin-neuraminidase (HN) gene of Newcastle disease virus strain Italien (ndv Italien): comparison with HNs of other strains and expression by a vaccinia recombinant.
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence.
The major gangliosides of human peripheral blood monocytes/macrophages: absence of ganglio series structures.
The neuraminidase of Newcastle disease virus inhibited in the elution-inhibition reaction.
The pathogenesis of Newcastle disease: A comparison of selected Newcastle disease virus wild-type strains and their infectious clones.
The regulatory roles of cell surface sialylation and N-glycans in human B cell lymphoma cell adhesion to galectin-1.
The role of individual oligosaccharide chains in the activities of the HN glycoprotein of Newcastle disease virus.
The role of the individual cysteine residues in the formation of the mature, antigenic HN protein of Newcastle disease virus.
The second receptor binding site of the globular head of the Newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion.
The site of bluetongue virus attachment to glycophorins from a number of animal erythrocytes.
The synergistic neutralization of Newcastle disease virus by two monoclonal antibodies to its haemagglutinin-neuraminidase protein.
The use of in situ hybridization and immunohistochemistry to study the pathogenesis of various Newcastle disease virus strains and recombinants in embryonated chicken eggs.
Therapeutic targeting of liver cancer with a recombinant DNA vaccine containing the hemagglutinin-neuraminidase gene of Newcastle disease virus via apoptotic-dependent pathways.
Thermal inactivation of Newcastle disease virus. I. Coupled inactivation rates of hemagglutinating and neuraminidase activities.
Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein.
Tissue-specific heterogeneity in alpha-dystroglycan sialoglycosylation. Skeletal muscle alpha-dystroglycan is a latent receptor for Vicia villosa agglutinin b4 masked by sialic acid modification.
Topological and operational delineation of antigenic sites on the HN glycoprotein of Newcastle disease virus and their structural requirements.
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25.
Transfection of the Newcastle disease virus hemagglutinin-neuraminidase gene into murine myeloma cells for induction of host-versus-tumor immune response.
Translation and membrane insertion of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.
Two single mutations in the fusion protein of Newcastle disease virus confer hemagglutinin-neuraminidase independent fusion promotion and attenuate the pathogenicity in chickens.
Use of conformationally restricted pyridinium alpha-D-N-acetylneuraminides to probe specificity in bacterial and viral sialidases.
Vaccination against Newcastle disease with a recombinant baculovirus hemagglutinin-neuraminidase subunit vaccine.
Vaccination of chickens with a recombinant fowlpox virus containing the hemagglutinin-neuraminidase gene of Newcastle disease virus under the control of the fowlpox virus thymidine kinase promoter.
Variation of a newcastle disease virus hemagglutinin-neuraminidase linear epitope.
Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.
Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein.
Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3.
[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
[Antigenic differences in the glycoproteins of the Newcastle disease virus]
[Evaluation of Newcastle disease virus with derivated hemagglutinin-neuraminidase gene of mesogenic strain]
[Expression of a cloned hemagglutinin-neuraminidase gene from Newcastle disease virus in murine myeloma cells]
[Lability of neuraminidase and hemagglutinin in cells of a primary culture of chick embryo fibroblasts infected with Newcastle disease virus]
[Restoration of the biological activity of hemagglutinin--neuraminidase in NDV with phospholipids]
[Role of intracellular proteinases and glycosidases in the degradation of the 'large glycoprotein' responsible for the neuraminidase and hemagglutinating activity of the Newcastle disease virus]
Obesity
Acidic sialidase activity is aberrant in obese and diabetic mice.
Arterial Stiffening in Western Diet-Fed Mice Is Associated with Increased Vascular Elastin, Transforming Growth Factor-?, and Plasma Neuraminidase.
Polymorphonuclear leukocytic sialic acid and sialidase activity in obesity.
Obstetric Labor, Premature
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora.
Orthomyxoviridae Infections
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Characterization of a newly emerged genetic cluster of H1N1 and H1N2 swine influenza virus in the United States.
Characterization of contemporary 2010.1 H3N2 swine influenza A viruses circulating in United States pigs.
Comparison of the pathogenesis of two genetically different H3N2 influenza A viruses in pigs.
Complete sequences of the neuraminidase genes of swine influenza viruses (H1N1) associated with the respiratory disease in pigs.
Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains.
Evolution and antigenic advancement of N2 neuraminidase of swine influenza A viruses circulating in the United States following two separate introductions from human seasonal viruses.
Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection.
Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus.
Influenza A Virus in Backyard Pigs and Poultry in Rural Cambodia.
Large outbreak of swine influenza in southern Japan caused by reassortant (H1N2) influenza viruses: its epizootic background and characterization of the causative viruses.
Locally Acquired Human Infection with Swine-Origin Influenza A(H3N2) Variant Virus, Australia, 2018.
Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza.
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
Population susceptibility to a variant swine-origin influenza virus A(H3N2) in Vietnam, 2011-2012.
Reassortant Eurasian Avian-Like Influenza A(H1N1) Virus from a Severely Ill Child, Hunan Province, China, 2015.
Reassortant Pandemic (H1N1) 2009 virus in pigs, United Kingdom.
Sialidase of swine influenza A viruses: variation of the recognition specificities for sialyl linkages and for the molecular species of sialic acid with the year of isolation.
Single-step multiplex conventional and real-time reverse transcription polymerase chain reaction assays for simultaneous detection and subtype differentiation of Influenza A virus in swine.
Studies on antigenic variations of the haemagglutinin and neuraminidase of swine influenza virus isolates.
The first Swedish H1N2 swine influenza virus isolate represents an uncommon reassortant.
The Origin of Novel Avian Influenza A (H7N9) and Mutation Dynamics for Its Human-To-Human Transmissible Capacity.
The possible origin H1N1 (Hsw1N1) virus in the swine population of Japan and antigenic analysis of the isolates.
[Origin of hemagglutinin and neuraminidase gene of swine influenza A H1N1 viruses]
[Phylogenetic analysis based on hemagglutinin and neuraminidase genes between swine influenza virus and human influenza A/H3N2 virus strains isolated in Zhejiang province]
[Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase]
Osteonecrosis
Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.
Osteosarcoma
Antitumor effect of the Newcastle disease viral hemagglutinin-neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells.
[Effect of attenuated expression of neuraminidase 3 via RNA interference on the proliferation and apoptosis of osteosarcoma MG-63 cells].
Otitis
Effect of lacto-N-neotetraose, asialoganglioside-GM1 and neuraminidase on adherence of otitis media-associated serotypes of Streptococcus pneumoniae to chinchilla tracheal epithelium.
Pneumococcal Neuraminidase A (NanA) Promotes Biofilm Formation and Synergizes with Influenza A Virus in Nasal Colonization and Middle Ear Infection.
Otitis Media
Antiviral Medications in Seasonal and Pandemic Influenza.
Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model.
Experimental alteration of chinchilla middle ear mucosae by bacterial neuraminidase.
Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model.
Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media.
Otitis Media with Effusion
Experimental alteration of chinchilla middle ear mucosae by bacterial neuraminidase.
Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model.
Neuraminidase activity in middle ear effusions.
Purification and properties of Streptococcus pneumoniae neuraminidase.
Ovarian Neoplasms
Desialylation of Atg5 by sialidase (Neu2) enhances autophagosome formation to induce anchorage-dependent cell death in ovarian cancer cells.
Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in human ovarian cancer.
Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
Factors effecting the measurement of tumor-associated MUC1 mucins in serum.
Pregnancy-associated beta 1-macroglobulin: detection on the surface of ovarian cancer cell lines.
[Multidimensional Analysis of Hippocampal Excitatory Neurotransmission and Development of Analytical Tools for Glycans].
[Ovarian cancer: treatment by specific neuraminidase]
Pancreatic Neoplasms
Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells.
Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells.
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.
Pancreatitis
[Flow cytometry detection of erythrocyte antigens and antibodies. Technical aspects and new clinical applications]
Papilloma
Assessment of cell surface glycoconjugates in normal, benign and malignant human nasal mucosa.
Immunohistochemical localization of peanut lectin binding sites on human brain tumors as determined by peroxidase-antiperoxidase technique in paraffin sections.
Papilloma, Inverted
Assessment of cell surface glycoconjugates in normal, benign and malignant human nasal mucosa.
Papillomavirus Infections
Approved Antiviral Drugs over the Past 50 Years.
Paramyxoviridae Infections
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid analogs structurally modified by thiocarbamoylalkyl groups at the C-4 position: Synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1.
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid analogues structurally modified at the C-4 position: synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1.
2beta,3beta-Difluorosialic acid derivatives structurally modified at the C-4 position: synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1.
A cell fusion-inhibiting monoclonal antibody binds to the presumed stalk domain of the human parainfluenza type 2 virus hemagglutinin-neuraminidase protein.
A fluorometric procedure for measuring the neuraminidase activity: its application to the determination of this activity in influenza and parainfluenza viruses.
A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.
A I131V Substitution in the Fusion Glycoprotein of Human Parainfluenza Virus Type 1 Enhances Syncytium Formation and Virus Growth.
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
A probable model of the inhibitory action of ceruloplasmin on the multiplication of some myxo- and paramyxoviruses.
A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3.
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.
A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
A role for caveolin 1 in assembly and budding of the paramyxovirus parainfluenza virus 5.
A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism.
A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.
A single amino acid changes enhances the fusion promotion activity of human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.
A single amino acid mutation at position 170 of human parainfluenza virus type 1 fusion glycoprotein induces obvious syncytium formation and caspase-3-dependent cell death.
Amino acid substitutions contributing to ?2,6-sialic acid linkage binding specificity of human parainfluenza virus type 3 hemagglutinin-neuraminidase.
An oligosaccharide at the C-terminus of the F-specific domain in the stalk of the human parainfluenza virus 3 hemagglutinin-neuraminidase modulates fusion.
Analysis of parainfluenza virus-5 hemagglutinin-neuraminidase protein mutants that are blocked in internalization and degradation.
Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities.
Antigenic structure, function, and evolution of the hemagglutinin-neuraminidase protein of human parainfluenza virus type 1.
Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus.
Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces.
Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).
Cell receptors for paramyxoviruses.
Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins.
Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies.
Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo.
Crystallization of biologically active hemagglutinin-neuraminidase glycoprotein dimers proteolytically cleaved from human parainfluenza virus type 1.
Crystals of hemagglutinin-neuraminidase of parainfluenza virus contain triple-stranded helices.
Delineation of four antigenic sites on a paramyxovirus glycoprotein via which monoclonal antibodies mediate distinct antiviral activities.
Detailed genetic analysis of hemagglutinin-neuraminidase glycoprotein gene in human parainfluenza virus type 1 isolates from patients with acute respiratory infection between 2002 and 2009 in Yamagata prefecture, Japan.
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.
Differences in bovine parainfluenza 3 virus variants studied by sequencing of the genes of viral envelope proteins.
Distinct hemagglutinin and neuraminidase epitopes involved in antigenic variation of recent human parainfluenza virus type 2 isolates.
Down-regulation of paramyxovirus hemagglutinin-neuraminidase glycoprotein surface expression by a mutant fusion protein containing a retention signal for the endoplasmic reticulum.
Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.
Effects of hemagglutinin-neuraminidase protein mutations on cell-cell fusion mediated by human parainfluenza type 2 virus.
Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
Effects of neuraminidase on airway reactivity in the guinea pig.
Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.
Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Exploring human parainfluenza virus type-1 hemagglutinin-neuraminidase as a target for inhibitor discovery.
Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase.
Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase.
Expression and characterization of soluble human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.
Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus.
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies.
Fixation of oligosaccharides to a surface may increase the susceptibility to human parainfluenza virus 1, 2, or 3 hemagglutinin-neuraminidase.
Flexibility of the head-stalk linker domain of paramyxovirus HN glycoprotein is essential for triggering virus fusion.
Full conversion of the hemagglutinin-neuraminidase specificity of the parainfluenza virus 5 fusion protein by replacement of 21 amino acids in its head region with those of the simian virus 41 fusion protein.
Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses.
Functional analysis of amino acids at stalk/head interface of human parainfluenza virus type 3 hemagglutinin-neuraminidase protein in the membrane fusion process.
Functional characterization of bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins expressed by adenovirus recombinants.
Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses.
Fusion activation by a headless parainfluenza virus 5 hemagglutinin-neuraminidase stalk suggests a modular mechanism for triggering.
Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II.
Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutinin-neuraminidase in membrane fusion.
Genetic variation and evolution of human parainfluenza virus type 1 hemagglutinin neuraminidase: analysis of 12 clinical isolates.
Glycosylation of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 1 affects its functional but not its antigenic properties.
Hemagglutinin-neuraminidase gene sequence-based reclassification of human parainfluenza virus 3 variants.
Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.
Hijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategy.
Homooligomerization of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 occurs before the acquisition of correct intramolecular disulfide bonds and mature immunoreactivity.
Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein.
Human parainfluenza virus 3 neuraminidase activity contributes to dendritic cell maturation.
Human parainfluenza virus infection of the airway epithelium: the viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity.
Human parainfluenza virus type 1 evolution combines cocirculation of strains and development of geographically restricted lineages.
Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant.
Human parainfluenza virus type 3: analysis of the cytoplasmic tail and transmembrane anchor of the hemagglutinin-neuraminidase protein in promoting cell fusion.
Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin.
Identification of regions on the hemagglutinin-neuraminidase protein of human parainfluenza virus type 2 important for promoting cell fusion.
Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
Infection of human airway epithelium by human and avian strains of influenza a virus.
Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based HPIV3 vaccines.
Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein.
Inhibition of human parainfluenza virus type 1 sialidase by analogs of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid.
Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites.
Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position.
Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo.
Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.
Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies.
Intracellular processing and transport of NH2-terminally truncated forms of a hemagglutinin-neuraminidase type II glycoprotein.
Live bivalent vaccine for parainfluenza and influenza virus infections.
Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.
Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry.
Mechanism of interference mediated by human parainfluenza virus type 3 infection.
Membrane fusion promoted by increasing surface densities of the paramyxovirus F and HN proteins: comparison of fusion reactions mediated by simian virus 5 F, human parainfluenza virus type 3 F, and influenza virus HA.
Molecular cloning and sequence analysis of the human parainfluenza 3 virus genes encoding the surface glycoproteins, F and HN.
Monoclonal antibodies reveal extensive antigenic differences between the hemagglutinin-neuraminidase glycoproteins of human and bovine parainfluenza 3 viruses.
Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein.
Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir).
Mutations in the HRB linker of human parainfluenza virus type 3 fusion protein reveal its importance for fusion activity.
N-glycosylation contributes to the limited cross-reactivity between hemagglutinin neuraminidase proteins of human parainfluenza virus type 4A and 4B.
N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.
Neuraminidase activity and syncytial formation in variants of parainfluenza 3 virus.
Neuraminidase activity of a bovine strain of parainfluenza 3 virus.
Neuraminidase inhibitors as antiviral agents.
Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983.
Nucleotide sequence of the coding and flanking regions of the human parainfluenza virus 3 hemagglutinin-neuraminidase gene: comparison with other paramyxoviruses.
O glycosylation of glycoprotein G of human respiratory syncytial virus is specified within the divergent ectodomain.
Outbreak of Human Parainfluenza Virus Type 1 in a Kindergarten from China, 2018.
Parainfluenza 3 virus: plaque-type variants lacking neuraminidase activity.
Parainfluenza virus surface projections: glycoproteins with haemagglutinin and neuraminidase activities.
Parainfluenza virus type 1 reduces the affinity of agonists for muscarinic receptors in guinea-pig lung and heart.
Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
Paramyxovirus fusion (F) protein and hemagglutinin-neuraminidase (HN) protein interactions: intracellular retention of F and HN does not affect transport of the homotypic HN or F protein.
Paramyxovirus mediated cell fusion requires co-expression of both the fusion and hemagglutinin-neuraminidase glycoproteins.
Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site.
Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase.
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses.
Quantitative comparison of human parainfluenza virus hemagglutinin-neuraminidase receptor binding and receptor cleavage.
Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.
Receptor specificities of human respiroviruses.
Receptor-Binding Specificity of the Human Parainfluenza Virus Type 1 Hemagglutinin-Neuraminidase Glycoprotein.
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Regions on the hemagglutinin-neuraminidase proteins of human parainfluenza virus type-1 and Sendai virus important for membrane fusion.
Relative affinity of the human parainfluenza virus type 3 hemagglutinin-neuraminidase for sialic acid correlates with virus-induced fusion activity.
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study.
Respiratory viruses predisposing to bacterial infections: role of neuraminidase.
Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response.
Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein.
Roles of conserved residues in the receptor binding sites of human parainfluenza virus type 3 HN protein.
Sequence determination of the hemagglutinin-neuraminidase (HN) gene of human parainfluenza type 2 virus and the construction of a phylogenetic tree for HN proteins of all the paramyxoviruses that are infectious to humans.
Sequence of the hemagglutinin-neuraminidase gene of human parainfluenza virus type 1.
Structural Insights into Human Parainfluenza Virus 3 Hemagglutinin-Neuraminidase Using Unsaturated 3- N-Substituted Sialic Acids as Probes.
Structural studies of the parainfluenza virus 5 hemagglutinin-neuraminidase tetramer in complex with its receptor, sialyllactose.
Structure and mutagenesis of the parainfluenza virus 5 hemagglutinin-neuraminidase stalk domain reveals a four-helix bundle and the role of the stalk in fusion promotion.
Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein.
Structure of the Parainfluenza Virus 5 (PIV5) Hemagglutinin-Neuraminidase (HN) Ectodomain.
Syncytium formation by recombinant vaccinia viruses carrying bovine parainfluenza 3 virus envelope protein genes.
Syntheses of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified by ?-acylaminoamido groups at the C-4 position using isocyanide-based four-component coupling and biological evaluation as inhibitors of human parainfluenza virus type 1.
Syntheses of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified by N-sulfonylamidino groups at the C-4 position and biological evaluation as inhibitors of human parainfluenza virus type 1.
Synthesis and evaluation of 4-O-alkylated 2-deoxy-2,3-didehydro-N-acetylneuraminic acid derivatives as inhibitors of human parainfluenza virus type-3 sialidase activity.
The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.
The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion.
The Fusion Protein Specificity of the Parainfluenza Virus Hemagglutinin-Neuraminidase Protein Is Not Solely Defined by the Primary Structure of Its Stalk Domain.
The Hemagglutinin-Neuraminidase (HN) Head Domain and the Fusion (F) Protein Stalk Domain of the Parainfluenza Viruses Affect the Specificity of the HN-F Interaction.
The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity.
The human parainfluenza virus type-1 prototypic strain contains a heat-labile hemagglutinin-neuraminidase protein.
THE NEURAMINIDASE OF PARAINFLUENZA VIRUS (TYPE 2).
The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.
The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.
Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion.
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Wheat germ cell-free system-based production of hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 for generation and characterization of monoclonal antibody.
[Inhibition of the infectivity of enveloped viruses while retaining the specific biological activity of the viral proteins]
[Prokaryotic expression of HN gene of bovine parainfluenza virus type 3 and the establishment of indirect ELISA method].
[Study on functions of N-carbohydrate chains in human parainfluenza virus type 3 hemagglutinin-neuraminidase protein].
[The rapid detection kit based on neuraminidase activity of influenza virus]
Paraproteinemias
Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Parasitemia
A bloodstream Trypanosoma congolense sialidase could be involved in anemia during experimental trypanosomiasis.
Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.
Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection.
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Parkinson Disease
Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
Parotitis
Hemagglutinin-neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore.
Pasteurella Infections
Serological response to Pasteurella multocida NanH sialidase in persistently colonized rabbits.
Periodontal Diseases
Structural Significance of the ?1K396 Residue Found in the Porphyromonas gingivalis Sialidase ?-Propeller Domain: A Computational Study with Implications for Novel Therapeutics Against Periodontal Disease.
The use of a rapid assay to detect the neuraminidase production in oral Porphyromonas spp. isolated from dogs and humans.
Periodontitis
A surface-exposed neuraminidase affects complement resistance and virulence of the oral spirochaete Treponema denticola.
Glycosidase activities in gingival crevicular fluid in subjects with adult periodontitis or gingivitis.
Structural Significance of the ?1K396 Residue Found in the Porphyromonas gingivalis Sialidase ?-Propeller Domain: A Computational Study with Implications for Novel Therapeutics Against Periodontal Disease.
The sialidase inhibitor, DANA, reduces Porphyromonas gingivalis pathogenicity and exerts anti-inflammatory effects: An in vitro and in vivo experiment.
The use of a rapid assay to detect the neuraminidase production in oral Porphyromonas spp. isolated from dogs and humans.
[Cloning and sequence analysis of a sialidase gene (siaHI) from Bacteroides forsythus ATCC 43037]
Peritonitis
Increase of plasma neuraminidase activity in experimental peritonitis.
Survey of neuraminidase production by Clostridium butyricum, Clostridium beijerinckii, and Clostridium difficile strains from clinical and nonclinical sources.
Persistent Infection
A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa.
Accidental persistent infection of cell lines by Newcastle disease virus, showing three unusual features--defective neuraminidase, temperature sensitivity and intranuclear inclusions.
Fusion properties of cells infected with human parainfluenza virus type 3: receptor requirements for viral spread and virus-mediated membrane fusion.
Investigation of T-cell responses and viral mRNA persistence in lymph nodes of pigs infected with porcine rubulavirus.
Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.
Production of the Pseudomonas aeruginosa neuraminidase is increased under hyperosmolar conditions and is regulated by genes involved in alginate expression.
Restriction of cell surface expression of Sendai virus hemagglutinin-neuraminidase glycoprotein correlates with its higher instability in persistently and standard plus defective interfering virus infected BHK-21 cells.
[Persistent influenza virus infection. Molecular genetic characteristics of ts mutants selected during persistence]
Peste-des-Petits-Ruminants
Competitive enzyme-linked immunosorbent assay based on monoclonal antibody and recombinant hemagglutinin for serosurveillance of rinderpest virus.
Cytotoxic T cell epitope in cattle from the attachment glycoproteins of rinderpest and peste des petits ruminants viruses.
Expression of biologically active Hemagglutinin-neuraminidase protein of Peste des petits ruminants virus in transgenic pigeonpea [Cajanus cajan (L) Millsp.].
Immune responses in goats to recombinant hemagglutinin-neuraminidase glycoprotein of Peste des petits ruminants virus: identification of a T cell determinant.
Immune responses to hemagglutinin-neuraminidase protein of peste des petits ruminants virus expressed in transgenic peanut plants in sheep.
Mapping of B-cell epitopic sites and delineation of functional domains on the hemagglutinin-neuraminidase protein of peste des petits ruminants virus.
The fusion protein of Peste des petits ruminants virus mediates biological fusion in the absence of hemagglutinin-neuraminidase protein.
The hemagglutinin-neuraminidase protein of peste des petits ruminants virus is biologically active when transiently expressed in mammalian cells.
Phaeohyphomycosis
Exploring the genomic diversity of black yeasts and relatives (Chaetothyriales, Ascomycota).
Picornaviridae Infections
Highlights in the development of new antiviral agents.
Plague
Cell surface sialic acid inhibits Cx43 gap junction functions in constructed Hela cancer cells involving in sialylated N-cadherin.
Conserved hydrophobic clusters on the surface of the Caf1A usher C-terminal domain are important for F1 antigen assembly.
Cytotoxic T cell lysis of target cells fused with liposomes containing influenza virus haemagglutinin and neuraminidase.
Effect of dimethylsulfoxide (DMSO) on virus replication and maturation.
[pH-dependent hemolytic and neuraminidase activity of remantadine-sensitive and -resistant variants of influenza virus]
Plasmacytoma
Neuraminidase sensitive antigenic determinants of plasma cell tumor membrane glycoproteins.
Pneumococcal Infections
Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A.
Investigating the role of pneumococcal neuraminidase A activity in isolates from pneumococcal haemolytic uraemic syndrome.
Otitis media: the chinchilla model.
Pneumococcal neuraminidase A: an essential upper airway colonization factor for Streptococcus pneumoniae.
Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.
The Ashwell receptor mitigates the lethal coagulopathy of sepsis.
The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation.
[Effects of neuraminidase in pneumococcal infections]
[Neuraminidase as pathogenic factor in pneumococcal infections]
[The virulence of Streptococcus pneumoniae strains--the causative agents of pneumococcal infection at different sites]
Pneumonia
Antiviral Medications in Seasonal and Pandemic Influenza.
Behavior of hospitalized severe influenza cases according to the outcome variable in Catalonia, Spain, during the 2017-2018 season.
DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.
DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation.
Extracellular neuraminidase production by a Pasteurella multocida A:3 strain associated with bovine pneumonia.
Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: treatment by exchange transfusion.
Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study.
Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.
Influence of age on symptoms and laboratory findings at presentation in patients with influenza-associated pneumonia.
Influenza A virus derived from persistently virus-infected cells shows attenuated cytotoxicity in cultured cells but virulent pathogenicity in mice.
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.
Intensive care management of influenza-associated pulmonary aspergillosis.
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study.
Neuraminidase production by a Pasteurella haemolytica A1 strain associated with bovine pneumonia.
Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.
Retrospective survey for sialidase activity in Mycoplasma pneumoniae isolates from cases of community-acquired pneumonia.
Streptococcus pneumoniae-induced hemolytic uremic syndrome: a case for early diagnosis.
The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.
Viral pneumonia.
Virtual Screening of compounds from Tabernaemontana divaricata for potential anti-bacterial activity.
[Assessment of the sensitivity of immunoprecipitation for the serodiagnosis of influenzal-bacterial pneumonias]
[Clinical Characteristics of Adult Onset RSV Infection During Two Consecutive Winter Seasons].
[Clinical features and outcome in 84 patients with influenza pneumonia]
[Clinical Features of Hospitalized Cases due to Influenza Virus A Infection in the 2011/2012 Season].
[Severe pneumonia with hemolysis caused by neuraminidase. Detection of cryptantigens by indirect immunofluorescent technic]
Pneumonia, Bacterial
2009 influenza A (H1N1): a clinical review.
Deletions in the Neuraminidase Stalk Region of H2N2 and H9N2 Avian Influenza Virus Subtypes Do Not Affect Postinfluenza Secondary Bacterial Pneumonia.
Influenza virus neuraminidase contributes to secondary bacterial pneumonia.
The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.
[Clinical features and outcome in 84 patients with influenza pneumonia]
Pneumonia, Necrotizing
Necrotizing pneumonia caused by nanC-carrying serotypes is associated with pneumococcal haemolytic uraemic syndrome in children.
Pneumonia, Pneumococcal
Deacetylation of sialic acid by esterases potentiates pneumococcal neuraminidase activity for mucin utilization, colonization and virulence.
Pneumonia, Viral
Efficacy of a Cap-Dependent Endonuclease Inhibitor and Neuraminidase Inhibitors against H7N9 Highly Pathogenic Avian Influenza Virus Causing Severe Viral Pneumonia in Cynomolgus Macaques.
Functional analysis of amino acids at stalk/head interface of human parainfluenza virus type 3 hemagglutinin-neuraminidase protein in the membrane fusion process.
Review of Non-Bacterial Infections in Respiratory Medicine: Viral Pneumonia.
Polycystic Kidney Diseases
Cloning and expression of a chitinase gene from Sanguibacter sp. C4.
Functional expression and characterization of a chitinase from the marine archaeon Halobacterium salinarum CECT 395 in Escherichia coli.
Genomic analysis and initial characterization of the chitinolytic system of Microbulbifer degradans strain 2-40.
Polycythemia Vera
[Glycoprotein sialylation and NEU1 and ST6GAL1 expressions in erythremia].
Pre-Eclampsia
Alpha 2,6-sialyltransferase I expression in the placenta of patients with preeclampsia.
Precancerous Conditions
Role of aberrant glycosylation enzymes in oral cancer progression.
Salivary glyco-sialylation changes monitors oral carcinogenesis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies.
Electrophoretic mobility distributions of normal human T and B lymphocytes and of peripheral blood lymphoblasts in acute lymphocytic leukemia: effects of neuraminidase and of solvent ionic strength.
Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland.
Pregnancy Complications
Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy.
Premature Birth
Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.
Combination of vaginal pH with vaginal sialidase and prolidase activities for prediction of low birth weight and preterm birth.
High sialidase levels increase preterm birth risk among women who are bacterial vaginosis-positive in early gestation.
Inhibition of sialidase activity and cellular invasion by the bacterial vaginosis pathogen Gardnerella vaginalis.
Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta-analysis of cohort studies.
The preterm prediction study: failure of midtrimester cervical sialidase level elevation to predict subsequent spontaneous preterm birth.
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora.
Prostatic Hyperplasia
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium.
T antigen expression in benign hyperplasia and adenocarcinoma of the prostate.
Prostatic Neoplasms
Effects of a human plasma membrane-associated sialidase siRNA on prostate cancer invasion.
Human cytosolic sialidase NEU2-low general tissue expression but involvement in PC-3 prostate cancer cell survival.
Increased sialidase activity in serum of cancer patients: Identification of sialidase and inhibitor activities in human serum.
Isoenzyme-Selective Inhibitors of Human Neuraminidases Reveal Distinct Effects on Cell Migration.
Isoenzymes of human prostate acid phosphatase.
Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signaling.
[Enzyme activity of neuraminidase 1 correlated with the biological behavior of prostate cancer PC3 and DU145 cell lines].
Proteinuria
Expression of sialidase and dystroglycan in human glomerular diseases.
In vivo enzymatic removal of alpha 2-->6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury.
Renal neuraminidase. Characterization in normal rat kidney and measurement in experimentally induced nephrotic syndrome.
Pseudomyxoma Peritonei
[Pseudomyxoma peritonei: a case with multiple metastases. Ultrastructural study and chemical analysis of the mucoid substance]
Puerperal Infection
[Relationship between vaginal sialidase bacteria vaginosis and chorioammionitis]
Pulmonary Aspergillosis
Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.
Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis.
Pulmonary Disease, Chronic Obstructive
[Metabolism of the main substance of the connective tissue in chronic obstructive pulmonary disease]
Pulmonary Edema
Neuraminidase Reprograms Lung Tissue and Potentiates Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Pulmonary Fibrosis
Attenuated pulmonary fibrosis in sialidase-3 knockout (Neu3-/-) mice.
High-Fat Diet-Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice Are Reduced by Inhibiting Sialidases.
Inhibiting Sialidase-Induced TGF-?1 Activation Attenuates Pulmonary Fibrosis in Mice.
Reduced Sialylation and Bioactivity of the Antifibrotic Protein Serum Amyloid P in the Sera of Patients with Idiopathic Pulmonary Fibrosis.
Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model.
Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis.
Purpura, Thrombocytopenic, Idiopathic
Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
Platelet desialylation and TFH cells-the novel pathway of immune thrombocytopenia.
Pyelonephritis
Pyelonephritis: renal urokinase and sialidase (neuraminidase) activity in rats fed a standard laboratory diet.
Rabies
A neuraminidase in duck embryo rabies vaccine.
Mechanism of rabies virus entry into CER cells.
Relapsing Fever
Carbosilane glycodendrimers.
Renal Insufficiency
In vivo enzymatic removal of alpha 2-->6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury.
Neuraminidase-like activity in sera of uremic anemic patients.
Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.
Respiratory Distress Syndrome
Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study.
The Neuraminidase Inhibitor Oseltamivir Is Effective Against A/Anhui/1/2013 (H7N9) Influenza Virus in a Mouse Model of Acute Respiratory Distress Syndrome.
Respiratory Insufficiency
DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation.
Respiratory Syncytial Virus Infections
Antiviral drugs: current state of the art.
Approved Antiviral Drugs over the Past 50 Years.
Respiratory viral infections occurring after hematopoietic stem cell transplantation.
Respiratory Tract Diseases
Influenza virus-related critical illness: prevention, diagnosis, treatment.
Respiratory Tract Infections
Analysis of delays in the prescription of oseltamivir in hospitals and potential for improvement.
Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens.
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis.
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses.
The role of antigenically different virus neuraminidases as structures implicated in receptor-binding processes.
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Retinal Degeneration
Altered expression of ?-galactosidase-1-like protein 3 (Glb1l3) in the retinal pigment epithelium (RPE)-specific 65-kDa protein knock-out mouse model of Leber's congenital amaurosis.
GM1 gangliosidosis type 2 in two siblings.
Rhabdomyolysis
Influenza-induced rhabdomyolysis after autologous peripheral blood stem cell transplantation for malignant lymphoma.
Rhabdomyosarcoma
Cells of rhabdomyosarcoma PA-23 tumor clones with high and low metastatic potential differ by activity of lysosomal sialidase.
Defective myogenic differentiation of human rhabdomyosarcoma cells is characterized by sialidase Neu2 loss of expression.
Rheumatic Fever
Neuraminidase production by streptococci from patients with glomerulonephritis.
Streptococcal neuraminidase and acute glomerulonephritis.
Rhinitis, Atrophic
[Pasteurelloses]
Rinderpest
A newly identified horseshoe crab lectin with specificity for blood group A antigen recognizes specific O-antigens of bacterial lipopolysaccharides.
The hemagglutinin-neuraminidase protein of peste des petits ruminants virus is biologically active when transiently expressed in mammalian cells.
RNA Virus Infections
Molecular strategies to inhibit the replication of RNA viruses.
Rotavirus Infections
Productive penetration of rotavirus in cultured cells induces coentry of the translation inhibitor alpha-sarcin.
Rubella
Morphology, biochemical analysis and neuraminidase activity of rubella virus.
Salmonella Infections
Implication of Sialidases in Salmonella Infection: Genome Release of Sialidase Knockout Strains from Salmonella enterica Serovar Typhimurium LT2.
Sandhoff Disease
Increased lung surfactant phosphatidylcholine in patients affected by lysosomal storage diseases.
Sarcoidosis
Anticarbohydrate autoantibodies to sialidase-treated erythrocytes and thymocytes in serum from patients with pulmonary sarcoidosis.
Sialidase activity and antibodies to sialidase-treated autologous erythrocytes in bronchoalveolar lavages from patients with idiopathic pulmonary fibrosis or sarcoidosis.
Sarcoidosis, Pulmonary
Sialidase activity and antibodies to sialidase-treated autologous erythrocytes in bronchoalveolar lavages from patients with idiopathic pulmonary fibrosis or sarcoidosis.
Sarcoma
Antitumor immune response following injection of neuraminidase-treated sarcoma cells.
Comparative immunogenicity of irradiated, neuraminidase treated, and fused cells of a strain-restricted sarcoma.
In vitro evidence that Vibrio Cholerae neuraminidase increases antigenicity of sarcoma cells.
Metastatic sarcoma. Combined surgical and immunotherapeutic approach. Neuraminidase treated tumor cells as tumor vaccine.
Preparation of fixed antigenic, non-oncogenic and protective neoplastic cells.
The effect of neuraminidase on the sensitivity of tumor cells toward lysis by antibody and complement or by sensitized lymphocytes.
Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase.
[Antitumor effect of a tumor-cell neuraminidase vaccine]
[Use of the enzyme neuraminidase for immunotherapeutic treatment of chemically induced carcinogenesis]
Sarcoma, Avian
Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
Neuraminidase activity and cell surface sialic acid turnover in Rous sarcoma virus transformed chick embryo fibroblasts.
Sarcoma, Yoshida
Inhibition of growth of rat Yoshida sarcoma using a neuraminidase treated tumour vaccine.
Scabies
Streptomyces scabies 87-22 possesses a functional tomatinase.
Scrub Typhus
Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi).
Seizures
Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis.
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
The effect of neuraminidase blocker on gabazine-induced seizures in rat hippocampus.
Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency.
Seminoma
Characterization of seminoma-derived placental-like alkaline phosphatase.
Electrophoretic heterogeneity of alkaline phosphatase isozymes in seminoma and normal testis.
Enzymatic heterogeneity of seminomas.
Sepsis
Accelerated Aging and Clearance of Host Anti-inflammatory Enzymes by Discrete Pathogens Fuels Sepsis.
Acute respiratory distress syndrome caused by influenza B virus infection in a patient with diffuse large B-cell lymphoma.
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.
Bacterial neuraminidase-mediated erythrocyte desialylation provokes cell surface aminophospholipid exposure.
Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment.
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.
Neuraminidase activity in Streptococcus sanguis and in the viridans group, and occurrence of acylneuraminate lyase in viridans organisms isolated from patients with septicemia.
Neuraminidase alters red blood cells in sepsis.
Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19.
Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis.
Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets.
Potent inhibition of bacterial neuraminidase activity by pterocarpans isolated from the roots of Lespedeza bicolor.
Red blood cell T-activation and hemolysis in surgical intensive care patients with severe infections.
Sialidase inhibitors DAMPen sepsis.
Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.
Severe Acute Respiratory Syndrome
Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein.
De Novo Drug Design of Targeted Chemical Libraries Based on Artificial Intelligence and Pair-Based Multiobjective Optimization.
The potential antiviral effect of major royal jelly protein2 and its isoform X1 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Insight on their sialidase activity and molecular docking.
Severe Combined Immunodeficiency
The map of chromosome 20.
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Shock, Septic
Acute respiratory distress syndrome caused by influenza B virus infection in a patient with diffuse large B-cell lymphoma.
Sialic Acid Storage Disease
Comparison of sialic acids excretion in spot urines and 24-hour-urines of children and adults.
Salla disease variants. Sialoylaciduric encephalopathy with increased sialidase activity in two non-Finnish children.
Small Cell Lung Carcinoma
Cellular site of synthesis and dynamics of cell surface re-expression of polysialic acid of the neural cell adhesion molecule.
P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.
Smallpox
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
Spinal Cord Injuries
Sialidase enhances recovery from spinal cord contusion injury.
Sialidase, chondroitinase ABC and combination therapy after spinal cord contusion injury.
Sporotrichosis
[Occurrence of neuraminidase in Sporothrix schenckii and Ceratocystis stenoceras and its role in ecology and pathomechanism of these fungi (author's transl)]
Spotted Fever Group Rickettsiosis
Genomic comparison of virulent Rickettsia rickettsii Sheila Smith and avirulent Rickettsia rickettsii Iowa.
Squamous Cell Carcinoma of Head and Neck
Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Staphylococcal Infections
[The immunomodulating action of the surface antigens of the influenza A virus in experimental staphylococcal infection]
Starvation
Glycosyl hydrolases of cell wall are induced by sugar starvation in Arabidopsis.
Status Epilepticus
Neuroaminidase reduces interictal spikes in a rat temporal lobe epilepsy model.
Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency.
steroid 21-monooxygenase deficiency
The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene.
Stomach Neoplasms
Co-expression of X-hapten-like antigen and antigen YH206 on mucin molecules.
Expression of Forssman glycolipid and blood group-related antigens A, Le(x), and Le(y) in human gastric cancer and in fetal tissues.
Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion.
The effect of sialidase inhibitors on hyaluronan-mediated escape from apoptosis induced by anti-cancer drugs in gastric cancer.
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Streptococcal Infections
Extracellular neuraminidase production of streptococci associated with acute nephritis.
Streptococcus pneumoniae Sialidase SpNanB-Catalyzed One-Pot Multienzyme (OPME) Synthesis of 2,7-Anhydro-Sialic Acids as Selective Sialidase Inhibitors.
Stroke
Influenza and Stroke Risk: A Key Target Not to be Missed?
Sialic acid and sialidase activity in acute stroke.
Superinfection
Influenza A virus neuraminidase limits viral superinfection.
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Neuraminidase-deficient Sendai virus HN mutants provide protection from homologous superinfection.
Retroviral infection of Syrian hamster BHK cells depends on age and susceptibility toward sialidase.
Swine Erysipelas
[Neuraminidase neutralizing and precipitating antibodies in commercial swine erysipelas antiserums]
Syncope
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Tachypnea
Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor.
Tay-Sachs Disease
Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells.
Tetanus
Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure.
Evidence for the functional role of monosialoganglioside GM1 in synaptic transmission in the rat hippocampus.
Excitability and ion content of cerebral tissues treated with alkylating agents, tetanus toxin, or a neuraminidase.
Possible role of sialocompounds in the uptake of choline into synaptosomes and nerve cell cultures.
Preparation of affinity-purified, biotinylated tetanus toxin, and characterization and localization of cell surface binding sites on nerve growth factor-treated PC12 cells.
Temperature-mediated interaction of tetanus toxin with cerebral neuron cultures: characterization of a neuraminidase-insensitive toxin-receptor complex.
Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain.
Tetanus toxin binds with high affinity to neuroblastoma x glioma hybrid cells NG 108-15 and impairs their stimulated acetylcholine release.
Tetanus toxin inhibits the evoked outflow of an inhibitory (GABA) and an excitatory (D-aspartate) amino acid from particulate brain cortex.
Thrombocytopenia
Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia.
Functional role of platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants.
Hepatocellular injury in Streptococcus pneumoniae-associated hemolytic uremic syndrome in children.
Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content.
Neuraminidase injections in rabbits. Reduced platelet surface charge, aggregation and thrombocytopenia.
Neuraminidase-induced thrombocytopenia in mice: effects on thrombopoiesis.
Oral exposure to Phytomonas serpens attenuates thrombocytopenia and leukopenia during acute infection with Trypanosoma cruzi.
Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.
Possible role of neuraminidase in the pathogenesis of arteritis and thrombocytopenia induced in rats by Erysipelothrix rhusiopathiae.
Protective effect of pantethine on experimental thrombocytopenia in the rat.
Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia.
Significance of platelets in an antimetastatic activity of bacterial lipopolysaccharide.
The Ashwell receptor mitigates the lethal coagulopathy of sepsis.
The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents.
Thrombosis
Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.
Thrombotic Microangiopathies
Atypical presentation of post infectious glomerulonephritis as malignant hypertension and thrombotic microangiopathy.
Toxoplasmosis
Computational probing of Toxoplasma gondii major surface antigen 1 (SAG1) for enhanced vaccine design against toxoplasmosis.
High expression of water-soluble recombinant antigenic domains of Toxoplasma gondii secretory organelles.
High Seroprevalence of Toxoplasmosis Detected by RDT among the Residents of Seokmo-do (Island) in Ganghwa-Gun, Incheon City, Korea.
Seroprevalence of Toxoplasmosis Detected by RDT in Residents near the DMZ (demilitarized zone) of Cheorwon-gun, Gangwon-do, Korea.
Trichomonas Infections
Bovine trichomoniasis as a model for development of vaccines against sexually-transmitted disease.
Triple Negative Breast Neoplasms
Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
Trypanosomiasis
A bloodstream Trypanosoma congolense sialidase could be involved in anemia during experimental trypanosomiasis.
Trypanosoma evansi sialidase: surface localization, properties and hydrolysis of ghost red blood cells and brain cells-implications in trypanosomiasis.
Trypanosomiasis, African
Biochemical characterization of trans-sialidase TS1 variants from Trypanosoma congolense.
Biochemical diversity in the Trypanosoma congolense trans-sialidase family.
CrystalDock: a novel approach to fragment-based drug design.
Production, purification and crystallization of a trans-sialidase from Trypanosoma vivax.
Regulation of Antigenic Variation by Trypanosoma brucei Telomere Proteins Depends on Their Unique DNA Binding Activities.
Silencing subtelomeric VSGs by Trypanosoma brucei RAP1 at the insect stage involves chromatin structure changes.
Suppression of subtelomeric VSG switching by Trypanosoma brucei TRF requires its TTAGGG repeat-binding activity.
Telomerase activity is required for the telomere G-overhang structure in Trypanosoma brucei.
Trans-sialidase from Trypanosoma brucei as a potential target for DNA vaccine development against African trypanosomiasis.
Trans-sialidase Protein as a Potential Serological Marker for African Trypanosomiasis.
Trypanosoma brucei Orc1 is essential for nuclear DNA replication and affects both VSG silencing and VSG switching.
Trypanosoma brucei RAP1 Has Essential Functional Domains That Are Required for Different Protein Interactions.
Trypanosoma brucei RAP1 maintains telomere and subtelomere integrity by suppressing TERRA and telomeric RNA:DNA hybrids.
Trypanosoma brucei TIF2 and TRF Suppress VSG Switching Using Overlapping and Independent Mechanisms.
Tuberculosis
Effects of Biomolecular Flexibility on Alchemical Calculations of Absolute Binding Free Energies.
Quantitative sputum analysis: neuraminidase and tuberculosis.
Sequence analysis of haemagglutinin and neuraminidase of H1N1 strain from a patient coinfected with Mycobacterium tuberculosis.
The Mycobacterium tuberculosis phagosome in human macrophages is isolated from the host cell cytoplasm.
Uremia
Neuraminidase-like activity in sera of uremic anemic patients.
Urinary Bladder Neoplasms
Increase of the in vitro complement-dependent cytotoxicity against autologous invasive human bladder tumor cells by neuraminidase treatment.
Sialidase NEU1 suppresses progression of human bladder cancer cells by inhibiting fibronectin-integrin ?5?1 interaction and Akt signaling pathway.
T-antigen. A prognostic indicator of high recurrence index in transitional carcinoma of the bladder.
[The study on Thomsen-Friedenreich antigen in bladder tumor]
Urolithiasis
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity.
In vivo effects of urease-producing bacteria involved with the pathogenesis of infection-induced urolithiasis on renal urokinase and sialidase activity.
The effect of calcium and magnesium ions on urinary urokinase and sialidase activity.
Vaccinia
A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.
A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
Analysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4+ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoprotein.
Biological activity of paramyxovirus fusion proteins: factors influencing formation of syncytia.
Biosynthesis, intracellular transport and enzymatic activity of an avian influenza A virus neuraminidase: role of unpaired cysteines and individual oligosaccharides.
Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity.
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.
Differences in the role of the cytoplasmic domain of human parainfluenza virus fusion proteins.
Expression of cDNA encoding the Sendai virus hemagglutinin-neuraminidase gene: characterization of wild-type and mutant gene products.
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses.
Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
Immunobiological properties of influenza A (H7N9) hemagglutinin and neuraminidase proteins.
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein.
Interaction between vaccinia virus and human blood platelets.
Loss of glycosylation at Asn144 alters the substrate preference of the N8 influenza A virus neuraminidase.
Mice lacking CD8+ T cells develop greater numbers of IgA-producing cells in response to a respiratory virus infection.
Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses.
Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.
Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes.
Regions on the hemagglutinin-neuraminidase proteins of human parainfluenza virus type-1 and Sendai virus important for membrane fusion.
Sialic acid is cleaved from glycoconjugates at the cell surface when influenza virus neuraminidases are expressed from recombinant vaccinia viruses.
The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion.
The hemagglutinin-neuraminidase (HN) gene of Newcastle disease virus strain Italien (ndv Italien): comparison with HNs of other strains and expression by a vaccinia recombinant.
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
Vaginal Discharge
[Relationship between vaginal sialidase bacteria vaginosis and chorioammionitis]
Vaginal Diseases
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China.
Vaginitis
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China.
Sialidase activity in aerobic vaginitis is equal to levels during bacterial vaginosis.
[Interaction between vaginal micro-environment alterations and HPV16 infection in cervical intraepithelial neoplasia].
Vaginosis, Bacterial
A Biochemiluminescent Sialidase Assay for Diagnosis of Bacterial Vaginosis.
A tetravalent sialic acid-coated tetraphenylethene luminogen with aggregation-induced emission characteristics: design, synthesis and application for sialidase activity assay, high-throughput screening of sialidase inhibitors and diagnosis of bacterial vaginosis.
Among pregnant women with bacterial vaginosis, the hydrolytic enzymes sialidase and prolidase are positively associated with interleukin-1beta.
Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial.
Bacterial vaginosis in pregnant adolescents: proinflammatory cytokine and bacterial sialidase profile. Cross-sectional study.
Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.
BVBLUE test for diagnosis of bacterial vaginosis in pregnant women attending antenatal care at Phramongkutklao Hospital.
BVBlue test for diagnosis of bacterial vaginosis.
Cervicovaginal cytokines, sialidase activity and bacterial load in reproductive-aged women with intermediate vaginal flora.
Correlation of local interleukin-8 with immunoglobulin A against Gardnerella vaginalis hemolysin and with prolidase and sialidase levels in women with bacterial vaginosis.
Determination of immunoglobulin A against Gardnerella vaginalis hemolysin, sialidase, and prolidase activities in vaginal fluid: implications for adverse pregnancy outcomes.
Gardnerella vaginalis comprises three distinct genotypes of which only two produce sialidase.
Gardnerella vaginalis Subgroups Defined by cpn60 Sequencing and Sialidase Activity in Isolates from Canada, Belgium and Kenya.
Immunoglobulin A response against Gardnerella vaginalis hemolysin and sialidase activity in bacterial vaginosis.
Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis.
Inhibition of sialidase activity and cellular invasion by the bacterial vaginosis pathogen Gardnerella vaginalis.
Nanophotonic Sialidase Immunoassay for Bacterial Vaginosis Diagnosis.
Prevalence of vaginolysin, sialidase and phospholipase genes in Gardnerella vaginalis isolates between bacterial vaginosis and healthy individuals.
Sialidase activity in aerobic vaginitis is equal to levels during bacterial vaginosis.
Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora.
The Effects of Hormones and Vaginal Microflora on the Glycome of the Female Genital Tract: Cervical-Vaginal Fluid.
The presence of the putative Gardnerella vaginalis sialidase A gene in vaginal specimens is associated with bacterial vaginosis biofilm.
The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
The preterm prediction study: failure of midtrimester cervical sialidase level elevation to predict subsequent spontaneous preterm birth.
Use of 5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid in a novel spot test To identify sialidase activity in vaginal swabs from women with bacterial vaginosis.
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora.
Vaginal microflora associated with bacterial vaginosis in nonpregnant women: reliability of sialidase detection.
[Relationship between vaginal sialidase bacteria vaginosis and chorioammionitis]
[Sialidase activity in women with bacterial vaginosis]
Vascular System Injuries
Dual Specificity of Human Plasma Lactose-Binding Immunoglobulin to Anomers of Terminal Galactose Enables Recognition of Desialylated Lipoprotein(a) and Xenoantigens.
Vesicular Stomatitis
A novel chimeric oncolytic virus vector for improved safety and efficacy in hepatocellular carcinoma.
An enzymatic assay reveals that proteins destined for the apical or basolateral domains of an epithelial cell line share the same late Golgi compartments.
Cellular adsorption function of the sialoglycoprotein of vesicular stomatitis virus and its neuraminic acid.
Cross-reactive anti-vesicular stomatitis virus (VSV) cytotoxic T lymphocytes recognize the major surface glycoprotein.
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.
Influenza vaccine: progress in a vaccine that elicits a broad immune response.
Integration of membrane proteins into the endoplasmic reticulum requires GTP.
Intracellular processing of the vesicular stomatitis virus glycoprotein and the Newcastle disease virus hemagglutinin-neuraminidase glycoprotein.
Role of viral envelope sialic acid in membrane fusion mediated by the vesicular stomatitis virus envelope glycoprotein.
Viremia
[Variability of influenza A2 viruses in nature]
Virus Diseases
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.
A Cost-Effectiveness Analysis of Neuraminidase Inhibitors for Influenza Virus Infections in an Adult-Outpatient Setting in Japan.
A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.
A glycosyl hydrolase activity of mammalian reovirus sigma1 protein can contribute to viral infection through a mucus layer.
A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens.
A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.
A novel genotyping and quantitative analysis of neuraminidase inhibitor-resistance associated mutations in influenza A viruses by single nucleotide polymorphism analysis.
A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture.
A randomized study of standard versus double dose oseltamivir for treating influenza in the community.
A rapid LC-MS/MS quantification of peramivir using a simple and inexpensive sample precipitation: application to PK.
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.
A Sero-Survey of Subtype H3 Influenza A Virus Infection in Dogs and Cats in Japan.
A sialosyl sulfonate as a potent inhibitor of influenza virus replication.
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.
Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity.
Amide-sialoside protein conjugates as neomucin bioshields prevent influenza virus infection.
An enzymatic assay reveals that proteins destined for the apical or basolateral domains of an epithelial cell line share the same late Golgi compartments.
Analysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4+ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoprotein.
Analysis of the protective effect of the haemagglutinin-neuraminidase protein in Newcastle disease virus infection.
Anti-Influenza Activity of an Ethyl Acetate Fraction of a Rhus verniciflua Ethanol Extract by Neuraminidase Inhibition.
Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.
Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial.
Antibody Neutralization of an Influenza Virus that Uses Neuraminidase for Receptor Binding.
Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
Antigenic validation of recombinant hemagglutinin-neuraminidase protein of Newcastle disease virus expressed in Saccharomyces cerevisiae.
Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
Antiviral activity of the plant extracts from Thuja orientalis, Aster spathulifolius, and Pinus thunbergii against influenza virus A/PR/8/34.
Antiviral drugs in current clinical use.
Antiviral drugs: current state of the art.
Approaches and strategies for the treatment of influenza virus infections.
Approved Antiviral Drugs over the Past 50 Years.
Aromatic sialic acid analogues as potential inhibitors of influenza virus neuraminidase.
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor.
Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
Characterization of SA-11 rotavirus receptorial structures on human colon carcinoma cell line HT-29.
Characterization of sialidase from an influenza A (H3N2) virus strain: kinetic parameters and substrate specificity.
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin.
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.
Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.
Comparison of single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection: A phase III randomized, double-blind study.
Comprehensive profiling of translation initiation in influenza virus infected cells.
Computational studies of sialyllactones: methods and uses.
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.
Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan.
Consensus QSAR model for identifying novel H5N1 inhibitors.
Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.
Current and future antiviral therapy of severe seasonal and avian influenza.
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.
Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice.
Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
Design of fluorinated sialic acid analog inhibitor to H5 hemagglutinin of H5N1 influenza virus through molecular dynamics simulation study.
Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections.
Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Detection and management of antiviral resistance for influenza viruses.
Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.
Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo.
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.
Diverse and Unexpected Roles of Human Monocytes/Macrophages in the Immune Response to Influenza Virus.
Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.
Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution.
Dynamics of viral growth, viral enzymatic activity, and antigenicity in murine lungs during the course of influenza pneumonia.
Effect of inflammatory cell mediators on M2 muscarinic receptors in the lungs.
Effect of specific immunity to viral neuraminidase on subsequent influenza virus infection in man.
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
Efficacy of a high-yield attenuated vaccine strain wholly derived from avian influenza viruses by use of reverse genetics.
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.
Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.
Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.
Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection.
Evaluation of diagnostic tests for influenza in a pediatric practice.
Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.
Evolutionarily conserved residues at an oligomerization interface of the influenza A virus neuraminidase are essential for viral survival.
Exploring human parainfluenza virus type-1 hemagglutinin-neuraminidase as a target for inhibitor discovery.
Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase.
Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.
Functional balance between haemagglutinin and neuraminidase in influenza virus infections.
Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination.
Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Gangliosides as binding sites in SA-11 rotavirus infection of LLC-MK2 cells.
Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus.
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
GS-4104 (Gilead Sciences Inc).
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.
H9N2 Influenza Virus Infections in Human Cells Require a Balance between Neuraminidase Sialidase Activity and Hemagglutinin Receptor Affinity.
Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.
Highlights in the development of new antiviral agents.
Homo- and heterosubtypic low pathogenic avian influenza exposure on H5N1 highly pathogenic avian influenza virus infection in wood ducks (Aix sponsa).
Human genetics and responses to influenza vaccination: clinical implications.
Human parainfluenza virus 3 neuraminidase activity contributes to dendritic cell maturation.
Identification of a linear epitope on the haemagglutinin protein of pandemic A/H1N1 2009 influenza virus using monoclonal antibodies.
Identification of antigenic epitopes in the hemagglutinin protein of H7 avian influenza virus.
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.
Identification of influenza A nucleoprotein as an antiviral target.
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection.
Identification of Suitable Natural Inhibitor against Influenza A (H1N1) Neuraminidase Protein by Molecular Docking.
IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection.
Immunohistochemical Findings of an Autopsied Lung Specimen from a Patient with Pandemic Influenza (A/H1N1pdm) Virus Infection.
Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice.
Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
In silico biology of H1N1: molecular modelling of novel receptors and docking studies of inhibitors to reveal new insight in flu treatment.
In vitro and in vivo activities of anti-influenza virus compound T-705.
In vitro and in vivo characterization of novel neuraminidase substitutions in influenza A(H1N1)pdm09 identified using Laninamivir-mediated in vitro selection.
In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.
In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors.
Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104.
Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.
Influenza Neuraminidase: Underrated Role in Receptor Binding.
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
Influenza vaccine, anti-influenza drugs, and rapid diagnosis in Japan.
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
Influenza virus changes cell-surface glycoproteins including major histocompatibility complex determinants on lymphocytes.
Influenza virus glycoprotein-reactive human monoclonal antibodies.
Influenza virus infection of mouse lymphoblasts alters the binding affinity of anti-H-2 antibody: requirement for viral neuraminidase.
Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections.
Influenza Virus Neuraminidase Engages CD83 and Promotes Pulmonary Injury.
Influenza Virus Neuraminidase Structure and Functions.
Influenza virus resistance to neuraminidase inhibitors.
Influenza viruses: basic biology and potential drug targets.
Inhibition of Influenza A Virus Infection by Fucoidan Targeting Viral Neuraminidase and Cellular EGFR Pathway.
Inhibition of influenza A virus sialidase activity by sulfatide.
Inhibition of influenza viral neuraminidase activity by collectins.
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion.
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Involvement of gangliosides in rabies virus infection.
In Vitro Evaluation of Synergistic Inhibitory Effects of Neuraminidase Inhibitors and Methylglyoxal Against Influenza Virus Infection.
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
L-Ficolin Binds to the Glycoproteins Hemagglutinin and Neuraminidase and Inhibits Influenza A Virus Infection Both in vitro and in vivo.
Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.
Laninamivir Octanoate and Artificial Surfactant Combination Therapy Significantly Increases Survival of Mice Infected with Lethal Influenza H1N1 Virus.
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Locking the 150-cavity open: in silico design and verification of influenza neuraminidase inhibitors.
Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection.
Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance.
Metabolic Oligosaccharide Engineering with Alkyne Sialic Acids Confers Neuraminidase Resistance and Inhibits Influenza Reproduction.
Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.
Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
Molecular docking analysis of zanamavir with haem agglutinin neuraminidase of human para influenza virus type 3.
Molecular Docking, 3D-QSAR studies and in-silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors.
Morin Hydrate Inhibits Influenza Virus entry into Host Cells and Has Anti-inflammatory Effect in Influenza-infected Mice.
Mouse Saliva Inhibits Transit of Influenza Virus to the Lower Respiratory Tract by Efficiently Blocking Influenza Virus Neuraminidase Activity.
Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets.
Multidrug-Resistant Pandemic (H1N1) 2009 Infection in Immunocompetent Child.
Mutants of an influenza A reassortant which are cold-sensitive (cs) as well as temperature-sensitive (ts): on the role of the neuraminidase activity for influenza virus infection.
N1 neuraminidase of H5N1 avian influenza A virus complexed with sialic acid and zanamivir - A study by molecular docking and molecular dynamics simulation.
Neuraminidase activity of influenza virus-infected cells: localization and properties.
Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection.
Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection.
Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.
Novel hemagglutinin-based influenza virus inhibitors.
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.
Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses.
Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.
Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.
Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex.
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
Parvovirus infection of cells by using variants of the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains.
Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors.
Pneumococcal surface protein A contributes to secondary Streptococcus pneumoniae infection after influenza virus infection.
Professional oral care reduces influenza infection in elderly.
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.
Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.
Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.
Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.
Proximity Ligation-Based Fluorogenic Imaging Agents for Neuraminidases.
R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses.
Recent Advances in Neuraminidase Inhibitor Development as Anti-influenza Drugs.
Recent progress in rational drug design of neuraminidase inhibitors.
Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor.
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Respiratory viral infections occurring after hematopoietic stem cell transplantation.
Roles of neuraminidase in the initial stage of influenza virus infection.
Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.
Sequence and phylogenetic analyses of neuraminidase gene of Iranian seasonal influenza H1N1 viruses from 2005-2009 and corresponding vaccine strains.
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.
Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design.
Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor.
Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus.
Suppression of influenza virus infection by an N-thioacetylneuraminic acid acrylamide copolymer resistant to neuraminidase.
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Swine-origin influenza A (H3N2) virus infection in two children--Indiana and Pennsylvania, July-August 2011.
Synthesis and chemical characterization of several perfluorinated sialic acid glycals and evaluation of their in vitro antiviral activity against Newcastle disease virus.
Synthesis of a carbocyclic sialic acid analogue for the inhibition of influenza virus neuraminidase.
Synthesis of novel pentacyclic triterpene-Neu5Ac2en derivatives and investigation of their in vitro anti-influenza entry activity.
Synthesis of Pyrazine-1,3-thiazine Hybrid Analogues as Antiviral Agent Against HIV-1, Influenza A (H1N1), Enterovirus 71 (EV71), and Coxsackievirus B3 (CVB3).
Synthesis of sialoglycopolypeptide for potentially blocking influenza virus infection using a rat alpha2,6-sialyltransferase expressed in BmNPV bacmid-injected silkworm larvae.
Targets for the induction of protective immunity against influenza a viruses.
The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study.
The amino-terminal region of the neuraminidase protein from avian H5N1 influenza virus is important for its biosynthetic transport to the host cell surface.
The Detection of a Low Pathogenicity Avian Influenza Virus Subtype H9 Infection in a Turkey Breeder Flock in the United Kingdom.
The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures.
The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses.
The role of sialidase in influenza virus infection.
The Role of Sialylation in Respiratory Viral Infection and Treatment.
The use of sialidase therapy for respiratory viral infections.
Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection.
Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity.
Transforming growth factor-?: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis.
Treatment of community-acquired lower respiratory tract infections during pregnancy.
Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice.
Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody.
Viral neuraminidase treatment of dendritic cells enhances antigen-specific CD8(+) T cell proliferation, but does not account for the CD4(+) T cell independence of the CD8(+) T cell response during influenza virus infection.
Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors.
Zanamivir (Glaxo Wellcome).
[Antigenic and biochemical analysis of the proteins of influenza virus A/USSR/Alma-Ata/13/81 with hemagglutinin H1]
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
[Contemporary threat of influenza virus infection]
[Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
[Role of neuraminidase inhibitors for the treatment of influenza A virus infections]
[Structure and properties of neuraminidase originating from various sources]
[The induction by the influenza virus A/H1N1 (serovariant Hsw1N1) and its glycoproteins of congenital pathology in mice]
[The smaller number of influenza patients with neuropsychiatric events had taken oseltamivir beforehand]
Visna
Characterization of visna virus envelope neuraminic acid.
Vitamin E Deficiency
[Activation of lipoxygenase, neuraminidase and phospholipase A in cellular and subcellular membranes in carbon tetrachloride poisoning and vitamin E deficiency]
Warts
Approved Antiviral Drugs over the Past 50 Years.
Whooping Cough
A mechanism of action for anaphylatoxin C3a stimulation of mast cells.
Adhesion of Bordetella pertussis to sulfatides and to the GalNAc beta 4Gal sequence found in glycosphingolipids.
Binding of pertussis toxin to lipid vesicles containing glycolipids.
Histamine release, an undesired effect of thrombin inhibitors with basic character, is mediated through direct activation of G(i) proteins.
Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli.
Lectin-like binding of pertussis toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein.
Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action.
Role of a putative polysaccharide locus in Bordetella biofilm development.
Study of the activation mechanism of adriamycin on rat mast cells.
Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.
Trichinella spiralis: histamine secretion induced by TSL-1 antigens from unsensitized mast cells.
Wilms Tumor
[Lectin histochemistry in the kidney and renal tumors]
Zika Virus Infection
Cell surface ?2,3-linked sialic acid facilitates Zika virus internalization.